
<html lang="en"     class="pb-page"  data-request-id="06d9c4a3-a06d-493f-a0e2-516cb2c5ce7d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-4;website:website:acspubs;article:article:10.1021/acs.jmedchem.6b01355;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer" /></meta><meta name="dc.Creator" content="Rui  Xiong" /></meta><meta name="dc.Creator" content="Jiong  Zhao" /></meta><meta name="dc.Creator" content="Lauren M.  Gutgesell" /></meta><meta name="dc.Creator" content="Yueting  Wang" /></meta><meta name="dc.Creator" content="Sue  Lee" /></meta><meta name="dc.Creator" content="Bhargava  Karumudi" /></meta><meta name="dc.Creator" content="Huiping  Zhao" /></meta><meta name="dc.Creator" content="Yunlong  Lu" /></meta><meta name="dc.Creator" content="Debra A.  Tonetti" /></meta><meta name="dc.Creator" content="Gregory R. J.  Thatcher" /></meta><meta name="dc.Description" content="Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-ind..." /></meta><meta name="Description" content="Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-ind..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 10, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01355" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01355" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01355" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01355" /></link>
        
    
    

<title>Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01355" /></meta><meta property="og:title" content="Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0019.jpeg" /></meta><meta property="og:description" content="Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene. Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with 2 (GDC-0810/ARN-810) used for comparison. Two BT SERDs with superior in vitro activity to 2 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to that with 2." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01355"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01355">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01355&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01355&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01355&amp;href=/doi/10.1021/acs.jmedchem.6b01355" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1325-1342</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01270" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01379" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rui++Xiong">Rui Xiong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-6350-9037" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiong++Zhao">Jiong Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lauren+M.++Gutgesell">Lauren M. Gutgesell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yueting++Wang">Yueting Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sue++Lee">Sue Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bhargava++Karumudi">Bhargava Karumudi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huiping++Zhao">Huiping Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yunlong++Lu">Yunlong Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Debra+A.++Tonetti">Debra A. Tonetti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+R.+J.++Thatcher">Gregory R. J. Thatcher</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-7757-1739" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff3"><span class="aff-text"><sup>†</sup>Department of Medicinal Chemistry & Pharmacognosy, <sup>‡</sup>Department of Biopharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#314559504552595443714458521f545544"><span class="__cf_email__" data-cfemail="5c28343d283f34392e1c29353f72393829">[email protected]</span></a>. Phone: 312-355-5282.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01355&amp;href=/doi/10.1021%2Facs.jmedchem.6b01355" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1325–1342</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 24, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 September 2016</li><li><span class="item_label"><b>Published</b> online</span>10 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 February 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01355" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01355</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1325%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRui%2BXiong%252C%2BJiong%2BZhao%252C%2BLauren%2BM.%2BGutgesell%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D4%26contentID%3Dacs.jmedchem.6b01355%26title%3DNovel%2BSelective%2BEstrogen%2BReceptor%2BDownregulators%2B%2528SERDs%2529%2BDeveloped%2Bagainst%2BTreatment-Resistant%2BBreast%2BCancer%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1342%26publicationDate%3DFebruary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01355"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3141</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01355" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rui&quot;,&quot;last_name&quot;:&quot;Xiong&quot;},{&quot;first_name&quot;:&quot;Jiong&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;M. Gutgesell&quot;},{&quot;first_name&quot;:&quot;Yueting&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Sue&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Bhargava&quot;,&quot;last_name&quot;:&quot;Karumudi&quot;},{&quot;first_name&quot;:&quot;Huiping&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Yunlong&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Debra&quot;,&quot;last_name&quot;:&quot;A. Tonetti&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;R. J. Thatcher&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1325-1342&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01355&quot;},&quot;abstract&quot;:&quot;Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene. Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with 2 (GDC-0810/ARN-810) used for comparison. Two BT SERDs with superior in vitro activity to 2 were studied for bioavailability and shown to cause regression &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01355&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01355" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01355&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01355" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01355&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01355" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01355&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01355&amp;href=/doi/10.1021/acs.jmedchem.6b01355" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01355" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01355" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26pmid%3D28117994%26genre%3Darticle%26aulast%3DXiong%26date%3D2017%26atitle%3DNovel%2BSelective%2BEstrogen%2BReceptor%2BDownregulators%2B%2528SERDs%2529%2BDeveloped%2Bagainst%2BTreatment-Resistant%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D4%26spage%3D1325%26epage%3D1342%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/jmcmar.2017.60.issue-4/20170223/jmcmar.2017.60.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene. Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with <b>2</b> (GDC-0810/ARN-810) used for comparison. Two BT SERDs with superior in vitro activity to <b>2</b> were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to that with <b>2</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Approximately 70% of breast cancer patients have estrogen receptor positive (ER+) tumors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The selective estrogen receptor modulator (SERM), tamoxifen,<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> and aromatase inhibitors (AIs) represent first-line treatment for ER+ patients;<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> however, up to 50% of patients either do not respond or acquire resistance within 5 years of treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Multiple mechanisms contribute to the development of an ER+ and treatment resistant (TR) phenotype, in which growth is endocrine-independent, including ligand-independent constitutive activation of ER.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Selective ER downregulators (SERDs) have the potential to block endocrine-dependent and -independent ER signaling by ablation of ER and have been recognized to offer a therapeutic approach to ER+ breast cancer in both early stage and more advanced TR cases.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a></div><div class="NLM_p">The first generation SERD fulvestrant (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>; <b>1</b>)<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> has poor physicochemical and pharmacokinetic (PK) characteristics, requiring intramuscular injection and resulting in a lag of 3–6 months to reach steady-state concentrations.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>1</b>, first reported as the “pure anti-estrogen” ICI 182780,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> has been widely used to probe ER signaling, and the mechanism of action is now understood to involve rapid, proteasome-dependent degradation of the receptor.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Recent work on <b>1</b>, using radiolabeled estradiol, reported a strong correlation between ER degradation and clinical benefit; however, partial engagement of ER, caused by poor physicochemical properties, limited optimum therapeutic efficacy in some patients.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative selective estrogen receptor downregulators (SERDs) and selective estrogen receptor modulators (SERMs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">GW 5638 (<b>3</b>),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> a second generation nonsteroidal triphenylethylene-based SERD that progressed to phase I clinical trials, has the characteristic acrylate side chain that provides key hydrogen bonds with helix 12 and opens a hydrophobic surface thought to induce degradation by the 26S proteasome.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> The clinical efficacy of <b>1</b>, despite its poor physicochemical and PK characteristics, has inspired contemporary interest in orally bioavailable SERDs. The recent intensive interest in discovery and development of novel orally bioavailable SERDs is highlighted by the pursuit of SERDs on multiple scaffolds<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(19-22)</a> and the clinical development of GDC-0810 (ARN-810, <b>2</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a> (<i>R</i>)-6-[2-[ethyl[4-(2-ethylaminoethyl)benzyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol (RAD-1901),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(23)</a> and AZD-9496 (<b>4</b>)<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(24, 25)</a> by Genentech, Radius Health, and Astra Zeneca, respectively.</div><div class="NLM_p last">The SERM raloxifene (<b>6</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(26)</a> has been used in breast cancer chemoprevention and chronic treatment of postmenopausal osteoporosis for almost 2 decades, representing a clinically proven and safe scaffold that we have exploited in the design of novel ER-directed ligands.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(27-29)</a> Herein, we report a medicinal chemistry campaign toward development of novel orally bioavailable SERDs based on the benzothiophen-6-ol (BT) core of the SERMs <b>6</b> and arzoxifene (<b>5</b>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(30)</a> Other reports on the use of a BT scaffold by Novartis<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(22)</a> and Shoda<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(31)</a> reported modest potency where data was made available. Our structural optimization of the molecular topology was guided by antiproliferative potency in TR and parent cell lines, potency in ERα degradation assays, and potency against ERα activation in cell-based reporter assays. The use of 2D and 3D cultures and two different TR cell lines, of which one is a model of tamoxifen resistance (extended tamoxifen treatment) and the second is a model of AI resistance (extended estrogen deprivation), led to novel orally bioavailable SERDs with subnanomolar potency in endocrine-sensitive and TR cell lines and efficacy in a TR ER+ breast cancer mouse xenograft study.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Structure Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have reported a number of approaches to modify the BT scaffold to diversify biological activity of ER ligands.<a onclick="showRef(event, 'ref28 ref29 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref33 ref34 ref35 ref36 ref37 ref38">(27, 28, 32-37)</a> Replacement of the archetypical SERM 2-phenoxyethylamino side chain of <b>5</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) by an acrylate-containing side chain was envisioned simplistically to provide the basis for SERD activity. The acrylate side chain is designed to engage in a hydrogen bonding network with helix 12 in simile with <b>3</b> in complex with ERα (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>). This side chain is also a key feature of newer generation SERDs. Compound <b>5</b> was originally designed to overcome the low oral bioavailability of <b>6</b>, although in Phase 3 trials, compound <b>5</b> did not show superiority in efficacy and safety to <b>6</b>.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(38, 39)</a> Mindful of the extensive glucuronidation<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(40, 41)</a> and low bioavailability of <b>6</b>, we attempted to mitigate these effects in the design of novel SERDs using structural knowledge gained from lasofoxifene (<b>7</b>),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(42)</a> a phenolic SERM with high reported bioavailability (>60% in rats), rationalized by the disruption of planar topology. Therefore, to enhance the oral bioavailability of BT-SERDs, we inserted a ketone linker at the BT 2-position and decorated the 2-benzoyl substituent with planarity-breaking groups at the 2′, 4′, 5′, and 6′ positions (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Molecular docking of a putative SERD (<b>14a</b>), designed using these principles, is shown in the ERα ligand binding domain (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>; <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), demonstrating that the acrylate side chain remains able to make similar contacts as those of <b>3</b> in complex with ERα. A further analysis of docking data reveals two unoccupied hydrophobic cavities formed by Leu-384 and Leu-428; the latter pocket is fully occupied by the ethyl group of <b>3</b> in the crystal structure, and both pockets can potentially be used to enhance the potency of novel SERDs.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel benzothiophene-based SERDs. (A) The BT core common to <b>5</b> and <b>6</b> provided the scaffold for the design of BT-SERDs by replacing the basic side chain with an acrylate side chain and inserting a ketone linker at the 2-position, with further diversification of the 2-substituent. (B) Prototype BT-SERD (<b>14a</b>) docked to ERα LBD (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>), showing similar global topology compared to the <b>3</b>–ER complex. The acrylate side chain interaction with helix 12 is a key structural feature of SERD–ER complexes. (C) Residues within 5 Å of <b>14a</b> are highlighted, and two hydrophobic cavities in the vicinity of Leu-384 and Phe-425 are circled in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> outlines the general synthetic route for preparing BT-SERDs, <b>14a</b>–<b>h</b>. The synthetic strategy utilized a key starting material, 3-chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbonyl chloride (<b>8</b>), which allows modification of both the 2 and 3 positions of the benzothiophene scaffold. The acyl chloride of <b>8</b> was converted to a Weinreb amide, followed by Grignard reaction to functionalize this position. The C–O bond formation at the 3-position proved to be troublesome. In the synthesis of <b>5</b>, Palkowitz and colleagues reported a reaction sequence to prepare the oxygen linkage that involved bromination, oxidation of the sulfur to sulfoxide, and subsequent nucleophilic aromatic displacement.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(30)</a> A subsequent paper examined the possibility of using transition metal-catalyzed reactions, such as the copper iodide-catalyzed or palladium-catalyzed etherification of aryl halides for C–O bond formation.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(43)</a> Unfortunately, both failed. Herein, we utilized the 2-keto group to activate the 3 position and directly formed the oxygen linkage with the corresponding substituted phenols through a nucleophilic aromatic substitution. Selective deprotection of methyl ether over diaryl ether was achieved using BF<sub>3</sub>·SMe<sub>2</sub>, which also showed better yield compared to the other common demethylating reagent, BBr<sub>3</sub>. The acrylate group was installed by standard Heck coupling of aryl bromide with methyl acrylate using a palladium catalyst.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, Et<sub>3</sub>N, DCM, RT, overnight, 76%; (b) Grignard reagent, THF, 0 °C to RT, 2–12 h; (c) 4-bromophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (d) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT, 24–48 h; (e) methyl acrylate, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 110 °C; (f) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><div class="NLM_p">Compounds <b>16a</b>, <b>16b</b>, and <b>19</b> were prepared using a similar strategy as depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Methyl 6-hydroxy-2-naphthoate or methyl 7-hydroxyquinoline-3-carboxylate was directly coupled to the BT core through a nucleophilic aromatic substitution reaction. Since <b>16a</b> and <b>16b</b> do not contain an acrylate group, simultaneous deprotection of phenol methyl ether and ester groups was conducted using BF<sub>3</sub>·SMe<sub>2</sub> at 35 °C for 48 h. In the preparation of compound <b>17</b>, an unprotected 4-aminophenol was selectively coupled to the BT core with good yield (81%). A similar S<sub>N</sub>Ar reaction using an unprotected 4-aminophenol that selectively reacts at the phenol group was reported by Wang and colleagues.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(44)</a> Demethylation of compound <b>17</b> followed by amide coupling afforded compound <b>19</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 6-hydroxy-2-naphthoate, methyl 7-hydroxyquinoline-3-carboxylate, or 4-aminophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (b) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT or 35 °C, 48 h; (c) (i) methyl 2-chloro-2-oxoacetate, Et<sub>3</sub>N, DCM, (ii) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><div class="NLM_p">In the synthesis of <b>24a</b>–<b>c</b>, compound <b>8</b> was directly used in preference to compound <b>9</b> when the corresponding Grignard reagents were insufficiently reactive toward the Weinreb amide (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The remaining steps were analogous to those used in the synthesis of <b>14a</b>–<b>h</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Grignard reagent, THF, 0 °C to RT, 2–12 h; (b) 4-bromophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (c) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT, 24–48 h; (d) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 110 °C; (e) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><div class="NLM_p">For compounds <b>28b</b> and <b>28c</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) that contain Cl substituents, methyl (<i>E</i>)-3-(4-hydroxyphenyl) acrylate was used in the S<sub>N</sub>Ar coupling to avoid the potential selectivity problem in Heck reactions. Methyl (<i>E</i>)-3-(4-hydroxyphenyl) acrylate was less reactive compared to 4-bromophenol in this reaction, and the reaction temperature was raised to 90 °C to compensate. Selective deprotection of phenol methyl ether over methyl ester was conducted using BF<sub>3</sub>·SMe<sub>2</sub> in an ice water bath. A small amount of ester hydrolysis product was also observed by LC-MS, and this amount can be reduced by careful control of reaction temperature. Overall, our concise synthetic route produced a test compound library in 4–6 steps.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Grignard reagent, THF, 0 °C to RT, 2–12 h; (b) methyl (<i>E</i>)-3-(4-hydroxyphenyl)acrylate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C; (c) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT, 24–48 h; (d) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Biological Testing</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our therapeutic objective was to discover a novel, potent, orally bioavailable SERD with preclinical efficacy in TR, endocrine-resistant, ER+ breast cancer that is capable of inhibiting growth of multiple cell lines in culture and effecting regression of tumors in a mouse xenograft study. The ER+ cell lines tested were endocrine and tamoxifen-sensitive (MCF-7:WS8) or treatment resistant (TR: MCF-7:5C, MCF-7:TAM1, MCF-7/PKCα). MCF-7:TAM1 cells are a model for tamoxifen resistance, whereas MCF-7:5C cells are a model for AI resistance; however, all three TR cell lines are endocrine-independent and tamoxifen-insensitive. Rather than use ER degradation as the primary assay, as described by Callis<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(45)</a> and Lai,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a> we measured as our primary screen the ability of novel SERDs to inhibit growth of TR MCF-7:5C cells, assessed by DNA assay on the sixth day after treatment. The MCF-7:5C cell line was obtained by long-term deprivation of E<sub>2</sub> and can be seen as a model of AI-resistant ER+ breast cancer.<a onclick="showRef(event, 'ref28 ref47'); return false;" href="javascript:void(0);" class="ref ref28 ref47">(27, 46)</a> The clinical SERD, <b>1</b>, was used for comparison in early testing of our novel oral SERDs (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">Figures S1 and S2</a>), but <b>2</b> was selected as a more appropriate control for further studies since it is an orally bioavailable SERD currently in Phase 2 clinical trials. Results in the primary assay are reported as inhibition of cell growth relative to vehicle (0%) and <b>2</b> (1 μM) treated cells (100%) (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Cell viability of the MCF-7:WS8 ER+ endocrine-dependent parental cell line was used as a counterscreen to exclude potential ER agonists or general cytotoxins. The secondary screen was the measurement of ER degradation, obtaining potency and efficacy using in-cell westerns in MCF-7:WS8 cells (<a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, and <a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">S2</a> and <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Loss of ERα was verified by standard western blots in both MCF-7:WS8 and TR MCF-7:5C cells (data in <a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">Figure S1</a>). The relative binding affinity of selected SERDs to full-length ERα was evaluated in a radioligand displacement assay (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Tertiary assays relied upon measurement of ERα antagonism in endocrine-dependent MCF-7:WS8 cells cotreated with 0.1 nM E<sub>2</sub>, with the response being normalized to control treated cells (0%) and E<sub>2</sub> (0.1 nM) treated cells (100%). The representative data from this series of primary to tertiary screens, comparing <b>2</b> to BT-SERD <b>28c</b>, are depicted in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> (panel A shows viability of TR MCF-7:5C cells, panel B shows viability of MCF-7:WS8 cells, panel C shows dose-dependent ER downregulation, and panel D shows antagonism of E<sub>2</sub> action at ERα).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Optimization of the “Warhead” Using Growth Inhibition Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Cell survival was normalized to DMSO control (100%) and <b>2</b> (1 μM) treatment (0%).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Maximum efficacy <100% is observed when treatment fails to inhibit cell growth to the level observed for <b>2</b> (100%) at 100 × IC<sub>50</sub>. NI = no inhibition. Data show mean ± SEM from at least three cell passages (triplicates in each passage)</p></div></div><div></div></div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In-cell western assay of ERα in MCF-7:WS8 cell cultures. Cells were incubated with increasing concentrations of <b>2</b> (ARN-810), <b>24b</b>, <b>24c</b>, <b>28c</b>, or E<sub>2</sub> for 24 h before ERα protein levels were measured using in-cell western, as described in the <a class="ref internalNav" href="#sec10" aria-label="Experimental Section">Experimental Section</a>, and imaged using a LI-COR Odyssey NIR system: (left) ERα (green) is seen to decrease with increasing SERD concentration (green anti-ERα antibody); (middle) CellTag 700 (red) is used for normalization; and (right) the color merged plate clearly shows loss of ERα in response to SERD treatment. Data quantitation is shown in <a class="ref internalNav" href="#fig4" aria-label="Figures 4">Figures 4</a>C and <a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">S2</a> and <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Optimization of 2-Benzothiophene Substituent Using Growth Inhibition Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Cell survival was normalized to DMSO control (100%) and 1 μM <b>2</b> (0%) assessed in a 6 day cell viability assay with one time drug treatment.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Cell survival was normalized to DMSO control (100%) and 1 μM <b>2</b> (0%) assessed in a 4 day cell viability assay with one time drug treatment.</p></div><div class="footnote" id="t2fn3"><sup>Table ab</sup><p class="last">Values in parentheses indicate <100% maximal efficacy (<i>E</i><sub>max</sub>). Data show mean ± SEM from at least three cell passages (triplicates in each passage). NI = no inhibition.</p></div></div><div></div></div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Profiling SERDs: <b>2</b> and <b>28c</b>. (A) Cell viability of TR MCF-7:5C breast cancer cells 4 days after drug treatment, normalized to vehicle (100%). (B) Cell viability of parent endocrine-sensitive MCF-7:WS8 breast cancer cells 4 days after drug treatment, normalized to vehicle (100%). (C) Estrogen receptor downregulation using in-cell western assay in MCF-7:WS8 cells. Data were normalized to 1 μM <b>2</b> as 0% and DMSO control as 100%. (D) ERα antagonism using ERE-luciferase reporter assay in MCF-7:WS8 cells. Data was normalized to 1 μM <b>2</b> as 0% and 0.1 nM E<sub>2</sub> as 100%. Data show mean and SEM from at least three cell passages.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. ERα Degradation, Antagonism of E<sub>2</sub> Signaling, ERα Relative Binding Affinity, and Inhibition of Growth of ER+ Cells Cultured in 3D Spheroids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0017.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0018.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Potency for induction of ER degradation measured at 10 concentrations using in-cell westerns (ICW).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Potency of antagonism of ERE-luciferase reporter.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Spheroid growth inhibition after SERD treatment (100 nM) expressed as % relative to DMSO vehicle control (100%). Data show mean and SEM.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Binding affinities calculated by the formula: <i>K</i><sub>i</sub> = (<i>K</i><sub>d</sub>[estradiol]/RBA) × 100, where the <i>K</i><sub>d</sub> for estradiol is 0.2 nM.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Relative binding affinity (RBA) values, determined by radioligand displacement assays expressed as IC<sub>50</sub> estradiol/IC<sub>50</sub> compound × 100 (RBA, estradiol = 100%).</p></div></div><div></div></div><div class="NLM_p">SERDs obtained from the primary and secondary screens were characterized in a further TR ER+ cell line (MCF-7:TAM1) obtained from long-term exposure to tamoxifen;<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(47)</a> therefore, it is a model of tamoxifen resistance. To provide an increased level of cellular complexity, we studied drug effects in 3D spheroidal cell cultures that better mimic the in vivo tumor microenvironment, including cell–cell interactions and a hypoxic core (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> and <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Cell viability in 3D cell cultures was quantified by ATP assay on day 14 after compound treatment (100 nM).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SERDs inhibit growth of MCF-7:TAM1 spheroids at day 10: DMSO (A), <b>2</b> 1 nM (B), <b>28c</b> (1 nM) (C), and <b>28c</b> (10 nM) (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Structure Optimization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the crystal structures of SERDs <b>3</b> and <b>4</b> complexed with ERα (PDB IDs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC">5ACC</a>), the planar phenyl acrylate side chain simultaneously forms a water-mediated hydrogen bond with Leu-536 and Tyr-537 of helix 12 and a hydrogen bond with Asp-351. The consequent conformational change to the AF2 domain is hypothesized to promote proteosomal ER degradation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Acrylate SERDs are currently in clinical trials; however, the potential susceptibility of acrylate to Michael addition and Phase 1 and 2 metabolism caused us to explore phenyl acrylate bioisosteres. BT-SERD <b>14b</b> with a cinnamate side chain showed good potency in inhibiting the growth of both MCF-7:5C and MCF-7:WS8 cells (IC<sub>50</sub> = 1.3 and 0.9 nM, respectively), and in comparison, the fused ring analogues containing naphthalene (<b>16a</b>) and quinoline (<b>16b</b>) bioisosteres showed only modestly compromised potency in MCF-7:5C cells (IC<sub>50</sub> = 4.8 and 32.3 nM, respectively) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, the maximum efficacy of <b>16b</b> in inhibiting cell growth was only 52% compared to the positive control compound <b>2</b> at 1 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">Figure S3</a>). The α-carboxy amide bioisostere (<b>19</b>) conserves the sp<sup>2</sup> centers of the acrylate, but it showed reduced efficacy: it was unable to inhibit growth of MCF-7:5C cells to the same degree as <b>2</b>, although its potency was high (IC<sub>50</sub> = 1.7 nM, <i>E</i><sub>max</sub> = 64%). Neither <b>16b</b> nor <b>19</b> was observed to inhibit growth of the parent MCF-7:WS8 cells. Reduced potency, coupled with reduced efficacy in TR cells or the parent cell line, led us to return to the phenyl acrylate series for further structure optimization.</div><div class="NLM_p">In our previous work on selective human ER partial agonists (ShERPAs),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(27)</a> we explored the ability of ER to accommodate a range of substituents exploiting the plasticity of helix 11. Similarly, in the candidate SERDs developed herein, we inserted a ketone linker between the BT core and the phenyl group at the 2-position and subsequently explored a variety of 2-phenyl substituents to fine tune the molecular topology and to gain potency in our primary and secondary screens. In addition to the normal use of electron-withdrawing substituents to minimize Phase 1 metabolism, as introduced above, we expected that disruption of planarity would attenuate Phase 2 metabolism of the BT-phenol. The activity of these BT-SERDs, derived from measuring responses at >10 concentrations, is summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. The prototype of the series, <b>14a</b> with an undecorated 2-phenyl ring, displayed high but comparatively moderate potency against both MCF-7:5C and MCF-7:WS8 cells (IC<sub>50</sub> = 13 and 2.2 nM, respectively). Adding an o-methyl group (<b>14b</b>) to exploit the hydrophobic pocket formed by Phe-425 and Leu-428 increased the potency against both TR and parent cell lines (IC<sub>50</sub> = 1.3 and 0.9 nM, respectively), and an o-ethyl group was well tolerated (<b>14c</b>) (IC<sub>50</sub> = 1.2 and 0.8 nM in TR and parent cell lines, respectively). Other monosubstitutions of the 2-phenyl group did not improve activity, although it was interesting that replacement of the 2-phenyl group in the 3-methyl thiophene analogue (<b>14f</b>) did not lead to complete loss of activity (IC<sub>50</sub> = 12.5 and 1 nM in TR and parent cell lines, respectively). Exploration of other heterocycles at this position would be a promising approach to modulate the physicochemical and ADMET properties of next generation SERDs. The partial efficacy of some candidate SERDs (<b>14d</b>, <b>14e</b>, <b>16b</b>, and <b>19</b>) and the differential activity in TR versus parent cell lines are features common to ShERPAs<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(27)</a> and other classes of BT-based ER ligands, which will be the focus of future reports.</div><div class="NLM_p">Toward our objective of high potency in primary screens and disrupted planarity, further 2-phenyl substitutions were explored building on identification of compound <b>14b</b> as a potent and efficacious SERD. Introduction of fluorine at the 4′ position (compound <b>14g</b>) slightly enhanced potency in MCF-7:5C and MCF-7:WS8 cells (IC<sub>50</sub> = 1.0 and 0.4 nM in TR and parent cell lines, respectively), whereas fluorine at the 5′ position (<b>14h</b>) reduced potency (IC<sub>50</sub> = 4.7 and 0.7 nM in TR and parent cell lines, respectively). Adding a second methyl group at either the 4′ or 6′ position (<b>24a</b> and <b>28a</b>) improved potency against MCF-7:5C cells almost 3-fold compared to compound <b>14b</b> (IC<sub>50</sub> = 0.4 and 0.5 nM in TR cell lines). A second small hydrophobic pocket formed by Leu-525 and Leu-384 (discernible in crystal structure PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>) can explain the improved potency of <b>28a</b>. 2′-,4′-,6′-Trisubstituted 2-phenyl compounds were highly potent, regardless of whether the 4′ position substituent was Me (<b>24b</b>), F (<b>24c</b>), or Cl (<b>28c</b>). Methyl and ethyl groups at the 2′-position were preferred to exploit the small hydrophobic pocket formed by Phe-425 and Leu-428, and further modification at both the 4′ and 6′ positions with methyl and halogens enhanced potency in growth inhibition of both TR and parent MCF-7 cell lines.</div><div class="NLM_p">In summary, although planar mimics of phenyl acrylate, such as naphthalene and quinolone, were potent and efficacious in inhibiting the growth of TR MCF-7:5C and parent MCF-7:WS8 cells, the phenyl acrylate “warhead” provided superior potency. Incorporation of a substituent at the o-position of the 2-phenyl group, in compound <b>14b</b>, significantly increased the potency of cell growth inhibition compared to the unsubstituted 2-phenyl homologue. Docking analysis showed that this methyl group could insert into a hydrophobic pocket formed by Phe-425 and Leu-428 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). A second methyl group at the 6′-position further enhanced activity, putatively by stabilizing ER conformations in which this group occupies a pocket close to Leu-525. A third methyl or a halogen group at the 4′-position of the 2-phenyl group led to SERDs with an excellent profile of activity in cell cultures. Docking analysis of these 2′,4′,6′-trisubstituted SERDs showed that the 4′ substituent rested in the vicinity of Met-421 in a region of the ligand binding pocket that also contains the His-524 residue that is important in stabilizing the E<sub>2</sub>/ERα complex.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compounds <b>14a</b> (A), <b>14b</b> (B), and <b>28c</b> (C) were docked to ER LBD (pdb ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ak2">5ak2</a>). Compound <b>14a</b> has minimum contacts with hydrophobic pockets (close to Phe-425 and Leu-384), whereas compound <b>14b</b> and <b>28c</b> have methyl groups that tightly fit into the hydrophobic cavity, corresponding to better potency in cell viability assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Validation of SERD Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Six compounds (<b>14b</b>, <b>14g</b>, <b>24a</b>, <b>24c</b>, <b>28a</b>, and <b>28c</b>) with high potency and efficacy in growth inhibition of TR MCF-7:5C and parent MCF-7:WS8 cells were further characterized. Most importantly, to define these compounds as SERDs, the level of ERα expression was measured in a cell-based immunofluorescence assay (ICW) at 24 h in MCF-7:WS8 cells. Exemplar ICW images are shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> for compounds <b>24b</b>, <b>24c</b>, and <b>28c</b>. We normalized the response to 100% (DMSO vehicle) and 0% as the response to excess, saturating concentrations of compound <b>2</b> (1 μM), which was essentially the maximal response to compound <b>2</b>. As a control SERD, compound <b>2</b> was a potent ERα downregulator with an IC<sub>50</sub> value of 0.8 nM, which is consistent with the literature reported number (0.7 nM).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a> All six of our compounds “downregulated” ERα with IC<sub>50</sub> ranging from 0.07 to 1.1 nM. Compound <b>28c</b> was the most potent compound in inhibiting cell growth of MCF-7:5C and MCF-7:WS8 cells and was also the most potent ER downregulator with an IC<sub>50</sub> of 0.07 nM. Potency data for ER downregulation obtained from 10 concentrations of <b>14b</b>, <b>14g</b>, <b>24a</b>, <b>24c</b>, <b>28a</b>, and <b>28c</b> are summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. A direct dose-dependent ER degradation comparison of <b>1</b>, <b>2</b>, <b>28c</b>, and <b>24c</b> is described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">Figure S2</a>.</div><div class="NLM_p">Verification that these compounds were ligands for ERα was obtained by measuring relative binding affinity (RBA) using a standard radioligand displacement assay with full-length ERα. RBA values were calculated as 100× (IC<sub>50</sub> E<sub>2</sub>/IC<sub>50</sub> test compound), with RBA for E<sub>2</sub> = 100%. The RBA data are compatible with nanomolar potency in ER-mediated events, showing that all compounds have ≥10% of the affinity of the potent, endogenous ligand, E<sub>2</sub>, for recombinant ERα. Measured RBA for ERα varied from 9.8% to a maximum of 40.3% for compound <b>28a</b>, with RBA for <b>2</b> measured at 53.4%. A quantitative correlation between RBA and cell-based transcriptional potency is not anticipated<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(27)</a> because ligand binding affinity to ER as part of a functional multiprotein complex at DNA is not expected to be identical to affinity for recombinant ER alone.</div><div class="NLM_p">The final validation of the potent ER ligands discovered in this work was to verify antagonist activity at ER. SERDs have come to be defined as estrogen antagonists with relation to signaling via estrogen response element (ERE), and indeed the archetypical SERD, <b>1</b>, was described in early work as a pure anti-estrogen.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Antagonist activity was measured using an ERE-luciferase reporter assay in the presence of E<sub>2</sub> (0.1 nM). All compounds were observed to be full pharmacological antagonists at ERα with potency ranging from <b>2</b> as the weakest antagonist (IC<sub>50</sub> = 11.1 nM, consistent with literature reports<a onclick="showRef(event, 'ref22 ref49'); return false;" href="javascript:void(0);" class="ref ref22 ref49">(21, 48)</a>) to <b>28c</b> as the most potent antagonist (IC<sub>50</sub> = 2.4 nM). Notably, although <b>14g</b> was slightly less potent in ER downregulation than <b>2</b>, this BT-SERD was twice as potent as <b>2</b> as an ER antagonist.</div><div class="NLM_p">Spheroid models are argued to provide a better prediction of therapeutic efficacy than “in plastico” monolayers that grow on hydrocarbon polymer surfaces by better mimicking the tumor microenvironment, including cell–cell interactions, lack of contact with a plastic surface, secreted extracellular matrix, and a hypoxic core.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(49)</a> Therefore, newly discovered SERDs were tested in 3D spheroid cultures of the parent ER+ breast cancer cell line MCF-7:WS8 and the TR cell line MCF-7:5C. Spheroids were grown for 1 day before initiating treatment with test compound (100 nM) in media. Media (100 μL) was replaced every 3 days until day 14. Measurement of spheroid/cell growth at day 15 by ATP assay showed significant inhibition of spheroid growth by SERDs relative to DMSO vehicle control; for example, <b>2</b>-treated spheroids had cell viability that was 15% of the vehicle control. Compounds <b>14g</b>, <b>24c</b>, and <b>28c</b> demonstrated strong growth inhibition effects, restricting spheroid formation to <5% of control. A second TR cell line, MCF-7:TAM1, was explored in 3D spheroid cultures to study both the effects of novel SERD <b>28c</b> versus <b>2</b> and prospective combination therapy. The ability of both SERDs to disrupt spheroid growth is demonstrated in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> and quantified in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>. To determine the potential of CDK4/6 inhibitor combination therapy in TR and parent ER+ breast cancer, doses of PD-0332991 (palbociclib, PD) were chosen that produced no significant (10 nM) or modest but significant (100 nM) inhibition of spheroid growth (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). In TR MCF-7:TAM1 and parent MCF-7:WS8 spheroid cultures, combination of both <b>28c</b> and <b>2</b> with CDK4/6 inhibitor showed synergistic inhibition of spheroid growth, with concentration dependence on SERD and kinase inhibitor.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Synergistic or additive effects of combination therapy of SERDs and CDK4/6 inhibitor PD-0332991 (PD) in MCF-7:WS8 and TR MCF-7:TAM1 spheroids quantified by ATP assay normalized to vehicle (DMSO) as 1.0. Data show mean and SEM with one-way ANOVA comparison with Tukey’s post-test relative to DMSO control group or comparison of SERD alone (10 nM) with SERD + PD (10 nM): <i>p</i> < * 0.05; <i>p</i> < ** 0.01; <i>p</i> < *** 0.005; <i>p</i> < **** 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">In Vivo Bioavailability and Efficacy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The plasma concentrations of <b>14b</b>, <b>14g</b>, <b>24a</b>, <b>24c</b>, <b>28a</b>, and <b>28c</b> at 0.5 and 4 h (100 mg/kg in a 0.5% CMC suspension p.o.) were measured as a preliminary screen to select a BT-SERD for study in an ectopic xenograft mouse model of endocrine-resistant ER+ breast cancer (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">Table S1</a>). We anticipated that the halide-substituted SERDs would demonstrate superior bioavailability because of attenuated Phase 2 metabolism. SERDs <b>24c</b>, <b>28a</b>, and <b>28c</b> showed the highest plasma levels in this preliminary study and were subjected to a further more detailed study of plasma bioavailability (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). SERDs <b>28a</b> and <b>28c</b> were ultimately selected for animal study in direct comparison to tamoxifen and <b>2</b>. The MCF-7:TAM1 xenograft model was allowed to establish for 5.5 weeks prior to treatment and was randomized to six treatment groups with an average tumor area of 0.325 cm<sup>2</sup>. Tamoxifen (100 mg/kg) was entirely without effect, demonstrating the anticipated resistance of this tumorigenic TR breast cancer cell line to tamoxifen (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). SERD <b>2</b> at a dose of 100 mg/kg, used previously in the literature,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> caused regression of tumor size by 21% at day 23 after treatment. Compound <b>28a</b> (100 mg/kg) also caused tumor regression similar to <b>2</b> (26.7% in tumor area reduction at day 23), whereas <b>28c</b> showed the best efficacy in tumor regression (49% reduction) at a dose of 100 mg/kg. Regression was dose-dependent for <b>28c</b>: at 30 mg/kg, average tumor area was reduced 27%. Injection of tumorigenic cells into mammary fat pads of nude mice produces distinct mammary tumors, allowing assessment of individual tumor response (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C), again demonstrating the efficacy of SERD <b>28c</b>. No weight loss was observed during the course of the animal study.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Plasma concentration of <b>24c</b>, <b>28a</b>, and <b>28c</b> after oral administration in PEG400/PVP/TW80/CMC in water, 9:0.5:0.5:90. The data was the average plasma concentration of three mice at 0.25, 0.5, 1, 2, 4, 8, and 12 h. (B, C) MCF7:TAM1 tumors were grown to an average section area of 0.32 cm<sup>2</sup> (as described in the <a class="ref internalNav" href="#sec10" aria-label="Experimental Section">Experimental Section</a>). Mice were then randomized into six treatment groups: control, tamoxifen, <b>2</b>, <b>28a</b>, and two doses of <b>28c</b>. Compounds were administrated by oral gavage daily: (B) mean tumor growth over 9 weeks showing mean and SEM; (C) individual tumor area change in percentage at day 23.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The SERM tamoxifen and third generation AIs, such as anastrozole, represent standard-of-care, first-line therapy for treatment of ER+ breast cancer. Although, tamoxifen therapy is associated with higher risk of uterine sarcoma, this is outweighed by the proven benefits of 5–10 years of tamoxifen pharmacotherapy.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> However, both tamoxifen and AI therapy are marked by high levels of resistance in which the cancer remains ER+ but does not require estrogen for growth and is insensitive to antagonism by tamoxifen and depletion of estrogen by AIs.<a onclick="showRef(event, 'ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54">(51-53)</a> A clinically effective oral SERD that is able to block and ablate ER is theoretically a preferred therapeutic approach. Clinical trials revealing the efficacy of <b>1</b> (500 mg) as a SERD for first-line therapy in breast cancer are recent:<a onclick="showRef(event, 'ref9 ref10 ref55 ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref55 ref56 ref57 ref58">(9, 10, 54-57)</a> for example, the FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) Phase 2 clinical trial showed that <b>1</b> (500 mg monthly injection) improved time to progression and overall survival versus anastrozole.<a onclick="showRef(event, 'ref9 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref9 ref55 ref56">(9, 54, 55)</a></div><div class="NLM_p">Cyclin D1 is highly expressed in ER+ breast cancer and, through inhibitors of CDK4 and CDK6, provides an effective target for breast cancer therapy.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> The clinical emergence of CDK4/6 inhibitors, beginning with palbociclib,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(59)</a> and the potential for rapid, early resistance to these inhibitors,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(60)</a> has provided impetus for combination therapy. The PALOMA3 (palbociclib combined with fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure) trial showed that combination therapy with a SERD and CDK4/6 inhibitor gave clinical benefit for heavily endocrine pretreated, advanced breast cancer patients.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Nevertheless, the optimum clinical benefit of <b>1</b> was limited by its poor physicochemical and PK properties. Compounds <b>2</b> and <b>3</b> are both triphenylethylene-based next generation SERDs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In <b>2</b>, the phenolic group of (2<i>E</i>)-3-[4-[(1<i>E</i>)-1-(4-hydroxyphenyl)-2-phenyl-1-buten-1-yl]phenyl]-2-propenoic acid (GW 7604) was replaced with an indazole bioisostere that greatly boosted bioavailability.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a> The discovery of a further next generation SERD, <b>4</b>, resulted from a high-throughput screening campaign: <b>4</b> contains a 1-aryl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indole scaffold, apparently devoid of any hydrogen-bonding interactions with either Glu-353 or Arg-394 and with a good PK profile.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(24)</a> Both <b>2</b> and <b>4</b> were reported to have physicochemical properties superior to <b>1</b> and are actively being studied in clinical trials.<a onclick="showRef(event, 'ref22 ref25 ref26 ref62'); return false;" href="javascript:void(0);" class="ref ref22 ref25 ref26 ref62">(21, 24, 25, 61)</a></div><div class="NLM_p">Previously we have reported design and synthesis of novel ER ligands based on the BT core, common to <b>5</b> and <b>6</b>, which manifest biological activity as SERMs, ER agonists (SEMs), and ShERPAs.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(27)</a> The BT scaffold has the advantage of broad knowledge of the metabolic and PK properties derived from <b>5</b> and <b>6</b>,<a onclick="showRef(event, 'ref28 ref29 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref33 ref34 ref35 ref36 ref37 ref38">(27, 28, 32-37)</a> and it provides highly potent modulation of ER-mediated biological activity. Herein, we have extended the utility of this scaffold to the design and synthesis of novel ER ligands by substituting an acrylate side chain at the BT 3-position and diversifying substituents at the 2-position, yielding potent, orally bioavailable SERDs.</div><div class="NLM_p">Of the novel SERDs developed in this research, five (<b>14g</b>, <b>24a</b>, <b>24c</b>, <b>28a</b>, and <b>28c</b>) showed subnanomolar potency in cell cultures toward downregulation/degradation of ERα and inhibition of growth of both TR and parent endocrine-dependent breast cancer cell lines. These SERDs were marginally more potent than <b>2</b> in these assays, and all were more efficacious than <b>2</b> in inhibiting growth of 3D spheroids; additionally, the two BT-SERDs tested in xenograft studies in comparison with <b>2</b> were equal or superior to <b>2</b>. The potency toward antagonism of E<sub>2</sub> at ERα/ERE was roughly an order of magnitude less than for ER degradation for all SERDs, compatible with growth inhibition in cell cultures being mediated by induction of ER degradation.</div><div class="NLM_p last">Multiple mechanisms of resistance to endocrine treatment (tamoxifen/AI) have been proposed in ER+ breast cancer.<a onclick="showRef(event, 'ref52 ref53 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71">(51, 52, 62-70)</a> In ER+ resistant (TR) cells, growth does not require E<sub>2</sub> and is insensitive to tamoxifen. It is argued that SERD binding to ERα induces a conformational change that opens a hydrophobic surface, which leads to accelerated ER degradation through the 26S proteosomal pathway.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(25)</a> Therefore, for a SERD to be effective in TR ER+ cell cultures and xenografts, ligand binding to ERα and an appropriate conformational change are required. It was seen as essential to develop SERDs capable of binding to ERα in TR breast cancer cell lines in which resistance was acquired to extended tamoxifen treatment (MCF-7:TAM1) and to extended E<sub>2</sub> deprivation (MCF-7:5C). Both cell lines responded to our novel BT-SERDs and to <b>2</b>, and the novel SERDs retained activity in the parent MCF-7:WS8 cell line.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, novel, orally bioavailable SERDs were discovered that possess potent dual activity as degraders and antagonists of ERα. These SERDs inhibited growth of endocrine-independent breast cancer cells with IC<sub>50</sub> values ranging from 0.3 to 12.5 nM. Six compounds were measured for oral drug exposure, and two novel SERDs were further validated in a TR xenograft model, demonstrating dose-dependent tumor regression. The potential of combination therapy with SERD <b>28c</b> and a CDK4/6 inhibitor was shown in the effects of palbociclib/<b>28c</b> coadministration at inhibiting the growth of ER+ TR 3D spheroid cell cultures. The comparison with <b>2</b> in all in vitro and in vivo assays of potency and efficacy demonstrated the equivalence or superiority of the novel BT-SERDs reported for the first time herein.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cell Lines and Culture Conditions</h3><div class="NLM_p last">MCF-7:WS8, MCF-7:5C, and MCF-7:TAM-1 cells were gifts from Dr. Tonetti’s lab at UIC. MCF-7:WS8 is hormone-dependent human breast cancer cell clone maintained in phenol red-containing RPMI-1640 medium supplemented with 10% FBS at 37 °C under 5% CO<sub>2</sub> that has been previously described.<a onclick="showRef(event, 'ref47 ref72'); return false;" href="javascript:void(0);" class="ref ref47 ref72">(46, 71)</a> MCF-7:5C cells were maintained in phenol red-free RPMI-1640 medium supplemented with 10% charcoal-dextran treated fetal bovine serum at 37 °C under 5% CO<sub>2</sub> as previously described.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(72, 73)</a> The MCF-7:5C cells served as AI-resistant cells and were generated from MCF-7:WS8 cells by long-term estrogen deprivation.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Cell Growth Assay</h3><div class="NLM_p last">Cells were grown in phenol red-free media for 2 days prior to each experiment. On the day of the experiment, cells were seeded in a 96-well plate at a density of 5000 cells/well and treated with either 0.1% (v/v) DMSO, 1 nM E<sub>2</sub>, or compounds prepared in phenol red-free media. All compounds were dissolved in DMSO and added to the medium at a final 1:1000 dilution. DNA content was determined on day 5 (WS8) or day 6 (5C) by Hoechst 33258 dye.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(74, 75)</a> Fluorescence signals were read by a Synergy H4 microplate reader (BioTek).</div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In-Cell Western Analysis</h3><div class="NLM_p last">MCF-7:WS8 cells were kept in stripped medium for 2 days, and 2.0 × 10<sup>4</sup> cells/well were plated in clear bottom 96-well black plates for 48 h prior to addition of compounds for 24 h. Fixation, detection of ESR1 (sc-8002), and analysis were performed per the manufacturer’s protocol using the In-Cell Western Assay Kits and LI-COR Odyssey infrared imaging system. Data was normalized to CellTag 700 stain.</div></div><div id="sec10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 3D Spheroid Growth Assay</h3><div class="NLM_p last">Spheroids were plated at 1000 cells/well in Corning 96-well black, clear round-bottom, ultralow attachment spheroid microplates and grown in the absence of treatment for 24 h. Spheroids were then treated with 2× treatment media following the removal of 100 μL of media from each well. Treatment was repeated every 2–3 days for 14 days. The CellTiter-Glo 3D Cell Viability Assay protocol was used to determine growth inhibition of the spheroids. On day 15, spheroid plates and reagent (CellTiter-Glo 3D reagent) were allowed to come to room temperature for 30 min. During this time, the spheroids were washed with PBS by removing 100 μL of media and replacing with PBS. From each well, 100 μL is then removed and replaced with 100 μL of the reagent, and spheroids were disrupted by pipetting. The plates were placed on a shaker for 5 min before equilibrating in dark for 25 min. From each well, 125 μL is then transferred to a white 96-well plate before recording luminescence using an empty well for the background reading.</div></div><div id="sec10_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Binding Affinity Studies</h3><div class="NLM_p last">Binding affinities were also determined by a competitive radiometric binding assay using 2 nM [<sup>3</sup>H]estradiol as tracer (PerkinElmer, Waltham, MA) and full-length purified human ERα (Pan Vera/Invitrogen, Carlsbad, CA), as reported previously.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(76, 77)</a> The RBA values were calculated using the following equation: IC<sub>50</sub> estradiol/IC<sub>50</sub> compound × 100.</div></div><div id="sec10_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Estrogen Response Elements (ERE) Luciferase Assay in MCF-7 Cells</h3><div class="NLM_p last">MCF-7:WS8 cells were kept in stripped medium for 3 days prior to treatment. Cells were plated at a density of 2 × 10<sup>4</sup> cells/well in 96-well plates and were cotransfected with 5 μg of pERE-luciferase plasmid per plate, which contains three copies of the <i>Xenopus laevis</i> vitellogenin A2 ERE upstream of firefly luciferase, and 0.5 μg of pRL-TK plasmid (Promega, Madison, WI) containing a cDNA encoding Renilla luciferase. Transfection was performed for 6 h using the Lipofectamine 2000 transfection reagent (Invitrogen) in Opti-MEM medium according to the manufacturer’s instructions. Cells were treated with test compounds after 6 h, and the luciferase activity was measured after 18 h of treatment using the dual luciferase assay system (Promega) with a Synergy H4 microplate reader (Bio Tek).</div></div><div id="sec10_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Animal Experiments</h3><div class="NLM_p last">The Animal Care and Use Committee of the University of Illinois at Chicago approved all of the procedures involving animals. MCF-7:Tam1 tumors were established in 4–6 week old ovariectomized athymic nude mice (Harlan Laboratories), and E<sub>2</sub> was administered via silastic capsules (1.0 cm) implanted subcutaneously between the scapulae as previously described.<a onclick="showRef(event, 'ref48 ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref48 ref79 ref80">(47, 78, 79)</a> SERD1 and SERD2 were administered per os at a dose of 100 or 30 mg/kg daily for 3.5 weeks in a formulation of 0.5% CMC/PEG-400/Tween-80/PVP (90:9:05:0.5). Tumor cross-sectional area was determined weekly using Vernier calipers and calculated using the formula (length/2) × (width/2) × π. Mean tumor area was plotted against time (in weeks) to monitor tumor growth.</div></div><div id="sec10_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General</h3><div class="NLM_p last">3-Chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbonyl chloride was purchased from Frontier Scientific Services, Inc. All chemicals and solvents were purchased from Sigma-Aldrich, Fisher Scientific, Matrix Scientific,or Oakwood Chemical and were used without further purification. <b>2</b> was synthesized using the protocols reported by Lai and colleagues.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a> Synthetic intermediates were purified using Biotage flash chromatography system on 230–400 mesh silica gel. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained using Bruker DPX-400 or Avance-400 spectrometer at 400 and 100 MHz, respectively. NMR chemical shifts are described in δ (ppm) using residual solvent peaks as standard (CDCl<sub>3</sub>, 7.26 ppm (<sup>1</sup>H), 77.16 ppm (<sup>13</sup>C); CD<sub>3</sub>OD, 3.31 ppm (<sup>1</sup>H), 49.00 ppm (<sup>13</sup>C); DMSO-<i>d</i><sub>6</sub>, 2.50 ppm (<sup>1</sup>H), 39.52 ppm (<sup>13</sup>C); acetone-<i>d</i><sub>6</sub>, 2.05 ppm (<sup>1</sup>H), 29.84 ppm (<sup>13</sup>C)). Data are reported in the following format: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, br = broad, m = multiplet, abq = ab quartet), number of protons, and coupling constants. High-resolution mass spectral data were measured in-house using a Shimadzu IT-TOF LC/MS for all final compounds. All compounds submitted for biological testing were confirmed to be ≥95% pure by analytical HPLC. Synthetic methods, spectral data, and HRMS for novel compounds are described in detail below.</div></div><div id="sec10_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Method for Preparing Grignard Reagent</h3><div class="NLM_p">To an oven-dried round-bottomed flask were added aryl bromide (1 equiv) in anhydrous tetrahydrofuran and magnesium turnings (1.1 equiv) under an argon atmosphere. One granule of iodine was added to initiate the reaction. The solution turned pale white and then brownish color along with strong heat release. The Grignard reagent was ready for use without further purification when the magnesium was consumed.</div><div id="sec10_9_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-Chloro-<i>N</i>,6-dimethoxy-<i>N</i>-methylbenzo[<i>b</i>]thiophene-2-carboxamide (<b>9</b>)</h4><div class="NLM_p last">In an oven-dried round-bottom flask was dissolved 3-chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbonyl chloride (8.9 g, 34.9 mmol) in 50 mL of anhydrous dichloromethane under an argon atmosphere. <i>N</i>,<i>O</i>-Dimethylhydroxylamine hydrochloride (3.75g, 38.4 mmol) was added in one portion. After stirring for 10 min, Et<sub>3</sub>N (17.6 g, 174.5 mmol) was added dropwise. The reaction mixture was stirred overnight until TLC showed the consumption of all starting materials; it was then quenched by ice water. The solution was extracted with ethyl acetate and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (5–50% ethyl acetate in hexane) to give 7.6 g of a white solid (yield, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82 (d, <i>J</i> = 8.9 Hz, 1H), 7.23 (s, 1H), 7.10 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 3.90 (s, 3H), 3.73 (s, 3H), 3.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 162.03, 159.89, 140.36, 130.19, 125.06, 124.16, 123.24, 116.11, 104.29, 62.05, 55.88, 33.75.</div></div><div id="sec10_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>10a</b>)</h4><div class="NLM_p last">To a solution of intermediate (<b>8</b>) (500 mg, 1.75 mmol) in anhydrous tetrahydrofuran under an argon atmosphere was added a 3 M solution of phenylmagnesium bromide (0.65 mL, 1.93, 1.1 equiv) dropwise. The reaction mixture was stirred overnight and quenched by 1 N HCl/ice water. The solution was extracted with ethyl acetate and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (1–15% ethyl acetate in hexane) to give 481 mg of a white solid (yield, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92–7.78 (m, 3H), 7.61 (t, <i>J</i> = 7.4 Hz, 1H), 7.49 (t, <i>J</i> = 7.6 Hz, 2H), 7.26 (d, <i>J</i> = 2.3 Hz, 1H), 7.12 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 3.92 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 188.94, 160.37, 140.96, 138.08, 132.88, 131.76, 131.05, 129.56, 128.34, 124.86, 124.77, 116.59, 104.31, 55.76.</div></div><div id="sec10_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (3-(4-Bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>11a</b>)</h4><div class="NLM_p last">Cesium carbonate (651.6 mg, 2.9 mmol, 2 equiv) was added in one portion to a solution of <b>10a</b> (440 mg, 1.45 mmol, 1 equiv) and 4-bromophenol (1.6 mmol, 1.1 equiv) in 5 mL of DMF. The reaction mixture was increased to 65 °C and stirred overnight. The reaction mixture was quenched by ice water, extracted with ethyl acetate, and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (1–25% ethyl acetate in hexane) to give 491 mg of a white solid (yield, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72–7.65 (m, 2H), 7.52–7.44 (m, 2H), 7.34 (t, <i>J</i> = 7.7 Hz, 2H), 7.28 (d, <i>J</i> = 2.1 Hz, 1H), 7.21–7.15 (m, 2H), 6.97 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.49–6.43 (m, 2H), 3.92 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 188.95, 160.72, 157.40, 147.59, 141.76, 138.49, 132.47, 132.40, 129.02, 128.09, 126.72, 125.92, 124.44, 117.33, 116.40, 115.07, 105.10, 55.88.</div></div><div id="sec10_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (3-(4-Bromophenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>12a</b>)</h4><div class="NLM_p last"><b>11a</b> (450 mg, 1.02 mmol) was dissolved in 10 mL of anhydrous dichloromethane at room temperature under an argon atomosphere. BF<sub>3</sub>·SMe<sub>2</sub> (2.5 mL, 10.4 mmol) was added dropwise to this solution in an ice/water bath. The reaction mixture was stirred until the starting material was consumed, as monitored by TLC, and then quenched by saturated NaHCO<sub>3</sub>/ice water. The reaction mixture was extracted with ethyl acetate and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (5–60% ethyl acetate in hexane) to give 410 mg of a white powder (yield, 94%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.62 (d, <i>J</i> = 7.2 Hz, 2H), 7.51 (t, <i>J</i> = 7.5 Hz, 1H), 7.44–7.32 (m, 3H), 7.25–7.21 (m, 3H), 6.91 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.49 (d, <i>J</i> = 9.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 190.76, 160.50, 158.77, 149.54, 143.24, 139.95, 133.47, 133.38, 129.69, 129.14, 126.80, 125.81, 125.53, 118.42, 117.39, 115.88, 108.74.</div></div><div id="sec10_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Methyl (<i>E</i>)-3-(4-((2-Benzoyl-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>13a</b>)</h4><div class="NLM_p last">To a sealed tube were suspended <b>12a</b> (400 mg, 0.94 mmol), methyl acrylate (400 mg, 4.65 mmol), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15% mol) in DMF (3 mL) and triethylamine (470 mg, 4.64 mmol). The reaction was heated at 110 °C for 6 h. The reaction mixture was quenched by water and extracted with ethyl acetate. The organic layers was collected and purified by flash chromatography (5–60% ethyl acetate in hexane) to give 251 mg of a white powder (yield, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 7.65 (d, <i>J</i> = 7.9 Hz, 2H), 7.56–7.52 (m, 4H), 7.39–7.34 (m, 4H), 6.93 (d, <i>J</i> = 8.8 Hz, 1H), 6.66 (d, <i>J</i> = 8.5 Hz, 2H), 6.47 (d, <i>J</i> = 16.1 Hz, 1H), 3.69 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 187.95, 166.69, 159.08, 158.90, 147.19, 143.62, 141.00, 138.11, 132.27, 130.10, 128.67, 128.32, 128.03, 124.63, 124.32, 124.29, 116.55, 116.51, 115.66, 108.03, 51.37.</div></div><div id="sec10_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>E</i>)-3-(4-((2-Benzoyl-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>14a</b>)</h4><div class="NLM_p last">To a solution of intermediate <b>13a</b> (105 mg, 0.16 mmol) in methanol (4 mL) was added a 10% LiOH solution (4 mL) dropwise. The reaction was monitored by TLC and quenched by 1 N HCl/ice water. After stirring for 10 min, the mixture was extracted with ethyl acetate. The organic layers were collected and purified by C18 chromatography (5–60% ethyl methanol in water) to give 77 mg of a white powder (yield, 77%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.66–7.58 (m, 2H), 7.55 (d, <i>J</i> = 16.0 Hz, 1H), 7.50 (d, <i>J</i> = 7.4 Hz, 1H), 7.43–7.34 (m, 5H), 7.28 (d, <i>J</i> = 2.0 Hz, 1H), 6.92 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.61 (d, <i>J</i> = 8.8 Hz, 2H), 6.32 (d, <i>J</i> = 16.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 190.76, 170.39, 161.08, 160.51, 149.38, 145.33, 143.23, 139.90, 133.38, 130.77, 130.47, 129.70, 129.13, 126.82, 125.95, 125.55, 118.13, 117.38, 116.96, 108.75. ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd. for C<sub>24</sub>H<sub>17</sub>O<sub>5</sub>S, 417.0797; observed, 417.0787.</div></div><div id="sec10_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Methyl 6-((6-Methoxy-2-(2-methylbenzoyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-naphthoate (<b>15a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>10a</b> (159 mg, yield 33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.48 (s, 1H), 7.96 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.64 (d, <i>J</i> = 9.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.7 Hz, 1H), 7.47 (d, <i>J</i> = 8.9 Hz, 1H), 7.32–7.27 (m, 2H), 7.16 (t, <i>J</i> = 7.5 Hz, 1H), 6.98 (t, <i>J</i> = 7.5 Hz, 1H), 6.95–6.86 (m, 2H), 6.77 (d, <i>J</i> = 2.2 Hz, 1H), 6.73 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 3.93 (s, 3H), 3.86 (s, 3H), 1.99 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.43, 167.05, 160.88, 158.00, 148.20, 142.08, 139.06, 136.21, 135.72, 131.02, 130.70, 130.36, 130.05, 128.52, 127.67, 127.47, 127.05, 126.85, 126.09, 126.02, 125.04, 124.43, 117.70, 116.38, 109.49, 105.09, 55.69, 52.11, 19.06.</div></div><div id="sec10_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-((6-Hydroxy-2-(2-methylbenzoyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-naphthoic Acid (<b>16a)</b></h4><div class="NLM_p last"><b>14a</b> (100 mg, 0.21 mmol) was dissolved in 3 mL of anhydrous dichloromethane at room temperature under an argon atomosphere. BF<sub>3</sub>·SMe<sub>2</sub> (1 mL, 4.2 mmol) was added dropwise to this solution in an ice water bath. After stirring for 30 min, the solution was heated to 35 °C. The reaction mixture was stirred until the starting material was consumed, as monitored by TLC, and then quenched by saturated NaHCO<sub>3</sub>/ice water. The reaction mixture was extracted with ethyl acetate and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (5–60% ethyl acetate in hexane) to give 37 mg of a white powder (yield, 38%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.47 (s, 1H), 7.93 (d, <i>J</i> = 8.4 Hz, 1H), 7.72 (d, <i>J</i> = 8.9 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 1H), 7.40 (d, <i>J</i> = 8.8 Hz, 1H), 7.30 (d, <i>J</i> = 1.9 Hz, 1H), 7.28–7.08 (m, 2H), 7.01 (t, <i>J</i> = 7.4 Hz, 1H), 6.94 (d, <i>J</i> = 7.6 Hz, 1H), 6.88 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.79 (s, 1H), 6.74 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 1.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 192.50, 169.84, 160.87, 159.24, 150.50, 143.78, 140.65, 137.54, 136.54, 132.21, 131.70, 131.42, 131.18, 130.09, 128.34, 128.08, 127.69, 127.38, 127.05, 126.27, 125.78, 118.69, 117.51, 110.58, 108.92, 19.19. ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd. for C<sub>27</sub>H<sub>18</sub>O<sub>5</sub>S, 455.0953; observed, 455.0939.</div></div><div id="sec10_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (3-(4-Aminophenoxy)-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2-methylphenyl)methanone (<b>17</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure similar to the preparation of <b>10a</b> (309 mg, yield 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 9.0 Hz, 1H), 7.36–7.29 (m, 1H), 7.25 (d, <i>J</i> = 2.1 Hz, 1H), 6.90 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.82–6.74 (m, 2H), 6.45–6.38 (m, 2H), 6.34–6.27 (m, 2H), 3.89 (s, 3H), 2.19 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 189.86, 163.56 (d, <i>J</i><sub>C–F</sub> = 249.4 Hz), 160.78, 151.44, 150.01, 142.22, 141.68, 139.52 (d, <i>J</i><sub>C–F</sub> = 8.5 Hz), 135.61 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 130.22 (d, <i>J</i><sub>C–F</sub> = 9.2 Hz), 127.25, 126.91, 125.07, 117.30 (d, <i>J</i><sub>C–F</sub> = 21.4 Hz), 116.09, 116.03, 115.93, 112.03 (d, <i>J</i><sub>C–F</sub> = 21.6 Hz), 105.05, 55.81, 19.56 (d, <i>J</i><sub>C–F</sub> = 1.2 Hz).</div></div><div id="sec10_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (3-(4-Aminophenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2-methylphenyl)methanone (<b>18</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>11a</b> (86 mg, yield 30%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.34–7.25 (m, 2H), 6.86–6.80 (m, 1H), 6.85–6.76 (m, 3H), 6.49 (d, <i>J</i> = 8.7 Hz, 2H), 6.26 (d, <i>J</i> = 8.8 Hz, 2H), 2.13 (s, 3H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 191.63, 164.75 (d, <i>J</i><sub>C–F</sub> = 248.2 Hz), 160.50, 152.55, 152.31, 143.72, 140.33 (d, <i>J</i><sub>C–F</sub> = 8.6 Hz), 137.11 (d, <i>J</i><sub>C–F</sub> = 3.1 Hz), 131.07 (d, <i>J</i><sub>C–F</sub> = 9.2 Hz), 127.24, 126.60, 126.23, 118.00 (d, <i>J</i><sub>C–F</sub> = 21.8 Hz), 117.43, 116.99, 116.82, 112.91 (d, <i>J</i><sub>C–F</sub> = 21.9 Hz), 108.76, 19.49.</div></div><div id="sec10_9_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-((4-((2-(4-Fluoro-2-methylbenzoyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)amino)-2-oxoacetic Acid (<b>19</b>)</h4><div class="NLM_p last">To an oven-dried flask charged with <b>17</b> (76 mg, 0.19 mmol) was added methyl 2-chloro-2-oxoacetate (28 mg, 0.23 mmol) with 3 mL of anhydrous tetrahydrofuran at room temperature under an argon atmosphere. Triethylamine (58.6 mg, 0.58 mmol) was added dropwise to this solution in an ice/water bath. The reaction mixture was stirred until the starting material was consumed, as monitored by TLC, and then quenched by saturated NaHCO<sub>3</sub>/ice water. The reaction mixture was extracted with ethyl acetate and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was dissolved in methanol (2 mL). A 10% LiOH solution (2 mL) was added dropwise. The reaction was monitored by TLC and quenched by 1 N HCl/ice water. After stirring for 10 min, the mixture was extracted with ethyl acetate. The organic layers were collected and purified by C18 chromatography (5–80% ethyl methanol in water) to give 47 mg of a white powder (yield, 52%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.46 (d, <i>J</i> = 8.3 Hz, 2H), 7.38–7.27 (m, 2H), 7.24 (s, 1H), 6.90–6.77 (m, 3H), 6.46 (d, <i>J</i> = 8.2 Hz, 2H), 2.11 (s, 3H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 191.26, 164.87 (d, <i>J</i><sub>C–F</sub> = 248.6 Hz), 162.90, 160.76, 157.91, 156.78, 150.82, 143.70, 140.40 (d, <i>J</i><sub>C–F</sub> = 8.6 Hz), 136.89 (d, <i>J</i><sub>C–F</sub> = 2.9 Hz), 133.35, 131.10 (d, <i>J</i><sub>C–F</sub> = 9.1 Hz), 127.30, 127.03, 125.84, 123.09, 118.11 (d, <i>J</i><sub>C–F</sub> = 21.7 Hz), 117.38, 116.16, 113.05 (d, <i>J</i><sub>C–F</sub> = 21.9 Hz), 108.85, 19.46. ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd. for C<sub>24</sub>H<sub>15</sub>FNO<sub>6</sub>S, 464.0604; observed, 464.0587.</div></div><div id="sec10_9_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(2,6-dimethylphenyl)methanone (<b>20a</b>)</h4><div class="NLM_p last">To a solution of 3-chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbonyl chloride (<b>7</b>) (522 mg, 2 mmol) in anhydrous tetrahydrofuran under an argon atmosphere was added 0.5 M solution of (2,6-dimethylphenyl)magnesium bromide (2.2 mmol, 1.1 equiv) dropwise. The reaction mixture was stirred overnight and quenched by 1 N HCl/ice water. The solution was extracted with ethyl acetate and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (1–15% ethyl acetate in hexane) to give 386 mg of a white solid (yield, 58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79 (d, <i>J</i> = 9.0 Hz, 1H), 7.26–7.18 (m, 2H), 7.12–7.02 (m, 3H), 3.90 (s, 3H), 2.22 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 192.58, 161.14, 142.18, 140.22, 134.18, 131.75, 129.31, 128.69, 127.84, 126.81, 125.55, 116.91, 104.53, 55.91, 19.31.</div></div><div id="sec10_9_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (3-(4-Bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(2,6-dimethylphenyl)methanone (<b>21a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>11a</b> (480 mg, yield 94%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (d, <i>J</i> = 8.9 Hz, 1H), 7.28 (d, <i>J</i> = 2.1 Hz, 1H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 7.04 (t, <i>J</i> = 7.6 Hz, 1H), 6.92 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.86 (d, <i>J</i> = 7.7 Hz, 2H), 6.34 (d, <i>J</i> = 8.9 Hz, 2H), 3.88 (s, 3H), 2.11 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 192.08, 160.94, 156.72, 148.28, 142.22, 140.16, 133.71, 131.95, 128.73, 128.49, 127.35, 126.59, 124.67, 116.52, 116.40, 114.74, 105.22, 55.75, 19.18.</div></div><div id="sec10_9_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (3-(4-Bromophenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(2,6-dimethylphenyl)methanone (<b>22a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>12a</b> (429 mg, yield 86%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.29 (s, 1H), 7.43 (d, <i>J</i> = 2.1 Hz, 1H), 7.35 (d, <i>J</i> = 8.8 Hz, 1H), 7.29 (d, <i>J</i> = 9.0 Hz, 2H), 7.06 (t, <i>J</i> = 7.6 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.90 (d, <i>J</i> = 7.5 Hz, 2H), 6.46 (d, <i>J</i> = 8.9 Hz, 2H), 2.08 (s, 6H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 191.96, 159.98, 157.87, 149.06, 142.90, 141.45, 134.37, 132.90, 129.46, 128.64, 128.13, 126.65, 125.75, 117.72, 117.26, 115.12, 109.12, 19.29.</div></div><div id="sec10_9_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Methyl (<i>E</i>)-3-(4-((2-(2,6-Dimethylbenzoyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>23a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>13a</b> (240 mg, yield 86%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.57 (d, <i>J</i> = 16.0 Hz, 1H), 7.35 (d, <i>J</i> = 8.7 Hz, 2H), 7.30–7.24 (m, 2H), 7.03 (t, <i>J</i> = 7.6 Hz, 1H), 6.88–6.80 (m, 3H), 6.45 (d, <i>J</i> = 8.7 Hz, 2H), 6.36 (d, <i>J</i> = 16.0 Hz, 1H), 3.75 (s, 3H), 2.06 (s, 6H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 194.05, 169.17, 160.99, 160.62, 150.45, 145.33, 143.89, 141.52, 134.80, 130.57, 130.30, 129.92, 128.47, 126.75, 125.99, 117.57, 117.27, 116.42, 109.04, 52.10, 19.34.</div></div><div id="sec10_9_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>E</i>)-3-(4-((2-(2,6-Dimethylbenzoyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>24a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>14a</b> (81 mg, yield 84%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.55 (d, <i>J</i> = 16.0 Hz, 1H), 7.32 (d, <i>J</i> = 8.7 Hz, 2H), 7.27–7.19 (m, 2H), 7.01 (t, <i>J</i> = 7.6 Hz, 1H), 6.87–6.77 (m, 3H), 6.43 (d, <i>J</i> = 8.6 Hz, 2H), 6.31 (d, <i>J</i> = 16.0 Hz, 1H), 2.04 (s, 6H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 194.06, 170.40, 160.93, 160.50, 150.47, 145.38, 143.86, 141.47, 134.76, 130.48, 130.35, 129.90, 128.44, 126.74, 125.99, 117.97, 117.55, 116.38, 109.04, 19.35. ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd. for C<sub>26</sub>H<sub>21</sub>O<sub>5</sub>S, 445.1110; observed, 445.1098.</div></div><div id="sec10_9_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(2,4-dimethylphenyl)methanone (<b>25a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>10a</b> (300 mg, yield 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (d, <i>J</i> = 9.0 Hz, 1H), 7.35 (d, <i>J</i> = 7.7 Hz, 1H), 7.23 (d, <i>J</i> = 2.2 Hz, 1H), 7.12–7.04 (m, 3H), 3.90 (s, 3H), 2.39 (s, 3H), 2.38 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.85, 160.72, 141.57, 141.27, 136.74, 136.38, 134.01, 131.94, 131.52, 128.73, 126.33, 125.82, 125.16, 116.72, 104.45, 55.87, 21.60, 19.81.</div></div><div id="sec10_9_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (4-Chloro-2,6-dimethylphenyl)(3-chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>25c</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>10a</b> (2.9 g, yield 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (d, <i>J</i> = 9.0 Hz, 1H), 7.25 (d, <i>J</i> = 2.2 Hz, 1H), 7.12–7.06 (m, 3H), 3.92 (s, 3H), 2.20 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.57, 161.34, 142.36, 138.73, 136.32, 134.85, 134.11, 131.70, 127.88, 127.13, 125.67, 117.09, 104.56, 55.96, 19.23.</div></div><div id="sec10_9_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Methyl (<i>E</i>)-3-(4-((2-(2,4-Dimethylbenzoyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>26a</b>)</h4><div class="NLM_p last">To an oven-dried round-bottom flask was added cesium carbonate (6.3 g, 19.2 mmol) in one portion to a solution of <b>25a</b> (3.2 g, 9.6 mmol) and methyl (<i>E</i>)-3-(4-hydroxyphenyl)acrylate (2.6 g, 14.4 mmol) in 12 mL of DMF. The reaction mixture was increased to 90 °C and stirred overnight. The reaction mixture was quenched by ice/water, extracted with ethyl acetate, and washed with brine. The organic extracts were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and then purified by flash chromatography (5–35% ethyl acetate in hexane) to give 3.5 g of a white solid (yield, 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57 (d, <i>J</i> = 16.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.9 Hz, 1H), 7.28 (d, <i>J</i> = 2.1 Hz, 1H), 7.23 (t, <i>J</i> = 8.9 Hz, 3H), 6.96 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.85 (d, <i>J</i> = 11.2 Hz, 2H), 6.47 (d, <i>J</i> = 8.8 Hz, 2H), 6.27 (d, <i>J</i> = 16.0 Hz, 1H), 3.91 (s, 3H), 3.79 (s, 3H), 2.29 (s, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.48, 167.65, 160.87, 160.01, 147.81, 144.09, 141.92, 140.64, 136.30, 136.22, 131.40, 129.33, 128.91, 128.29, 127.79, 127.05, 125.79, 124.43, 116.48, 116.43, 115.58, 105.11, 55.87, 51.79, 21.47, 19.38.</div></div><div id="sec10_9_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Methyl (<i>E</i>)-3-(4-((2-(4-Chloro-2,6-dimethylbenzoyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>26c</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>10a</b> (11.1 g, yield 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.59 (d, <i>J</i> = 16.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.9 Hz, 1H), 7.31–7.26 (m, <i>J</i> = 8.8 Hz, 3H), 6.94 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 6.79 (s, 2H), 6.45 (d, <i>J</i> = 8.7 Hz, 2H), 6.30 (d, <i>J</i> = 16.0 Hz, 1H), 3.91 (s, 3H), 3.79 (s, 3H), 2.05 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.15, 167.64, 161.29, 159.25, 148.51, 143.98, 142.52, 138.57, 136.01, 134.39, 130.08, 129.27, 129.19, 127.35, 126.80, 124.85, 116.77, 116.76, 115.09, 105.30, 55.94, 51.84, 19.21.</div></div><div id="sec10_9_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Methyl (<i>E</i>)-3-(4-((2-(2,4-Dimethylbenzoyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>27a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>12a</b> (2.1 g, yield 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.58 (d, <i>J</i> = 16.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.8 Hz, 1H), 7.25–7.15 (m, 4H), 7.04 (s, 1H), 6.91 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.86 (d, <i>J</i> = 10.0 Hz, 2H), 6.48 (d, <i>J</i> = 8.7 Hz, 2H), 6.27 (d, <i>J</i> = 16.0 Hz, 1H), 3.80 (s, 3H), 2.28 (s, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 191.12, 168.01, 160.03, 157.77, 148.39, 144.34, 141.94, 140.80, 136.24, 136.15, 131.45, 129.39, 128.86, 128.26, 127.26, 126.80, 125.86, 124.84, 116.36, 116.28, 115.61, 108.39, 51.94, 21.48, 19.38.</div></div><div id="sec10_9_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Methyl (<i>E</i>)-3-(4-((2-(4-Chloro-2,6-dimethylbenzoyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>27c</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>12a</b> (6.2 g, yield 65%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.60 (d, <i>J</i> = 16.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.7 Hz, 2H), 7.45 (d, <i>J</i> = 2.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.8 Hz, 1H), 6.99 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.89 (s, 2H), 6.57 (d, <i>J</i> = 8.7 Hz, 2H), 6.41 (d, <i>J</i> = 16.0 Hz, 1H), 3.73 (s, 3H), 2.08 (s, 6H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 190.88, 167.53, 160.15, 160.05, 149.24, 144.45, 143.05, 139.95, 136.83, 134.52, 130.28, 130.03, 128.38, 127.86, 126.65, 125.79, 117.45, 117.38, 115.90, 109.12, 51.67, 19.12.</div></div><div id="sec10_9_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>E</i>)-3-(4-((2-(2,4-Dimethylbenzoyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>28a</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>14a</b> (1.6 g, yield 83%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.58 (d, <i>J</i> = 16.0 Hz, 1H), 7.50–7.38 (m, 4H), 7.25 (d, <i>J</i> = 7.7 Hz, 1H), 7.01 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H)), 6.96–6.86 (m, 2H), 6.57 (d, <i>J</i> = 8.7 Hz, 2H), 6.38 (d, <i>J</i> = 16.0 Hz, 1H), 2.29 (s, 3H), 2.07 (s, 3H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 190.44, 167.80, 160.72, 159.80, 148.66, 144.67, 142.52, 141.14, 137.47, 136.47, 131.96, 130.35, 130.01, 128.72, 127.86, 126.99, 126.55, 125.39, 117.81, 117.15, 116.34, 108.90, 21.31, 19.33. ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd. for C<sub>26</sub>H<sub>21</sub>O<sub>5</sub>S, 445.1110; observed, 445.1100.</div></div><div id="sec10_9_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>E</i>)-3-(4-((2-(4-Chloro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>28c</b>)</h4><div class="NLM_p last">This compound was prepared by a procedure identical to the preparation of <b>14a</b> (2.1 g, yield 88%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.60 (d, <i>J</i> = 16.0 Hz, 1H), 7.51 (d, <i>J</i> = 8.6 Hz, 2H), 7.45 (d, <i>J</i> = 1.7 Hz, 1H), 7.39 (d, <i>J</i> = 8.8 Hz, 1H), 7.00 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H), 6.91 (s, 2H), 6.58 (d, <i>J</i> = 8.6 Hz, 2H), 6.40 (d, <i>J</i> = 16.0 Hz, 1H), 2.09 (s, 6H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 190.91, 167.77, 160.17, 160.00, 149.30, 144.62, 143.07, 139.99, 136.85, 134.53, 130.26, 130.17, 128.40, 127.88, 126.67, 125.82, 117.94, 117.38, 115.91, 109.13, 19.12. ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd. for C<sub>26</sub>H<sub>20</sub>ClO<sub>5</sub>S, 479.0720; observed, 479.0706.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01355">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">. The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01355" class="ext-link">10.1021/acs.jmedchem.6b01355</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">ER degradation of compounds <b>28a</b>, <b>28c</b>, <b>24b</b>, and <b>24c</b> (100 nM) verified by western blot; cell survival data (DNA) of compound <b>16b</b> in TR MCF-7:5C and TS MCF-7:WS8 cells; additional materials and methods; characterization data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">3D structure of 1R5K (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D structure of 5AK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_001.csv">jm6b01355_si_001.csv (2.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf">jm6b01355_si_002.pdf (450.75 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_003.pdb">jm6b01355_si_003.pdb (207.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_004.pdb">jm6b01355_si_004.pdb (336.71 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01355" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory R. J. Thatcher</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7757-1739" title="Orcid link">http://orcid.org/0000-0002-7757-1739</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#017569607562696473417468622f646574"><span class="__cf_email__" data-cfemail="3a4e525b4e59525f487a4f5359145f5e4f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rui Xiong</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6350-9037" title="Orcid link">http://orcid.org/0000-0002-6350-9037</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiong Zhao</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren M. Gutgesell</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yueting Wang</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sue Lee</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bhargava Karumudi</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huiping Zhao</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunlong Lu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debra A. Tonetti</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry & Pharmacognosy, ‡Department of Biopharmaceutical
Sciences, University of Illinois College
of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Rui Xiong and Jiong Zhao contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e3350-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by NIH R01 CA188017, the University of Illinois Cancer Center, UICentre (drug <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="20444953434f5645525960756963">[email protected]</a>), and UIC Center for Clinical and Translational Science grant UL1RR029879. We would like to thank Kathryn Carlson and Teresa Martin for technical assistance with the RBA assay and John A. Katzenellenbogen for helpful comments, all from the Department of Chemistry, University of Illinois at Urbana–Champaign.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> Abbreviations Used</h2><tr><td class="NLM_term">SERDs</td><td class="NLM_def"><p class="first last">selective estrogen receptor downregulators (or degraders)</p></td></tr><tr><td class="NLM_term">ER+</td><td class="NLM_def"><p class="first last">estrogen receptor positive</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulator</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">estrogen receptor α</p></td></tr><tr><td class="NLM_term">ERβ</td><td class="NLM_def"><p class="first last">estrogen receptor β</p></td></tr><tr><td class="NLM_term">E<sub>2</sub></td><td class="NLM_def"><p class="first last">estradiol</p></td></tr><tr><td class="NLM_term">BT</td><td class="NLM_def"><p class="first last">benzothiophene</p></td></tr><tr><td class="NLM_term">TR</td><td class="NLM_def"><p class="first last">treatment resistant</p></td></tr><tr><td class="NLM_term">AIs</td><td class="NLM_def"><p class="first last">aromatase inhibitors</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RBA</td><td class="NLM_def"><p class="first last">relative binding affinity</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">ERE</td><td class="NLM_def"><p class="first last">estrogen response element</p></td></tr><tr><td class="NLM_term">ICW</td><td class="NLM_def"><p class="first last">in-cell western</p></td></tr><tr><td class="NLM_term">ShERPAs</td><td class="NLM_def"><p class="first last">selective human ER partial agonists</p></td></tr><tr><td class="NLM_term">LBD</td><td class="NLM_def"><p class="first last">ligand binding domain</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">palbociclib</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 79 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Early Breast Cancer Trialists’ Collaborative Group</span><span> </span><span class="NLM_article-title">Tamoxifen for early breast cancer: an overview of the randomised trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">1451</span><span class="NLM_x">–</span> <span class="NLM_lpage">1467</span><span class="refDoi"> DOI: 10.1016/S0140-6736(97)11423-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2FS0140-6736%2897%2911423-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=9605801" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=1998&pages=1451-1467&author=Early+Breast+Cancer+Trialists%E2%80%99+Collaborative+Group&title=Tamoxifen+for+early+breast+cancer%3A+an+overview+of+the+randomised+trials&doi=10.1016%2FS0140-6736%2897%2911423-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2897%2911423-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252897%252911423-4%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DTamoxifen%2520for%2520early%2520breast%2520cancer%253A%2520an%2520overview%2520of%2520the%2520randomised%2520trials%26jtitle%3DLancet%26date%3D1998%26volume%3D351%26spage%3D1451%26epage%3D1467%26doi%3D10.1016%2FS0140-6736%2897%2911423-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.1993.tb13840.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1111%2Fj.1476-5381.1993.tb13840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=8242225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK3sXms1Wru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=1993&pages=507-517&author=V.+C.+Jordan&title=Fourteenth+Gaddum+Memorial+Lecture.+A+current+view+of+tamoxifen+for+the+treatment+and+prevention+of+breast+cancer&doi=10.1111%2Fj.1476-5381.1993.tb13840.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A current view of tamoxifen for the treatment and prevention of breast cancer</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">507-17</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">A review with ∼ 150 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2gSMvDLsn2rVg90H21EOLACvtfcHk0lgPdUs0RC12dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXms1Wru70%253D&md5=76a7bf0bbccfcde6774c3ae2eca4253a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1993.tb13840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1993.tb13840.x%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DFourteenth%2520Gaddum%2520Memorial%2520Lecture.%2520A%2520current%2520view%2520of%2520tamoxifen%2520for%2520the%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1993%26volume%3D110%26spage%3D507%26epage%3D517%26doi%3D10.1111%2Fj.1476-5381.1993.tb13840.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1146/annurev.pa.35.040195.001211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1146%2Fannurev.pa.35.040195.001211" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=195-211&author=V.+C.+Jordan&title=Tamoxifen%3A+toxicities+and+drug+resistance+during+the+treatment+and+prevention+of+breast+cancer&doi=10.1146%2Fannurev.pa.35.040195.001211"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.35.040195.001211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.35.040195.001211%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DTamoxifen%253A%2520toxicities%2520and%2520drug%2520resistance%2520during%2520the%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1995%26volume%3D35%26spage%3D195%26epage%3D211%26doi%3D10.1146%2Fannurev.pa.35.040195.001211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ragaz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coldman, A.</span><span> </span><span class="NLM_article-title">Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2018</span><span class="NLM_x">–</span> <span class="NLM_lpage">2024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=9626198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A280%3ADyaK1c3ovFCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2018-2024&author=J.+Ragazauthor=A.+Coldman&title=Survival+impact+of+adjuvant+tamoxifen+on+competing+causes+of+mortality+in+breast+cancer+survivors%2C+with+analysis+of+mortality+from+contralateral+breast+cancer%2C+cardiovascular+events%2C+endometrial+cancer%2C+and+thromboembolic+episodes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes</span></div><div class="casAuthors">Ragaz J; Coldman A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2018-24</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  This study provides estimates of the effect of tamoxifen treatment on mortality from four conditions known to be affected by tamoxifen in women who survive their breast cancer: contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic events.  These estimates are in addition to tamoxifen's impact on primary breast cancer mortality.  METHODS:  The effects of tamoxifen were calculated by the use of the published relative risk (RR) rates of the four conditions as affected by adjuvant tamoxifen and their application to the respective Canadian age-specific mortality rates for the same conditions.  The final mortality impact of tamoxifen was expressed as net mortality difference between users and nonusers of tamoxifen.  RESULTS:  At 10 years of follow-up, the sum of avoided deaths (contralateral breast cancer, cardiovascular events) and excess deaths (uterine cancer, thromboembolic episodes) resulted in an overall (net) mortality reduction because of tamoxifen use, with 3 to 41 avoided deaths per 1,000 tamoxifen-treated patients who were 50 to 80 years of age.  With the follow-up projected until the age of 90 years, the numbers of avoided late deaths attributed to tamoxifen ranged from 38 to 56 per 1,000 patients.  CONCLUSION:  Our calculations that pertain to late breast cancer survivors indicate that there is a more substantial mortality reduction as a result of deaths avoided from contralateral breast cancer and cardiovascular events, despite the moderately increased mortality from endometrial cancer and thromboembolic episodes.  The overall tamoxifen-associated mortality reduction occurs, in different magnitudes, in patients of all ages from 50 to 80 years at diagnosis of the primary breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmKcft3Gh8l1vAgqb2vdc5fW6udTcc2eZSkI5CQDrme7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3ovFCgug%253D%253D&md5=52fe3097fa0f03019d5d7a9b589830c7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRagaz%26aufirst%3DJ.%26aulast%3DColdman%26aufirst%3DA.%26atitle%3DSurvival%2520impact%2520of%2520adjuvant%2520tamoxifen%2520on%2520competing%2520causes%2520of%2520mortality%2520in%2520breast%2520cancer%2520survivors%252C%2520with%2520analysis%2520of%2520mortality%2520from%2520contralateral%2520breast%2520cancer%252C%2520cardiovascular%2520events%252C%2520endometrial%2520cancer%252C%2520and%2520thromboembolic%2520episodes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1998%26volume%3D16%26spage%3D2018%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span> </span><span class="NLM_article-title">Aromatase inhibitors in breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">2431</span><span class="NLM_x">–</span> <span class="NLM_lpage">2442</span><span class="refDoi"> DOI: 10.1056/NEJMra023246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1056%2FNEJMra023246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=12802030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2431-2442&author=I.+E.+Smithauthor=M.+Dowsett&title=Aromatase+inhibitors+in+breast+cancer&doi=10.1056%2FNEJMra023246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors in breast cancer</span></div><div class="casAuthors">Smith, Ian E.; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2431-2442</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the role of aromatase inhibitors and assess their potential for clin. use in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYF49NFDFgm7Vg90H21EOLACvtfcHk0lgvq8WRAlNurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D&md5=da7b56d4a1f0e7b2e27c8819a0ae0951</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra023246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra023246%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DAromatase%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2431%26epage%3D2442%26doi%3D10.1056%2FNEJMra023246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Dixon, J. M.</span><span> </span><span class="NLM_article-title">Endocrine resistance in breast cancer</span> <span class="citation_source-journal">New J. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1155/2014/390618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1155%2F2014%2F390618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1-27&author=J.+M.+Dixon&title=Endocrine+resistance+in+breast+cancer&doi=10.1155%2F2014%2F390618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1155%2F2014%2F390618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F390618%26sid%3Dliteratum%253Aachs%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEndocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNew%2520J.%2520Sci.%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D27%26doi%3D10.1155%2F2014%2F390618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Herynk, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuqua, S. A.</span><span> </span><span class="NLM_article-title">Estrogen receptors in resistance to hormone therapy</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">608</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1007/978-0-387-74039-3_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2F978-0-387-74039-3_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=608&publication_year=2007&pages=130-143&author=M.+H.+Herynkauthor=S.+A.+Fuqua&title=Estrogen+receptors+in+resistance+to+hormone+therapy&doi=10.1007%2F978-0-387-74039-3_10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-74039-3_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-0-387-74039-3_10%26sid%3Dliteratum%253Aachs%26aulast%3DHerynk%26aufirst%3DM.%2BH.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26atitle%3DEstrogen%2520receptors%2520in%2520resistance%2520to%2520hormone%2520therapy%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2007%26volume%3D608%26spage%3D130%26epage%3D143%26doi%3D10.1007%2F978-0-387-74039-3_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span> </span><span class="NLM_article-title">Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4883</span><span class="NLM_x">–</span> <span class="NLM_lpage">4887</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+selective+estrogen+receptor+downregulators+%28SERDs%29%2C+a+breakthrough+endocrine+therapy+for+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0lgvq8WRAlNurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%252C%2520a%2520breakthrough%2520endocrine%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ellis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewar, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasiowka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rukazenkov, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. F.</span><span> </span><span class="NLM_article-title">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3781</span><span class="NLM_x">–</span> <span class="NLM_lpage">3787</span><span class="refDoi"> DOI: 10.1200/JCO.2015.61.5831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1200%2FJCO.2015.61.5831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=26371134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSntb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3781-3787&author=M.+J.+Ellisauthor=A.+Llombart-Cussacauthor=D.+Feltlauthor=J.+A.+Dewarauthor=M.+Jasiowkaauthor=N.+Hewsonauthor=Y.+Rukazenkovauthor=J.+F.+Robertson&title=Fulvestrant+500+mg+versus+anastrozole+1+mg+for+the+first-line+treatment+of+advanced+breast+cancer%3A+overall+survival+analysis+from+the+phase+II+FIRST+study&doi=10.1200%2FJCO.2015.61.5831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study</span></div><div class="casAuthors">Ellis, Matthew J.; Llombart-Cussac, Antonio; Feltl, David; Dewar, John A.; Jasiowka, Marek; Hewson, Nicola; Rukazenkov, Yuri; Robertson, John F. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3781-3787</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">To compare overall survival (OS) for fulvestrant 500 mg vs. anastrozole as first-line endocrine therapy for advanced breast cancer.  The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicenter trial.  Postmenopausal women with estrogen receptor-pos., locally advanced/metastatic breast cancer who had no previous therapy for advanced disease received either fulvestrant 500 mg (days 0, 14, 28, and every 28 days thereafter) or anastrozole 1 mg (daily).  The primary end point (clin. benefit rate [72.5% and 67.0%]) and a follow-up anal. (median time to progression [23.4 mo and 13.1 mo]) have been reported previously for fulvestrant 500 mg and anastrozole, resp.  Subsequently, the protocol was amended to assess OS by unadjusted log-rank test after approx. 65% of patients had died.  Treatment effect on OS across several subgroups was examd.  Tolerability was evaluated by adverse event monitoring.  Results In total, 205 patients were randomly assigned (fulvestrant 500 mg, n = 102; anastrozole, n = 103).  At data cutoff, 61.8% (fulvestrant 500 mg, n = 63) and 71.8% (anastrozole, n = 74) had died.  The hazard ratio (95% CI) for OS with fulvestrant 500 mg vs. anastrozole was 0.70 (0.50 to 0.98; P = .04; median OS, 54.1 mo v 48.4 mo).  Treatment effects seemed generally consistent across the subgroups analyzed.  No new safety issues were obsd.  There are several limitations of this OS anal., including that it was not planned in the original protocol but instead was added after time-to-progression results were analyzed, and that not all patients participated in addnl. OS follow-up.  However, the present results suggest fulvestrant 500 mg extends OS vs. anastrozole.  This finding now awaits prospective confirmation in the larger phase III FALCON (Fulvestrant and Anastrozole Compared in Hormonal Therapy Na.ovrddot.ive Advanced Breast Cancer).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgcontOU3287Vg90H21EOLACvtfcHk0ljjCvGugGpCbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSntb3K&md5=45cb5f02224b33857d55e5cb5b69e775</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.61.5831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.61.5831%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%2BA.%26aulast%3DJasiowka%26aufirst%3DM.%26aulast%3DHewson%26aufirst%3DN.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26atitle%3DFulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520for%2520the%2520first-line%2520treatment%2520of%2520advanced%2520breast%2520cancer%253A%2520overall%2520survival%2520analysis%2520from%2520the%2520phase%2520II%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3781%26epage%3D3787%26doi%3D10.1200%2FJCO.2015.61.5831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colleoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeck, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theall, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D.</span><span> </span><span class="NLM_article-title">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00613-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2FS1470-2045%2815%2900613-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=26947331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=425-439&author=M.+Cristofanilliauthor=N.+C.+Turnerauthor=I.+Bondarenkoauthor=J.+Roauthor=S.+A.+Imauthor=N.+Masudaauthor=M.+Colleoniauthor=A.+DeMicheleauthor=S.+Loiauthor=S.+Vermaauthor=H.+Iwataauthor=N.+Harbeckauthor=K.+Zhangauthor=K.+P.+Theallauthor=Y.+Jiangauthor=C.+H.+Bartlettauthor=M.+Koehlerauthor=D.+Slamon&title=Fulvestrant+plus+palbociclib+versus+fulvestrant+plus+placebo+for+treatment+of+hormone-receptor-positive%2C+HER2-negative+metastatic+breast+cancer+that+progressed+on+previous+endocrine+therapy+%28PALOMA-3%29%3A+final+analysis+of+the+multicentre%2C+double-blind%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS1470-2045%2815%2900613-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial</span></div><div class="casAuthors">Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria; Slamon, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was assocd. with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer.  Identification of patients most suitable for the addn. of palbociclib to endocrine therapy after tumor recurrence is crucial for treatment optimization in metastatic breast cancer.  We aimed to confirm our earlier findings with this extended follow-up and show our results for subgroup and biomarker analyses.  In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-pos., HER2-neg. metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis at 144 centers in 17 countries.  Eligible patients-ie, any menopausal status, Eastern Cooperative Oncol. Group performance status 0-1, measurable disease or bone disease only, and disease relapse or progression after previous endocrine therapy for advanced disease during treatment or within 12 mo of completion of adjuvant therapy-were randomly assigned (2:1) via a centralised interactive web-based and voice-based randomisation system to receive oral palbociclib (125 mg daily for 3 wk followed by a week off over 28-day cycles) plus 500 mg fulvestrant (i.m. injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 28-day cycles) or placebo plus fulvestrant.  The primary endpoint was investigator-assessed progression-free survival.  Anal. was by intention to treat.  We also assessed endocrine therapy resistance by clin. parameters, quant. hormone-receptor expression, and tumor PIK3CA mutational status in circulating DNA at baseline.  This study is registered with ClinicalTrials.gov, NCT01942135.  Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo.  Study enrolment is closed and overall survival follow-up is in progress.  By March 16, 2015, 259 progression-free-survival events had occurred (145 in the fulvestrant plus palbociclib group and 114 in the fulvestrant plus placebo group); median follow-up was 8·9 mo (IQR 8·7-9·2).  Median progression-free survival was 9·5 mo (95% CI 9·2-11·0) in the fulvestrant plus palbociclib group and 4·6 mo (3·5-5·6) in the fulvestrant plus placebo group (hazard ratio 0·46, 95% CI 0·36-0·59, p<0·0001).  Grade 3 or 4 adverse events occurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group.  The most common grade 3 or 4 adverse events were neutropenia (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).  Serious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.  PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients for whom these data were available.  Neither PIK3CA status nor hormone-receptor expression level significantly affected treatment response.  Fulvestrant plus palbociclib was assocd. with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irresp. of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status.  The combination could be considered as a therapeutic option for patients with recurrent hormone-receptor-pos., HER2-neg. metastatic breast cancer that has progressed on previous endocrine therapy.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmN_mxQq1lWrVg90H21EOLACvtfcHk0ljjCvGugGpCbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D&md5=393ef72549634e00f26a0a1916565472</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900613-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900613-0%26sid%3Dliteratum%253Aachs%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DRo%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DTheall%26aufirst%3DK.%2BP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DBartlett%26aufirst%3DC.%2BH.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DSlamon%26aufirst%3DD.%26atitle%3DFulvestrant%2520plus%2520palbociclib%2520versus%2520fulvestrant%2520plus%2520placebo%2520for%2520treatment%2520of%2520hormone-receptor-positive%252C%2520HER2-negative%2520metastatic%2520breast%2520cancer%2520that%2520progressed%2520on%2520previous%2520endocrine%2520therapy%2520%2528PALOMA-3%2529%253A%2520final%2520analysis%2520of%2520the%2520multicentre%252C%2520double-blind%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D425%26epage%3D439%26doi%3D10.1016%2FS1470-2045%2815%2900613-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowler, J.</span><span> </span><span class="NLM_article-title">A potent specific pure antiestrogen with clinical potential</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+potent+specific+pure+antiestrogen+with+clinical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0ljjCvGugGpCbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520potent%2520specific%2520pure%2520antiestrogen%2520with%2520clinical%2520potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Robertson, J. F.</span><span> </span><span class="NLM_article-title">Fulvestrant (Faslodex) -- how to make a good drug better</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span><span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&author=J.+F.+Robertson&title=Fulvestrant+%28Faslodex%29+%2D%2D+how+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26atitle%3DFulvestrant%2520%2528Faslodex%2529%2520--%2520how%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Buzdar, A. U.</span><span> </span><span class="NLM_article-title">Endocrine therapy in the treatment of metastatic breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span><span class="refDoi"> DOI: 10.1053/sonc.2001.23495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1053%2Fsonc.2001.23495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=11402439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=291-304&author=A.+U.+Buzdar&title=Endocrine+therapy+in+the+treatment+of+metastatic+breast+cancer&doi=10.1053%2Fsonc.2001.23495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy in the treatment of metastatic breast cancer</span></div><div class="casAuthors">Buzdar, Aman U.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-304</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review with refs.  The goals of treating patients with metastatic breast cancer are to prolong survival, slow or halt disease progression, and enhance the patient's quality of life.  In patients with estrogen receptor (ER)-pos. cancers that are not progressing rapidly, endocrine therapy is generally the first treatment option.  If a patient initially responds to an endocrine agent and then progresses, another endocrine agent may still provide benefit.  Tamoxifen has been used as first-line therapy for metastatic breast cancer for many years.  Until recently, no other endocrine agent has shown superiority to tamoxifen in this setting.  The nonsteroidal aromatase inhibitors, anastrozole and letrozole, have been widely accepted as second-line therapy after failure of tamoxifen; they have replaced megestrol acetate in this setting.  Recently, anastrozole was shown to have at least equiv. efficacy and a superior side effect profile compared with tamoxifen for treating postmenopausal women in the first-line setting.  Thus, this aromatase inhibitor has become a viable option for first-line therapy in postmenopausal women.  Trials of letrozole in this setting are nearing completion.  Exemestane has been shown to be an effective second-line agent and to have at least some efficacy as a third-line agent even after failure of a nonsteroidal aromatase inhibitor.  Results are anxiously awaited from trials of new endocrine agents including the first member of a new class of endocrine agent, the estrogen-receptor down-regulator class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOWmWY0RsKVLVg90H21EOLACvtfcHk0lgsej4pZirbaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWksrw%253D&md5=7e74d3b61520e2bc0987370b20967b80</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1053%2Fsonc.2001.23495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsonc.2001.23495%26sid%3Dliteratum%253Aachs%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26atitle%3DEndocrine%2520therapy%2520in%2520the%2520treatment%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D291%26epage%3D304%26doi%3D10.1053%2Fsonc.2001.23495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Wittmann, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9549</span><span class="NLM_x">–</span> <span class="NLM_lpage">9560</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F0008-5472.CAN-07-1590" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9549-9560&author=B.+M.+Wittmannauthor=A.+Sherkauthor=D.+P.+McDonnell&title=Definition+of+functionally+important+mechanistic+differences+among+selective+estrogen+receptor+down-regulators&doi=10.1158%2F0008-5472.CAN-07-1590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1590%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DB.%2BM.%26aulast%3DSherk%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDefinition%2520of%2520functionally%2520important%2520mechanistic%2520differences%2520among%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9549%26epage%3D9560%26doi%3D10.1158%2F0008-5472.CAN-07-1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">van Kruchten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaudemans, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Lanschot, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Faassen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kema, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hospers, G. A.</span><span> </span><span class="NLM_article-title">Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&author=M.+van+Kruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schroderauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+residual+estrogen+receptor+availability+during+fulvestrant+therapy+in+patients+with+metastatic+breast+cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0lgsej4pZirbaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchroder%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520residual%2520estrogen%2520receptor%2520availability%2520during%2520fulvestrant%2520therapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henke, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momtahen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charifson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubahn, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H. R.</span><span> </span><span class="NLM_article-title">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1550</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span><span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Sauls&title=3-%5B4-%281%2C2-Diphenylbut-1-enyl%29phenyl%5Dacrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lgOMiKugYxHQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26atitle%3D3-%255B4-%25281%252C2-Diphenylbut-1-enyl%2529phenyl%255Dacrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Connor, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadwater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2917</span><span class="NLM_x">–</span> <span class="NLM_lpage">2922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=11306468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+using+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span></div><div class="casAuthors">Connor, Caroline E.; Norris, John D.; Broadwater, Gloria; Willson, Timothy M.; Gottardis, Marco M.; Dewhirst, Mark W.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2917-2922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators.  In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells.  We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER.  The biol. significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638.  Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2YSN94iysMbVg90H21EOLACvtfcHk0lgOMiKugYxHQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D&md5=d7ecae7d445901e2f2c4f133ebbacdc5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520using%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&author=Y.+L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+basis+for+an+unexpected+mode+of+SERM-mediated+ER+antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lgOMiKugYxHQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520basis%2520for%2520an%2520unexpected%2520mode%2520of%2520SERM-mediated%2520ER%2520antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Degorce, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J. S.</span><span> </span><span class="NLM_article-title">Investigation of (E)-3-[4-(2-oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3522</span><span class="NLM_x">–</span> <span class="NLM_lpage">3533</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3522-3533&author=S.+L.+Degorceauthor=A.+Baileyauthor=R.+Callisauthor=C.+De+Saviauthor=R.+Ducrayauthor=G.+Lamontauthor=P.+MacFaulauthor=M.+Maudetauthor=S.+Martinauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Peruauthor=J.+H.+Pinkauthor=P.+A.+Pleauthor=B.+Robertsauthor=J.+S.+Scott&title=Investigation+of+%28E%29-3-%5B4-%282-oxo-3-aryl-chromen-4-yl%29oxyphenyl%5Dacrylic+acids+as+oral+selective+estrogen+receptor+down-regulators&doi=10.1021%2Facs.jmedchem.5b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators</span></div><div class="casAuthors">Degorce, Sebastien L.; Bailey, Andrew; Callis, Rowena; De Savi, Chris; Ducray, Richard; Lamont, Gillian; MacFaul, Philip; Maudet, Mickael; Martin, Scott; Morgentin, Remy; Norman, Richard A.; Peru, Aurelien; Pink, Jennifer H.; Ple, Patrick A.; Roberts, Bryan; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3522-3533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chem. induced mammary tumors.  Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen receptor down-regulators, which led us to the discovery of potent down-regulating antagonists, such as 33.  Subsequent optimization and removal of the 7-hydroxy group led to coumarin 59, which had increased potency and improved rat bioavailability relative to SS5020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondIuhUFHcLrVg90H21EOLACvtfcHk0lhWxhBbD-2oXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D&md5=765350db346581eab5565468f35b55d9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00066%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DInvestigation%2520of%2520%2528E%2529-3-%255B4-%25282-oxo-3-aryl-chromen-4-yl%2529oxyphenyl%255Dacrylic%2520acids%2520as%2520oral%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3522%26epage%3D3533%26doi%3D10.1021%2Facs.jmedchem.5b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Scott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0lhWxhBbD-2oXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4888</span><span class="NLM_x">–</span> <span class="NLM_lpage">4904</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lhWxhBbD-2oXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Burks, H. E. K.; Rajeshri, G.; Kirby, C. A.; Nunez, J.; Peukert, S.; Springer, C.; Sun, Y.; Thomsen, N. M.</span><span> </span><span class="NLM_article-title">1,2,3,4-Tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders, and their preparation</span>. WO 2015092634,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+E.+K.+Burks&author=G.+Rajeshri&author=C.+A.+Kirby&author=J.+Nunez&author=S.+Peukert&author=C.+Springer&author=Y.+Sun&author=N.+M.+Thomsen&title=1%2C2%2C3%2C4-Tetrahydroisoquinoline+compounds+and+compositions+as+selective+estrogen+receptor+antagonists+and+degraders%2C+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%2BK.%26atitle%3D1%252C2%252C3%252C4-Tetrahydroisoquinoline%2520compounds%2520and%2520compositions%2520as%2520selective%2520estrogen%2520receptor%2520antagonists%2520and%2520degraders%252C%2520and%2520their%2520preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Garner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shomali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyttle, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattersley, G.</span><span> </span><span class="NLM_article-title">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1097%2FCAD.0000000000000271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=RAD1901%3A+a+novel%2C+orally+bioavailable+selective+estrogen+receptor+degrader+that+demonstrates+antitumor+activity+in+breast+cancer+xenograft+models&doi=10.1097%2FCAD.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRAD1901%253A%2520a%2520novel%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520that%2520demonstrates%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenograft%2520models%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2015%26volume%3D26%26spage%3D948%26epage%3D956%26doi%3D10.1097%2FCAD.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almeida, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayter, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetra hydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8128</span><span class="NLM_x">–</span> <span class="NLM_lpage">8140</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetra+hydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetra%2520hydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Weir, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almeida, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladd, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazolli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzola, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Cruz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Savi, C.</span><span> </span><span class="NLM_article-title">AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">3307</span><span class="NLM_x">–</span> <span class="NLM_lpage">3318</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F0008-5472.CAN-15-2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=27020862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3307-3318&author=H.+M.+Weirauthor=R.+H.+Bradburyauthor=M.+Lawsonauthor=A.+A.+Rabowauthor=D.+Buttarauthor=R.+J.+Callisauthor=J.+O.+Curwenauthor=C.+de+Almeidaauthor=P.+Ballardauthor=M.+Hulseauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=G.+Karoutchiauthor=P.+MacFaulauthor=T.+Mossauthor=R.+A.+Normanauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+Daviesauthor=G.+E.+Walkerauthor=Z.+Wilsonauthor=R.+Rowlinsonauthor=S.+Powellauthor=C.+Sadlerauthor=G.+Richmondauthor=B.+Laddauthor=E.+Pazolliauthor=A.+M.+Mazzolaauthor=C.+D%E2%80%99Cruzauthor=C.+De+Savi&title=AZD9496%3A+an+oral+estrogen+receptor+inhibitor+that+blocks+the+growth+of+ER-positive+and+ESR1-mutant+breast+tumors+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models</span></div><div class="casAuthors">Weir, Hazel M.; Bradbury, Robert H.; Lawson, Mandy; Rabow, Alfred A.; Buttar, David; Callis, Rowena J.; Curwen, Jon O.; de Almeida, Camila; Ballard, Peter; Hulse, Michael; Donald, Craig S.; Feron, Lyman J. L.; Karoutchi, Galith; MacFaul, Philip; Moss, Thomas; Norman, Richard A.; Pearson, Stuart E.; Tonge, Michael; Davies, Gareth; Walker, Graeme E.; Wilson, Zena; Rowlinson, Rachel; Powell, Steve; Sadler, Claire; Richmond, Graham; Ladd, Brendon; Pazolli, Ermira; Mazzola, Anne Marie; D'Cruz, Celina; De Savi, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3307-3318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly i.m. injection.  Given its present limitations of dosing and route of administration, a more flexible orally available compd. has been sought to pursue the potential benefits of this drug in patients with advanced metastatic disease.  Here we report the identification and characterization of AZD9496, a nonsteroidal small-mol. inhibitor of ERα, which is a potent and selective antagonist and downregulator of ERα in vitro and in vivo in ER-pos. models of breast cancer.  Significant tumor growth inhibition was obsd. as low as 0.5 mg/kg dose in the estrogen-dependent MCF-7 xenograft model, where this effect was accompanied by a dose-dependent decrease in PR protein levels, demonstrating potent antagonist activity.  Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors led to further growth-inhibitory effects compared with monotherapy alone.  Tumor regressions were also seen in a long-term estrogen-deprived breast model, where significant downregulation of ERα protein was obsd.  AZD9496 bound and downregulated clin. relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1-mutant patient-derived xenograft model that included a D538G mutation.  Collectively, the pharmacol. evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER+ breast cells that could provide meaningful benefit to ER+ breast cancer patients.  AZD9496 is currently being evaluated in a phase I clin. trial.  Cancer Res; 76(11); 3307-18. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4X3e2iYdcLVg90H21EOLACvtfcHk0lgcDrm5hByTjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D&md5=4ff8ab9a9cd379acc031b7c6fd27134c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2357%26sid%3Dliteratum%253Aachs%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DHulse%26aufirst%3DM.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DLadd%26aufirst%3DB.%26aulast%3DPazolli%26aufirst%3DE.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26atitle%3DAZD9496%253A%2520an%2520oral%2520estrogen%2520receptor%2520inhibitor%2520that%2520blocks%2520the%2520growth%2520of%2520ER-positive%2520and%2520ESR1-mutant%2520breast%2520tumors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3307%26epage%3D3318%26doi%3D10.1158%2F0008-5472.CAN-15-2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jevnikar, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemens, J. A.</span><span> </span><span class="NLM_article-title">Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1066</span><span class="refDoi"> DOI: 10.1021/jm00374a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00374a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=1057-1066&author=C.+D.+Jonesauthor=M.+G.+Jevnikarauthor=A.+J.+Pikeauthor=M.+K.+Petersauthor=L.+J.+Blackauthor=A.+R.+Thompsonauthor=J.+F.+Falconeauthor=J.+A.+Clemens&title=Antiestrogens.+2.+Structure-activity+studies+in+a+series+of+3-aroyl-2-arylbenzo%5Bb%5Dthiophene+derivatives+leading+to+%5B6-hydroxy-2-%284-hydroxyphenyl%29benzo%5Bb%5Dthien-3-yl%5D+%5B4-%5B2-%281-piperidinyl%29ethoxy%5D-phenyl%5Dmethanone+hydrochloride+%28LY156758%29%2C+a+remarkably+effective+estrogen+antagonist+with+only+minimal+intrinsic+estrogenicity&doi=10.1021%2Fjm00374a021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm00374a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00374a021%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJevnikar%26aufirst%3DM.%2BG.%26aulast%3DPike%26aufirst%3DA.%2BJ.%26aulast%3DPeters%26aufirst%3DM.%2BK.%26aulast%3DBlack%26aufirst%3DL.%2BJ.%26aulast%3DThompson%26aufirst%3DA.%2BR.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DClemens%26aufirst%3DJ.%2BA.%26atitle%3DAntiestrogens.%25202.%2520Structure-activity%2520studies%2520in%2520a%2520series%2520of%25203-aroyl-2-arylbenzo%255Bb%255Dthiophene%2520derivatives%2520leading%2520to%2520%255B6-hydroxy-2-%25284-hydroxyphenyl%2529benzo%255Bb%255Dthien-3-yl%255D%2520%255B4-%255B2-%25281-piperidinyl%2529ethoxy%255D-phenyl%255Dmethanone%2520hydrochloride%2520%2528LY156758%2529%252C%2520a%2520remarkably%2520effective%2520estrogen%2520antagonist%2520with%2520only%2520minimal%2520intrinsic%2520estrogenicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D1057%26epage%3D1066%26doi%3D10.1021%2Fjm00374a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Xiong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutgesell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado-Rivera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Selective human estrogen receptor partial agonists (ShERPAs) for tamoxifen-resistant breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=219-237&author=R.+Xiongauthor=H.+K.+Patelauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=L.+Delgado-Riveraauthor=T.+N.+Phamauthor=H.+Zhaoauthor=K.+Carlsonauthor=T.+Martinauthor=J.+A.+Katzenellenbogenauthor=T.+W.+Mooreauthor=D.+A.+Tonettiauthor=G.+R.+Thatcher&title=Selective+human+estrogen+receptor+partial+agonists+%28ShERPAs%29+for+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.5b01276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Patel, Hitisha K.; Gutgesell, Lauren M.; Zhao, Jiong; Delgado-Rivera, Loruhama; Pham, Thao N. D.; Zhao, Huiping; Carlson, Kathryn; Martin, Teresa; Katzenellenbogen, John A.; Moore, Terry W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Almost 70% of breast cancers are estrogen receptor α (ERα) pos.  Tamoxifen, a selective estrogen receptor modulator (SERM), represents the std. of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics.  Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clin. efficacy in patients with heavily treated breast cancer, although side effects in gynecol. tissues are unacceptable.  A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative.  We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent.  Novel benzothiophene derivs. with nanomolar potency in breast cancer cell cultures were designed.  Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines.  Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF_Xh3QGtO4LVg90H21EOLACvtfcHk0lg3Pq-fKjyb9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK&md5=f2bffc241b3de9c7537f9b5fa0c56f54</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01276%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDelgado-Rivera%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BN.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMoore%26aufirst%3DT.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DSelective%2520human%2520estrogen%2520receptor%2520partial%2520agonists%2520%2528ShERPAs%2529%2520for%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D219%26epage%3D237%26doi%3D10.1021%2Facs.jmedchem.5b01276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasena, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petukhov, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2692</span><span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+with+modulated+oxidative+activity+and+receptor+affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0lg3Pq-fKjyb9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520with%2520modulated%2520oxidative%2520activity%2520and%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Peng, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijewickrama, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1049</span><span class="refDoi"> DOI: 10.1021/cb9001848</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb9001848" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1039-1049&author=K.+W.+Pengauthor=H.+Wangauthor=Z.+Qinauthor=G.+T.+Wijewickramaauthor=M.+Luauthor=Z.+Wangauthor=J.+L.+Boltonauthor=G.+R.+Thatcher&title=Selective+estrogen+receptor+modulator+delivery+of+quinone+warheads+to+DNA+triggering+apoptosis+in+breast+cancer+cells&doi=10.1021%2Fcb9001848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulator Delivery of Quinone Warheads to DNA Triggering Apoptosis in Breast Cancer Cells</span></div><div class="casAuthors">Peng, Kuan-Wei; Wang, Huali; Qin, Zhihui; Wijewickrama, Gihani T.; Lu, Meiling; Wang, Zhican; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen exposure is a risk factor for breast cancer, and estrogen oxidative metabolites have been implicated in chem. carcinogenesis.  Oxidn. of the catechol metabolite of estrone (4-OHE) and the β-naphthohydroquinone metabolite of equilenin (4-OHEN) gives o-quinones that produce ROS and damage DNA by adduction and oxidn.  To differentiate hormonal and chem. carcinogenesis pathways in estrogen receptor pos. ER(+) cells, catechol or β-naphthohydroquinone warheads were conjugated to the selective estrogen receptor modulator (SERM) desmethylarzoxifene (DMA).  ER binding was retained in the DMA conjugates; both were antiestrogens with submicromolar potency in mammary and endometrial cells.  Cytotoxicity, apoptosis, and caspase-3/7 activation were compared in ER(+) and ER(-)MDA-MB-231 cells, and prodn. of ROS was detected using a fluorescent reporter.  Comparison was made to DMA, isolated warheads, and a DMA-mustard.  Conjugation of warheads to DMA increased cytotoxicity accompanied by induction of apoptosis and activation of caspase-3/7.  Activation of caspase-3/7, induction of apoptosis, and cytotoxicity were all increased significantly in ER(+) cells for the DMA conjugates.  ROS prodn. was localized in the nucleus for conjugates in ER(+) cells.  Observations are compatible with β-naphthohydroquinone and catechol groups being concd. in the nucleus by ER binding, where oxidn. and ROS prodn. result, concomitant with caspase-dependent apoptosis.  The results suggest that DNA damage induced by catechol estrogen metabolites can be amplified in ER(+) cells independent of hormonal activity.  The novel conjugation of quinone warheads to an ER-targeting SERM gives ER-dependent, enhanced apoptosis in mammary cancer cells of potential application in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJMjVFKkXUWrVg90H21EOLACvtfcHk0linfvzaiyyqJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb7J&md5=8855307c69ce84a310eced015d8daad9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fcb9001848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb9001848%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DK.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DWijewickrama%26aufirst%3DG.%2BT.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulator%2520delivery%2520of%2520quinone%2520warheads%2520to%2520DNA%2520triggering%2520apoptosis%2520in%2520breast%2520cancer%2520cells%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26spage%3D1039%26epage%3D1049%26doi%3D10.1021%2Fcb9001848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Palkowitz, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glasebrook, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrasher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehl, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetler, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullinan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pell, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, H. U.</span><span> </span><span class="NLM_article-title">Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1407</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span><span class="refDoi"> DOI: 10.1021/jm970167b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970167b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1407-1416&author=A.+D.+Palkowitzauthor=A.+L.+Glasebrookauthor=K.+J.+Thrasherauthor=K.+L.+Hauserauthor=L.+L.+Shortauthor=D.+L.+Phillipsauthor=B.+S.+Muehlauthor=M.+Satoauthor=P.+K.+Shetlerauthor=G.+J.+Cullinanauthor=T.+R.+Pellauthor=H.+U.+Bryant&title=Discovery+and+synthesis+of+%5B6-hydroxy-3-%5B4-%5B2-%281-piperidinyl%29ethoxy%5Dphenoxy%5D-2-%284-hydroxyphenyl%29%5Db+enzo%5Bb%5Dthiophene%3A+a+novel%2C+highly+potent%2C+selective+estrogen+receptor+modulator&doi=10.1021%2Fjm970167b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm970167b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970167b%26sid%3Dliteratum%253Aachs%26aulast%3DPalkowitz%26aufirst%3DA.%2BD.%26aulast%3DGlasebrook%26aufirst%3DA.%2BL.%26aulast%3DThrasher%26aufirst%3DK.%2BJ.%26aulast%3DHauser%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DL.%2BL.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DMuehl%26aufirst%3DB.%2BS.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DShetler%26aufirst%3DP.%2BK.%26aulast%3DCullinan%26aufirst%3DG.%2BJ.%26aulast%3DPell%26aufirst%3DT.%2BR.%26aulast%3DBryant%26aufirst%3DH.%2BU.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520%255B6-hydroxy-3-%255B4-%255B2-%25281-piperidinyl%2529ethoxy%255Dphenoxy%255D-2-%25284-hydroxyphenyl%2529%255Db%2520enzo%255Bb%255Dthiophene%253A%2520a%2520novel%252C%2520highly%2520potent%252C%2520selective%2520estrogen%2520receptor%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1407%26epage%3D1416%26doi%3D10.1021%2Fjm970167b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Shoda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demizu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, M.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2914</span><span class="NLM_x">–</span> <span class="NLM_lpage">2919</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.bmc.2016.04.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2914-2919&author=T.+Shodaauthor=M.+Katoauthor=T.+Fujisatoauthor=T.+Misawaauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Synthesis+and+evaluation+of+raloxifene+derivatives+as+a+selective+estrogen+receptor+down-regulator&doi=10.1016%2Fj.bmc.2016.04.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DFujisato%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DT.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520raloxifene%2520derivatives%2520as%2520a%2520selective%2520estrogen%2520receptor%2520down-regulator%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2914%26epage%3D2919%26doi%3D10.1016%2Fj.bmc.2016.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edirisinghe, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemachandra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasena, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e27876</span><span class="refDoi"> DOI: 10.1371/journal.pone.0027876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1371%2Fjournal.pone.0027876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=22140478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e27876&author=I.+Kastratiauthor=P.+D.+Edirisingheauthor=L.+P.+Hemachandraauthor=E.+R.+Chandrasenaauthor=J.+Choiauthor=Y.+T.+Wangauthor=J.+L.+Boltonauthor=G.+R.+Thatcher&title=Raloxifene+and+desmethylarzoxifene+block+estrogen-induced+malignant+transformation+of+human+breast+epithelial+cells&doi=10.1371%2Fjournal.pone.0027876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells</span></div><div class="casAuthors">Kastrati, Irida; Edirisinghe, Praneeth D.; Hemachandra, L-P-Madhubani P.; Chandrasena, Esala R.; Choi, Jaewoo; Wang, Yue-Ting; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e27876</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">There is assocn. between exposure to estrogens and the development and progression of hormone-dependent gynecol. cancers.  Chem. carcinogenesis by catechol estrogens derived from oxidative metab. is thought to contribute to breast cancer, yet exact mechanisms remain elusive.  Malignant transformation was studied in MCF-10A human mammary epithelial cells, since estrogens are not proliferative in this cell line.  The human and equine estrogen components of estrogen replacement therapy (ERT) and their catechol metabolites were studied, along with the influence of co-administration of selective estrogen receptor modulators (SERMs), raloxifene and desmethyl-arzoxifene (DMA) and histone deacetylase inhibitors.  Transformation was induced by human estrogens and selectively by the 4-OH catechol metabolite and to a lesser extent by an equine estrogen metabolite.  The obsd. estrogen-induced upregulation of CYP450 1B1 in estrogen receptor neg. MCF-10A cells, was compatible with a causal role for 4-OH catechol estrogens, as was attenuated transformation by CYP450 inhibitors.  Estrogen-induced malignant transformation was blocked by SERMs correlating with a redn. in formation of nucleobase catechol estrogen (NCE) adducts and formation of 8-oxo-dG.  NCE adducts can be formed consequent to DNA abasic site formation, but NCE adducts were also obsd. on incubation of estrogen quinones with free nucleotides.  These results suggest that NCE adducts may be a biomarker for cellular electrophilic stress, which together with 8-oxo-dG as a biomarker of oxidative stress correlate with malignant transformation induced by estrogen oxidative metabolites.  The obsd. attenuation of transformation by SERMs correlated with these biomarkers and may also be of clin. significance in breast cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTxGgBUQJyLVg90H21EOLACvtfcHk0linfvzaiyyqJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L&md5=70b8c37494d3ef4f48789ef0d1235dc9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0027876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0027876%26sid%3Dliteratum%253Aachs%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DEdirisinghe%26aufirst%3DP.%2BD.%26aulast%3DHemachandra%26aufirst%3DL.%2BP.%26aulast%3DChandrasena%26aufirst%3DE.%2BR.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%2BT.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DRaloxifene%2520and%2520desmethylarzoxifene%2520block%2520estrogen-induced%2520malignant%2520transformation%2520of%2520human%2520breast%2520epithelial%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De27876%26doi%3D10.1371%2Fjournal.pone.0027876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Abdelhamid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandevrede, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kundu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litosh, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiefer, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherezghiher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1021/cn100106a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100106a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=256-268&author=R.+Abdelhamidauthor=J.+Luoauthor=L.+Vandevredeauthor=I.+Kunduauthor=B.+Michalsenauthor=V.+A.+Litoshauthor=I.+T.+Schieferauthor=T.+Gherezghiherauthor=P.+Yaoauthor=Z.+Qinauthor=G.+R.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+provide+neuroprotection+by+a+novel+GPR30-dependent+mechanism&doi=10.1021%2Fcn100106a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel GPR30-Dependent Mechanism</span></div><div class="casAuthors">Abdelhamid, Ramy; Luo, Jia; Vande Vrede, Lawren; Kundu, Indraneel; Michalsen, Bradley; Litosh, Vladislav A.; Schiefer, Isaac T.; Gherezghiher, Teshome; Yao, Ping; Qin, Zhihui; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">256-268</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. benzothiophene SERM (BT-SERM) raloxifene was compared with estrogens in protection of primary rat neurons against oxygen-glucose deprivation (OGD).  Structure-activity relationships for neuroprotection were detd. for a family of BT-SERMs displaying a spectrum of ERα and ERβ binding affinity and agonist/antagonist activity, leading to discovery of a neuroprotective pharmacophore, present in the clin. relevant SERMS, raloxifene, and desmethylarzoxifene (DMA), for which submicromolar potency was obsd. for neuroprotection.  BT-SERM neuroprotection did not correlate with binding to ER or classical ER activity; however, both the neuroprotective SERMs and estrogens were shown, using pharmacol. probes, to activate the same kinase signaling cascades.  The antiestrogen ICI 182,780 inhibited the actions of estrogens but not those of BT-SERMs, whereas antagonism of the G-protein coupled receptor, GPR30, was effective for both SERMs and estrogens.  Since SERMs have antioxidant activity, ER-independent mechanisms were studied using the classical phenolic antioxidants, BHT and Trolox, and the Nrf2-dependent cytoprotective electrophile, sulforaphane.  However, neuroprotection by these agents was not sensitive to GPR30 antagonism.  Collectively, these data indicate that the activity of neuroprotective BT-SERMs is GPR30-dependent and ER-independent and not mediated by antioxidant effects.  Comparison of novel BT-SERM derivs. and analogs identified a neuroprotective pharmacophore of potential use in design of novel neuroprotective agents with a spectrum of ER activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvBt-wQmRmLrVg90H21EOLACvtfcHk0ljjAAc3pj9INw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D&md5=c1d5a55aee4f2271ec666b42f62b50c1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcn100106a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100106a%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelhamid%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DVandevrede%26aufirst%3DL.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DMichalsen%26aufirst%3DB.%26aulast%3DLitosh%26aufirst%3DV.%2BA.%26aulast%3DSchiefer%26aufirst%3DI.%2BT.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520provide%2520neuroprotection%2520by%2520a%2520novel%2520GPR30-dependent%2520mechanism%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D256%26epage%3D268%26doi%3D10.1021%2Fcn100106a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashgodom, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantvit, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overk, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Breemen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1124/dmd.108.023408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1124%2Fdmd.108.023408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=18936111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=161-169&author=Z.+Qinauthor=I.+Kastratiauthor=R.+T.+Ashgodomauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=Y.+Choiauthor=R.+B.+van+Breemenauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+modulation+of+oxidative+metabolism+in+design+of+improved+benzothiophene+selective+estrogen+receptor+modulators&doi=10.1124%2Fdmd.108.023408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Ashgodom, Rezene T.; Lantvit, Daniel D.; Overk, Cassia R.; Choi, Yongsoo; van Breemen, Richard B.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-169</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Raloxifene and arzoxifene are benzothiophene selective estrogen receptor modulators (SERMs) of clin. use in postmenopausal osteoporosis and treatment of breast cancer and potentially in hormone replacement therapy.  The benefits of arzoxifene are attributed to improved bioavailability over raloxifene, whereas the arzoxifene metabolite, desmethylarzoxifene (DMA) is a more potent antiestrogen.  As polyarom. phenolics, benzothiophene SERMs undergo oxidative metab. to electrophilic quinoids.  The long-term clin. use of SERMs demands increased understanding of correlations between structure and toxicity, with metab. being a key component.  A homologous series of 4'-substituted 4'-desmethoxyarzoxifene derivs. was developed, and metab. was studied in liver and intestinal microsomes.  Formation of glutathione conjugates was assayed in rat liver microsomes and novel adducts were characterized by liq. chromatog.-tandem mass spectrometry.  Formation of glucuronide conjugates was assayed in human intestine and liver microsomes, demonstrating formation of glucuronides ranging from 5 to 100% for the benzothiophene SERMs: this trend was inversely correlated with the loss of parent SERM in rat liver microsomal incubations.  MO calcns. generated thermodn. parameters for oxidn. that correlated with Hammett substituent consts.; however, metab. in liver microsomes correlated with a combination of both Hammett and Hansch lipophilicity parameters.  The results demonstrate a rich oxidative chem. for the benzothiophene SERMs, the amplitude of which can be powerfully modulated, in a predictable manner, by structural tuning of the 4'-substituent.  The predicted extensive metab. of DMA was confirmed in vivo and compared with the relatively stable arzoxifene and F-DMA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNnv4iRadE7Vg90H21EOLACvtfcHk0ljjAAc3pj9INw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D&md5=0fb317771152e0fbe4ddfb9c79f0fb3d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.023408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.023408%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DAshgodom%26aufirst%3DR.%2BT.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520modulation%2520of%2520oxidative%2520metabolism%2520in%2520design%2520of%2520improved%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D161%26epage%3D169%26doi%3D10.1124%2Fdmd.108.023408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunlap, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantvit, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overk, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2418</span><span class="NLM_x">–</span> <span class="NLM_lpage">2428</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1535-7163.MCT-07-0268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=17876041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2418-2428&author=B.+Yuauthor=B.+M.+Dietzauthor=T.+Dunlapauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=P.+Yaoauthor=Z.+Qinauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+modulation+of+reactivity%2Factivity+in+design+of+improved+benzothiophene+selective+estrogen+receptor+modulators%3A+induction+of+chemopreventive+mechanisms&doi=10.1158%2F1535-7163.MCT-07-0268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: Induction of chemopreventive mechanisms</span></div><div class="casAuthors">Yu, Bolan; Dietz, Birgit M.; Dunlap, Tareisha; Kastrati, Irida; Lantvit, Daniel D.; Overk, Cassia R.; Yao, Ping; Qin, Zhihui; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2418-2428</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERM) raloxifene and arzoxifene are in clin. use and clin. trials for chemoprevention of breast cancer and other indications.  These SERMs are "oxidatively labile" and therefore have potential to activate antioxidant responsive element (ARE) transcription of genes for cytoprotective phase II enzymes such as NAD(P)H-dependent quinone oxidoreductase 1 (NQO1).  To study this possible mechanism of cancer chemoprevention, a family of benzothiophene SERMs was developed with modulated redox activity, including arzoxifene and its metabolite desmethylarzoxifene (DMA).  The relative antioxidant activity of these SERMs was assayed and correlated with induction of NQO1 in murine and human liver cells.  DMA was found to induce NQO1 and to activate ARE more strongly than other SERMs, including raloxifene and 4-hydroxytamoxifen.  Livers from female, juvenile rats treated for 3 days with estradiol and/or with the benzothiophene SERMs arzoxifene, DMA, and F-DMA showed substantial induction of NQO1 by the benzothiophene SERMs.  No persuasive evidence in this assay or in MCF-7 breast cancer cells was obtained of a major role for the estrogen receptor in induction of NQO1 by the benzothiophene SERMs.  These results suggest that arzoxifene might provide chemopreventive benefits over raloxifene and other SERMs via metab. to DMA and stimulation of ARE-mediated induction of phase II enzymes.  The correlation of SERM structure with antioxidant activity and NQO1 induction also suggests that oxidative bioactivation of SERMs may be modulated to enhance chemopreventive activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosSszy7YqBrrVg90H21EOLACvtfcHk0ljjAAc3pj9INw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF&md5=11008f981dbbacdf5bd87e8919ef678a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0268%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DDietz%26aufirst%3DB.%2BM.%26aulast%3DDunlap%26aufirst%3DT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520modulation%2520of%2520reactivity%252Factivity%2520in%2520design%2520of%2520improved%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%253A%2520induction%2520of%2520chemopreventive%2520mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2418%26epage%3D2428%26doi%3D10.1158%2F1535-7163.MCT-07-0268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Overk, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asghodom, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantvit, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1520</span><span class="NLM_x">–</span> <span class="NLM_lpage">1526</span><span class="refDoi"> DOI: 10.1002/cmdc.200700104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1002%2Fcmdc.200700104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=17654759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1520-1526&author=C.+R.+Overkauthor=K.+W.+Pengauthor=R.+T.+Asghodomauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=Z.+Qinauthor=J.+Frasorauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structure-activity+relationships+for+a+family+of+benzothiophene+selective+estrogen+receptor+modulators+including+raloxifene+and+arzoxifene&doi=10.1002%2Fcmdc.200700104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene</span></div><div class="casAuthors">Overk, Cassia R.; Peng, Kuan-Wei; Asghodom, Rezene T.; Kastrati, Irida; Lantvit, Daniel D.; Qin, Zhihui; Frasor, Jonna; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1520-1526</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The search for the "ideal" selective estrogen receptor modulator (SERM) as a substitute for hormone replacement therapy (HRT) or use in cancer chemoprevention has focused on optimization of estrogen receptor (ER) ligand binding.  Based on the clin. and preclin. benzothiophene SERMs, raloxifene and arzoxifene, a family of SERMs has been developed to modulate activity and oxidative lability.  Antiestrogenic potency measured in human endometrial and breast cancer cells, and ER ligand binding data were correlated and seen to provide a guide to SERM design only when viewed in toto.  The in vitro studies were extended to the juvenile rat model, in which the desired antiestrogenic profile and putative cardiovascular benefits of SERMs were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJnWIhlKprLVg90H21EOLACvtfcHk0ljpFS0e5So3Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E&md5=da626d457446a6ed78ffa3f9939872b1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700104%26sid%3Dliteratum%253Aachs%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DPeng%26aufirst%3DK.%2BW.%26aulast%3DAsghodom%26aufirst%3DR.%2BT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructure-activity%2520relationships%2520for%2520a%2520family%2520of%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520including%2520raloxifene%2520and%2520arzoxifene%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1520%26epage%3D1526%26doi%3D10.1002%2Fcmdc.200700104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4’F-DMA, a new benzothiophene selective estrogen receptor modulator</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">787</span><span class="refDoi"> DOI: 10.1021/tx050326r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050326r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=779-787&author=H.+Liuauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Chemical+modification+modulates+estrogenic+activity%2C+oxidative+reactivity%2C+and+metabolic+stability+in+4%E2%80%99F-DMA%2C+a+new+benzothiophene+selective+estrogen+receptor+modulator&doi=10.1021%2Ftx050326r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Modification Modulates Estrogenic Activity, Oxidative Reactivity, and Metabolic Stability in 4'F-DMA, a New Benzothiophene Selective Estrogen Receptor Modulator</span></div><div class="casAuthors">Liu, Hong; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-787</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERMs), raloxifene and arzoxifene, in the clinic or clin. trials for treatment of breast cancer and postmenopausal symptoms, are highly susceptible to oxidative metab. and formation of electrophilic metabolites.  4'F-DMA, fluoro-substituted desmethyl arzoxifene (DMA), showed attenuated oxidn. to quinoids in incubation with rat hepatocytes as well as in rat and human liver microsomes.  Incubations of 4'F-DMA with hepatocytes yielded only one glucuronide conjugate and no GSH conjugates, whereas DMA underwent greater metab. giving two glucuronide conjugates, one sulfate conjugate, and two GSH conjugates.  Phase I and phase II metab. were further evaluated in human small intestine microsomes and in human intestinal Caco-2 cells.  In comparison to DMA, 4'F-DMA formed significantly less glucuronide and sulfate conjugates.  The formation of quinoids was further explored in hepatocytes in which DMA was obsd. to give concn.- and time-dependent depletion of GSH accompanied by damage to DNA, which showed inverse dependence on GSH; in contrast, GSH depletion and DNA damage were almost completely abrogated in incubations with 4'F-DMA. 4'F-DMA shows ligand binding affinity to estrogen receptor (ER)α and ERβ with similarity to both raloxifene and to DMA.  ER-mediated biol. activity was measured with the ERE-luciferase reporter system in transfected MCF-7 cells and Ishikawa cells, and in MCF-7 cells, proliferation was measured.  In all systems, 4'F-DMA exhibited antiestrogenic activity of comparable potency to raloxifene but did not manifest estrogenic properties, mirroring previous results on inhibition of estradiol-mediated induction of alk. phosphatase activity in Ishikawa cells.  These results suggest that 4'F-DMA might be an improved benzothiophene SERM with similar antiestrogenic activity to raloxifene but improved metabolic stability and attenuated toxicity, showing that simple chem. modification can abrogate oxidative bioactivation to potentially toxic metabolites without loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FltiqRoLAbVg90H21EOLACvtfcHk0ljpFS0e5So3Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D&md5=2ce12134bb346a54dc42bca0bb432063</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Ftx050326r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050326r%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DChemical%2520modification%2520modulates%2520estrogenic%2520activity%252C%2520oxidative%2520reactivity%252C%2520and%2520metabolic%2520stability%2520in%25204%25E2%2580%2599F-DMA%252C%2520a%2520new%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulator%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D779%26epage%3D787%26doi%3D10.1021%2Ftx050326r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Morello, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurz, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGregorio, M. W.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of selective estrogen receptor modulators</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.2165/00003088-200342040-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.2165%2F00003088-200342040-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=12648026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFWis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=361-372&author=K.+C.+Morelloauthor=G.+T.+Wurzauthor=M.+W.+DeGregorio&title=Pharmacokinetics+of+selective+estrogen+receptor+modulators&doi=10.2165%2F00003088-200342040-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of selective estrogen receptor modulators</span></div><div class="casAuthors">Morello, Karla C.; Wurz, Gregory T.; DeGregorio, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-372</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Selective estrogen receptor modulators (SERMs) are a class of compds. used to treat and prevent breast cancer and osteoporosis.  SERMs currently approved for use in patients include tamoxifen, toremifene and raloxifene.  These compds. are well tolerated in patients, and the most common adverse effects experienced in patients undergoing SERM therapy include vasomotor symptoms such as hot flashes and vaginal discharge.  New SERMs currently under development for use in the treatment and prevention of osteoporosis and breast cancer include ospemifene, a deriv. of toremifene, and arzoxifene, a compd. very similar in structure to raloxifene.  SERMs are administered orally at doses ranging from 20 to 60 mg/day.  Tamoxifen and toremifene have a bioavailability of approx. 100%, whereas that of raloxifene is only 2%.  SERMs are very highly bound to plasma proteins (>95%).  Tamoxifen and toremifene are metabolized by the cytochrome P 450 enzyme system, and raloxifene is metabolized by glucuronide conjugation.  The terminal elimination half-lives of these drugs range from 27.7 h to 7 days.  The pharmacokinetics of these compds. are affected in hepatically impaired patients, but not in renally impaired patients.  SERMs have several potential drug interactions with other agents, such as warfarin, rifampicin (rifampin), cholestyramine and aromatase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM59e60xM4P7Vg90H21EOLACvtfcHk0ljpFS0e5So3Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFWis7k%253D&md5=bad9ba129c37ed6003a4ff8738275353</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342040-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342040-00004%26sid%3Dliteratum%253Aachs%26aulast%3DMorello%26aufirst%3DK.%2BC.%26aulast%3DWurz%26aufirst%3DG.%2BT.%26aulast%3DDeGregorio%26aufirst%3DM.%2BW.%26atitle%3DPharmacokinetics%2520of%2520selective%2520estrogen%2520receptor%2520modulators%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26spage%3D361%26epage%3D372%26doi%3D10.2165%2F00003088-200342040-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Maximov, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">The Discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice</span> <span class="citation_source-journal">Curr. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span><span class="refDoi"> DOI: 10.2174/1574884711308020006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.2174%2F1574884711308020006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=23062036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1Ciu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=135-155&author=P.+Y.+Maximovauthor=T.+M.+Leeauthor=V.+C.+Jordan&title=The+Discovery+and+development+of+selective+estrogen+receptor+modulators+%28SERMs%29+for+clinical+practice&doi=10.2174%2F1574884711308020006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice</span></div><div class="casAuthors">Maximov, Philipp Y.; Lee, Theresa M.; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-155</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Selective estrogen receptor modulators (SERMs) are structurally different compds. that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists or antagonists.  These drugs have been intensively studied over the past decade and have proven to be a highly versatile group for the treatment of different conditions assocd. with postmenopausal women's health, including hormone responsive cancer and osteoporosis.  Tamoxifen, a failed contraceptive is currently used to treat all stages of breast cancer, chemoprevention in women at high risk for breast cancer and also has beneficial effects on bone mineral d. and serum lipids in postmenopausal women.  Raloxifene, a failed breast cancer drug, is the only SERM approved internationally for the prevention and treatment of postmenopausal osteoporosis and vertebral fractures.  However, although these SERMs have many benefits, they also have some potentially serious adverse effects, such as thromboembolic disorders and, in the case of tamoxifen, uterine cancer.  These adverse effects represent a major concern given that long-term therapy is required to prevent osteoporosis or prevent and treat breast cancer.  The search for the 'ideal' SERM, which would have estrogenic effects on bone and serum lipids, neutral effects on the uterus, and antiestrogenic effects on breast tissue, but none of the adverse effects assocd. with current therapies, is currently under way.  Ospemifene, lasofoxifene, bazedoxifene and arzoxifene, which are new SERM mols. with potentially greater efficacy and potency than previous SERMs, have been investigated for use in the treatment and prevention of osteoporosis.  These drugs have been shown to be comparably effective to conventional hormone replacement therapy in animal models, with potential indications for an improved safety profile.  Clin. efficacy data from ongoing phase III trials are available or are awaited for each SERM so that a true understanding of the therapeutic potential of these compds. can be obtained.  In this article, we describe the discovery and development of the group of medicines called SERMs.  The newer SERMs in late development: ospemifene, lasofoxifene, bazedoxifene, are arzoxifene are described in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHm6akpCPgJLVg90H21EOLACvtfcHk0liqpJncCowt-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1Ciu7o%253D&md5=7cddd250d63d64258fb21dacdd7d3043</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1574884711308020006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574884711308020006%26sid%3Dliteratum%253Aachs%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DT.%2BM.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DThe%2520Discovery%2520and%2520development%2520of%2520selective%2520estrogen%2520receptor%2520modulators%2520%2528SERMs%2529%2520for%2520clinical%2520practice%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D8%26spage%3D135%26epage%3D155%26doi%3D10.2174%2F1574884711308020006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2260</span><span class="NLM_x">–</span> <span class="NLM_lpage">2271</span><span class="refDoi"> DOI: 10.1021/tx800323w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800323w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=2260-2271&author=D.+Dalvieauthor=P.+Kangauthor=M.+Zientekauthor=C.+Xiangauthor=S.+Zhouauthor=R.+S.+Obach&title=Effect+of+intestinal+glucuronidation+in+limiting+hepatic+exposure+and+bioactivation+of+raloxifene+in+humans+and+rats&doi=10.1021%2Ftx800323w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Intestinal Glucuronidation in Limiting Hepatic Exposure and Bioactivation of Raloxifene in Humans and Rats</span></div><div class="casAuthors">Dalvie, Deepak; Kang, Ping; Zientek, Michael; Xiang, Cathie; Zhou, Sue; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2260-2271</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene (Evista) is a second generation selective estrogen receptor modulator used in the treatment of osteoporosis and for chemoprevention of breast cancer.  It is bioactivated to reactive intermediates, which covalently bind to proteins and form GSH conjugates upon incubation with NADPH and GSH-supplemented human and rat liver microsomes.  Despite these in vitro findings, no major raloxifene-related toxic events have been reported upon its oral administration to humans.  This disconnect between safety of raloxifene and its in vitro bioactivation is attributed to its presystemic metab. via glucuronidation.  Current studies investigated the effect of hepatic and intestinal glucuronidation in modulating hepatic availability of raloxifene and its subsequent bioactivation, in vitro.  The study design involved preincubation of raloxifene with intestinal microsomes followed by a sequential incubation with liver microsomes.  The degree of bioactivation of raloxifene was assessed from the percentage of GSH conjugate formed in liver microsomal incubations or the amt. of covalent binding of raloxifene-related material to liver microsomal proteins.  The results indicated that human intestinal glucuronidation limited the hepatic exposure of raloxifene that underwent bioactivation in the liver.  Similar expts. with rat microsomal prepns. showed very little effect of intestinal glucuronidation.  This effect of intestinal glucuronidation and the obsd. species difference were explained by comparing the efficiency (Clint) of glucuronidation and oxidn. in the two species.  These findings suggested that even though the rate of bioactivation in the two species was similar, the Clint of glucuronidation was 7.5-fold higher in the human intestine as compared to rats.  These results support the hypothesis that intestinal glucuronidation modulates the amt. of raloxifene undergoing bioactivation by liver and corroborate the importance of assessing other competitive metabolic pathways and species differences in metab. prior to extrapolation of bioactivation results from rats to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-CeHG1UEOrVg90H21EOLACvtfcHk0liqpJncCowt-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O&md5=69f878c5dd77d57379745df37cf9121b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx800323w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800323w%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DP.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DEffect%2520of%2520intestinal%2520glucuronidation%2520in%2520limiting%2520hepatic%2520exposure%2520and%2520bioactivation%2520of%2520raloxifene%2520in%2520humans%2520and%2520rats%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D2260%26epage%3D2271%26doi%3D10.1021%2Ftx800323w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kemp, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J. C.</span><span> </span><span class="NLM_article-title">Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">694</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1124/dmd.30.6.694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1124%2Fdmd.30.6.694" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=694-700&author=D.+C.+Kempauthor=P.+W.+Fanauthor=J.+C.+Stevens&title=Characterization+of+raloxifene+glucuronidation+in+vitro%3A+contribution+of+intestinal+metabolism+to+presystemic+clearance&doi=10.1124%2Fdmd.30.6.694"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.6.694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.6.694%26sid%3Dliteratum%253Aachs%26aulast%3DKemp%26aufirst%3DD.%2BC.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DStevens%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520raloxifene%2520glucuronidation%2520in%2520vitro%253A%2520contribution%2520of%2520intestinal%2520metabolism%2520to%2520presystemic%2520clearance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D694%26epage%3D700%26doi%3D10.1124%2Fdmd.30.6.694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Rosati, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Silva Jardine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toler, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebbinghaus, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhold, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjoa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetnam, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arriola, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirie, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkalcevic, G. T.</span><span> </span><span class="NLM_article-title">Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2928</span><span class="NLM_x">–</span> <span class="NLM_lpage">2931</span><span class="refDoi"> DOI: 10.1021/jm980048b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980048b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2928-2931&author=R.+L.+Rosatiauthor=P.+Da+Silva+Jardineauthor=K.+O.+Cameronauthor=D.+D.+Thompsonauthor=H.+Z.+Keauthor=S.+M.+Tolerauthor=T.+A.+Brownauthor=L.+C.+Panauthor=C.+F.+Ebbinghausauthor=A.+R.+Reinholdauthor=N.+C.+Elliottauthor=B.+N.+Newhouseauthor=C.+M.+Tjoaauthor=P.+M.+Sweetnamauthor=M.+J.+Coleauthor=M.+W.+Arriolaauthor=J.+W.+Gauthierauthor=D.+T.+Crawfordauthor=D.+F.+Nickersonauthor=C.+M.+Pirieauthor=H.+Qiauthor=H.+A.+Simmonsauthor=G.+T.+Tkalcevic&title=Discovery+and+preclinical+pharmacology+of+a+novel%2C+potent%2C+nonsteroidal+estrogen+receptor+agonist%2Fantagonist%2C+CP-336156%2C+a+diaryltetrahydronaphthalene&doi=10.1021%2Fjm980048b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm980048b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980048b%26sid%3Dliteratum%253Aachs%26aulast%3DRosati%26aufirst%3DR.%2BL.%26aulast%3DDa%2BSilva%2BJardine%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DToler%26aufirst%3DS.%2BM.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DPan%26aufirst%3DL.%2BC.%26aulast%3DEbbinghaus%26aufirst%3DC.%2BF.%26aulast%3DReinhold%26aufirst%3DA.%2BR.%26aulast%3DElliott%26aufirst%3DN.%2BC.%26aulast%3DNewhouse%26aufirst%3DB.%2BN.%26aulast%3DTjoa%26aufirst%3DC.%2BM.%26aulast%3DSweetnam%26aufirst%3DP.%2BM.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DArriola%26aufirst%3DM.%2BW.%26aulast%3DGauthier%26aufirst%3DJ.%2BW.%26aulast%3DCrawford%26aufirst%3DD.%2BT.%26aulast%3DNickerson%26aufirst%3DD.%2BF.%26aulast%3DPirie%26aufirst%3DC.%2BM.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DSimmons%26aufirst%3DH.%2BA.%26aulast%3DTkalcevic%26aufirst%3DG.%2BT.%26atitle%3DDiscovery%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520novel%252C%2520potent%252C%2520nonsteroidal%2520estrogen%2520receptor%2520agonist%252Fantagonist%252C%2520CP-336156%252C%2520a%2520diaryltetrahydronaphthalene%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2928%26epage%3D2931%26doi%3D10.1021%2Fjm980048b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">David, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellet-Rostaing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier dit Chabert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, M.</span><span> </span><span class="NLM_article-title">Fournier dit Chabert, J.; Lemaire, M. Efficient access to 2-aryl-3-substituted benzo[b]thiophenes</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3569</span><span class="NLM_x">–</span> <span class="NLM_lpage">3573</span><span class="refDoi"> DOI: 10.1021/jo0500378</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0500378" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=3569-3573&author=E.+Davidauthor=J.+Perrinauthor=S.+Pellet-Rostaingauthor=J.+Fournier+dit+Chabertauthor=M.+Lemaire&title=Fournier+dit+Chabert%2C+J.%3B+Lemaire%2C+M.+Efficient+access+to+2-aryl-3-substituted+benzo%5Bb%5Dthiophenes&doi=10.1021%2Fjo0500378"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjo0500378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0500378%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DE.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DPellet-Rostaing%26aufirst%3DS.%26aulast%3DFournier%2Bdit%2BChabert%26aufirst%3DJ.%26aulast%3DLemaire%26aufirst%3DM.%26atitle%3DFournier%2520dit%2520Chabert%252C%2520J.%253B%2520Lemaire%252C%2520M.%2520Efficient%2520access%2520to%25202-aryl-3-substituted%2520benzo%255Bb%255Dthiophenes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D3569%26epage%3D3573%26doi%3D10.1021%2Fjo0500378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Jia, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">Synthesis and properties of novel electroactive poly(amic acid) and polyimide copolymers bearing pendant oligoaniline groups</span> <span class="citation_source-journal">Polym. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1300</span><span class="NLM_x">–</span> <span class="NLM_lpage">1306</span><span class="refDoi"> DOI: 10.1039/c1py00035g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1039%2Fc1py00035g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Kgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1300-1306&author=X.+T.+Jiaauthor=D.+M.+Chaoauthor=H.+T.+Liuauthor=L.+B.+Heauthor=T.+Zhengauthor=X.+J.+Bianauthor=C.+Wang&title=Synthesis+and+properties+of+novel+electroactive+poly%28amic+acid%29+and+polyimide+copolymers+bearing+pendant+oligoaniline+groups&doi=10.1039%2Fc1py00035g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and properties of novel electroactive poly(amic acid) and polyimide copolymers bearing pendant oligoaniline groups</span></div><div class="casAuthors">Jia, Xiaoteng; Chao, Danming; Liu, Hongtao; He, Libing; Zheng, Tian; Bian, Xiujie; Wang, Ce</div><div class="citationInfo"><span class="NLM_cas:title">Polymer Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1300-1306</span>CODEN:
                <span class="NLM_cas:coden">PCOHC2</span>;
        ISSN:<span class="NLM_cas:issn">1759-9962</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of novel electroactive copolymers of poly(amic acid) (PAA) bearing pendant aniline tetramer groups were prepd. via direct polycondensation from novel electroactive diamine (EDA), 4,4'-diaminodiphenyl ether (p-ODA) and 3,3',4,4'-biphenyltetracarboxylic dianhydride (s-BPDA).  The structures of the copolymers were confirmed by FT-IR and 1H NMR measurements.  Then the prepd. PAA copolymers were heated at 300 °C to induce cyclization, and transformed into polyimide (PI) films.  The obtained PI films exhibited excellent thermal stability and outstanding mech. properties.  The PAA copolymers films had reversible redox couples with good cycle stability.  The stepwise oxidn. of as-prepd. PAA copolymers by ammonium persulfate is monitored by UV-vis spectroscopy.  The absorption peak at 571 nm underwent a red shift when it transformed from emeraldine state to pernigraniline state.  Moreover, the PAA copolymers films revealed electrochromic behaviors with a color change from yellowish at its neutral state, to green, and finally to dark blue.  They also exhibited extremely high optical contrast (%ΔT) up to 63% at 700 nm, moderate coloration efficiency (CE ≈ 100 cm2 C-1) and low switching times of 3.9 s at 0.8 V and 1.3 s for fast bleaching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVZIhyNBB6SLVg90H21EOLACvtfcHk0ljTZVjyUqaUyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Kgs7Y%253D&md5=40c6e19cbf425e55a34a4f185c588007</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2Fc1py00035g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1py00035g%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DX.%2BT.%26aulast%3DChao%26aufirst%3DD.%2BM.%26aulast%3DLiu%26aufirst%3DH.%2BT.%26aulast%3DHe%26aufirst%3DL.%2BB.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DBian%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520properties%2520of%2520novel%2520electroactive%2520poly%2528amic%2520acid%2529%2520and%2520polyimide%2520copolymers%2520bearing%2520pendant%2520oligoaniline%2520groups%26jtitle%3DPolym.%2520Chem.%26date%3D2011%26volume%3D2%26spage%3D1300%26epage%3D1306%26doi%3D10.1039%2Fc1py00035g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Callis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Challinor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G.</span><span> </span><span class="NLM_article-title">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">748</span><span class="NLM_x">–</span> <span class="NLM_lpage">759</span><span class="refDoi"> DOI: 10.1177/1087057115580298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1177%2F1087057115580298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25851036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=748-759&author=R.+Callisauthor=A.+Rabowauthor=M.+Tongeauthor=R.+Bradburyauthor=M.+Challinorauthor=K.+Robertsauthor=K.+Jonesauthor=G.+Walker&title=A+screening+assay+cascade+to+identify+and+characterize+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1177%2F1087057115580298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span></div><div class="casAuthors">Callis, Rowena; Rabow, Alfred; Tonge, Michael; Bradbury, Robert; Challinor, Mairi; Roberts, Karen; Jones, Karen; Walker, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compds. with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments.  Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compds., but such approaches can be limited due to low throughput and sensitivity, resp.  We have used an endogenous cell-imaging strategy that has both the throughput and sensitivity to support a large-scale hit-to-lead program to identify novel compds.  A screening cascade with a suite of assays has been developed to characterize compds. that modulate estrogen receptor α (ERα)-mediated signaling or downregulate ERα levels in cells.  Initially, from a focused high-throughput screening, novel ERα binders were identified that could be modified chem. into ERα downregulators.  Following this, cellular assays helped det. the mechanism of action of compds. to distinguish between on-target and off-target compds. and differentiate SERDs, selective estrogen receptor modulator (SERM) compds., and agonist ERα ligands.  Data are shown to exemplify the characterization of ERα-mediated signaling inhibitors using a selection of literature compds. and illustrate how this cascade has been used to drive the chem. design of novel SERD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNNWMPPJDNrVg90H21EOLACvtfcHk0ljTZVjyUqaUyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE&md5=13c27dbf08f315d469f81b2bcefb4499</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1177%2F1087057115580298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115580298%26sid%3Dliteratum%253Aachs%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DBradbury%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DA%2520screening%2520assay%2520cascade%2520to%2520identify%2520and%2520characterize%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D748%26epage%3D759%26doi%3D10.1177%2F1087057115580298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Jiang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yingling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1016/0303-7207(92)90104-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2F0303-7207%2892%2990104-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1301400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=77-86&author=S.+Y.+Jiangauthor=D.+M.+Wolfauthor=J.+M.+Yinglingauthor=C.+Changauthor=V.+C.+Jordan&title=An+estrogen+receptor+positive+MCF-7+clone+that+is+resistant+to+antiestrogens+and+estradiol&doi=10.1016%2F0303-7207%2892%2990104-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol</span></div><div class="casAuthors">Jiang, Shun Yuan; Wolf, Douglas M.; Yingling, Jonathan M.; Chang, Chawnshang; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    </div><div class="casAbstract">The antiestrogen tamoxifen has been successfully used to control estrogen receptor (ER)- and progesterone receptor-pos. breast cancer.  However, the development of antiestrogen resistance is frequently obsd. in patients following long-term treatment.  The development of antiestrogen resistance was studied in vitro, and an antiestrogen resistant variant of MCF-7 cells (clone 5C) was established after long-term culture in estrogen-free medium.  The growth of clone 5C cells was not altered by either estradiol or the antiestrogens 4-hydroxytamoxifen and ICI 164,384.  Estrogen-stimulated progesterone receptor and reporter gene expression were markedly reduced in 5C cells compared to wild-type MCF-7 cells.  Only minor alteration in the levels of ER and no alteration in the affinity of ER for ligand were found in 5C cells.  No mutation of ER cDNA in 5C cells was detected by polymerase chain reaction and DNA sequencing.  This study demonstrates that change(s) in ER-mediated gene expression rather than the amino acid sequence of the ER itself may be assocd. with the development of at least one form of antiestrogen resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7D95adwlHwLVg90H21EOLACvtfcHk0ljTZVjyUqaUyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D&md5=3bfb8ea4c10526f1477410c7cf6a03d7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0303-7207%2892%2990104-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-7207%252892%252990104-E%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DS.%2BY.%26aulast%3DWolf%26aufirst%3DD.%2BM.%26aulast%3DYingling%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAn%2520estrogen%2520receptor%2520positive%2520MCF-7%2520clone%2520that%2520is%2520resistant%2520to%2520antiestrogens%2520and%2520estradiol%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D1992%26volume%3D90%26spage%3D77%26epage%3D86%26doi%3D10.1016%2F0303-7207%2892%2990104-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Molloy, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherezghiher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalsen, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maximov, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span> </span><span class="NLM_article-title">Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2515</span><span class="NLM_x">–</span> <span class="NLM_lpage">2526</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1535-7163.MCT-14-0319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25205655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2515-2526&author=M.+E.+Molloyauthor=B.+E.+Whiteauthor=T.+Gherezghiherauthor=B.+T.+Michalsenauthor=R.+Xiongauthor=H.+Patelauthor=H.+Zhaoauthor=P.+Y.+Maximovauthor=V.+C.+Jordanauthor=G.+R.+Thatcherauthor=D.+A.+Tonetti&title=Novel+selective+estrogen+mimics+for+the+treatment+of+tamoxifen-resistant+breast+cancer&doi=10.1158%2F1535-7163.MCT-14-0319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Molloy, Mary Ellen; White, Bethany E. Perez; Gherezghiher, Teshome; Michalsen, Bradley T.; Xiong, Rui; Patel, Hitisha; Zhao, Huiping; Maximov, Philipp Y.; Jordan, V. Craig; Thatcher, Gregory R. J.; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2515-2526</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endocrine-resistant breast cancer is a major clin. obstacle.  The use of 17β-estradiol (E2) has reemerged as a potential treatment option following exhaustive use of tamoxifen or aromatase inhibitors, although side effects have hindered its clin. usage.  Protein kinase C alpha (PKCα) expression was shown to be a predictor of disease outcome for patients receiving endocrine therapy and may predict a pos. response to an estrogenic treatment.  Here, we have investigated the use of novel benzothiophene selective estrogen mimics (SEM) as an alternative to E2 for the treatment of tamoxifen-resistant breast cancer.  Following in vitro characterization of SEMs, a panel of clin. relevant PKCα-expressing, tamoxifen-resistant models were used to investigate the antitumor effects of these compds.  SEM treatment resulted in growth inhibition and apoptosis of tamoxifen-resistant cell lines in vitro.  In vivo SEM treatment induced tumor regression of tamoxifen-resistant T47D:A18/PKCα and T47D:A18-TAM1 tumor models.  T47D:A18/PKCα tumor regression was accompanied by translocation of estrogen receptor (ER) α to extranuclear sites, possibly defining a mechanism through which these SEMs initiate tumor regression.  SEM treatment did not stimulate growth of E2-dependent T47D:A18/neo tumors.  In addn., unlike E2 or tamoxifen, treatment with SEMs did not stimulate uterine wt. gain.  These findings suggest the further development of SEMs as a feasible therapeutic strategy for the treatment of endocrine-resistant breast cancer without the side effects assocd. with E2.  Mol Cancer Ther; 13(11); 2515-26. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64x3RCcDeYbVg90H21EOLACvtfcHk0linTUE3k9WiUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N&md5=203055e50477bcb1c98ea4c7844cf4b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0319%26sid%3Dliteratum%253Aachs%26aulast%3DMolloy%26aufirst%3DM.%2BE.%26aulast%3DWhite%26aufirst%3DB.%2BE.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DMichalsen%26aufirst%3DB.%2BT.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520selective%2520estrogen%2520mimics%2520for%2520the%2520treatment%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2515%26epage%3D2526%26doi%3D10.1158%2F1535-7163.MCT-14-0319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisele, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanArsdale, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dann, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primeau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5121</span><span class="NLM_x">–</span> <span class="NLM_lpage">5130</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1078-0432.CCR-15-0360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25991817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5121-5130&author=S.+E.+Wardellauthor=M.+J.+Ellisauthor=H.+M.+Alleyauthor=K.+Eiseleauthor=T.+VanArsdaleauthor=S.+G.+Dannauthor=K.+T.+Arndtauthor=T.+Primeauauthor=E.+Griffinauthor=J.+Shaoauthor=R.+Crowderauthor=J.+P.+Laiauthor=J.+D.+Norrisauthor=D.+P.+McDonnellauthor=S.+Li&title=Efficacy+of+SERD%2FSERM+hybrid-CDK4%2F6+inhibitor+combinations+in+models+of+endocrine+therapy-resistant+breast+cancer&doi=10.1158%2F1078-0432.CCR-15-0360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer</span></div><div class="casAuthors">Wardell, Suzanne E.; Ellis, Matthew J.; Alley, Holly M.; Eisele, Koleen; Van Arsdale, Todd; Dann, Stephen G.; Arndt, Kim T.; Primeau, Tina; Griffin, Elizabeth; Shao, Jieya; Crowder, Robert; Lai, Jin-Ping; Norris, John D.; McDonnell, Donald P.; Li, Shunqiang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5121-5130</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)-pos. breast cancer.  However, ESR1 mutations or other ligand-independent ESR1 activation mechanisms limit the duration of response.  The clin. efficacy of fulvestrant, a selective estrogen receptor downregulator (SERD) that competitively inhibits agonist binding to ESR1 and triggers receptor downregulation, has confirmed that ESR1 frequently remains engaged in endocrine therapy-resistant cancers.  We evaluated the activity of a new class of selective estrogen receptor modulators (SERM)/SERD hybrids (SSH) that downregulate ESR1 in relevant models of endocrine-resistant breast cancer.  Building on the observation that concurrent inhibition of ESR1 and the cyclin-dependent kinases 4 and 6 (CDK4/6) significantly increased progression-free survival in advanced patients, we explored the activity of different SERD- or SSH-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant ESR1+ breast cancer.  Exptl. Design: SERDs, SSHs, and the CDK4/6 inhibitor palbociclib were evaluated as single agents or in combination in established cellular and animal models of endocrine therapy-resistant ESR1+ breast cancer.  Results: The combination of palbociclib with a SERD or an SSH was shown to effectively inhibit the growth of MCF7 cell or ESR1-mutant patient-derived tumor xenografts.  In tamoxifen-resistant MCF7 xenografts, the palbociclib/SERD or SSH combination resulted in an increased duration of response as compared with either drug alone.  Conclusions: A SERD- or SSH-palbociclib combination has therapeutic potential in breast tumors resistant to endocrine therapies or those expressing ESR1 mutations.  Clin Cancer Res; 21(22); 5121-30. ©2015 AACR.  See related commentary by DeMichele and Chodosh, p.  4999.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZJESmSBzCpLVg90H21EOLACvtfcHk0linTUE3k9WiUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbnK&md5=73be58473ccda7c811fa010334c60479</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0360%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DEisele%26aufirst%3DK.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DDann%26aufirst%3DS.%2BG.%26aulast%3DArndt%26aufirst%3DK.%2BT.%26aulast%3DPrimeau%26aufirst%3DT.%26aulast%3DGriffin%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DJ.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DEfficacy%2520of%2520SERD%252FSERM%2520hybrid-CDK4%252F6%2520inhibitor%2520combinations%2520in%2520models%2520of%2520endocrine%2520therapy-resistant%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D5121%26epage%3D5130%26doi%3D10.1158%2F1078-0432.CCR-15-0360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Leek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimes, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, A.</span><span> </span><span class="NLM_article-title">Methods: using three-dimensional culture (spheroids) as an in vitro model of tumour hypoxia</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">899</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.1007/978-3-319-26666-4_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2F978-3-319-26666-4_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=899&publication_year=2016&pages=167-196&author=R.+Leekauthor=D.+R.+Grimesauthor=A.+L.+Harrisauthor=A.+McIntyre&title=Methods%3A+using+three-dimensional+culture+%28spheroids%29+as+an+in+vitro+model+of+tumour+hypoxia&doi=10.1007%2F978-3-319-26666-4_10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-26666-4_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-26666-4_10%26sid%3Dliteratum%253Aachs%26aulast%3DLeek%26aufirst%3DR.%26aulast%3DGrimes%26aufirst%3DD.%2BR.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DMcIntyre%26aufirst%3DA.%26atitle%3DMethods%253A%2520using%2520three-dimensional%2520culture%2520%2528spheroids%2529%2520as%2520an%2520in%2520vitro%2520model%2520of%2520tumour%2520hypoxia%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2016%26volume%3D899%26spage%3D167%26epage%3D196%26doi%3D10.1007%2F978-3-319-26666-4_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Davies, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arriagada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alencar, V. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonfill, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delmestri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inbar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khaled, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kielanowska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittra, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peralta, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pernas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petruzelka, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienkowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radhika, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubach, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tort, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urrutia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, R.</span><span> </span><span class="NLM_article-title">Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61963-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2FS0140-6736%2812%2961963-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=805-816&author=C.+Daviesauthor=H.+C.+Panauthor=J.+Godwinauthor=R.+Grayauthor=R.+Arriagadaauthor=V.+Rainaauthor=M.+Abrahamauthor=V.+H.+M.+Alencarauthor=A.+Badranauthor=X.+Bonfillauthor=J.+Bradburyauthor=M.+Clarkeauthor=R.+Collinsauthor=S.+R.+Davisauthor=A.+Delmestriauthor=J.+F.+Forbesauthor=P.+Haddadauthor=M.+F.+Houauthor=M.+Inbarauthor=H.+Khaledauthor=J.+Kielanowskaauthor=W.+H.+Kwanauthor=B.+S.+Mathewauthor=I.+Mittraauthor=B.+Mullerauthor=A.+Nicolucciauthor=O.+Peraltaauthor=F.+Pernasauthor=L.+Petruzelkaauthor=T.+Pienkowskiauthor=R.+Radhikaauthor=B.+Rajanauthor=M.+T.+Rubachauthor=S.+Tortauthor=G.+Urrutiaauthor=M.+Valentiniauthor=Y.+C.+Wangauthor=R.+Peto&title=Long-term+effects+of+continuing+adjuvant+tamoxifen+to+10+years+versus+stopping+at+5+years+after+diagnosis+of+oestrogen+receptor-positive+breast+cancer%3A+ATLAS%2C+a+randomised+trial&doi=10.1016%2FS0140-6736%2812%2961963-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961963-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961963-1%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DH.%2BC.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DArriagada%26aufirst%3DR.%26aulast%3DRaina%26aufirst%3DV.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DAlencar%26aufirst%3DV.%2BH.%2BM.%26aulast%3DBadran%26aufirst%3DA.%26aulast%3DBonfill%26aufirst%3DX.%26aulast%3DBradbury%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DS.%2BR.%26aulast%3DDelmestri%26aufirst%3DA.%26aulast%3DForbes%26aufirst%3DJ.%2BF.%26aulast%3DHaddad%26aufirst%3DP.%26aulast%3DHou%26aufirst%3DM.%2BF.%26aulast%3DInbar%26aufirst%3DM.%26aulast%3DKhaled%26aufirst%3DH.%26aulast%3DKielanowska%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DW.%2BH.%26aulast%3DMathew%26aufirst%3DB.%2BS.%26aulast%3DMittra%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DB.%26aulast%3DNicolucci%26aufirst%3DA.%26aulast%3DPeralta%26aufirst%3DO.%26aulast%3DPernas%26aufirst%3DF.%26aulast%3DPetruzelka%26aufirst%3DL.%26aulast%3DPienkowski%26aufirst%3DT.%26aulast%3DRadhika%26aufirst%3DR.%26aulast%3DRajan%26aufirst%3DB.%26aulast%3DRubach%26aufirst%3DM.%2BT.%26aulast%3DTort%26aufirst%3DS.%26aulast%3DUrrutia%26aufirst%3DG.%26aulast%3DValentini%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DPeto%26aufirst%3DR.%26atitle%3DLong-term%2520effects%2520of%2520continuing%2520adjuvant%2520tamoxifen%2520to%252010%2520years%2520versus%2520stopping%2520at%25205%2520years%2520after%2520diagnosis%2520of%2520oestrogen%2520receptor-positive%2520breast%2520cancer%253A%2520ATLAS%252C%2520a%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D805%26epage%3D816%26doi%3D10.1016%2FS0140-6736%2812%2961963-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Robinson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vats, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonigro, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyana-Sundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodges, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gursky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roychowdhury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienta, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rae, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Poznak, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunju, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span><span class="refDoi"> DOI: 10.1038/ng.2823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1038%2Fng.2823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=24185510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1446-1451&author=D.+R.+Robinsonauthor=Y.+M.+Wuauthor=P.+Vatsauthor=F.+Suauthor=R.+J.+Lonigroauthor=X.+Caoauthor=S.+Kalyana-Sundaramauthor=R.+Wangauthor=Y.+Ningauthor=L.+Hodgesauthor=A.+Gurskyauthor=J.+Siddiquiauthor=S.+A.+Tomlinsauthor=S.+Roychowdhuryauthor=K.+J.+Pientaauthor=S.+Y.+Kimauthor=J.+S.+Robertsauthor=J.+M.+Raeauthor=C.+H.+Van+Poznakauthor=D.+F.+Hayesauthor=R.+Chughauthor=L.+P.+Kunjuauthor=M.+Talpazauthor=A.+F.+Schottauthor=A.+M.+Chinnaiyan&title=Activating+ESR1+mutations+in+hormone-resistant+metastatic+breast+cancer&doi=10.1038%2Fng.2823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Vats, Pankaj; Su, Fengyun; Lonigro, Robert J.; Cao, Xuhong; Kalyana-Sundaram, Shanker; Wang, Rui; Ning, Yu; Hodges, Lynda; Gursky, Amy; Siddiqui, Javed; Tomlins, Scott A.; Roychowdhury, Sameek; Pienta, Kenneth J.; Kim, Scott Y.; Roberts, J. Scott; Rae, James M.; Van Poznak, Catherine H.; Hayes, Daniel F.; Chugh, Rashmi; Kunju, Lakshmi P.; Talpaz, Moshe; Schott, Anne F.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express estrogen receptor-α (ER-α, encoded by ESR1).  Through a prospective clin. sequencing program for advanced cancers, we enrolled 11 patients with ER-pos. metastatic breast cancer.  Whole-exome and transcriptome anal. showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain (LBD), all of whom had been treated with anti-estrogens and estrogen deprivation therapies.  A survey of The Cancer Genome Atlas (TCGA) identified four endometrial cancers with similar mutations of ESR1.  The five new LBD-localized ESR1 mutations identified here (encoding p.Leu536Gln, p.Tyr537Ser, p.Tyr537Cys, p.Tyr537Asn and p.Asp538Gly) were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.  Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQSL6mlhMOrVg90H21EOLACvtfcHk0liuI-K5ilhOFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN&md5=af9e69d6064726af238fe74dad7d2204</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fng.2823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2823%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DGursky%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DRae%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BPoznak%26aufirst%3DC.%2BH.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DActivating%2520ESR1%2520mutations%2520in%2520hormone-resistant%2520metastatic%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fng.2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Toy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakr, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gala, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span> </span><span class="NLM_article-title">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1445</span><span class="refDoi"> DOI: 10.1038/ng.2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1038%2Fng.2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=24185512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1439-1445&author=W.+Toyauthor=Y.+Shenauthor=H.+Wonauthor=B.+Greenauthor=R.+A.+Sakrauthor=M.+Willauthor=Z.+Liauthor=K.+Galaauthor=S.+Fanningauthor=T.+A.+Kingauthor=C.+Hudisauthor=D.+Chenauthor=T.+Taranauthor=G.+Hortobagyiauthor=G.+Greeneauthor=M.+Bergerauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=ESR1+ligand-binding+domain+mutations+in+hormone-resistant+breast+cancer&doi=10.1038%2Fng.2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span></div><div class="casAuthors">Toy, Weiyi; Shen, Yang; Won, Helen; Green, Bradley; Sakr, Rita A.; Will, Marie; Li, Zhiqiang; Gala, Kinisha; Fanning, Sean; King, Tari A.; Hudis, Clifford; Chen, David; Taran, Tetiana; Hortobagyi, Gabriel; Greene, Geoffrey; Berger, Michael; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition.  However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting.  We conducted a comprehensive genetic anal. of two independent cohorts of metastatic ER-pos. breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.  These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations.  Mol. dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor.  Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.  These data implicate LBD-mutant forms of ER in mediating clin. resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KQLxyqE3lrVg90H21EOLACvtfcHk0liuI-K5ilhOFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ&md5=1f7c247e079d08a463db4e20ec0f9d17</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fng.2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2822%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DSakr%26aufirst%3DR.%2BA.%26aulast%3DWill%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DGala%26aufirst%3DK.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DESR1%2520ligand-binding%2520domain%2520mutations%2520in%2520hormone-resistant%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26spage%3D1439%26epage%3D1445%26doi%3D10.1038%2Fng.2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Fanning, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayne, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dharmarajan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novick, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchamukhi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajkhorshid, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span> <span class="citation_source-journal">Elife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e12792</span><span class="refDoi"> DOI: 10.7554/eLife.12792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.7554%2FeLife.12792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=26836308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e12792&author=S.+W.+Fanningauthor=C.+G.+Mayneauthor=V.+Dharmarajanauthor=K.+E.+Carlsonauthor=T.+A.+Martinauthor=S.+J.+Novickauthor=W.+Toyauthor=B.+Greenauthor=S.+Panchamukhiauthor=B.+S.+Katzenellenbogenauthor=E.+Tajkhorshidauthor=P.+R.+Griffinauthor=Y.+Shenauthor=S.+Chandarlapatyauthor=J.+A.+Katzenellenbogenauthor=G.+L.+Greene&title=Estrogen+receptor+alpha+somatic+mutations+Y537S+and+D538G+confer+breast+cancer+endocrine+resistance+by+stabilizing+the+activating+function-2+binding+conformation&doi=10.7554%2FeLife.12792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span></div><div class="casAuthors">Fanning, Sean W.; Mayne, Christopher G.; Dharmarajan, Venkatasubramanian; Carlson, Kathryn E.; Martin, Teresa A.; Novick, Scott J.; Toy, Weiyi; Green, Bradley; Panchamukhi, Srinivas; Katzenellenbogen, Benita S.; Tajkhorshid, Emad; Griffin, Patrick R.; Shen, Yang; Chandarlapaty, Sarat; Katzenellenbogen, John A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e12792/1-e12792/25</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), esp. Y537S and D538G, have been linked to acquired resistance to endocrine therapies.  Cell based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance.  Here, we integrate biophys. and structural biol. data to reveal how these mutations lead to a constitutively active and antiestrogen resistant ERα.  We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced.  Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuokHLHqfD7Vg90H21EOLACvtfcHk0lhk4cyfidjpRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D&md5=417a51b5b7c9c3976befd25db4fb2003</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.7554%2FeLife.12792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.12792%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DMartin%26aufirst%3DT.%2BA.%26aulast%3DNovick%26aufirst%3DS.%2BJ.%26aulast%3DToy%26aufirst%3DW.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DPanchamukhi%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DEstrogen%2520receptor%2520alpha%2520somatic%2520mutations%2520Y537S%2520and%2520D538G%2520confer%2520breast%2520cancer%2520endocrine%2520resistance%2520by%2520stabilizing%2520the%2520activating%2520function-2%2520binding%2520conformation%26jtitle%3DElife%26date%3D2016%26volume%3D5%26spage%3De12792%26doi%3D10.7554%2FeLife.12792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Robertson, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4530</span><span class="NLM_x">–</span> <span class="NLM_lpage">4535</span><span class="refDoi"> DOI: 10.1200/JCO.2008.21.1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1200%2FJCO.2008.21.1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=19704066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4530-4535&author=J.+F.+Robertsonauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=E.+Macphersonauthor=J.+Lindemannauthor=M.+J.+Ellis&title=Activity+of+fulvestrant+500+mg+versus+anastrozole+1+mg+as+first-line+treatment+for+advanced+breast+cancer%3A+results+from+the+FIRST+study&doi=10.1200%2FJCO.2008.21.1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span></div><div class="casAuthors">Robertson, John F. R.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; MacPherson, Euan; Lindemann, Justin; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4530-4535</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the clin. activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-pos. breast cancer in postmenopausal women.  Patients and Methods: FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study of a fulvestrant high-dose (HD) regimen (500 mg/mo plus 500 mg on day 14 of month 1) vs. anastrozole (1 mg/d).  The primary efficacy end point was clin. benefit rate (CBR), defined as the proportion of patients experiencing an objective response (OR) or stable disease for ≥ 24 wk.  The primary anal. was performed 6 mo after the last patient was randomly assigned.  Results: CBR was similar for fulvestrant HD (n = 102) and anastrozole (n = 103), 72.5% v 67.0%, resp. (odds ratio, 1.30; 95% CI, 0.72 to 2.38; P = .386).  Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%.  Time to progression (TTP) was significantly longer for fulvestrant vs. anastrozole (median TTP not reached for fulvestrant HD v 12.5 mo for anastrozole; hazard ratio, 0.63; 95% CI, 0.39 to 1.00; P = .0496).  Duration of OR and CB also numerically favored fulvestrant HD.  Both treatments were well tolerated, with no significant differences in the incidence of prespecified adverse events.  Conclusion: First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was assocd. with significantly longer TTP.  Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-OU2SQaTsabVg90H21EOLACvtfcHk0lhk4cyfidjpRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J&md5=a7a6f5cd7fcdbc8cb6839a2800cd5cb8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.1136%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivity%2520of%2520fulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520the%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4530%26epage%3D4535%26doi%3D10.1200%2FJCO.2008.21.1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Robertson, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ’FIRST’ study</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1007/s10549-012-2192-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2Fs10549-012-2192-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=23065000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2qt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2012&pages=503-511&author=J.+F.+Robertsonauthor=J.+P.+Lindemannauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=L.+Emersonauthor=A.+Deanauthor=M.+J.+Ellis&title=Fulvestrant+500+mg+versus+anastrozole+1+mg+for+the+first-line+treatment+of+advanced+breast+cancer%3A+follow-up+analysis+from+the+randomized+%E2%80%99FIRST%E2%80%99+study&doi=10.1007%2Fs10549-012-2192-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized FIRST' study</span></div><div class="casAuthors">Robertson, John F. R.; Lindemann, Justin P. O.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; Emerson, Laura; Dean, Andrew; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">503-511</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-pos. (HR+) advanced breast cancer.  At data cut-off, only 36 % of patients had progressed and the median time to progression (TTP) had not been reached for fulvestrant.  Here, we report follow-up data for TTP for fulvestrant 500 mg vs. anastrozole 1 mg.  Key inclusion criteria were postmenopausal women with estrogen receptor-pos. and/or progesterone receptor-pos. locally advanced or metastatic breast cancer and no prior endocrine therapy.  Key exclusion criteria were presence of life-threatening metastases and prior treatment with a non-approved drug.  Fulvestrant was administered 500 mg/mo plus 500 mg on day 14 of month 1; anastrozole was administered 1 mg/day.  TTP was defined by modified Response Evaluation Criteria in Solid Tumors v1.0 before data cut-off for the primary anal., and investigator opinion after data cut-off.  Best overall response to subsequent therapy and serious adverse events are also reported.  In total, 205 patients received fulvestrant 500 mg (n = 102) or anastrozole (n = 103).  Follow-up anal. was performed when 79.5 % of patients had discontinued study treatment.  Median TTP was 23.4 mo for fulvestrant vs. 13.1 mo for anastrozole; a 34 % redn. in risk of progression (hazard ratio 0.66; 95 % confidence interval: 0.47, 0.92; P = 0.01).  Best overall response to subsequent therapy and clin. benefit rate for subsequent endocrine therapy was similar between the treatment groups.  No new safety concerns for fulvestrant 500 mg were documented.  These longer-term, follow-up results confirm efficacy benefit for fulvestrant 500 mg vs. anastrozole as first-line endocrine therapy for HR+ advanced breast cancer in terms of TTP, and, importantly, show similar best overall response rates to subsequent endocrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy8Wj4FyrbY7Vg90H21EOLACvtfcHk0lhk4cyfidjpRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2qt7vM&md5=f4fd805737cb8eb7fc8d007fbcf99e01</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs10549-012-2192-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-012-2192-4%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26aulast%3DLindemann%26aufirst%3DJ.%2BP.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DEmerson%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DA.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DFulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520for%2520the%2520first-line%2520treatment%2520of%2520advanced%2520breast%2520cancer%253A%2520follow-up%2520analysis%2520from%2520the%2520randomized%2520%25E2%2580%2599FIRST%25E2%2580%2599%2520study%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D136%26spage%3D503%26epage%3D511%26doi%3D10.1007%2Fs10549-012-2192-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Zaman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winterhalder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasler-Strub, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochlitz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berset, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiliders, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondeau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neven, P.</span><span> </span><span class="NLM_article-title">Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1212</span><span class="NLM_x">–</span> <span class="NLM_lpage">1220</span><span class="refDoi"> DOI: 10.1016/j.ejca.2015.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.ejca.2015.03.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=1212-1220&author=K.+Zamanauthor=R.+Winterhalderauthor=C.+Mamotauthor=U.+Hasler-Strubauthor=C.+Rochlitzauthor=A.+Muellerauthor=C.+Bersetauthor=H.+Wilidersauthor=L.+Pereyauthor=C.+B.+Rudolfauthor=H.+Hawleauthor=S.+Rondeauauthor=P.+Neven&title=Fulvestrant+with+or+without+selumetinib%2C+a+MEK+1%2F2+inhibitor%2C+in+breast+cancer+progressing+after+aromatase+inhibitor+therapy%3A+a+multicentre+randomised+placebo-controlled+double-blind+phase+II+trial%2C+SAKK+21%2F08&doi=10.1016%2Fj.ejca.2015.03.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DZaman%26aufirst%3DK.%26aulast%3DWinterhalder%26aufirst%3DR.%26aulast%3DMamot%26aufirst%3DC.%26aulast%3DHasler-Strub%26aufirst%3DU.%26aulast%3DRochlitz%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DA.%26aulast%3DBerset%26aufirst%3DC.%26aulast%3DWiliders%26aufirst%3DH.%26aulast%3DPerey%26aufirst%3DL.%26aulast%3DRudolf%26aufirst%3DC.%2BB.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DRondeau%26aufirst%3DS.%26aulast%3DNeven%26aufirst%3DP.%26atitle%3DFulvestrant%2520with%2520or%2520without%2520selumetinib%252C%2520a%2520MEK%25201%252F2%2520inhibitor%252C%2520in%2520breast%2520cancer%2520progressing%2520after%2520aromatase%2520inhibitor%2520therapy%253A%2520a%2520multicentre%2520randomised%2520placebo-controlled%2520double-blind%2520phase%2520II%2520trial%252C%2520SAKK%252021%252F08%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2015%26volume%3D51%26spage%3D1212%26epage%3D1220%26doi%3D10.1016%2Fj.ejca.2015.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loibl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aktas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenegg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Saenz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margeli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liedtke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachsmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De la Haba-Rodriguez, J. R.</span><span> </span><span class="NLM_article-title">Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span><span class="refDoi"> DOI: 10.1200/JCO.2014.57.2388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1200%2FJCO.2014.57.2388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25691671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntVWltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1045-1052&author=M.+Martinauthor=S.+Loiblauthor=G.+von+Minckwitzauthor=S.+Moralesauthor=N.+Martinezauthor=A.+Guerreroauthor=A.+Antonauthor=B.+Aktasauthor=W.+Schoeneggauthor=M.+Munozauthor=J.+A.+Garcia-Saenzauthor=M.+Gilauthor=M.+Ramosauthor=M.+Margeliauthor=E.+Carrascoauthor=C.+Liedtkeauthor=G.+Wachsmannauthor=K.+Mehtaauthor=J.+R.+De+la+Haba-Rodriguez&title=Phase+III+trial+evaluating+the+addition+of+bevacizumab+to+endocrine+therapy+as+first-line+treatment+for+advanced+breast+cancer%3A+the+letrozole%2Ffulvestrant+and+avastin+%28LEA%29+study&doi=10.1200%2FJCO.2014.57.2388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study</span></div><div class="casAuthors">Martin, Miguel; Loibl, Sibylle; von Minckwitz, Gunter; Morales, Serafin; Martinez, Noelia; Guerrero, Angel; Anton, Antonio; Aktas, Bahriye; Schoenegg, Winfried; Munoz, Montserrat; Garcia-Saenz, Jose ngel; Gil, Miguel; Ramos, Manuel; Margeli, Mireia; Carrasco, Eva; Liedtke, Cornelia; Wachsmann, Grischa; Mehta, Keyur; De la Haba-Rodriguez, Juan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1045-1052</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To test whether combining bevacizumab, an anti-vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET.  Patients and Methods: A multicenter, randomized, open-label, phase III, binational (Spain and Germany) study added bevacizumab (15 mg/kg every 3 wk) to ET (ET-B; letrozole or fulvestrant) as first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -neg. and hormone receptor-pos. advanced breast cancer.  We compared progression-free survival (PFS), overall survival (OS), overall response rate (ORR), response duration (RD), time to treatment failure (TTF), clin. benefit rate (CBR), and safety.  Results: From 380 patients recruited (2007 to 2011), 374 were analyzed by intent to-treat (184 patients on ET and 190 patients on ET-B).  Median age was 65 years, 270 patients (72%) had Eastern Cooperative Oncol. Group performance status of 0, 178 patients (48%) had visceral metastases, and 171 patients (46%) and 195 patients (52%) had received prior chemotherapy or ET, resp.  Median PFS was 14.4 mo in the ET arm and 19.3 mo in the ET-B arm (hazard ratio, 0.83; 95% CI, 0.65 to 1.06; P = .126).  ORR, CBR, and RD with ET vs. ET-B were 22% vs. 41% (P < .001), 67% vs. 77% (P = .041), and 13.3 mo vs. 17.6 mo (P = .434), resp.  TTF and OS were comparable in both arms.  Grade 3 to 4 hypertension, aminotransferase elevation, and proteinuria were significantly higher in the ET-B arm.  Eight patients (4.2%) receiving ET-B died during study or within 30 days of end of treatment.  Conclusion: The addn. of bevacizumab to ET in first-line treatment failed to produce a statistically significant increase in PFS or OS in women with HER2-neg./hormone receptor-pos. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGA5oKmTG3sLVg90H21EOLACvtfcHk0liVKIfyzZPW-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntVWltLk%253D&md5=596f4923ccaf8126e492504efc2df4b6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.57.2388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.57.2388%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DN.%26aulast%3DGuerrero%26aufirst%3DA.%26aulast%3DAnton%26aufirst%3DA.%26aulast%3DAktas%26aufirst%3DB.%26aulast%3DSchoenegg%26aufirst%3DW.%26aulast%3DMunoz%26aufirst%3DM.%26aulast%3DGarcia-Saenz%26aufirst%3DJ.%2BA.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DM.%26aulast%3DMargeli%26aufirst%3DM.%26aulast%3DCarrasco%26aufirst%3DE.%26aulast%3DLiedtke%26aufirst%3DC.%26aulast%3DWachsmann%26aufirst%3DG.%26aulast%3DMehta%26aufirst%3DK.%26aulast%3DDe%2Bla%2BHaba-Rodriguez%26aufirst%3DJ.%2BR.%26atitle%3DPhase%2520III%2520trial%2520evaluating%2520the%2520addition%2520of%2520bevacizumab%2520to%2520endocrine%2520therapy%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520the%2520letrozole%252Ffulvestrant%2520and%2520avastin%2520%2528LEA%2529%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1045%26epage%3D1052%26doi%3D10.1200%2FJCO.2014.57.2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Yu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicinski, P.</span><span> </span><span class="NLM_article-title">Specific protection against breast cancers by cyclin D1 ablation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1038/35082500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1038%2F35082500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2001&pages=1017-1021&author=Q.+Yuauthor=Y.+Gengauthor=P.+Sicinski&title=Specific+protection+against+breast+cancers+by+cyclin+D1+ablation&doi=10.1038%2F35082500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2F35082500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35082500%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DGeng%26aufirst%3DY.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DSpecific%2520protection%2520against%2520breast%2520cancers%2520by%2520cyclin%2520D1%2520ablation%26jtitle%3DNature%26date%3D2001%26volume%3D411%26spage%3D1017%26epage%3D1021%26doi%3D10.1038%2F35082500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span><span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0liVKIfyzZPW-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Herrera-Abreu, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palafox, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asghar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutts, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Murillas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grueso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pancholi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span> </span><span class="NLM_article-title">Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">2301</span><span class="NLM_x">–</span> <span class="NLM_lpage">2313</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-0728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F0008-5472.CAN-15-0728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=27020857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2301-2313&author=M.+T.+Herrera-Abreuauthor=M.+Palafoxauthor=U.+Asgharauthor=M.+A.+Rivasauthor=R.+J.+Cuttsauthor=I.+Garcia-Murillasauthor=A.+Pearsonauthor=M.+Guzmanauthor=O.+Rodriguezauthor=J.+Gruesoauthor=M.+Belletauthor=J.+Cortesauthor=R.+Elliottauthor=S.+Pancholiauthor=J.+Baselgaauthor=M.+Dowsettauthor=L.+A.+Martinauthor=N.+C.+Turnerauthor=V.+Serra&title=Early+adaptation+and+acquired+resistance+to+CDK4%2F6+inhibition+in+estrogen+receptor-positive+breast+cancer&doi=10.1158%2F0008-5472.CAN-15-0728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Herrera-Abreu, Maria Teresa; Palafox, Marta; Asghar, Uzma; Rivas, Martin A.; Cutts, Rosalind J.; Garcia-Murillas, Isaac; Pearson, Alex; Guzman, Marta; Rodriguez, Olga; Grueso, Judit; Bellet, Meritxell; Corties, Javier; Elliott, Richard; Pancholi, Sunil; Baselga, Josiee; Dowsett, Mitch; Martin, Lesley-Ann; Turner, Nicholas C.; Serra, Violeta</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2301-2313</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of the CDK4/6 cell-cycle kinases have shown clin. efficacy in estrogen receptor (ER)-pos. metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance.  Here we report that ER-pos. breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry.  This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, which reduced the levels of cyclin D1 (CCND1) and other G1-S cyclins, abolished pRb phosphorylation, and inhibited activation of S-phase transcriptional programs.  Combined targeting of both CDK4/6 and PI3K triggered cancer cell apoptosis in vitro and in patient-derived tumor xenograft (PDX) models, resulting in tumor regression and improved disease control.  Furthermore, a triple combination of endocrine therapy, CDK4/6, and PI3K inhibition was more effective than paired combinations, provoking rapid tumor regressions in a PDX model.  Mechanistic investigations showed that acquired resistance to CDK4/6 inhibition resulted from bypass of cyclin D1-CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss.  Notably, although PI3K inhibitors could prevent resistance to CDK4/6 inhibitors, they failed to resensitize cells once resistance had been acquired.  However, we found that cells acquiring resistance to CDK4/6 inhibitors due to CCNE1 amplification could be resensitized by targeting CDK2.  Overall, our results illustrate convergent mechanisms of early adaptation and acquired resistance to CDK4/6 inhibitors that enable alternate means of S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHNNElBQntOLVg90H21EOLACvtfcHk0lg06HBj_Rpi0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D&md5=675a4562d545338fa16347c0a2f076f0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0728%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera-Abreu%26aufirst%3DM.%2BT.%26aulast%3DPalafox%26aufirst%3DM.%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DRivas%26aufirst%3DM.%2BA.%26aulast%3DCutts%26aufirst%3DR.%2BJ.%26aulast%3DGarcia-Murillas%26aufirst%3DI.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DBellet%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DL.%2BA.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DSerra%26aufirst%3DV.%26atitle%3DEarly%2520adaptation%2520and%2520acquired%2520resistance%2520to%2520CDK4%252F6%2520inhibition%2520in%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2301%26epage%3D2313%26doi%3D10.1158%2F0008-5472.CAN-15-0728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrazate, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalla, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kategaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govek, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giltnane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertz, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tantawy, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span> </span><span class="NLM_article-title">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span> <span class="citation_source-journal">Elife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e15828</span><span class="refDoi"> DOI: 10.7554/eLife.15828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.7554%2FeLife.15828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=27410477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e15828&author=J.+D.+Josephauthor=B.+Darimontauthor=W.+Zhouauthor=A.+Arrazateauthor=A.+Youngauthor=E.+Ingallaauthor=K.+Walterauthor=R.+A.+Blakeauthor=J.+Nonomiyaauthor=Z.+Guanauthor=L.+Kategayaauthor=S.+P.+Govekauthor=A.+G.+Laiauthor=M.+Kahramanauthor=D.+Brighamauthor=J.+Sensintaffarauthor=N.+Luauthor=G.+Shaoauthor=J.+Qianauthor=K.+Grillotauthor=M.+Moonauthor=R.+Prudenteauthor=E.+Bischoffauthor=K.+J.+Leeauthor=C.+Bonnefousauthor=K.+L.+Douglasauthor=J.+D.+Julienauthor=J.+Y.+Nagasawaauthor=A.+Aparicioauthor=J.+Kaufmanauthor=B.+Haleyauthor=J.+M.+Giltnaneauthor=I.+E.+Wertzauthor=M.+R.+Lacknerauthor=M.+A.+Nanniniauthor=D.+Sampathauthor=L.+Schwarzauthor=H.+C.+Manningauthor=M.+N.+Tantawyauthor=C.+L.+Arteagaauthor=R.+A.+Heymanauthor=P.+J.+Rixauthor=L.+Friedmanauthor=N.+D.+Smithauthor=C.+Metcalfeauthor=J.+H.+Hager&title=The+selective+estrogen+receptor+downregulator+GDC-0810+is+efficacious+in+diverse+models+of+ER%2B+breast+cancer&doi=10.7554%2FeLife.15828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span></div><div class="casAuthors">Joseph, James D.; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A.; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P.; Lai, Andiliy G.; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L.; Julien, Jackaline D.; Nagasawa, Johnny Y.; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M.; Wertz, Ingrid E.; Lackner, Mark R.; Nannini, Michelle A.; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L.; Heyman, Richard A.; Rix, Peter J.; Friedman, Lori; Smith, Nicholas D.; Metcalfe, Ciara; Hager, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e15828/1-e15828/34</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies.  The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERa signaling, and provides a strong rationale for continued targeting of ERa.  Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERa degrdn., antagonism and pharmacokinetic properties.  GDC-0810 induces a distinct ERa conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action.  GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERa mutations.  GDC-0810 is currently being evaluated in Phase II clin. studies in women with ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML4fZixufB7Vg90H21EOLACvtfcHk0lg06HBj_Rpi0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D&md5=cfdf9624f8b260a732b92caab0bb2d58</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.7554%2FeLife.15828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.15828%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DZ.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DJulien%26aufirst%3DJ.%2BD.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DNannini%26aufirst%3DM.%2BA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSchwarz%26aufirst%3DL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26aulast%3DTantawy%26aufirst%3DM.%2BN.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520selective%2520estrogen%2520receptor%2520downregulator%2520GDC-0810%2520is%2520efficacious%2520in%2520diverse%2520models%2520of%2520ER%252B%2520breast%2520cancer%26jtitle%3DElife%26date%3D2016%26volume%3D5%26spage%3De15828%26doi%3D10.7554%2FeLife.15828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Jordan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span> </span><span class="NLM_article-title">Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1023/B:BREA.0000041623.21338.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1023%2FB%3ABREA.0000041623.21338.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15377841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2004&pages=167-180&author=N.+J.+Jordanauthor=J.+M.+Geeauthor=D.+Barrowauthor=A.+E.+Wakelingauthor=R.+I.+Nicholson&title=Increased+constitutive+activity+of+PKB%2FAkt+in+tamoxifen+resistant+breast+cancer+MCF-7+cells&doi=10.1023%2FB%3ABREA.0000041623.21338.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells</span></div><div class="casAuthors">Jordan, Nicola J.; Gee, Julia M. W.; Barrow, Denise; Wakeling, Alan E.; Nicholson, Robert I.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-180</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">The tamoxifen-resistant (TAM-R) MCF-7 breast cancer cell line has been used as a model to identify the signaling pathways that enable resistant cancer cells to grow independently of steroid hormones.  In TAM-R cells, peptide growth factor signaling pathways appear to be important in modified cell behavior, growth and survival.  The PI3 kinase signaling components Akt1 and Akt2 are expressed at similar levels by both parental wild-type MCF-7 and TAM-R cells, but Akt1 phosphorylation is significantly increased in TAM-R cells grown under basal conditions.  High levels of basal Akt, GSK3α/β and p70S6 kinase phosphorylation are all inhibited by the PI3 kinase inhibitor, LY 294002.  The ligands for the EGFR/erbB1 receptor, EGF (epidermal growth factor) and TGFα (transforming growth factor-α) demonstrate an increased ability to activate Akt in TAM-R compared with parental MCF-7 cells and it is proposed that the preferred autocrine or paracrine activation of Akt occurs via the erbB heterodimer EGFR/erbB2 in TAM-R cells.  Akt phosphorylation is reduced by gefitinib ("Iressa"/ZD1839).  The results suggest that the PI3 kinase pathway plays a role in proliferation of TAM-R cells and is important in the increased EGF induced membrane ruffling detected in the resistant cells.  Increased Akt1 activation may contribute to the aggressive phenotype of tamoxifen resistant ER (estrogen receptor) pos. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJR02KTM_eirVg90H21EOLACvtfcHk0lipIQi3YpPnmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOqtLc%253D&md5=0a4af8f540511d0145d806b92e74e99c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1023%2FB%3ABREA.0000041623.21338.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ABREA.0000041623.21338.47%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DN.%2BJ.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DBarrow%26aufirst%3DD.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DIncreased%2520constitutive%2520activity%2520of%2520PKB%252FAkt%2520in%2520tamoxifen%2520resistant%2520breast%2520cancer%2520MCF-7%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2004%26volume%3D87%26spage%3D167%26epage%3D180%26doi%3D10.1023%2FB%3ABREA.0000041623.21338.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Schiff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massarweh, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharwani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arpino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimawi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span> </span><span class="NLM_article-title">Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1007/s00280-005-0108-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2Fs00280-005-0108-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=16273359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gnu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=10-20&issue=Suppl+1&author=R.+Schiffauthor=S.+A.+Massarwehauthor=J.+Shouauthor=L.+Bharwaniauthor=G.+Arpinoauthor=M.+Rimawiauthor=C.+K.+Osborne&title=Advanced+concepts+in+estrogen+receptor+biology+and+breast+cancer+endocrine+resistance%3A+implicated+role+of+growth+factor+signaling+and+estrogen+receptor+coregulators&doi=10.1007%2Fs00280-005-0108-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators</span></div><div class="casAuthors">Schiff, Rachel; Massarweh, Suleiman A.; Shou, Jiang; Bharwani, Lavina; Arpino, Grazia; Rimawi, Mothaffar; Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">s10-s20</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor (ER), mediating estrogen-signaling stimuli, is a dominant regulator and a key therapeutic target in breast cancer etiol. and progression.  Endocrine therapy, blocking the ER pathway, is one of the most important systemic therapies in breast cancer management, but de novo and acquired resistance is still a major clin. problem.  New research highlights the role of both genomic and nongenomic ER activities and their intimate mol. crosstalk with growth factor receptor and other signaling kinase pathways in endocrine resistance.  These signaling pathways, when overexpressed and/or hyperactivated, can modulate both activities of ER, resulting in endocrine resistance.  Thus, these signal transduction receptors and signaling mols. may serve as both predictive markers and novel therapeutic targets to circumvent endocrine resistance.  Compelling exptl. and clin. evidence suggest that the epidermal growth factor/HER2/neu receptor (EGFR/HER2) pathway might play a distinct role in endocrine resistance, and esp. in resistance to selective estrogen receptor modulators (SERMs) such as tamoxifen.  Results from preclin. studies of treatment combinations with various endocrine therapy drugs together with several potent anti-EGFR/HER2 inhibitors are very promising, and clin. trials to see whether this new strategy is effective in patients are now ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRCyO-TiKZjrVg90H21EOLACvtfcHk0lipIQi3YpPnmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gnu73F&md5=22bd6e9f463a4f16afd19a5e74fe9883</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs00280-005-0108-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-005-0108-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DMassarweh%26aufirst%3DS.%2BA.%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DBharwani%26aufirst%3DL.%26aulast%3DArpino%26aufirst%3DG.%26aulast%3DRimawi%26aufirst%3DM.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DAdvanced%2520concepts%2520in%2520estrogen%2520receptor%2520biology%2520and%2520breast%2520cancer%2520endocrine%2520resistance%253A%2520implicated%2520role%2520of%2520growth%2520factor%2520signaling%2520and%2520estrogen%2520receptor%2520coregulators%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2005%26volume%3D56%26issue%3DSuppl%25201%26spage%3D10%26epage%3D20%26doi%3D10.1007%2Fs00280-005-0108-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Kilker, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planas-Silva, M. D.</span><span> </span><span class="NLM_article-title">Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells</span> <span class="citation_source-journal">J. Steroid Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1016/j.jsbmb.2004.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.jsbmb.2004.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15544931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=63-71&author=R.+L.+Kilkerauthor=M.+W.+Hartlauthor=T.+M.+Rutherfordauthor=M.+D.+Planas-Silva&title=Cyclin+D1+expression+is+dependent+on+estrogen+receptor+function+in+tamoxifen-resistant+breast+cancer+cells&doi=10.1016%2Fj.jsbmb.2004.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells</span></div><div class="casAuthors">Kilker, Robin L.; Hartl, Michael W.; Rutherford, Tina M.; Planas-Silva, Maricarmen D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">63-71</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of resistance to tamoxifen, the most common antiestrogen used in the treatment of breast cancer, is a frequent and severe clin. problem.  Tamoxifen-resistant tumors are still capable of responding to other hormonal therapies such as those that downregulate estrogen receptor expression.  Mechanisms leading to acquisition of tamoxifen-resistant but hormone-sensitive growth are not completely understood.  In tamoxifen-sensitive breast cancer cells, tamoxifen inhibits, whereas estrogen induces, expression of cyclin D1, a key cell cycle regulatory protein.  Ectopic expression of cyclin D1 can lead to antiestrogen resistance.  Thus, to det. whether cyclin D1 is involved in the growth of tamoxifen-resistant cells, the authors developed several tamoxifen-resistant variants from MCF-7 cells.  These variants grow in the absence of estrogen or in the presence of tamoxifen, but their growth is inhibited by estrogen receptor downregulators.  We show here that cyclin D1 expression is maintained at comparable levels in all tamoxifen-resistant variants, whereas pS2, another estrogen-regulated protein, is not.  The addn. of physiol. levels of estrogen further stimulates cyclin D1 expression and proliferation.  In contrast, treatment with estrogen receptor downregulators decreases cyclin D1 expression and proliferation.  Thus, changes in cyclin D1 expression upon 2nd-line hormonal therapy may predict hormonal sensitivity of tamoxifen-resistant tumors.  These studies suggest that estrogen receptor mediates cyclin D1 expression and growth of tamoxifen-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokX6Xvg8m6lbVg90H21EOLACvtfcHk0lipIQi3YpPnmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslWgsrk%253D&md5=9432e0d1038063db958deedde3d7cc40</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DKilker%26aufirst%3DR.%2BL.%26aulast%3DHartl%26aufirst%3DM.%2BW.%26aulast%3DRutherford%26aufirst%3DT.%2BM.%26aulast%3DPlanas-Silva%26aufirst%3DM.%2BD.%26atitle%3DCyclin%2520D1%2520expression%2520is%2520dependent%2520on%2520estrogen%2520receptor%2520function%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D92%26spage%3D63%26epage%3D71%26doi%3D10.1016%2Fj.jsbmb.2004.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Hui, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finney, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span> </span><span class="NLM_article-title">Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">6916</span><span class="NLM_x">–</span> <span class="NLM_lpage">6923</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6916-6923&author=R.+Huiauthor=G.+L.+Finneyauthor=J.+S.+Carrollauthor=C.+S.+Leeauthor=E.+A.+Musgroveauthor=R.+L.+Sutherland&title=Constitutive+overexpression+of+cyclin+D1+but+not+cyclin+E+confers+acute+resistance+to+antiestrogens+in+T-47D+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DR.%26aulast%3DFinney%26aufirst%3DG.%2BL.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DConstitutive%2520overexpression%2520of%2520cyclin%2520D1%2520but%2520not%2520cyclin%2520E%2520confers%2520acute%2520resistance%2520to%2520antiestrogens%2520in%2520T-47D%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6916%26epage%3D6923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Sherr, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. M.</span><span> </span><span class="NLM_article-title">Living with or without cyclins and cyclin-dependent kinases</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2699</span><span class="NLM_x">–</span> <span class="NLM_lpage">2711</span><span class="refDoi"> DOI: 10.1101/gad.1256504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1101%2Fgad.1256504" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=2699-2711&author=C.+J.+Sherrauthor=J.+M.+Roberts&title=Living+with+or+without+cyclins+and+cyclin-dependent+kinases&doi=10.1101%2Fgad.1256504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1101%2Fgad.1256504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1256504%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26atitle%3DLiving%2520with%2520or%2520without%2520cyclins%2520and%2520cyclin-dependent%2520kinases%26jtitle%3DGenes%2520Dev.%26date%3D2004%26volume%3D18%26spage%3D2699%26epage%3D2711%26doi%3D10.1101%2Fgad.1256504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Caldon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sergio, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthukaruppan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boersma, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barraclough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Print, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span> </span><span class="NLM_article-title">Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1499</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1535-7163.MCT-11-0963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=22564725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1488-1499&author=C.+E.+Caldonauthor=C.+M.+Sergioauthor=J.+Kangauthor=A.+Muthukaruppanauthor=M.+N.+Boersmaauthor=A.+Stoneauthor=J.+Barracloughauthor=C.+S.+Leeauthor=M.+A.+Blackauthor=L.+D.+Millerauthor=J.+M.+Geeauthor=R.+I.+Nicholsonauthor=R.+L.+Sutherlandauthor=C.+G.+Printauthor=E.+A.+Musgrove&title=Cyclin+E2+overexpression+is+associated+with+endocrine+resistance+but+not+insensitivity+to+CDK2+inhibition+in+human+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-11-0963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells</span></div><div class="casAuthors">Caldon, C. Elizabeth; Sergio, C. Marcelo; Kang, Jian; Muthukaruppan, Anita; Boersma, Marijke N.; Stone, Andrew; Barraclough, Jane; Lee, Christine S.; Black, Michael A.; Miller, Lance D.; Gee, Julia M.; Nicholson, Rob I.; Sutherland, Robert L.; Print, Cristin G.; Musgrove, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1488-1499</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer.  We therefore examd. the role of cyclin E2 in antiestrogen resistance in vitro and its potential for therapeutic targeting through cyclin-dependent kinase (CDK) inhibition.  High expression of CCNE2, but not CCNE1, was characteristic of the luminal B and HER2 subtypes of breast cancer and was strongly predictive of shorter distant metastasis-free survival following endocrine therapy.  After antiestrogen treatment of MCF-7 breast cancer cells, cyclin E2 mRNA and protein were downregulated and cyclin E2-CDK2 activity decreased.  However, this regulation was lost in tamoxifen-resistant (MCF-7 TAMR) cells, which overexpressed cyclin E2.  Expression of either cyclin E1 or E2 in T-47D breast cancer cells conferred acute antiestrogen resistance, suggesting that cyclin E overexpression contributes to the antiestrogen resistance of tamoxifen-resistant cells.  Ectopic expression of cyclin E1 or E2 also reduced sensitivity to CDK4, but not CDK2, inhibition.  Proliferation of tamoxifen-resistant cells was inhibited by RNAi-mediated knockdown of cyclin E1, cyclin E2, or CDK2.  Furthermore, CDK2 inhibition of E-cyclin overexpressing cells and tamoxifen-resistant cells restored sensitivity to tamoxifen or CDK4 inhibition.  Cyclin E2 overexpression is therefore a potential mechanism of resistance to both endocrine therapy and CDK4 inhibition.  CDK2 inhibitors hold promise as a component of combination therapies in endocrine-resistant disease as they effectively inhibit cyclin E1 and E2 overexpressing cells and enhance the efficacy of other therapeutics.  Mol Cancer Ther; 11(7); 1488-99. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOrjoY6RnTk7Vg90H21EOLACvtfcHk0lhdfRskpyBWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D&md5=0d1b47e6b62a4fce919aa5fcf40c227a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0963%26sid%3Dliteratum%253Aachs%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DSergio%26aufirst%3DC.%2BM.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DMuthukaruppan%26aufirst%3DA.%26aulast%3DBoersma%26aufirst%3DM.%2BN.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DBlack%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DL.%2BD.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DPrint%26aufirst%3DC.%2BG.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCyclin%2520E2%2520overexpression%2520is%2520associated%2520with%2520endocrine%2520resistance%2520but%2520not%2520insensitivity%2520to%2520CDK2%2520inhibition%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1488%26epage%3D1499%26doi%3D10.1158%2F1535-7163.MCT-11-0963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Caldon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span> </span><span class="NLM_article-title">Cell cycle control in breast cancer cells</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1002/jcb.20690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1002%2Fjcb.20690" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=261-274&author=C.+E.+Caldonauthor=R.+J.+Dalyauthor=R.+L.+Sutherlandauthor=E.+A.+Musgrove&title=Cell+cycle+control+in+breast+cancer+cells&doi=10.1002%2Fjcb.20690"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20690%26sid%3Dliteratum%253Aachs%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCell%2520cycle%2520control%2520in%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2006%26volume%3D97%26spage%3D261%26epage%3D274%26doi%3D10.1002%2Fjcb.20690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Moriai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, N.</span><span> </span><span class="NLM_article-title">Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span><span class="refDoi"> DOI: 10.1007/s10549-008-0164-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2Fs10549-008-0164-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=18815881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvF2gsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2009&pages=261-271&author=R.+Moriaiauthor=N.+Tsujiauthor=M.+Moriaiauthor=D.+Kobayashiauthor=N.+Watanabe&title=Survivin+plays+as+a+resistant+factor+against+tamoxifen-induced+apoptosis+in+human+breast+cancer+cells&doi=10.1007%2Fs10549-008-0164-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells</span></div><div class="casAuthors">Moriai, Ryosuke; Tsuji, Naoki; Moriai, Mikako; Kobayashi, Daisuke; Watanabe, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-271</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tamoxifen has been the mainstay of endocrine therapy for estrogen receptor-pos. breast cancer.  However, approx. 40% of breast cancer patients do not respond to tamoxifen treatment.  Further, most tumors eventually acquire tamoxifen resistance.  Therefore, it is necessary to develop effective modalities to enhance the efficacy of tamoxifen in breast cancer treatment.  In this study, we investigated the mechanism by which breast cancer cells develop resistance against tamoxifen from the viewpoint of tamoxifen-induced apoptosis.  Overexpression of the anti-apoptotic mol. survivin rendered the human breast cancer cells MCF-7 resistant to tamoxifen-induced apoptosis.  To examine whether the down-regulation of survivin can enhance tamoxifen-induced apoptosis, we introduced siRNA targeting the survivin gene (survivin-siRNA) into MCF-7 cells.  Survivin-siRNA transfection not only induced apoptosis without tamoxifen treatment but also augmented the tamoxifen-induced apoptosis.  We have previously demonstrated that 3-hydroxy-3-methylglutaryl CoA reductase inhibitors (HRIs), which are widely used to reduce the serum cholesterol levels in hypercholesterolemia patients, decreases survivin expression in colon cancer cells.  To develop a pharmacol. approach for improving the efficacy of tamoxifen treatment, we detd. whether HRIs can enhance tamoxifen-induced apoptosis.  Lovastatin, an HRI, down-regulated the expression of survivin protein in MCF-7 cells in a dose-dependent manner.  In addn., the proportion of apoptotic cells induced by the tamoxifen and lovastatin combination was greater than the theor. additive effect.  These results suggest that survivin may function as a factor inducing resistance against tamoxifen-induced apoptosis, and the combined use of tamoxifen and HRI may be a novel approach to overcome tamoxifen resistance in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph8jSstaG16LVg90H21EOLACvtfcHk0lhdfRskpyBWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvF2gsL4%253D&md5=6a8c3441a524e9daa89cb94b68a58a47</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs10549-008-0164-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-008-0164-5%26sid%3Dliteratum%253Aachs%26aulast%3DMoriai%26aufirst%3DR.%26aulast%3DTsuji%26aufirst%3DN.%26aulast%3DMoriai%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DD.%26aulast%3DWatanabe%26aufirst%3DN.%26atitle%3DSurvivin%2520plays%2520as%2520a%2520resistant%2520factor%2520against%2520tamoxifen-induced%2520apoptosis%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2009%26volume%3D117%26spage%3D261%26epage%3D271%26doi%3D10.1007%2Fs10549-008-0164-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoog, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncalves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiken, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saied, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuntoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchens, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phommaly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavuri, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEachern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pluard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naughton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aft, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillanders, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSchryver, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Angulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-therapy-resistant+ESR1+variants+revealed+by+genomic+characterization+of+breast-cancer-derived+xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0ljxilpd7e4E_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-therapy-resistant%2520ESR1%2520variants%2520revealed%2520by%2520genomic%2520characterization%2520of%2520breast-cancer-derived%2520xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Pink, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2321</span><span class="NLM_x">–</span> <span class="NLM_lpage">2330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=2321-2330&author=J.+J.+Pinkauthor=V.+C.+Jordan&title=Models+of+estrogen+receptor+regulation+by+estrogens+and+antiestrogens+in+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPink%26aufirst%3DJ.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DModels%2520of%2520estrogen%2520receptor%2520regulation%2520by%2520estrogens%2520and%2520antiestrogens%2520in%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26spage%3D2321%26epage%3D2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osipo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kidawi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandel, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1746</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span><span class="refDoi"> DOI: 10.1093/jnci/dji400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1093%2Fjnci%2Fdji400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=16333030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=1746-1759&author=J.+S.+Lewisauthor=K.+Meekeauthor=C.+Osipoauthor=E.+A.+Rossauthor=N.+Kidawiauthor=T.+Liauthor=E.+Bellauthor=N.+S.+Chandelauthor=V.+C.+Jordan&title=Intrinsic+mechanism+of+estradiol-induced+apoptosis+in+breast+cancer+cells+resistant+to+estrogen+deprivation&doi=10.1093%2Fjnci%2Fdji400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation</span></div><div class="casAuthors">Lewis, Joan S.; Meeke, Kathleen; Osipo, Clodia; Ross, Eric A.; Kidawi, Noman; Li, Tianyu; Bell, Eric; Chandel, Navdeep S.; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1746-1759</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously developed an estrogen receptor (ER)-pos. breast cancer cell line (MCF-7:5C) that is resistant to long-term estrogen deprivation and undergoes rapid and complete apoptosis in the presence of physiol. concns. of 17β-estradiol.  Here, we investigated the role of the mitochondrial apoptotic pathway in this process.  Methods: Apoptosis in MCF-7:5C cells treated with estradiol, fulvestrant, or vehicle (control) was investigated by annexin V-propidium iodide double staining and 4',6-diamidino-2-phenylindole (DAPI) staining.  Apoptosis was also analyzed in MCF-7:5C cells transiently transfected with small interfering RNAs (siRNAs) to apoptotic pathway components.  Expression of apoptotic pathway intermediates was measured by western blot anal.  Mitochondrial transmembrane potential (ψm) was detd. by rhodamine-123 retention assay.  Mitochondrial pathway activity was detd. by cytochrome c release and cleavage of poly(ADP-ribose) polymerase (PARP) protein.  Tumorigenesis was studied in ovariectomized athymic mice that were injected with MCF-7:5C cells.  Differences between the treatment groups and control group were detd. by two-sample t test or one-factor anal. of variance.  All statistical tests were two-sided.  Results: MCF-7:5C cells treated with estradiol underwent apoptosis and showed increased expression of proapoptotic proteins, decreased ψm, enhanced cytochrome c release, and PARP cleavage compared with cells treated with fulvestrant or vehicle.  Blockade of Bax, Bim, and p53 mRNA expression by siRNA reduced estradiol-induced apoptosis relative to control by 76% [95% confidence interval (CI) = 73% to 79%, P<.001], 85% [95% CI = 90% to 80%, P<.001], and 40% [95% CI = 45% to 35%, P<.001], resp., whereas blockade of FasL by siRNA had no effect.  Estradiol caused complete regression of MCF-7:5C tumors in vivo.  Conclusion: The mitochondrial pathway of apoptosis plays a crit. role in estradiol-induced apoptosis in long-term estrogen-deprived breast cancer cells.  Physiol. concns. of estradiol could potentially be used to induce apoptosis and tumor regression in tumors that have developed resistance to aromatase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0fGAoI50tabVg90H21EOLACvtfcHk0ljxilpd7e4E_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSjurnN&md5=8107a7d125731549936a7268fb9e1138</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdji400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdji400%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DMeeke%26aufirst%3DK.%26aulast%3DOsipo%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DE.%2BA.%26aulast%3DKidawi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DBell%26aufirst%3DE.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DIntrinsic%2520mechanism%2520of%2520estradiol-induced%2520apoptosis%2520in%2520breast%2520cancer%2520cells%2520resistant%2520to%2520estrogen%2520deprivation%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2005%26volume%3D97%26spage%3D1746%26epage%3D1759%26doi%3D10.1093%2Fjnci%2Fdji400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osipo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal</span> <span class="citation_source-journal">J. Steroid Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.jsbmb.2004.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.jsbmb.2004.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15862958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVKks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=131-141&author=J.+S.+Lewisauthor=C.+Osipoauthor=K.+Meekeauthor=V.+C.+Jordan&title=Estrogen-induced+apoptosis+in+a+breast+cancer+model+resistant+to+long-term+estrogen+withdrawal&doi=10.1016%2Fj.jsbmb.2004.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal</span></div><div class="casAuthors">Lewis, J. S.; Osipo, C.; Meeke, K.; Jordan, V. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">131-141</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Estrogen suppression through the use of an aromatase inhibitor is an effective endocrine treatment option for postmenopausal breast cancer patients with estrogen receptor (ER)-pos. disease, however, there are concerns that long-term estrogen deprivation will inevitably lead to resistance.  To address the issue of acquired resistance to long-term estrogen deprivation our lab. has developed an ER+/PR- hormone-independent breast cancer cell line, MCF-7:5C which is a variant clone of wild-type MCF-7 cells.  Originally, these cells were cultured in estrogen-free MEM contg. 5% charcoal-stripped calf serum and were found to be resistant to both estradiol (E2) and antiestrogens.  Interestingly, a completely different phenomenon was obsd. when MCF-7:5C cells were cultured in phenol red-free RPMI 1640 medium contg. 10% charcoal-stripped fetal bovine serum (SFS).  Using DNA quantitation assays, the authors examd. the effect of E2 on the growth of MCF-7:5C cells under different media conditions.  These results showed that 10-9 M E2 caused a dramatic 90% redn. in the growth of MCF-7:5C cells cultured in RPMI medium contg. 10% SFS but did not have any significant inhibitory effects on cells cultured in MEM media.  Addnl. expts. were performed to det. whether the medium or the serum facilitated the inhibitory effects of E2 and the results indicated that it was the serum.  Annexin V and DAPI staining confirmed that the E2-induced growth inhibition of MCF-7:5C cells was due to apoptosis.  We also examd. the tumorigenic potential of MCF-7:5C cells by injecting 1 × 107 cells/site into ovariectomized athymic mice and found that these cells, previously cultured in RPMI media, spontaneously grew into tumors in the absence of E2.  Overall, these results show that low concns. (>10-11 M) of E2 are capable of inducing apoptosis in an aromatase resistant breast cancer cell model and that this effect is highly influenced by the medium in which the cells are grown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhS-VZhkUY2rVg90H21EOLACvtfcHk0lha4rrVkxWbbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVKks74%253D&md5=5b11562cc6ecd12fc4056f8446f9f47f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DOsipo%26aufirst%3DC.%26aulast%3DMeeke%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DEstrogen-induced%2520apoptosis%2520in%2520a%2520breast%2520cancer%2520model%2520resistant%2520to%2520long-term%2520estrogen%2520withdrawal%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D94%26spage%3D131%26epage%3D141%26doi%3D10.1016%2Fj.jsbmb.2004.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Labarca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paigen, K.</span><span> </span><span class="NLM_article-title">A simple, rapid, and sensitive DNA assay procedure</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/0003-2697(80)90165-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2F0003-2697%2880%2990165-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1980&pages=344-352&author=C.+Labarcaauthor=K.+Paigen&title=A+simple%2C+rapid%2C+and+sensitive+DNA+assay+procedure&doi=10.1016%2F0003-2697%2880%2990165-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0003-2697%2880%2990165-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-2697%252880%252990165-7%26sid%3Dliteratum%253Aachs%26aulast%3DLabarca%26aufirst%3DC.%26aulast%3DPaigen%26aufirst%3DK.%26atitle%3DA%2520simple%252C%2520rapid%252C%2520and%2520sensitive%2520DNA%2520assay%2520procedure%26jtitle%3DAnal.%2520Biochem.%26date%3D1980%26volume%3D102%26spage%3D344%26epage%3D352%26doi%3D10.1016%2F0003-2697%2880%2990165-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Daxhelet, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coene, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoet, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocito, C. G.</span><span> </span><span class="NLM_article-title">Spectrofluorometry of dyes with DNAs of different base composition and conformation</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span><span class="refDoi"> DOI: 10.1016/0003-2697(89)90152-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2F0003-2697%2889%2990152-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=1989&pages=401-403&author=G.+A.+Daxheletauthor=M.+M.+Coeneauthor=P.+P.+Hoetauthor=C.+G.+Cocito&title=Spectrofluorometry+of+dyes+with+DNAs+of+different+base+composition+and+conformation&doi=10.1016%2F0003-2697%2889%2990152-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2F0003-2697%2889%2990152-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-2697%252889%252990152-8%26sid%3Dliteratum%253Aachs%26aulast%3DDaxhelet%26aufirst%3DG.%2BA.%26aulast%3DCoene%26aufirst%3DM.%2BM.%26aulast%3DHoet%26aufirst%3DP.%2BP.%26aulast%3DCocito%26aufirst%3DC.%2BG.%26atitle%3DSpectrofluorometry%2520of%2520dyes%2520with%2520DNAs%2520of%2520different%2520base%2520composition%2520and%2520conformation%26jtitle%3DAnal.%2520Biochem.%26date%3D1989%26volume%3D179%26spage%3D401%26epage%3D403%26doi%3D10.1016%2F0003-2697%2889%2990152-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, H. N.</span><span> </span><span class="NLM_article-title">Photoaffinity labels for estrogen binding proteins of rat uterus</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4085</span><span class="NLM_x">–</span> <span class="NLM_lpage">4092</span><span class="refDoi"> DOI: 10.1021/bi00745a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00745a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1973&pages=4085-4092&author=J.+A.+Katzenellenbogenauthor=H.+J.+Johnsonauthor=H.+N.+Myers&title=Photoaffinity+labels+for+estrogen+binding+proteins+of+rat+uterus&doi=10.1021%2Fbi00745a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labels for estrogen binding proteins of rat uterus</span></div><div class="casAuthors">Katzenellenbogen, John A.; Johnson, Howard J., Jr.; Myers, Harvey N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4085-92</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The binding affinity of 14 estrone, estradiol, and hexestrol derivs. bearing a photosensitive function (either diazocarbonyl group or aryl azide) and their precursors for rat uterine estrogen binding protein was measured by a competitive binding assay.  Introduction of substituents lowered binding affinity in all cases, esp. when 1 or both of the hydroxyl groups were blocked.  Substituents at positions 2, 4, and 16 were tolerated reasonably well.  Derivs. in which the A-ring hydroxyl is internally hydrogen bonded to a nitro group have very low affinity, but the nitro group was well tolerated at position 4, where it does not hydrogen bond to the hydroxyl.  The binding affinity of all the derivs. reflected the relative binding affinity of the parent ligands:  hexestrol > estradiol > estrone.  3-Azidohexestrol [50548-21-5] and 3,3'-diazidohexestrol [50548-22-6] >5%, had the greatest binding affinity and could selectively label estrogen binding protein directly in the impure state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzUNSnonz6bLVg90H21EOLACvtfcHk0lha4rrVkxWbbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D&md5=99f1bdfa830d881939130942394e47be</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fbi00745a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00745a010%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BJ.%26aulast%3DMyers%26aufirst%3DH.%2BN.%26atitle%3DPhotoaffinity%2520labels%2520for%2520estrogen%2520binding%2520proteins%2520of%2520rat%2520uterus%26jtitle%3DBiochemistry%26date%3D1973%26volume%3D12%26spage%3D4085%26epage%3D4092%26doi%3D10.1021%2Fbi00745a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span> </span><span class="NLM_article-title">Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">14897</span><span class="NLM_x">–</span> <span class="NLM_lpage">14905</span><span class="refDoi"> DOI: 10.1021/bi971746l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi971746l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=14897-14905&author=K.+E.+Carlsonauthor=I.+Choiauthor=A.+Geeauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Altered+ligand+binding+properties+and+enhanced+stability+of+a+constitutively+active+estrogen+receptor%3A+evidence+that+an+open+pocket+conformation+is+required+for+ligand+interaction&doi=10.1021%2Fbi971746l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction</span></div><div class="casAuthors">Carlson, Kathryn E.; Choi, Inho; Gee, Arvin; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14897-14905</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To elucidate the ligand binding properties of the estrogen receptor (ER) and how ligand access to and release from the ligand binding pocket is affected by the conformational state of the receptor, the authors have measured the rates of estradiol assocn. and dissocn., the equil. binding, and the stability of estradiol binding to denaturants, comparing wild-type human ER and a point mutant (Y537S ER) that shows full constitutive activity, i.e., the same full transcriptional activity in the absence or presence of estrogen.  Ligand binding kinetics and affinity were measured with the full-length (1-595) ERs and with truncated forms of both receptors contg. domains C through F (including the DNA binding, hinge, and ligand binding domains, amino acids 175-595) or domains E and F (the ligand binding domain; amino acids 304-595).  With all ERs, the rates of ligand assocn. and dissocn. were considerably slower with the Y537S mutant ER than with wild-type ER (6-fold and 3-4-fold, resp.).  These marked differences in ligand on and off rates for the wild-type and Y537S receptors result in a predicted (k-1/k+1) and measured Kd that is 2-fold lower for Y537S ER compared to wild-type ER.  The binding of estradiol by wild-type ER was disrupted by high concns. of urea (above 2 M), whereas the Y537S ER was distinctly more resistant to this disruption.  These results are consistent with a model in which wild-type ER in the absence of ligand adopts a transcriptionally inactive collapsed pocket conformation, stabilized by specific interactions of Y537 with nearby regions of ER.  When estradiol is bound, the wild-type ER adopts a transcriptionally active, closed pocket (ligand occupied) conformation.  By contrast, the Y537S mutant ER favors the transcriptionally active closed pocket conformation, whether occupied by ligand or not, the latter state (closed pocket but unoccupied) accounting for its constitutive activity.  The authors' findings suggest that the entry or exit of ligand from the binding pocket requires that ER adopt an open pocket conformation.  The reduced rates of ligand assocn. and dissocn. in the constitutively active form of the ER, as well as its greater resistance to disruption of ligand binding by urea, support the supposition that the rate at which this open pocket conformation can be accessed from the unoccupied or ligand-occupied Y537S ER is slower than from the unoccupied or occupied forms of wild-type ER.  Thus, the binding and release of ligand by ER require that the receptor access an open pocket state, and the ease with which this state can be accessed is affected by mutations that alter receptor conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpASth-0158cLVg90H21EOLACvtfcHk0li_LeovJUSK_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D&md5=905b74d7bd576c661a10daad28913fd8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fbi971746l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi971746l%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DGee%26aufirst%3DA.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAltered%2520ligand%2520binding%2520properties%2520and%2520enhanced%2520stability%2520of%2520a%2520constitutively%2520active%2520estrogen%2520receptor%253A%2520evidence%2520that%2520an%2520open%2520pocket%2520conformation%2520is%2520required%2520for%2520ligand%2520interaction%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D14897%26epage%3D14905%26doi%3D10.1021%2Fbi971746l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Chisamore, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentrem, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span> </span><span class="NLM_article-title">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3156</span><span class="NLM_x">–</span> <span class="NLM_lpage">3165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=11595710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3156-3165&author=M.+J.+Chisamoreauthor=Y.+Ahmedauthor=D.+J.+Bentremauthor=V.+C.+Jordanauthor=D.+A.+Tonetti&title=Novel+antitumor+effect+of+estradiol+in+athymic+mice+injected+with+a+T47D+breast+cancer+cell+line+overexpressing+protein+kinase+Calpha"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase cα</span></div><div class="casAuthors">Chisamore, Michael J.; Ahmed, Yasmin; Bentrem, David J.; Jordan, V. Craig; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3156-3165</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to tamoxifen (TAM) represents a significant challenge to the management of breast cancer.  We previously reported that the estrogen receptor (ER)-neg. hormone-independent T47D:C42 cell line has both elevated protein kinase Cα (PKCα) protein expression and basal activator protein-1 activity compared with the parental ER+ (hormone-dependent) T47D:A18 cell line.  Stable transfection of PKCα to the T47D:A18 breast cancer cell line results in increased basal activator protein-1 activity, reduced ER function, increased proliferation rate, and hormone-independent growth (Tonetti et al., Br. J. Cancer, 83: 782-791, 2000).  In this report, we further characterize the role of PKCα overexpression in vivo to elucidate a possible mol. mechanism of tamoxifen resistance.  To det. whether the T47D:A18/PKCα cell line would produce hormone-independent tumors in athymic mice, we injected T47D:A18, T47D:A18/neo, or the T47D:A18/PKCα20 cell clones bilaterally into the mammary fat pads of athymic mice.  Tumor growth was evaluated following treatment with estradiol (E2), TAM, and the pure antiestrogen, ICI 182780.  Mice receiving either T47D:A18 or T47D:A18/neo cells produced tumors that grew in response to E2 treatment, whereas the untreated control and TAM-treated groups showed no tumor growth.  Interestingly, mice receiving the T47D:A18/PKCα20 clone produced tumors in both the control and TAM groups, whereas tumor growth was inhibited in mice treated with E2.  PKCα was also overexpressed in an MCF-7 tumor model that also exhibited TAM-stimulated and E2-induced regression.  These results suggest that overexpression of PKCα in breast tumors results in hormone-independent tumor growth that cannot be inhibited by TAM treatment.  Furthermore, the finding that E2 has an antitumor effect on breast tumors overexpressing PKCα is a novel observation that may have important therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Yd2zilR7XbVg90H21EOLACvtfcHk0li_LeovJUSK_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D&md5=e132ea7de154480f42b7f701b796401c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChisamore%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DY.%26aulast%3DBentrem%26aufirst%3DD.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520antitumor%2520effect%2520of%2520estradiol%2520in%2520athymic%2520mice%2520injected%2520with%2520a%2520T47D%2520breast%2520cancer%2520cell%2520line%2520overexpressing%2520protein%2520kinase%2520Calpha%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3156%26epage%3D3165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Perez White, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span> </span><span class="NLM_article-title">Extranuclear ERalpha is associated with regression of T47D PKCalpha-overexpressing, tamoxifen-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="refDoi"> DOI: 10.1186/1476-4598-12-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1186%2F1476-4598-12-34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=23634843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt12qt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=34&author=B.+Perez+Whiteauthor=M.+E.+Molloyauthor=H.+Zhaoauthor=Y.+Zhangauthor=D.+A.+Tonetti&title=Extranuclear+ERalpha+is+associated+with+regression+of+T47D+PKCalpha-overexpressing%2C+tamoxifen-resistant+breast+cancer&doi=10.1186%2F1476-4598-12-34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer</span></div><div class="casAuthors">Perez White, Bethany; Molloy, Mary Ellen; Zhao, Huiping; Zhang, Yiyun; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Prior to the introduction of tamoxifen, high dose estradiol was used to treat breast cancer patients with similar efficacy as tamoxifen, albeit with some undesirable side effects.  There is renewed interest to utilize estradiol to treat endocrine resistant breast cancers, esp. since findings from several preclin. models and clin. trials indicate that estradiol may be a rational second-line therapy in patients exhibiting resistance to tamoxifen and/or aromatase inhibitors.  We and others reported that breast cancer patients bearing protein kinase C alpha (PKCα)-expressing tumors exhibit endocrine resistance and tumor aggressiveness.  Our T47D:A18/PKCα preclin. model is tamoxifen-resistant, hormone-independent, yet is inhibited by 17β-estradiol (E2) in vivo.  We previously reported that E2-induced T47D:A18/PKCα tumor regression requires extranuclear ERα and interaction with the extracellular matrix.  Methods: T47D:A18/PKCα cells were grown in vitro using two-dimensional (2D) cell culture, three-dimensional (3D) Matrigel and in vivo by establishing xenografts in athymic mice.  Immunofluoresence confocal microscopy and co-localization were applied to det. estrogen receptor alpha (ERα) subcellular localization.  Co-immunopptn. and western blot were used to examine interaction of ERα with caveolin-1.  Results: We report that although T47D:A18/PKCα cells are cross-resistant to raloxifene in cell culture and in Matrigel, raloxifene induces regression of tamoxifen-resistant tumors.  ERα rapidly translocates to extranuclear sites during T47D:A18/PKCα tumor regression in response to both raloxifene and E2, whereas ERα is primarily localized in the nucleus in proliferating tumors.  E2 treatment induced complete tumor regression whereas cessation of raloxifene treatment resulted in tumor regrowth accompanied by re-localization of ERα to the nucleus.  T47D:A18/neo tumors that do not overexpress PKCα maintain ERα in the nucleus during tamoxifen-mediated regression.  An assocn. between ERα and caveolin-1 increases in tumors regressing in response to E2.  Conclusions: Extranuclear ERα plays a role in the regression of PKCα-overexpressing tamoxifen-resistant tumors.  These studies underline the unique role of extranuclear ERα in E2- and raloxifene-induced tumor regression that may have implications for treatment of endocrine-resistant PKCα-expressing tumors encountered in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3dl-xeGYbWbVg90H21EOLACvtfcHk0li_LeovJUSK_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt12qt7w%253D&md5=cc902496a93ae81c99847d5f16b89512</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-34%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%2BWhite%26aufirst%3DB.%26aulast%3DMolloy%26aufirst%3DM.%2BE.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DExtranuclear%2520ERalpha%2520is%2520associated%2520with%2520regression%2520of%2520T47D%2520PKCalpha-overexpressing%252C%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D34%26doi%3D10.1186%2F1476-4598-12-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaomeng Zhang, Yazhou Wang, Xue Li, Jie Wu, Liwen Zhao, Wei Li, <span class="NLM_string-name hlFld-ContribAuthor">Jian Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7575-7595. <a href="https://doi.org/10.1021/acs.jmedchem.1c00280" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00280%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDynamics-Based%252BDiscovery%252Bof%252BNovel%25252C%252BPotent%252BBenzoic%252BAcid%252BDerivatives%252Bas%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252Bfor%252BER%2525CE%2525B1%25252B%252BBreast%252BCancer%26aulast%3DZhang%26aufirst%3DXiaomeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D13022021%26date%3D31052021%26volume%3D64%26issue%3D11%26spage%3D7575%26epage%3D7595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yunlong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wukun Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15094-15114. <a href="https://doi.org/10.1021/acs.jmedchem.0c00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00913%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%25253A%252BA%252BPromising%252BStrategy%252Bfor%252BEstrogen%252BReceptor%252BPositive%252BEndocrine-Resistant%252BBreast%252BCancer%26aulast%3DLu%26aufirst%3DYunlong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D02112020%26volume%3D63%26issue%3D24%26spage%3D15094%26epage%3D15114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Thomas A. Moss, Amber Balazs, Bernard Barlaam, Jason Breed, Rodrigo J. Carbajo, Elisabetta Chiarparin, Paul R. J. Davey, Oona Delpuech, Stephen Fawell, David I. Fisher, Sladjana Gagrica, Eric T. Gangl, Tyler Grebe, Ryan D. Greenwood, Sudhir Hande, Holia Hatoum-Mokdad, Kara Herlihy, Samantha Hughes, Thomas A. Hunt, Hoan Huynh, Sophie L. M. Janbon, Tony Johnson, Stefan Kavanagh, Teresa Klinowska, Mandy Lawson, Andrew S. Lister, Stacey Marden, Dermot F. McGinnity, Christopher J. Morrow, J. Willem M. Nissink, Daniel H. O’Donovan, Bo Peng, Radoslaw Polanski, Darren S. Stead, Stephen Stokes, Kumar Thakur, Scott R. Throner, Michael J. Tucker, Jeffrey Varnes, Haixia Wang, David M. Wilson, Dedong Wu, Ye Wu, Bin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Wenzhan Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14530-14559. <a href="https://doi.org/10.1021/acs.jmedchem.0c01163" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01163%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAZD9833%25252C%252Ba%252BPotent%252Band%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252Band%252BAntagonist%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07072020%26date%3D29092020%26date%3D10092020%26volume%3D63%26issue%3D23%26spage%3D14530%26epage%3D14559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Laura Cooper, Adam Schafer, Yangfeng Li, Han Cheng, Bani Medegan Fagla, Zhengnan Shen, Raghad Nowar, Katherine Dye, Manu Anantpadma, Robert A. Davey, Gregory R. J. Thatcher, Lijun Rong, <span class="NLM_string-name hlFld-ContribAuthor">Rui Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11085-11099. <a href="https://doi.org/10.1021/acs.jmedchem.0c01001" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DScreening%252Band%252BReverse-Engineering%252Bof%252BEstrogen%252BReceptor%252BLigands%252Bas%252BPotent%252BPan-Filovirus%252BInhibitors%26aulast%3DCooper%26aufirst%3DLaura%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11062020%26date%3D22092020%26date%3D04092020%26volume%3D63%26issue%3D19%26spage%3D11085%26epage%3D11099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yangfeng Li, Jiong Zhao, Lauren M. Gutgesell, Zhengnan Shen, Kiira Ratia, Katherine Dye, Oleksii Dubrovskyi, Huiping Zhao, Fei Huang, Debra A. Tonetti, Gregory R. J. Thatcher, <span class="NLM_string-name hlFld-ContribAuthor">Rui Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7186-7210. <a href="https://doi.org/10.1021/acs.jmedchem.0c00456" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00456%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BPyrrolopyridone%252BBromodomain%252Band%252BExtra-Terminal%252BMotif%252B%252528BET%252529%252BInhibitors%252BEffective%252Bin%252BEndocrine-Resistant%252BER%25252B%252BBreast%252BCancer%252Bwith%252BAcquired%252BResistance%252Bto%252BFulvestrant%252Band%252BPalbociclib%26aulast%3DLi%26aufirst%3DYangfeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18032020%26date%3D15062020%26date%3D26052020%26volume%3D63%26issue%3D13%26spage%3D7186%26epage%3D7210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brett L. Roberts, Zhi-Xiong Ma, Ang Gao, Eric D. Leisten, Dan Yin, Wei Xu, <span class="NLM_string-name hlFld-ContribAuthor">Weiping Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 1487-1496. <a href="https://doi.org/10.1021/acschembio.0c00140" title="DOI URL">https://doi.org/10.1021/acschembio.0c00140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.0c00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.0c00140%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DTwo-Stage%252BStrategy%252Bfor%252BDevelopment%252Bof%252BProteolysis%252BTargeting%252BChimeras%252Band%252Bits%252BApplication%252Bfor%252BEstrogen%252BReceptor%252BDegraders%26aulast%3DRoberts%26aufirst%3DBrett%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D07042020%26date%3D16042020%26date%3D07042020%26volume%3D15%26issue%3D6%26spage%3D1487%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yunlong Lu, Lauren M. Gutgesell, Rui Xiong, Jiong Zhao, Yangfeng Li, Carlo I. Rosales, Michael Hollas, Zhengnan Shen, Jesse Gordon-Blake, Katherine Dye, Yueting Wang, Sue Lee, Hu Chen, Donghong He, Oleksii Dubrovyskyii, Huiping Zhao, Fei Huang, Amy W. Lasek, Debra A. Tonetti, <span class="NLM_string-name hlFld-ContribAuthor">Gregory R. J. Thatcher</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 11301-11323. <a href="https://doi.org/10.1021/acs.jmedchem.9b01580" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01580%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BBasic%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252Bfor%252BEndocrine%252BTherapy%252BResistant%252BBreast%252BCancer%26aulast%3DLu%26aufirst%3DYunlong%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22092019%26date%3D10122019%26date%3D20112019%26volume%3D62%26issue%3D24%26spage%3D11301%26epage%3D11323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Jason Breed, Rodrigo J. Carbajo, Paul R. Davey, Ryan Greenwood, Hoan K. Huynh, Teresa Klinowska, Christopher J. Morrow, Thomas A. Moss, Radoslaw Polanski, J. Willem M. Nissink, Jeffrey Varnes, <span class="NLM_string-name hlFld-ContribAuthor">Bin Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1492-1497. <a href="https://doi.org/10.1021/acsmedchemlett.9b00370" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBuilding%252BBridges%252Bin%252Ba%252BSeries%252Bof%252BEstrogen%252BReceptor%252BDegraders%25253A%252BAn%252BApplication%252Bof%252BMetathesis%252Bin%252BMedicinal%252BChemistry%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D23092019%26date%3D25092019%26date%3D23092019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Andrew Bailey, David Buttar, Rodrigo J. Carbajo, Jon Curwen, Paul R. J. Davey, Robert D. M. Davies, Sébastien L. Degorce, Craig Donald, Eric Gangl, Ryan Greenwood, Sam D. Groombridge, Tony Johnson, Scott Lamont, Mandy Lawson, Andrew Lister, Christopher J. Morrow, Thomas A. Moss, Jennifer H. Pink, <span class="NLM_string-name hlFld-ContribAuthor">Radoslaw Polanski</span>. </span><span class="cited-content_cbyCitation_article-title">Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1593-1608. <a href="https://doi.org/10.1021/acs.jmedchem.8b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTricyclic%252BIndazoles%2525E2%252580%252594A%252BNovel%252BClass%252Bof%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252BAntagonists%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D23112018%26date%3D30012019%26date%3D14012019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy Lai, Celine Bonnefous, Karensa Douglas, John Sensintaffar, Nhin Liu, KyoungJin Lee, Anna Aparicio, Josh Kaufman, Jing Qian, Gang Shao, Rene Prudente, James D. Joseph, Beatrice Darimont, Daniel Brigham, Richard Heyman, Peter J. Rix, Jeffrey H. Hager, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 50-55. <a href="https://doi.org/10.1021/acsmedchemlett.8b00414" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMaximizing%252BER-%2525CE%2525B1%252BDegradation%252BMaximizes%252BActivity%252Bin%252Ba%252BTamoxifen-Resistant%252BBreast%252BCancer%252BModel%25253A%252BIdentification%252Bof%252BGDC-0927%26aulast%3DKahraman%26aufirst%3DMehmet%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07092018%26date%3D06122018%26date%3D17122018%26date%3D06122018%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Johnny Nagasawa, Steven Govek, Mehmet Kahraman, Andiliy Lai, Celine Bonnefous, Karensa Douglas, John Sensintaffar, Nhin Lu, KyoungJin Lee, Anna Aparicio, Josh Kaufman, Jing Qian, Gang Shao, Rene Prudente, James D. Joseph, Beatrice Darimont, Daniel Brigham, Kate Maheu, Richard Heyman, Peter J. Rix, Jeffrey H. Hager, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7917-7928. <a href="https://doi.org/10.1021/acs.jmedchem.8b00921" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00921</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ban%252BOrally%252BBioavailable%252BChromene-Based%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%252BThat%252BDemonstrates%252BRobust%252BActivity%252Bin%252Ba%252BModel%252Bof%252BTamoxifen-Resistant%252BBreast%252BCancer%26aulast%3DNagasawa%26aufirst%3DJohnny%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09062018%26date%3D04092018%26date%3D07082018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Min</span>, <span class="hlFld-ContribAuthor ">Valeria Sanabria  Guillen</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>, <span class="hlFld-ContribAuthor ">Yuechao  Zhao</span>, <span class="hlFld-ContribAuthor ">Yvonne  Ziegler</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Christopher G.  Mayne</span>, <span class="hlFld-ContribAuthor ">Sathish  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Sung Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">Kathryn E.  Carlson</span>, <span class="hlFld-ContribAuthor ">Kendall W.  Nettles</span>, <span class="hlFld-ContribAuthor ">Benita S.  Katzenellenbogen</span>, and <span class="hlFld-ContribAuthor ">John A.  Katzenellenbogen</span>  . </span><span class="cited-content_cbyCitation_article-title">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (14)
                                     , 6321-6336. <a href="https://doi.org/10.1021/acs.jmedchem.7b00585" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00585</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00585%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdamantyl%252BAntiestrogens%252Bwith%252BNovel%252BSide%252BChains%252BReveal%252Ba%252BSpectrum%252Bof%252BActivities%252Bin%252BSuppressing%252BEstrogen%252BReceptor%252BMediated%252BActivities%252Bin%252BBreast%252BCancer%252BCells%26aulast%3DMin%26aufirst%3DJian%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D04052017%26date%3D14072017%26date%3D27072017%26date%3D28062017%26volume%3D60%26issue%3D14%26spage%3D6321%26epage%3D6336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fahmida  Rasha</span>, <span class="hlFld-ContribAuthor ">Monica  Sharma</span>, <span class="hlFld-ContribAuthor ">Kevin  Pruitt</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of endocrine therapy resistance in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2021,</strong> <em>532 </em>, 111322. <a href="https://doi.org/10.1016/j.mce.2021.111322" title="DOI URL">https://doi.org/10.1016/j.mce.2021.111322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2021.111322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2021.111322%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DMechanisms%252Bof%252Bendocrine%252Btherapy%252Bresistance%252Bin%252Bbreast%252Bcancer%26aulast%3DRasha%26aufirst%3DFahmida%26date%3D2021%26volume%3D532%26spage%3D111322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nallappan  Sundaravelu</span>, <span class="hlFld-ContribAuthor ">Tushar  Singha</span>, <span class="hlFld-ContribAuthor ">Anuradha  Nandy</span>, <span class="hlFld-ContribAuthor ">Govindasamy  Sekar</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed domino synthesis of multi-substituted benzo[
              b
              ]thiophene through radical cyclization using xanthate as a sulfur surrogate. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (37)
                                     , 4512-4515. <a href="https://doi.org/10.1039/D0CC08429H" title="DOI URL">https://doi.org/10.1039/D0CC08429H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC08429H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC08429H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCopper-catalyzed%252Bdomino%252Bsynthesis%252Bof%252Bmulti-substituted%252Bbenzo%25255B%252Bb%252B%25255Dthiophene%252Bthrough%252Bradical%252Bcyclization%252Busing%252Bxanthate%252Bas%252Ba%252Bsulfur%252Bsurrogate%26aulast%3DSundaravelu%26aufirst%3DNallappan%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D37%26spage%3D4512%26epage%3D4515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlo I.  Rosales</span>, <span class="hlFld-ContribAuthor ">Lauren M.  Gutgesell</span>, <span class="hlFld-ContribAuthor ">Kiira M.  Ratia</span>, <span class="hlFld-ContribAuthor ">Gregory R.J.  Thatcher</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen Receptor Modulators. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-74. <a href="https://doi.org/10.1002/0471266949.bmc054.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc054.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc054.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc054.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DEstrogen%252BReceptor%252BModulators%26aulast%3DRosales%26aufirst%3DCarlo%2BI.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D74%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Xin  Lin</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Chenna  Liu</span>, <span class="hlFld-ContribAuthor ">Xinglong  Chi</span>, <span class="hlFld-ContribAuthor ">Yulan  Zhang</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104714. <a href="https://doi.org/10.1016/j.bioorg.2021.104714" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104714%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2H-chromene-3-carbonyl%252Bderivatives%252Bas%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERDs%252529%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DLu%26aufirst%3DXiang%26date%3D2021%26volume%3D109%26spage%3D104714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tyler B.  Faust</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Philip P.  Chamberlain</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Approaches to Targeted Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Cancer Biology</span><span> <strong>2021,</strong> <em>5 </em>
                                    (1)
                                     , 181-201. <a href="https://doi.org/10.1146/annurev-cancerbio-051420-114114" title="DOI URL">https://doi.org/10.1146/annurev-cancerbio-051420-114114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-cancerbio-051420-114114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-cancerbio-051420-114114%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Cancer%2520Biology%26atitle%3DSmall-Molecule%252BApproaches%252Bto%252BTargeted%252BProtein%252BDegradation%26aulast%3DFaust%26aufirst%3DTyler%2BB.%26date%3D2021%26volume%3D5%26issue%3D1%26spage%3D181%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurent  Besret</span>, <span class="hlFld-ContribAuthor ">Sébastien  d’Heilly</span>, <span class="hlFld-ContribAuthor ">Cathy  Aubert</span>, <span class="hlFld-ContribAuthor ">Guillaume  Bluet</span>, <span class="hlFld-ContribAuthor ">Florence  Gruss-Leleu</span>, <span class="hlFld-ContribAuthor ">Françoise  Le-Gall</span>, <span class="hlFld-ContribAuthor ">Anne  Caron</span>, <span class="hlFld-ContribAuthor ">Laurent  Andrieu</span>, <span class="hlFld-ContribAuthor ">Sylvie  Vincent</span>, <span class="hlFld-ContribAuthor ">Maysoun  Shomali</span>, <span class="hlFld-ContribAuthor ">Monsif  Bouaboula</span>, <span class="hlFld-ContribAuthor ">Carole  Voland</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Ming</span>, <span class="hlFld-ContribAuthor ">Sébastien  Roy</span>, <span class="hlFld-ContribAuthor ">Srinivas  Rao</span>, <span class="hlFld-ContribAuthor ">Chantal  Carrez</span>, <span class="hlFld-ContribAuthor ">Erwan  Jouannot</span>. </span><span class="cited-content_cbyCitation_article-title">Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader. </span><span class="cited-content_cbyCitation_journal-name">EJNMMI Research</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13550-020-00646-w" title="DOI URL">https://doi.org/10.1186/s13550-020-00646-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13550-020-00646-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13550-020-00646-w%26sid%3Dliteratum%253Aachs%26jtitle%3DEJNMMI%2520Research%26atitle%3DTranslational%252Bstrategy%252Busing%252Bmultiple%252Bnuclear%252Bimaging%252Bbiomarkers%252Bto%252Bevaluate%252Btarget%252Bengagement%252Band%252Bearly%252Btherapeutic%252Befficacy%252Bof%252BSAR439859%25252C%252Ba%252Bnovel%252Bselective%252Bestrogen%252Breceptor%252Bdegrader%26aulast%3DBesret%26aufirst%3DLaurent%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Wang</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (22)
                                     , 2072-2097. <a href="https://doi.org/10.1002/cmdc.202000473" title="DOI URL">https://doi.org/10.1002/cmdc.202000473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000473%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BQuest%252Bfor%252BOrally%252BAvailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%26aulast%3DWang%26aufirst%3DLucia%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D22%26spage%3D2072%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanchan  Vishnoi</span>, <span class="hlFld-ContribAuthor ">Navin  Viswakarma</span>, <span class="hlFld-ContribAuthor ">Ajay  Rana</span>, <span class="hlFld-ContribAuthor ">Basabi  Rana</span>. </span><span class="cited-content_cbyCitation_article-title">Transcription Factors in Cancer Development and Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (8)
                                     , 2296. <a href="https://doi.org/10.3390/cancers12082296" title="DOI URL">https://doi.org/10.3390/cancers12082296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12082296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12082296%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTranscription%252BFactors%252Bin%252BCancer%252BDevelopment%252Band%252BTherapy%26aulast%3DVishnoi%26aufirst%3DKanchan%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D8%26spage%3D2296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Narae  Hwang</span>, <span class="hlFld-ContribAuthor ">Su Wol  Chung</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfasalazine attenuates tamoxifen-induced toxicity in human retinal pigment epithelial cells. </span><span class="cited-content_cbyCitation_journal-name">BMB Reports</span><span> <strong>2020,</strong> <em>53 </em>
                                    (5)
                                     , 284-289. <a href="https://doi.org/10.5483/BMBRep.2020.53.5.041" title="DOI URL">https://doi.org/10.5483/BMBRep.2020.53.5.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5483/BMBRep.2020.53.5.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5483%2FBMBRep.2020.53.5.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBMB%2520Reports%26atitle%3DSulfasalazine%252Battenuates%252Btamoxifen-induced%252Btoxicity%252Bin%252Bhuman%252Bretinal%252Bpigment%252Bepithelial%252Bcells%26aulast%3DHwang%26aufirst%3DNarae%26date%3D2020%26volume%3D53%26issue%3D5%26spage%3D284%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bagora  Bayala</span>, <span class="hlFld-ContribAuthor ">Abdou Azaque  Zoure</span>, <span class="hlFld-ContribAuthor ">Silvère  Baron</span>, <span class="hlFld-ContribAuthor ">Cyrille  de Joussineau</span>, <span class="hlFld-ContribAuthor ">Jacques  Simpore</span>, <span class="hlFld-ContribAuthor ">Jean-Marc A.  Lobaccaro</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (10)
                                     , 3690. <a href="https://doi.org/10.3390/ijms21103690" title="DOI URL">https://doi.org/10.3390/ijms21103690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21103690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21103690%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPharmacological%252BModulation%252Bof%252BSteroid%252BActivity%252Bin%252BHormone-Dependent%252BBreast%252Band%252BProstate%252BCancers%25253A%252BEffect%252Bof%252BSome%252BPlant%252BExtract%252BDerivatives%26aulast%3DBayala%26aufirst%3DBagora%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D10%26spage%3D3690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shagufta</span>, <span class="hlFld-ContribAuthor ">Irshad  Ahmad</span>, <span class="hlFld-ContribAuthor ">Shimy  Mathew</span>, <span class="hlFld-ContribAuthor ">Sofia  Rahman</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (4)
                                     , 438-454. <a href="https://doi.org/10.1039/C9MD00570F" title="DOI URL">https://doi.org/10.1039/C9MD00570F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00570F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bselective%252Bestrogen%252Breceptor%252Bdownregulators%252B%252528SERDs%252529%252Bfor%252Bthe%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DShagufta%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D4%26spage%3D438%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roman A.  Irgashev</span>, <span class="hlFld-ContribAuthor ">Nadezhda S.  Demina</span>, <span class="hlFld-ContribAuthor ">Gennady L.  Rusinov</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of 2,3-disubstituted benzo[
              b
              ]thieno[2,3-
              d
              ]thiophenes and benzo[4,5]selenopheno[3,2-
              b
              ]thiophenes using the Fiesselmann thiophene synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (16)
                                     , 3164-3168. <a href="https://doi.org/10.1039/D0OB00300J" title="DOI URL">https://doi.org/10.1039/D0OB00300J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00300J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00300J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConstruction%252Bof%252B2%25252C3-disubstituted%252Bbenzo%25255B%252Bb%252B%25255Dthieno%25255B2%25252C3-%252Bd%252B%25255Dthiophenes%252Band%252Bbenzo%25255B4%25252C5%25255Dselenopheno%25255B3%25252C2-%252Bb%252B%25255Dthiophenes%252Busing%252Bthe%252BFiesselmann%252Bthiophene%252Bsynthesis%26aulast%3DIrgashev%26aufirst%3DRoman%2BA.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D16%26spage%3D3164%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuihua  Zhang</span>, <span class="hlFld-ContribAuthor ">Qunlin  Li</span>, <span class="hlFld-ContribAuthor ">Yujie  Ren</span>, <span class="hlFld-ContribAuthor ">Fei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling studies of benzothiophene-containing derivatives as promising selective estrogen receptor downregulators: a combination of 3D-QSAR, molecular docking and molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em> </em>, 1-22. <a href="https://doi.org/10.1080/07391102.2020.1751717" title="DOI URL">https://doi.org/10.1080/07391102.2020.1751717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1751717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1751717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bmodeling%252Bstudies%252Bof%252Bbenzothiophene-containing%252Bderivatives%252Bas%252Bpromising%252Bselective%252Bestrogen%252Breceptor%252Bdownregulators%25253A%252Ba%252Bcombination%252Bof%252B3D-QSAR%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DZhang%26aufirst%3DCuihua%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaitlyn J.  Andreano</span>, <span class="hlFld-ContribAuthor ">Suzanne E.  Wardell</span>, <span class="hlFld-ContribAuthor ">Jennifer G.  Baker</span>, <span class="hlFld-ContribAuthor ">Taylor K.  Desautels</span>, <span class="hlFld-ContribAuthor ">Robert  Baldi</span>, <span class="hlFld-ContribAuthor ">Christina A.  Chao</span>, <span class="hlFld-ContribAuthor ">Kendall A.  Heetderks</span>, <span class="hlFld-ContribAuthor ">Yeeun  Bae</span>, <span class="hlFld-ContribAuthor ">Rui  Xiong</span>, <span class="hlFld-ContribAuthor ">Debra A.  Tonetti</span>, <span class="hlFld-ContribAuthor ">Lauren M.  Gutgesell</span>, <span class="hlFld-ContribAuthor ">Jiong  Zhao</span>, <span class="hlFld-ContribAuthor ">Jessica A.  Sorrentino</span>, <span class="hlFld-ContribAuthor ">Delita A.  Thompson</span>, <span class="hlFld-ContribAuthor ">John E.  Bisi</span>, <span class="hlFld-ContribAuthor ">Jay C.  Strum</span>, <span class="hlFld-ContribAuthor ">Gregory R. J.  Thatcher</span>, <span class="hlFld-ContribAuthor ">John D.  Norris</span>. </span><span class="cited-content_cbyCitation_article-title">G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>180 </em>
                                    (3)
                                     , 635-646. <a href="https://doi.org/10.1007/s10549-020-05575-9" title="DOI URL">https://doi.org/10.1007/s10549-020-05575-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-020-05575-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-020-05575-9%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DG1T48%25252C%252Ban%252Boral%252Bselective%252Bestrogen%252Breceptor%252Bdegrader%25252C%252Band%252Bthe%252BCDK4%25252F6%252Binhibitor%252Blerociclib%252Binhibit%252Btumor%252Bgrowth%252Bin%252Banimal%252Bmodels%252Bof%252Bendocrine-resistant%252Bbreast%252Bcancer%26aulast%3DAndreano%26aufirst%3DKaitlyn%2BJ.%26date%3D2020%26date%3D2020%26volume%3D180%26issue%3D3%26spage%3D635%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kalaiarasi  Chinnasamy</span>, <span class="hlFld-ContribAuthor ">Manjula  Saravanan</span>, <span class="hlFld-ContribAuthor ">Kumaradhas  Poomani</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of binding mechanism and downregulation of elacestrant for wild and L536S mutant estrogen receptor‐α through molecular dynamics simulation and binding free energy analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Chemistry</span><span> <strong>2020,</strong> <em>41 </em>
                                    (2)
                                     , 97-109. <a href="https://doi.org/10.1002/jcc.26076" title="DOI URL">https://doi.org/10.1002/jcc.26076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcc.26076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcc.26076%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Chemistry%26atitle%3DInvestigation%252Bof%252Bbinding%252Bmechanism%252Band%252Bdownregulation%252Bof%252Belacestrant%252Bfor%252Bwild%252Band%252BL536S%252Bmutant%252Bestrogen%252Breceptor%2525E2%252580%252590%2525CE%2525B1%252Bthrough%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bbinding%252Bfree%252Benergy%252Banalysis%26aulast%3DChinnasamy%26aufirst%3DKalaiarasi%26date%3D2020%26date%3D2019%26volume%3D41%26issue%3D2%26spage%3D97%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kalaiarasi  Chinnasamy</span>, <span class="hlFld-ContribAuthor ">Manjula  Saravanan</span>, <span class="hlFld-ContribAuthor ">Kumaradhas  Poomani</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of binding and antagonism/downregulation of brilanestrant molecule in estrogen receptor-α via quantum mechanics/molecular mechanics, molecular dynamics and binding free energy calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (1)
                                     , 219-235. <a href="https://doi.org/10.1080/07391102.2019.1574605" title="DOI URL">https://doi.org/10.1080/07391102.2019.1574605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1574605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1574605%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DEvaluation%252Bof%252Bbinding%252Band%252Bantagonism%25252Fdownregulation%252Bof%252Bbrilanestrant%252Bmolecule%252Bin%252Bestrogen%252Breceptor-%2525CE%2525B1%252Bvia%252Bquantum%252Bmechanics%25252Fmolecular%252Bmechanics%25252C%252Bmolecular%252Bdynamics%252Band%252Bbinding%252Bfree%252Benergy%252Bcalculations%26aulast%3DChinnasamy%26aufirst%3DKalaiarasi%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D1%26spage%3D219%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Songyin  Huang</span>, <span class="hlFld-ContribAuthor ">Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Zhi-Mei  Liang</span>, <span class="hlFld-ContribAuthor ">Na-Na  Li</span>, <span class="hlFld-ContribAuthor ">Yujie  Liu</span>, <span class="hlFld-ContribAuthor ">Yinghua  Zhu</span>, <span class="hlFld-ContribAuthor ">Dingzhun  Liao</span>, <span class="hlFld-ContribAuthor ">Xiao Zhen  Zhou</span>, <span class="hlFld-ContribAuthor ">Kun Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Yandan  Yao</span>, <span class="hlFld-ContribAuthor ">Man-Li  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fcell.2019.00322" title="DOI URL">https://doi.org/10.3389/fcell.2019.00322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2019.00322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2019.00322%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTargeting%252BPin1%252Bby%252BAll-Trans%252BRetinoic%252BAcid%252B%252528ATRA%252529%252BOvercomes%252BTamoxifen%252BResistance%252Bin%252BBreast%252BCancer%252Bvia%252BMultifactorial%252BMechanisms%26aulast%3DHuang%26aufirst%3DSongyin%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Javad  Behravan</span>, <span class="hlFld-ContribAuthor ">Atefeh  Razazan</span>, <span class="hlFld-ContribAuthor ">Ghazal  Behravan</span>. </span><span class="cited-content_cbyCitation_article-title">Towards Breast Cancer Vaccines, Progress and Challenges. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Discovery Technologies</span><span> <strong>2019,</strong> <em>16 </em>
                                    (3)
                                     , 251-258. <a href="https://doi.org/10.2174/1570163815666180502164652" title="DOI URL">https://doi.org/10.2174/1570163815666180502164652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570163815666180502164652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570163815666180502164652%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Discovery%2520Technologies%26atitle%3DTowards%252BBreast%252BCancer%252BVaccines%25252C%252BProgress%252Band%252BChallenges%26aulast%3DBehravan%26aufirst%3DJavad%26date%3D2019%26volume%3D16%26issue%3D3%26spage%3D251%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yulia A.  Volkova</span>, <span class="hlFld-ContribAuthor ">Andrey S.  Kozlov</span>, <span class="hlFld-ContribAuthor ">Marya K.  Kolokolova</span>, <span class="hlFld-ContribAuthor ">Denis Y.  Uvarov</span>, <span class="hlFld-ContribAuthor ">Sergey A.  Gorbatov</span>, <span class="hlFld-ContribAuthor ">Olga E.  Andreeva</span>, <span class="hlFld-ContribAuthor ">Alexander M.  Scherbakov</span>, <span class="hlFld-ContribAuthor ">Igor V.  Zavarzin</span>. </span><span class="cited-content_cbyCitation_article-title">Steroidal N-Sulfonylimidates: Synthesis and biological evaluation in breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 694-706. <a href="https://doi.org/10.1016/j.ejmech.2019.06.048" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.048%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSteroidal%252BN-Sulfonylimidates%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%252Bin%252Bbreast%252Bcancer%252Bcells%26aulast%3DVolkova%26aufirst%3DYulia%2BA.%26date%3D2019%26volume%3D179%26spage%3D694%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Yun  Guo</span>, <span class="hlFld-ContribAuthor ">Shang-Ming-Zhu  Zeng</span>, <span class="hlFld-ContribAuthor ">Girdhar Singh  Deora</span>, <span class="hlFld-ContribAuthor ">Qing-Shan  Li</span>, <span class="hlFld-ContribAuthor ">Ban-Feng  Ruan</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1318-1337. <a href="https://doi.org/10.2174/1568026619666190619142504" title="DOI URL">https://doi.org/10.2174/1568026619666190619142504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190619142504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190619142504%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DEstrogen%252BReceptor%252B%2525CE%2525B1%252B%252528ER%2525CE%2525B1%252529-targeting%252BCompounds%252Band%252BDerivatives%25253A%252BRecent%252BAdvances%252Bin%252BStructural%252BModification%252Band%252BBioactivity%26aulast%3DGuo%26aufirst%3DWei-Yun%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1318%26epage%3D1337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcus  Söderström</span>, <span class="hlFld-ContribAuthor ">Edouard  Zamaratski</span>, <span class="hlFld-ContribAuthor ">Luke R.  Odell</span>. </span><span class="cited-content_cbyCitation_article-title">BF
              3
              ·SMe
              2
              for Thiomethylation, Nitro Reduction and Tandem Reduction/SMe Insertion of Nitrogen Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (31-32)
                                     , 5402-5408. <a href="https://doi.org/10.1002/ejoc.201900503" title="DOI URL">https://doi.org/10.1002/ejoc.201900503</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900503%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DBF%252B3%252B%2525C2%2525B7SMe%252B2%252Bfor%252BThiomethylation%25252C%252BNitro%252BReduction%252Band%252BTandem%252BReduction%25252FSMe%252BInsertion%252Bof%252BNitrogen%252BHeterocycles%26aulast%3DS%25C3%25B6derstr%25C3%25B6m%26aufirst%3DMarcus%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D31-32%26spage%3D5402%26epage%3D5408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanmay  Saha</span>, <span class="hlFld-ContribAuthor ">Subhajit  Makar</span>, <span class="hlFld-ContribAuthor ">Rayala  Swetha</span>, <span class="hlFld-ContribAuthor ">Gopichand  Gutti</span>, <span class="hlFld-ContribAuthor ">Sushil K.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen signaling: An emanating therapeutic target for breast cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>177 </em>, 116-143. <a href="https://doi.org/10.1016/j.ejmech.2019.05.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEstrogen%252Bsignaling%25253A%252BAn%252Bemanating%252Btherapeutic%252Btarget%252Bfor%252Bbreast%252Bcancer%252Btreatment%26aulast%3DSaha%26aufirst%3DTanmay%26date%3D2019%26volume%3D177%26spage%3D116%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Silong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiye  Hu</span>, <span class="hlFld-ContribAuthor ">Yuan  Xiao</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Chune  Dong</span>, <span class="hlFld-ContribAuthor ">Shengtang  Huang</span>, <span class="hlFld-ContribAuthor ">Hai-Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>172 </em>, 48-61. <a href="https://doi.org/10.1016/j.ejmech.2019.03.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploring%252Bthe%252BPROTAC%252Bdegron%252Bcandidates%25253A%252BOBHSA%252Bwith%252Bdifferent%252Bside%252Bchains%252Bas%252Bnovel%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERDs%252529%26aulast%3DLi%26aufirst%3DYuanyuan%26date%3D2019%26volume%3D172%26spage%3D48%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengfeng  Cai</span>, <span class="hlFld-ContribAuthor ">Lu  Cai</span>, <span class="hlFld-ContribAuthor ">Zhuchao  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Pan</span>, <span class="hlFld-ContribAuthor ">Minghong  Wang</span>, <span class="hlFld-ContribAuthor ">Su  Chen</span>, <span class="hlFld-ContribAuthor ">Manuel  Luis</span>, <span class="hlFld-ContribAuthor ">Chunmei  Cen</span>, <span class="hlFld-ContribAuthor ">Ewelina  Biskup</span>. </span><span class="cited-content_cbyCitation_article-title">Prognostic role of Tif1γ expression and circulating tumor cells in patients with breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Medicine Reports</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/mmr.2019.10033" title="DOI URL">https://doi.org/10.3892/mmr.2019.10033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/mmr.2019.10033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fmmr.2019.10033%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Medicine%2520Reports%26atitle%3DPrognostic%252Brole%252Bof%252BTif1%2525CE%2525B3%252Bexpression%252Band%252Bcirculating%252Btumor%252Bcells%252Bin%252Bpatients%252Bwith%252Bbreast%252Bcancer%26aulast%3DCai%26aufirst%3DFengfeng%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moataz S.  Hendy</span>, <span class="hlFld-ContribAuthor ">Aya A.  Ali</span>, <span class="hlFld-ContribAuthor ">Lubna  Ahmed</span>, <span class="hlFld-ContribAuthor ">Reham  Hossam</span>, <span class="hlFld-ContribAuthor ">Alaa  Mostafa</span>, <span class="hlFld-ContribAuthor ">Mohamed M.  Elmazar</span>, <span class="hlFld-ContribAuthor ">Bassem H.  Naguib</span>, <span class="hlFld-ContribAuthor ">Yasmeen M.  Attia</span>, <span class="hlFld-ContribAuthor ">Mahmoud Salama  Ahmed</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>166 </em>, 281-290. <a href="https://doi.org/10.1016/j.ejmech.2019.01.068" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.068%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdrug%252Bdesign%25252C%252Bsynthesis%25252C%252BIn%2525C2%2525A0vitro%25252C%252Band%252BIn%2525C2%2525A0vivo%252Bbiological%252Bevaluation%252Bof%252Bindole-based%252Bbiomimetic%252Banalogs%252Btargeting%252Bestrogen%252Breceptor-%2525CE%2525B1%252Binhibition%26aulast%3DHendy%26aufirst%3DMoataz%2BS.%26date%3D2019%26volume%3D166%26spage%3D281%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matic  Pavlin</span>, <span class="hlFld-ContribAuthor ">Angelo  Spinello</span>, <span class="hlFld-ContribAuthor ">Marzia  Pennati</span>, <span class="hlFld-ContribAuthor ">Nadia  Zaffaroni</span>, <span class="hlFld-ContribAuthor ">Silvia  Gobbi</span>, <span class="hlFld-ContribAuthor ">Alessandra  Bisi</span>, <span class="hlFld-ContribAuthor ">Giorgio  Colombo</span>, <span class="hlFld-ContribAuthor ">Alessandra  Magistrato</span>. </span><span class="cited-content_cbyCitation_article-title">A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-17364-4" title="DOI URL">https://doi.org/10.1038/s41598-017-17364-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-17364-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-17364-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252BComputational%252BAssay%252Bof%252BEstrogen%252BReceptor%252B%2525CE%2525B1%252BAntagonists%252BReveals%252Bthe%252BKey%252BCommon%252BStructural%252BTraits%252Bof%252BDrugs%252BEffectively%252BFighting%252BRefractory%252BBreast%252BCancers%26aulast%3DPavlin%26aufirst%3DMatic%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mara  Livezey</span>, <span class="hlFld-ContribAuthor ">Ji Eun  Kim</span>, <span class="hlFld-ContribAuthor ">David J.  Shapiro</span>. </span><span class="cited-content_cbyCitation_article-title">A New Role for Estrogen Receptor α in Cell Proliferation and Cancer: Activating the Anticipatory Unfolded Protein Response. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fendo.2018.00325" title="DOI URL">https://doi.org/10.3389/fendo.2018.00325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2018.00325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2018.00325%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DA%252BNew%252BRole%252Bfor%252BEstrogen%252BReceptor%252B%2525CE%2525B1%252Bin%252BCell%252BProliferation%252Band%252BCancer%25253A%252BActivating%252Bthe%252BAnticipatory%252BUnfolded%252BProtein%252BResponse%26aulast%3DLivezey%26aufirst%3DMara%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara  Sannino</span>, <span class="hlFld-ContribAuthor ">Jeffrey L.  Brodsky</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting protein quality control pathways in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">BMC Biology</span><span> <strong>2017,</strong> <em>15 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12915-017-0449-4" title="DOI URL">https://doi.org/10.1186/s12915-017-0449-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12915-017-0449-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12915-017-0449-4%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Biology%26atitle%3DTargeting%252Bprotein%252Bquality%252Bcontrol%252Bpathways%252Bin%252Bbreast%252Bcancer%26aulast%3DSannino%26aufirst%3DSara%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative selective estrogen receptor downregulators (SERDs) and selective estrogen receptor modulators (SERMs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel benzothiophene-based SERDs. (A) The BT core common to <b>5</b> and <b>6</b> provided the scaffold for the design of BT-SERDs by replacing the basic side chain with an acrylate side chain and inserting a ketone linker at the 2-position, with further diversification of the 2-substituent. (B) Prototype BT-SERD (<b>14a</b>) docked to ERα LBD (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>), showing similar global topology compared to the <b>3</b>–ER complex. The acrylate side chain interaction with helix 12 is a key structural feature of SERD–ER complexes. (C) Residues within 5 Å of <b>14a</b> are highlighted, and two hydrophobic cavities in the vicinity of Leu-384 and Phe-425 are circled in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, Et<sub>3</sub>N, DCM, RT, overnight, 76%; (b) Grignard reagent, THF, 0 °C to RT, 2–12 h; (c) 4-bromophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (d) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT, 24–48 h; (e) methyl acrylate, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 110 °C; (f) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 6-hydroxy-2-naphthoate, methyl 7-hydroxyquinoline-3-carboxylate, or 4-aminophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (b) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT or 35 °C, 48 h; (c) (i) methyl 2-chloro-2-oxoacetate, Et<sub>3</sub>N, DCM, (ii) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Grignard reagent, THF, 0 °C to RT, 2–12 h; (b) 4-bromophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (c) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT, 24–48 h; (d) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 110 °C; (e) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Grignard reagent, THF, 0 °C to RT, 2–12 h; (b) methyl (<i>E</i>)-3-(4-hydroxyphenyl)acrylate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C; (c) BF<sub>3</sub>·SMe<sub>2</sub>, DCM, 0 °C to RT, 24–48 h; (d) LiOH, MeOH, H<sub>2</sub>O, RT, 4 h.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In-cell western assay of ERα in MCF-7:WS8 cell cultures. Cells were incubated with increasing concentrations of <b>2</b> (ARN-810), <b>24b</b>, <b>24c</b>, <b>28c</b>, or E<sub>2</sub> for 24 h before ERα protein levels were measured using in-cell western, as described in the <a class="ref internalNav" href="#sec10" aria-label="Experimental Section">Experimental Section</a>, and imaged using a LI-COR Odyssey NIR system: (left) ERα (green) is seen to decrease with increasing SERD concentration (green anti-ERα antibody); (middle) CellTag 700 (red) is used for normalization; and (right) the color merged plate clearly shows loss of ERα in response to SERD treatment. Data quantitation is shown in <a class="ref internalNav" href="#fig4" aria-label="Figures 4">Figures 4</a>C and <a href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf" class="ext-link">S2</a> and <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Profiling SERDs: <b>2</b> and <b>28c</b>. (A) Cell viability of TR MCF-7:5C breast cancer cells 4 days after drug treatment, normalized to vehicle (100%). (B) Cell viability of parent endocrine-sensitive MCF-7:WS8 breast cancer cells 4 days after drug treatment, normalized to vehicle (100%). (C) Estrogen receptor downregulation using in-cell western assay in MCF-7:WS8 cells. Data were normalized to 1 μM <b>2</b> as 0% and DMSO control as 100%. (D) ERα antagonism using ERE-luciferase reporter assay in MCF-7:WS8 cells. Data was normalized to 1 μM <b>2</b> as 0% and 0.1 nM E<sub>2</sub> as 100%. Data show mean and SEM from at least three cell passages.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SERDs inhibit growth of MCF-7:TAM1 spheroids at day 10: DMSO (A), <b>2</b> 1 nM (B), <b>28c</b> (1 nM) (C), and <b>28c</b> (10 nM) (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compounds <b>14a</b> (A), <b>14b</b> (B), and <b>28c</b> (C) were docked to ER LBD (pdb ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ak2">5ak2</a>). Compound <b>14a</b> has minimum contacts with hydrophobic pockets (close to Phe-425 and Leu-384), whereas compound <b>14b</b> and <b>28c</b> have methyl groups that tightly fit into the hydrophobic cavity, corresponding to better potency in cell viability assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Synergistic or additive effects of combination therapy of SERDs and CDK4/6 inhibitor PD-0332991 (PD) in MCF-7:WS8 and TR MCF-7:TAM1 spheroids quantified by ATP assay normalized to vehicle (DMSO) as 1.0. Data show mean and SEM with one-way ANOVA comparison with Tukey’s post-test relative to DMSO control group or comparison of SERD alone (10 nM) with SERD + PD (10 nM): <i>p</i> < * 0.05; <i>p</i> < ** 0.01; <i>p</i> < *** 0.005; <i>p</i> < **** 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/medium/jm-2016-01355m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Plasma concentration of <b>24c</b>, <b>28a</b>, and <b>28c</b> after oral administration in PEG400/PVP/TW80/CMC in water, 9:0.5:0.5:90. The data was the average plasma concentration of three mice at 0.25, 0.5, 1, 2, 4, 8, and 12 h. (B, C) MCF7:TAM1 tumors were grown to an average section area of 0.32 cm<sup>2</sup> (as described in the <a class="ref internalNav" href="#sec10" aria-label="Experimental Section">Experimental Section</a>). Mice were then randomized into six treatment groups: control, tamoxifen, <b>2</b>, <b>28a</b>, and two doses of <b>28c</b>. Compounds were administrated by oral gavage daily: (B) mean tumor growth over 9 weeks showing mean and SEM; (C) individual tumor area change in percentage at day 23.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01355/20170216/images/large/jm-2016-01355m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01355&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 79 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Early Breast Cancer Trialists’ Collaborative Group</span><span> </span><span class="NLM_article-title">Tamoxifen for early breast cancer: an overview of the randomised trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">1451</span><span class="NLM_x">–</span> <span class="NLM_lpage">1467</span><span class="refDoi"> DOI: 10.1016/S0140-6736(97)11423-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2FS0140-6736%2897%2911423-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=9605801" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=1998&pages=1451-1467&author=Early+Breast+Cancer+Trialists%E2%80%99+Collaborative+Group&title=Tamoxifen+for+early+breast+cancer%3A+an+overview+of+the+randomised+trials&doi=10.1016%2FS0140-6736%2897%2911423-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2897%2911423-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252897%252911423-4%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DTamoxifen%2520for%2520early%2520breast%2520cancer%253A%2520an%2520overview%2520of%2520the%2520randomised%2520trials%26jtitle%3DLancet%26date%3D1998%26volume%3D351%26spage%3D1451%26epage%3D1467%26doi%3D10.1016%2FS0140-6736%2897%2911423-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.1993.tb13840.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1111%2Fj.1476-5381.1993.tb13840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=8242225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK3sXms1Wru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=1993&pages=507-517&author=V.+C.+Jordan&title=Fourteenth+Gaddum+Memorial+Lecture.+A+current+view+of+tamoxifen+for+the+treatment+and+prevention+of+breast+cancer&doi=10.1111%2Fj.1476-5381.1993.tb13840.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A current view of tamoxifen for the treatment and prevention of breast cancer</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">507-17</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">A review with ∼ 150 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2gSMvDLsn2rVg90H21EOLACvtfcHk0ljqMB7-rw2agg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXms1Wru70%253D&md5=76a7bf0bbccfcde6774c3ae2eca4253a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1993.tb13840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1993.tb13840.x%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DFourteenth%2520Gaddum%2520Memorial%2520Lecture.%2520A%2520current%2520view%2520of%2520tamoxifen%2520for%2520the%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1993%26volume%3D110%26spage%3D507%26epage%3D517%26doi%3D10.1111%2Fj.1476-5381.1993.tb13840.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1146/annurev.pa.35.040195.001211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1146%2Fannurev.pa.35.040195.001211" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=195-211&author=V.+C.+Jordan&title=Tamoxifen%3A+toxicities+and+drug+resistance+during+the+treatment+and+prevention+of+breast+cancer&doi=10.1146%2Fannurev.pa.35.040195.001211"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.35.040195.001211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.35.040195.001211%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DTamoxifen%253A%2520toxicities%2520and%2520drug%2520resistance%2520during%2520the%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1995%26volume%3D35%26spage%3D195%26epage%3D211%26doi%3D10.1146%2Fannurev.pa.35.040195.001211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ragaz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coldman, A.</span><span> </span><span class="NLM_article-title">Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2018</span><span class="NLM_x">–</span> <span class="NLM_lpage">2024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=9626198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A280%3ADyaK1c3ovFCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2018-2024&author=J.+Ragazauthor=A.+Coldman&title=Survival+impact+of+adjuvant+tamoxifen+on+competing+causes+of+mortality+in+breast+cancer+survivors%2C+with+analysis+of+mortality+from+contralateral+breast+cancer%2C+cardiovascular+events%2C+endometrial+cancer%2C+and+thromboembolic+episodes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes</span></div><div class="casAuthors">Ragaz J; Coldman A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2018-24</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  This study provides estimates of the effect of tamoxifen treatment on mortality from four conditions known to be affected by tamoxifen in women who survive their breast cancer: contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic events.  These estimates are in addition to tamoxifen's impact on primary breast cancer mortality.  METHODS:  The effects of tamoxifen were calculated by the use of the published relative risk (RR) rates of the four conditions as affected by adjuvant tamoxifen and their application to the respective Canadian age-specific mortality rates for the same conditions.  The final mortality impact of tamoxifen was expressed as net mortality difference between users and nonusers of tamoxifen.  RESULTS:  At 10 years of follow-up, the sum of avoided deaths (contralateral breast cancer, cardiovascular events) and excess deaths (uterine cancer, thromboembolic episodes) resulted in an overall (net) mortality reduction because of tamoxifen use, with 3 to 41 avoided deaths per 1,000 tamoxifen-treated patients who were 50 to 80 years of age.  With the follow-up projected until the age of 90 years, the numbers of avoided late deaths attributed to tamoxifen ranged from 38 to 56 per 1,000 patients.  CONCLUSION:  Our calculations that pertain to late breast cancer survivors indicate that there is a more substantial mortality reduction as a result of deaths avoided from contralateral breast cancer and cardiovascular events, despite the moderately increased mortality from endometrial cancer and thromboembolic episodes.  The overall tamoxifen-associated mortality reduction occurs, in different magnitudes, in patients of all ages from 50 to 80 years at diagnosis of the primary breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmKcft3Gh8l1vAgqb2vdc5fW6udTcc2eYL9DWzlB9WsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3ovFCgug%253D%253D&md5=52fe3097fa0f03019d5d7a9b589830c7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRagaz%26aufirst%3DJ.%26aulast%3DColdman%26aufirst%3DA.%26atitle%3DSurvival%2520impact%2520of%2520adjuvant%2520tamoxifen%2520on%2520competing%2520causes%2520of%2520mortality%2520in%2520breast%2520cancer%2520survivors%252C%2520with%2520analysis%2520of%2520mortality%2520from%2520contralateral%2520breast%2520cancer%252C%2520cardiovascular%2520events%252C%2520endometrial%2520cancer%252C%2520and%2520thromboembolic%2520episodes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1998%26volume%3D16%26spage%3D2018%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span> </span><span class="NLM_article-title">Aromatase inhibitors in breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">2431</span><span class="NLM_x">–</span> <span class="NLM_lpage">2442</span><span class="refDoi"> DOI: 10.1056/NEJMra023246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1056%2FNEJMra023246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=12802030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2431-2442&author=I.+E.+Smithauthor=M.+Dowsett&title=Aromatase+inhibitors+in+breast+cancer&doi=10.1056%2FNEJMra023246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors in breast cancer</span></div><div class="casAuthors">Smith, Ian E.; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2431-2442</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the role of aromatase inhibitors and assess their potential for clin. use in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYF49NFDFgm7Vg90H21EOLACvtfcHk0liVcEhD1hVLpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D&md5=da7b56d4a1f0e7b2e27c8819a0ae0951</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra023246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra023246%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DAromatase%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2431%26epage%3D2442%26doi%3D10.1056%2FNEJMra023246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Dixon, J. M.</span><span> </span><span class="NLM_article-title">Endocrine resistance in breast cancer</span> <span class="citation_source-journal">New J. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1155/2014/390618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1155%2F2014%2F390618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1-27&author=J.+M.+Dixon&title=Endocrine+resistance+in+breast+cancer&doi=10.1155%2F2014%2F390618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1155%2F2014%2F390618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F390618%26sid%3Dliteratum%253Aachs%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEndocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNew%2520J.%2520Sci.%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D27%26doi%3D10.1155%2F2014%2F390618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Herynk, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuqua, S. A.</span><span> </span><span class="NLM_article-title">Estrogen receptors in resistance to hormone therapy</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">608</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1007/978-0-387-74039-3_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2F978-0-387-74039-3_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=608&publication_year=2007&pages=130-143&author=M.+H.+Herynkauthor=S.+A.+Fuqua&title=Estrogen+receptors+in+resistance+to+hormone+therapy&doi=10.1007%2F978-0-387-74039-3_10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-74039-3_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-0-387-74039-3_10%26sid%3Dliteratum%253Aachs%26aulast%3DHerynk%26aufirst%3DM.%2BH.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26atitle%3DEstrogen%2520receptors%2520in%2520resistance%2520to%2520hormone%2520therapy%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2007%26volume%3D608%26spage%3D130%26epage%3D143%26doi%3D10.1007%2F978-0-387-74039-3_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span> </span><span class="NLM_article-title">Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4883</span><span class="NLM_x">–</span> <span class="NLM_lpage">4887</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+selective+estrogen+receptor+downregulators+%28SERDs%29%2C+a+breakthrough+endocrine+therapy+for+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0liVcEhD1hVLpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%252C%2520a%2520breakthrough%2520endocrine%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ellis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewar, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasiowka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rukazenkov, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. F.</span><span> </span><span class="NLM_article-title">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3781</span><span class="NLM_x">–</span> <span class="NLM_lpage">3787</span><span class="refDoi"> DOI: 10.1200/JCO.2015.61.5831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1200%2FJCO.2015.61.5831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=26371134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSntb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3781-3787&author=M.+J.+Ellisauthor=A.+Llombart-Cussacauthor=D.+Feltlauthor=J.+A.+Dewarauthor=M.+Jasiowkaauthor=N.+Hewsonauthor=Y.+Rukazenkovauthor=J.+F.+Robertson&title=Fulvestrant+500+mg+versus+anastrozole+1+mg+for+the+first-line+treatment+of+advanced+breast+cancer%3A+overall+survival+analysis+from+the+phase+II+FIRST+study&doi=10.1200%2FJCO.2015.61.5831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study</span></div><div class="casAuthors">Ellis, Matthew J.; Llombart-Cussac, Antonio; Feltl, David; Dewar, John A.; Jasiowka, Marek; Hewson, Nicola; Rukazenkov, Yuri; Robertson, John F. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3781-3787</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">To compare overall survival (OS) for fulvestrant 500 mg vs. anastrozole as first-line endocrine therapy for advanced breast cancer.  The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicenter trial.  Postmenopausal women with estrogen receptor-pos., locally advanced/metastatic breast cancer who had no previous therapy for advanced disease received either fulvestrant 500 mg (days 0, 14, 28, and every 28 days thereafter) or anastrozole 1 mg (daily).  The primary end point (clin. benefit rate [72.5% and 67.0%]) and a follow-up anal. (median time to progression [23.4 mo and 13.1 mo]) have been reported previously for fulvestrant 500 mg and anastrozole, resp.  Subsequently, the protocol was amended to assess OS by unadjusted log-rank test after approx. 65% of patients had died.  Treatment effect on OS across several subgroups was examd.  Tolerability was evaluated by adverse event monitoring.  Results In total, 205 patients were randomly assigned (fulvestrant 500 mg, n = 102; anastrozole, n = 103).  At data cutoff, 61.8% (fulvestrant 500 mg, n = 63) and 71.8% (anastrozole, n = 74) had died.  The hazard ratio (95% CI) for OS with fulvestrant 500 mg vs. anastrozole was 0.70 (0.50 to 0.98; P = .04; median OS, 54.1 mo v 48.4 mo).  Treatment effects seemed generally consistent across the subgroups analyzed.  No new safety issues were obsd.  There are several limitations of this OS anal., including that it was not planned in the original protocol but instead was added after time-to-progression results were analyzed, and that not all patients participated in addnl. OS follow-up.  However, the present results suggest fulvestrant 500 mg extends OS vs. anastrozole.  This finding now awaits prospective confirmation in the larger phase III FALCON (Fulvestrant and Anastrozole Compared in Hormonal Therapy Na.ovrddot.ive Advanced Breast Cancer).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgcontOU3287Vg90H21EOLACvtfcHk0ljUjV93Z9CpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSntb3K&md5=45cb5f02224b33857d55e5cb5b69e775</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.61.5831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.61.5831%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%2BA.%26aulast%3DJasiowka%26aufirst%3DM.%26aulast%3DHewson%26aufirst%3DN.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26atitle%3DFulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520for%2520the%2520first-line%2520treatment%2520of%2520advanced%2520breast%2520cancer%253A%2520overall%2520survival%2520analysis%2520from%2520the%2520phase%2520II%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3781%26epage%3D3787%26doi%3D10.1200%2FJCO.2015.61.5831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colleoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeck, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theall, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D.</span><span> </span><span class="NLM_article-title">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00613-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2FS1470-2045%2815%2900613-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=26947331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=425-439&author=M.+Cristofanilliauthor=N.+C.+Turnerauthor=I.+Bondarenkoauthor=J.+Roauthor=S.+A.+Imauthor=N.+Masudaauthor=M.+Colleoniauthor=A.+DeMicheleauthor=S.+Loiauthor=S.+Vermaauthor=H.+Iwataauthor=N.+Harbeckauthor=K.+Zhangauthor=K.+P.+Theallauthor=Y.+Jiangauthor=C.+H.+Bartlettauthor=M.+Koehlerauthor=D.+Slamon&title=Fulvestrant+plus+palbociclib+versus+fulvestrant+plus+placebo+for+treatment+of+hormone-receptor-positive%2C+HER2-negative+metastatic+breast+cancer+that+progressed+on+previous+endocrine+therapy+%28PALOMA-3%29%3A+final+analysis+of+the+multicentre%2C+double-blind%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS1470-2045%2815%2900613-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial</span></div><div class="casAuthors">Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria; Slamon, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was assocd. with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer.  Identification of patients most suitable for the addn. of palbociclib to endocrine therapy after tumor recurrence is crucial for treatment optimization in metastatic breast cancer.  We aimed to confirm our earlier findings with this extended follow-up and show our results for subgroup and biomarker analyses.  In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-pos., HER2-neg. metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis at 144 centers in 17 countries.  Eligible patients-ie, any menopausal status, Eastern Cooperative Oncol. Group performance status 0-1, measurable disease or bone disease only, and disease relapse or progression after previous endocrine therapy for advanced disease during treatment or within 12 mo of completion of adjuvant therapy-were randomly assigned (2:1) via a centralised interactive web-based and voice-based randomisation system to receive oral palbociclib (125 mg daily for 3 wk followed by a week off over 28-day cycles) plus 500 mg fulvestrant (i.m. injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 28-day cycles) or placebo plus fulvestrant.  The primary endpoint was investigator-assessed progression-free survival.  Anal. was by intention to treat.  We also assessed endocrine therapy resistance by clin. parameters, quant. hormone-receptor expression, and tumor PIK3CA mutational status in circulating DNA at baseline.  This study is registered with ClinicalTrials.gov, NCT01942135.  Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo.  Study enrolment is closed and overall survival follow-up is in progress.  By March 16, 2015, 259 progression-free-survival events had occurred (145 in the fulvestrant plus palbociclib group and 114 in the fulvestrant plus placebo group); median follow-up was 8·9 mo (IQR 8·7-9·2).  Median progression-free survival was 9·5 mo (95% CI 9·2-11·0) in the fulvestrant plus palbociclib group and 4·6 mo (3·5-5·6) in the fulvestrant plus placebo group (hazard ratio 0·46, 95% CI 0·36-0·59, p<0·0001).  Grade 3 or 4 adverse events occurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group.  The most common grade 3 or 4 adverse events were neutropenia (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).  Serious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.  PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients for whom these data were available.  Neither PIK3CA status nor hormone-receptor expression level significantly affected treatment response.  Fulvestrant plus palbociclib was assocd. with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irresp. of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status.  The combination could be considered as a therapeutic option for patients with recurrent hormone-receptor-pos., HER2-neg. metastatic breast cancer that has progressed on previous endocrine therapy.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmN_mxQq1lWrVg90H21EOLACvtfcHk0ljUjV93Z9CpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D&md5=393ef72549634e00f26a0a1916565472</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900613-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900613-0%26sid%3Dliteratum%253Aachs%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DRo%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DTheall%26aufirst%3DK.%2BP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DBartlett%26aufirst%3DC.%2BH.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DSlamon%26aufirst%3DD.%26atitle%3DFulvestrant%2520plus%2520palbociclib%2520versus%2520fulvestrant%2520plus%2520placebo%2520for%2520treatment%2520of%2520hormone-receptor-positive%252C%2520HER2-negative%2520metastatic%2520breast%2520cancer%2520that%2520progressed%2520on%2520previous%2520endocrine%2520therapy%2520%2528PALOMA-3%2529%253A%2520final%2520analysis%2520of%2520the%2520multicentre%252C%2520double-blind%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D425%26epage%3D439%26doi%3D10.1016%2FS1470-2045%2815%2900613-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowler, J.</span><span> </span><span class="NLM_article-title">A potent specific pure antiestrogen with clinical potential</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+potent+specific+pure+antiestrogen+with+clinical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0ljUjV93Z9CpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520potent%2520specific%2520pure%2520antiestrogen%2520with%2520clinical%2520potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Robertson, J. F.</span><span> </span><span class="NLM_article-title">Fulvestrant (Faslodex) -- how to make a good drug better</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">774</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span><span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&author=J.+F.+Robertson&title=Fulvestrant+%28Faslodex%29+%2D%2D+how+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26atitle%3DFulvestrant%2520%2528Faslodex%2529%2520--%2520how%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Buzdar, A. U.</span><span> </span><span class="NLM_article-title">Endocrine therapy in the treatment of metastatic breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span><span class="refDoi"> DOI: 10.1053/sonc.2001.23495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1053%2Fsonc.2001.23495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=11402439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=291-304&author=A.+U.+Buzdar&title=Endocrine+therapy+in+the+treatment+of+metastatic+breast+cancer&doi=10.1053%2Fsonc.2001.23495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy in the treatment of metastatic breast cancer</span></div><div class="casAuthors">Buzdar, Aman U.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-304</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review with refs.  The goals of treating patients with metastatic breast cancer are to prolong survival, slow or halt disease progression, and enhance the patient's quality of life.  In patients with estrogen receptor (ER)-pos. cancers that are not progressing rapidly, endocrine therapy is generally the first treatment option.  If a patient initially responds to an endocrine agent and then progresses, another endocrine agent may still provide benefit.  Tamoxifen has been used as first-line therapy for metastatic breast cancer for many years.  Until recently, no other endocrine agent has shown superiority to tamoxifen in this setting.  The nonsteroidal aromatase inhibitors, anastrozole and letrozole, have been widely accepted as second-line therapy after failure of tamoxifen; they have replaced megestrol acetate in this setting.  Recently, anastrozole was shown to have at least equiv. efficacy and a superior side effect profile compared with tamoxifen for treating postmenopausal women in the first-line setting.  Thus, this aromatase inhibitor has become a viable option for first-line therapy in postmenopausal women.  Trials of letrozole in this setting are nearing completion.  Exemestane has been shown to be an effective second-line agent and to have at least some efficacy as a third-line agent even after failure of a nonsteroidal aromatase inhibitor.  Results are anxiously awaited from trials of new endocrine agents including the first member of a new class of endocrine agent, the estrogen-receptor down-regulator class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOWmWY0RsKVLVg90H21EOLACvtfcHk0lh6vY4m7glqKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWksrw%253D&md5=7e74d3b61520e2bc0987370b20967b80</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1053%2Fsonc.2001.23495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsonc.2001.23495%26sid%3Dliteratum%253Aachs%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26atitle%3DEndocrine%2520therapy%2520in%2520the%2520treatment%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D291%26epage%3D304%26doi%3D10.1053%2Fsonc.2001.23495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Wittmann, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9549</span><span class="NLM_x">–</span> <span class="NLM_lpage">9560</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F0008-5472.CAN-07-1590" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9549-9560&author=B.+M.+Wittmannauthor=A.+Sherkauthor=D.+P.+McDonnell&title=Definition+of+functionally+important+mechanistic+differences+among+selective+estrogen+receptor+down-regulators&doi=10.1158%2F0008-5472.CAN-07-1590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1590%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DB.%2BM.%26aulast%3DSherk%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDefinition%2520of%2520functionally%2520important%2520mechanistic%2520differences%2520among%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9549%26epage%3D9560%26doi%3D10.1158%2F0008-5472.CAN-07-1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">van Kruchten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaudemans, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Lanschot, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Faassen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kema, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hospers, G. A.</span><span> </span><span class="NLM_article-title">Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&author=M.+van+Kruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schroderauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+residual+estrogen+receptor+availability+during+fulvestrant+therapy+in+patients+with+metastatic+breast+cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0lh6vY4m7glqKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchroder%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520residual%2520estrogen%2520receptor%2520availability%2520during%2520fulvestrant%2520therapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henke, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momtahen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charifson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubahn, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H. R.</span><span> </span><span class="NLM_article-title">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1550</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span><span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Sauls&title=3-%5B4-%281%2C2-Diphenylbut-1-enyl%29phenyl%5Dacrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lhLULhsMEwLkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26atitle%3D3-%255B4-%25281%252C2-Diphenylbut-1-enyl%2529phenyl%255Dacrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Connor, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadwater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2917</span><span class="NLM_x">–</span> <span class="NLM_lpage">2922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=11306468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+using+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span></div><div class="casAuthors">Connor, Caroline E.; Norris, John D.; Broadwater, Gloria; Willson, Timothy M.; Gottardis, Marco M.; Dewhirst, Mark W.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2917-2922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators.  In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells.  We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER.  The biol. significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638.  Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2YSN94iysMbVg90H21EOLACvtfcHk0lhLULhsMEwLkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D&md5=d7ecae7d445901e2f2c4f133ebbacdc5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520using%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&author=Y.+L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+basis+for+an+unexpected+mode+of+SERM-mediated+ER+antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lhLULhsMEwLkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520basis%2520for%2520an%2520unexpected%2520mode%2520of%2520SERM-mediated%2520ER%2520antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Degorce, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J. S.</span><span> </span><span class="NLM_article-title">Investigation of (E)-3-[4-(2-oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3522</span><span class="NLM_x">–</span> <span class="NLM_lpage">3533</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3522-3533&author=S.+L.+Degorceauthor=A.+Baileyauthor=R.+Callisauthor=C.+De+Saviauthor=R.+Ducrayauthor=G.+Lamontauthor=P.+MacFaulauthor=M.+Maudetauthor=S.+Martinauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Peruauthor=J.+H.+Pinkauthor=P.+A.+Pleauthor=B.+Robertsauthor=J.+S.+Scott&title=Investigation+of+%28E%29-3-%5B4-%282-oxo-3-aryl-chromen-4-yl%29oxyphenyl%5Dacrylic+acids+as+oral+selective+estrogen+receptor+down-regulators&doi=10.1021%2Facs.jmedchem.5b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators</span></div><div class="casAuthors">Degorce, Sebastien L.; Bailey, Andrew; Callis, Rowena; De Savi, Chris; Ducray, Richard; Lamont, Gillian; MacFaul, Philip; Maudet, Mickael; Martin, Scott; Morgentin, Remy; Norman, Richard A.; Peru, Aurelien; Pink, Jennifer H.; Ple, Patrick A.; Roberts, Bryan; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3522-3533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chem. induced mammary tumors.  Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen receptor down-regulators, which led us to the discovery of potent down-regulating antagonists, such as 33.  Subsequent optimization and removal of the 7-hydroxy group led to coumarin 59, which had increased potency and improved rat bioavailability relative to SS5020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondIuhUFHcLrVg90H21EOLACvtfcHk0lhLULhsMEwLkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D&md5=765350db346581eab5565468f35b55d9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00066%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DInvestigation%2520of%2520%2528E%2529-3-%255B4-%25282-oxo-3-aryl-chromen-4-yl%2529oxyphenyl%255Dacrylic%2520acids%2520as%2520oral%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3522%26epage%3D3533%26doi%3D10.1021%2Facs.jmedchem.5b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Scott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0ljO_nH6Ja-LsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4888</span><span class="NLM_x">–</span> <span class="NLM_lpage">4904</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0ljO_nH6Ja-LsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Burks, H. E. K.; Rajeshri, G.; Kirby, C. A.; Nunez, J.; Peukert, S.; Springer, C.; Sun, Y.; Thomsen, N. M.</span><span> </span><span class="NLM_article-title">1,2,3,4-Tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders, and their preparation</span>. WO 2015092634,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+E.+K.+Burks&author=G.+Rajeshri&author=C.+A.+Kirby&author=J.+Nunez&author=S.+Peukert&author=C.+Springer&author=Y.+Sun&author=N.+M.+Thomsen&title=1%2C2%2C3%2C4-Tetrahydroisoquinoline+compounds+and+compositions+as+selective+estrogen+receptor+antagonists+and+degraders%2C+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%2BK.%26atitle%3D1%252C2%252C3%252C4-Tetrahydroisoquinoline%2520compounds%2520and%2520compositions%2520as%2520selective%2520estrogen%2520receptor%2520antagonists%2520and%2520degraders%252C%2520and%2520their%2520preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Garner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shomali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyttle, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattersley, G.</span><span> </span><span class="NLM_article-title">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1097%2FCAD.0000000000000271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=RAD1901%3A+a+novel%2C+orally+bioavailable+selective+estrogen+receptor+degrader+that+demonstrates+antitumor+activity+in+breast+cancer+xenograft+models&doi=10.1097%2FCAD.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRAD1901%253A%2520a%2520novel%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520that%2520demonstrates%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenograft%2520models%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2015%26volume%3D26%26spage%3D948%26epage%3D956%26doi%3D10.1097%2FCAD.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almeida, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayter, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetra hydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8128</span><span class="NLM_x">–</span> <span class="NLM_lpage">8140</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetra+hydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetra%2520hydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Weir, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almeida, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladd, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazolli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzola, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Cruz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Savi, C.</span><span> </span><span class="NLM_article-title">AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">3307</span><span class="NLM_x">–</span> <span class="NLM_lpage">3318</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F0008-5472.CAN-15-2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=27020862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3307-3318&author=H.+M.+Weirauthor=R.+H.+Bradburyauthor=M.+Lawsonauthor=A.+A.+Rabowauthor=D.+Buttarauthor=R.+J.+Callisauthor=J.+O.+Curwenauthor=C.+de+Almeidaauthor=P.+Ballardauthor=M.+Hulseauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=G.+Karoutchiauthor=P.+MacFaulauthor=T.+Mossauthor=R.+A.+Normanauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+Daviesauthor=G.+E.+Walkerauthor=Z.+Wilsonauthor=R.+Rowlinsonauthor=S.+Powellauthor=C.+Sadlerauthor=G.+Richmondauthor=B.+Laddauthor=E.+Pazolliauthor=A.+M.+Mazzolaauthor=C.+D%E2%80%99Cruzauthor=C.+De+Savi&title=AZD9496%3A+an+oral+estrogen+receptor+inhibitor+that+blocks+the+growth+of+ER-positive+and+ESR1-mutant+breast+tumors+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models</span></div><div class="casAuthors">Weir, Hazel M.; Bradbury, Robert H.; Lawson, Mandy; Rabow, Alfred A.; Buttar, David; Callis, Rowena J.; Curwen, Jon O.; de Almeida, Camila; Ballard, Peter; Hulse, Michael; Donald, Craig S.; Feron, Lyman J. L.; Karoutchi, Galith; MacFaul, Philip; Moss, Thomas; Norman, Richard A.; Pearson, Stuart E.; Tonge, Michael; Davies, Gareth; Walker, Graeme E.; Wilson, Zena; Rowlinson, Rachel; Powell, Steve; Sadler, Claire; Richmond, Graham; Ladd, Brendon; Pazolli, Ermira; Mazzola, Anne Marie; D'Cruz, Celina; De Savi, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3307-3318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly i.m. injection.  Given its present limitations of dosing and route of administration, a more flexible orally available compd. has been sought to pursue the potential benefits of this drug in patients with advanced metastatic disease.  Here we report the identification and characterization of AZD9496, a nonsteroidal small-mol. inhibitor of ERα, which is a potent and selective antagonist and downregulator of ERα in vitro and in vivo in ER-pos. models of breast cancer.  Significant tumor growth inhibition was obsd. as low as 0.5 mg/kg dose in the estrogen-dependent MCF-7 xenograft model, where this effect was accompanied by a dose-dependent decrease in PR protein levels, demonstrating potent antagonist activity.  Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors led to further growth-inhibitory effects compared with monotherapy alone.  Tumor regressions were also seen in a long-term estrogen-deprived breast model, where significant downregulation of ERα protein was obsd.  AZD9496 bound and downregulated clin. relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1-mutant patient-derived xenograft model that included a D538G mutation.  Collectively, the pharmacol. evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER+ breast cells that could provide meaningful benefit to ER+ breast cancer patients.  AZD9496 is currently being evaluated in a phase I clin. trial.  Cancer Res; 76(11); 3307-18. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4X3e2iYdcLVg90H21EOLACvtfcHk0liFD1-mPLAgWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D&md5=4ff8ab9a9cd379acc031b7c6fd27134c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2357%26sid%3Dliteratum%253Aachs%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DHulse%26aufirst%3DM.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DLadd%26aufirst%3DB.%26aulast%3DPazolli%26aufirst%3DE.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26atitle%3DAZD9496%253A%2520an%2520oral%2520estrogen%2520receptor%2520inhibitor%2520that%2520blocks%2520the%2520growth%2520of%2520ER-positive%2520and%2520ESR1-mutant%2520breast%2520tumors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3307%26epage%3D3318%26doi%3D10.1158%2F0008-5472.CAN-15-2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jevnikar, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemens, J. A.</span><span> </span><span class="NLM_article-title">Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1057</span><span class="NLM_x">–</span> <span class="NLM_lpage">1066</span><span class="refDoi"> DOI: 10.1021/jm00374a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00374a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=1057-1066&author=C.+D.+Jonesauthor=M.+G.+Jevnikarauthor=A.+J.+Pikeauthor=M.+K.+Petersauthor=L.+J.+Blackauthor=A.+R.+Thompsonauthor=J.+F.+Falconeauthor=J.+A.+Clemens&title=Antiestrogens.+2.+Structure-activity+studies+in+a+series+of+3-aroyl-2-arylbenzo%5Bb%5Dthiophene+derivatives+leading+to+%5B6-hydroxy-2-%284-hydroxyphenyl%29benzo%5Bb%5Dthien-3-yl%5D+%5B4-%5B2-%281-piperidinyl%29ethoxy%5D-phenyl%5Dmethanone+hydrochloride+%28LY156758%29%2C+a+remarkably+effective+estrogen+antagonist+with+only+minimal+intrinsic+estrogenicity&doi=10.1021%2Fjm00374a021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm00374a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00374a021%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJevnikar%26aufirst%3DM.%2BG.%26aulast%3DPike%26aufirst%3DA.%2BJ.%26aulast%3DPeters%26aufirst%3DM.%2BK.%26aulast%3DBlack%26aufirst%3DL.%2BJ.%26aulast%3DThompson%26aufirst%3DA.%2BR.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DClemens%26aufirst%3DJ.%2BA.%26atitle%3DAntiestrogens.%25202.%2520Structure-activity%2520studies%2520in%2520a%2520series%2520of%25203-aroyl-2-arylbenzo%255Bb%255Dthiophene%2520derivatives%2520leading%2520to%2520%255B6-hydroxy-2-%25284-hydroxyphenyl%2529benzo%255Bb%255Dthien-3-yl%255D%2520%255B4-%255B2-%25281-piperidinyl%2529ethoxy%255D-phenyl%255Dmethanone%2520hydrochloride%2520%2528LY156758%2529%252C%2520a%2520remarkably%2520effective%2520estrogen%2520antagonist%2520with%2520only%2520minimal%2520intrinsic%2520estrogenicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D1057%26epage%3D1066%26doi%3D10.1021%2Fjm00374a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Xiong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutgesell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado-Rivera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Selective human estrogen receptor partial agonists (ShERPAs) for tamoxifen-resistant breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=219-237&author=R.+Xiongauthor=H.+K.+Patelauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=L.+Delgado-Riveraauthor=T.+N.+Phamauthor=H.+Zhaoauthor=K.+Carlsonauthor=T.+Martinauthor=J.+A.+Katzenellenbogenauthor=T.+W.+Mooreauthor=D.+A.+Tonettiauthor=G.+R.+Thatcher&title=Selective+human+estrogen+receptor+partial+agonists+%28ShERPAs%29+for+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.5b01276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Patel, Hitisha K.; Gutgesell, Lauren M.; Zhao, Jiong; Delgado-Rivera, Loruhama; Pham, Thao N. D.; Zhao, Huiping; Carlson, Kathryn; Martin, Teresa; Katzenellenbogen, John A.; Moore, Terry W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Almost 70% of breast cancers are estrogen receptor α (ERα) pos.  Tamoxifen, a selective estrogen receptor modulator (SERM), represents the std. of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics.  Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clin. efficacy in patients with heavily treated breast cancer, although side effects in gynecol. tissues are unacceptable.  A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative.  We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent.  Novel benzothiophene derivs. with nanomolar potency in breast cancer cell cultures were designed.  Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines.  Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF_Xh3QGtO4LVg90H21EOLACvtfcHk0ljA9wekwBJyQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK&md5=f2bffc241b3de9c7537f9b5fa0c56f54</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01276%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDelgado-Rivera%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BN.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMoore%26aufirst%3DT.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DSelective%2520human%2520estrogen%2520receptor%2520partial%2520agonists%2520%2528ShERPAs%2529%2520for%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D219%26epage%3D237%26doi%3D10.1021%2Facs.jmedchem.5b01276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasena, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petukhov, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2692</span><span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+with+modulated+oxidative+activity+and+receptor+affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0ljA9wekwBJyQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520with%2520modulated%2520oxidative%2520activity%2520and%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Peng, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijewickrama, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1049</span><span class="refDoi"> DOI: 10.1021/cb9001848</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb9001848" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1039-1049&author=K.+W.+Pengauthor=H.+Wangauthor=Z.+Qinauthor=G.+T.+Wijewickramaauthor=M.+Luauthor=Z.+Wangauthor=J.+L.+Boltonauthor=G.+R.+Thatcher&title=Selective+estrogen+receptor+modulator+delivery+of+quinone+warheads+to+DNA+triggering+apoptosis+in+breast+cancer+cells&doi=10.1021%2Fcb9001848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulator Delivery of Quinone Warheads to DNA Triggering Apoptosis in Breast Cancer Cells</span></div><div class="casAuthors">Peng, Kuan-Wei; Wang, Huali; Qin, Zhihui; Wijewickrama, Gihani T.; Lu, Meiling; Wang, Zhican; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen exposure is a risk factor for breast cancer, and estrogen oxidative metabolites have been implicated in chem. carcinogenesis.  Oxidn. of the catechol metabolite of estrone (4-OHE) and the β-naphthohydroquinone metabolite of equilenin (4-OHEN) gives o-quinones that produce ROS and damage DNA by adduction and oxidn.  To differentiate hormonal and chem. carcinogenesis pathways in estrogen receptor pos. ER(+) cells, catechol or β-naphthohydroquinone warheads were conjugated to the selective estrogen receptor modulator (SERM) desmethylarzoxifene (DMA).  ER binding was retained in the DMA conjugates; both were antiestrogens with submicromolar potency in mammary and endometrial cells.  Cytotoxicity, apoptosis, and caspase-3/7 activation were compared in ER(+) and ER(-)MDA-MB-231 cells, and prodn. of ROS was detected using a fluorescent reporter.  Comparison was made to DMA, isolated warheads, and a DMA-mustard.  Conjugation of warheads to DMA increased cytotoxicity accompanied by induction of apoptosis and activation of caspase-3/7.  Activation of caspase-3/7, induction of apoptosis, and cytotoxicity were all increased significantly in ER(+) cells for the DMA conjugates.  ROS prodn. was localized in the nucleus for conjugates in ER(+) cells.  Observations are compatible with β-naphthohydroquinone and catechol groups being concd. in the nucleus by ER binding, where oxidn. and ROS prodn. result, concomitant with caspase-dependent apoptosis.  The results suggest that DNA damage induced by catechol estrogen metabolites can be amplified in ER(+) cells independent of hormonal activity.  The novel conjugation of quinone warheads to an ER-targeting SERM gives ER-dependent, enhanced apoptosis in mammary cancer cells of potential application in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJMjVFKkXUWrVg90H21EOLACvtfcHk0lg3AOX6nsv48Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb7J&md5=8855307c69ce84a310eced015d8daad9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fcb9001848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb9001848%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DK.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DWijewickrama%26aufirst%3DG.%2BT.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulator%2520delivery%2520of%2520quinone%2520warheads%2520to%2520DNA%2520triggering%2520apoptosis%2520in%2520breast%2520cancer%2520cells%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26spage%3D1039%26epage%3D1049%26doi%3D10.1021%2Fcb9001848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Palkowitz, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glasebrook, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrasher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehl, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetler, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullinan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pell, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, H. U.</span><span> </span><span class="NLM_article-title">Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1407</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span><span class="refDoi"> DOI: 10.1021/jm970167b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970167b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1407-1416&author=A.+D.+Palkowitzauthor=A.+L.+Glasebrookauthor=K.+J.+Thrasherauthor=K.+L.+Hauserauthor=L.+L.+Shortauthor=D.+L.+Phillipsauthor=B.+S.+Muehlauthor=M.+Satoauthor=P.+K.+Shetlerauthor=G.+J.+Cullinanauthor=T.+R.+Pellauthor=H.+U.+Bryant&title=Discovery+and+synthesis+of+%5B6-hydroxy-3-%5B4-%5B2-%281-piperidinyl%29ethoxy%5Dphenoxy%5D-2-%284-hydroxyphenyl%29%5Db+enzo%5Bb%5Dthiophene%3A+a+novel%2C+highly+potent%2C+selective+estrogen+receptor+modulator&doi=10.1021%2Fjm970167b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm970167b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970167b%26sid%3Dliteratum%253Aachs%26aulast%3DPalkowitz%26aufirst%3DA.%2BD.%26aulast%3DGlasebrook%26aufirst%3DA.%2BL.%26aulast%3DThrasher%26aufirst%3DK.%2BJ.%26aulast%3DHauser%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DL.%2BL.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DMuehl%26aufirst%3DB.%2BS.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DShetler%26aufirst%3DP.%2BK.%26aulast%3DCullinan%26aufirst%3DG.%2BJ.%26aulast%3DPell%26aufirst%3DT.%2BR.%26aulast%3DBryant%26aufirst%3DH.%2BU.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520%255B6-hydroxy-3-%255B4-%255B2-%25281-piperidinyl%2529ethoxy%255Dphenoxy%255D-2-%25284-hydroxyphenyl%2529%255Db%2520enzo%255Bb%255Dthiophene%253A%2520a%2520novel%252C%2520highly%2520potent%252C%2520selective%2520estrogen%2520receptor%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1407%26epage%3D1416%26doi%3D10.1021%2Fjm970167b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Shoda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demizu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, M.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2914</span><span class="NLM_x">–</span> <span class="NLM_lpage">2919</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.bmc.2016.04.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2914-2919&author=T.+Shodaauthor=M.+Katoauthor=T.+Fujisatoauthor=T.+Misawaauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Synthesis+and+evaluation+of+raloxifene+derivatives+as+a+selective+estrogen+receptor+down-regulator&doi=10.1016%2Fj.bmc.2016.04.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DFujisato%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DT.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520raloxifene%2520derivatives%2520as%2520a%2520selective%2520estrogen%2520receptor%2520down-regulator%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2914%26epage%3D2919%26doi%3D10.1016%2Fj.bmc.2016.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edirisinghe, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemachandra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasena, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e27876</span><span class="refDoi"> DOI: 10.1371/journal.pone.0027876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1371%2Fjournal.pone.0027876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=22140478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e27876&author=I.+Kastratiauthor=P.+D.+Edirisingheauthor=L.+P.+Hemachandraauthor=E.+R.+Chandrasenaauthor=J.+Choiauthor=Y.+T.+Wangauthor=J.+L.+Boltonauthor=G.+R.+Thatcher&title=Raloxifene+and+desmethylarzoxifene+block+estrogen-induced+malignant+transformation+of+human+breast+epithelial+cells&doi=10.1371%2Fjournal.pone.0027876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells</span></div><div class="casAuthors">Kastrati, Irida; Edirisinghe, Praneeth D.; Hemachandra, L-P-Madhubani P.; Chandrasena, Esala R.; Choi, Jaewoo; Wang, Yue-Ting; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e27876</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">There is assocn. between exposure to estrogens and the development and progression of hormone-dependent gynecol. cancers.  Chem. carcinogenesis by catechol estrogens derived from oxidative metab. is thought to contribute to breast cancer, yet exact mechanisms remain elusive.  Malignant transformation was studied in MCF-10A human mammary epithelial cells, since estrogens are not proliferative in this cell line.  The human and equine estrogen components of estrogen replacement therapy (ERT) and their catechol metabolites were studied, along with the influence of co-administration of selective estrogen receptor modulators (SERMs), raloxifene and desmethyl-arzoxifene (DMA) and histone deacetylase inhibitors.  Transformation was induced by human estrogens and selectively by the 4-OH catechol metabolite and to a lesser extent by an equine estrogen metabolite.  The obsd. estrogen-induced upregulation of CYP450 1B1 in estrogen receptor neg. MCF-10A cells, was compatible with a causal role for 4-OH catechol estrogens, as was attenuated transformation by CYP450 inhibitors.  Estrogen-induced malignant transformation was blocked by SERMs correlating with a redn. in formation of nucleobase catechol estrogen (NCE) adducts and formation of 8-oxo-dG.  NCE adducts can be formed consequent to DNA abasic site formation, but NCE adducts were also obsd. on incubation of estrogen quinones with free nucleotides.  These results suggest that NCE adducts may be a biomarker for cellular electrophilic stress, which together with 8-oxo-dG as a biomarker of oxidative stress correlate with malignant transformation induced by estrogen oxidative metabolites.  The obsd. attenuation of transformation by SERMs correlated with these biomarkers and may also be of clin. significance in breast cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTxGgBUQJyLVg90H21EOLACvtfcHk0lg3AOX6nsv48Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L&md5=70b8c37494d3ef4f48789ef0d1235dc9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0027876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0027876%26sid%3Dliteratum%253Aachs%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DEdirisinghe%26aufirst%3DP.%2BD.%26aulast%3DHemachandra%26aufirst%3DL.%2BP.%26aulast%3DChandrasena%26aufirst%3DE.%2BR.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%2BT.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DRaloxifene%2520and%2520desmethylarzoxifene%2520block%2520estrogen-induced%2520malignant%2520transformation%2520of%2520human%2520breast%2520epithelial%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De27876%26doi%3D10.1371%2Fjournal.pone.0027876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Abdelhamid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandevrede, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kundu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litosh, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiefer, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherezghiher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1021/cn100106a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100106a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=256-268&author=R.+Abdelhamidauthor=J.+Luoauthor=L.+Vandevredeauthor=I.+Kunduauthor=B.+Michalsenauthor=V.+A.+Litoshauthor=I.+T.+Schieferauthor=T.+Gherezghiherauthor=P.+Yaoauthor=Z.+Qinauthor=G.+R.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+provide+neuroprotection+by+a+novel+GPR30-dependent+mechanism&doi=10.1021%2Fcn100106a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel GPR30-Dependent Mechanism</span></div><div class="casAuthors">Abdelhamid, Ramy; Luo, Jia; Vande Vrede, Lawren; Kundu, Indraneel; Michalsen, Bradley; Litosh, Vladislav A.; Schiefer, Isaac T.; Gherezghiher, Teshome; Yao, Ping; Qin, Zhihui; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">256-268</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. benzothiophene SERM (BT-SERM) raloxifene was compared with estrogens in protection of primary rat neurons against oxygen-glucose deprivation (OGD).  Structure-activity relationships for neuroprotection were detd. for a family of BT-SERMs displaying a spectrum of ERα and ERβ binding affinity and agonist/antagonist activity, leading to discovery of a neuroprotective pharmacophore, present in the clin. relevant SERMS, raloxifene, and desmethylarzoxifene (DMA), for which submicromolar potency was obsd. for neuroprotection.  BT-SERM neuroprotection did not correlate with binding to ER or classical ER activity; however, both the neuroprotective SERMs and estrogens were shown, using pharmacol. probes, to activate the same kinase signaling cascades.  The antiestrogen ICI 182,780 inhibited the actions of estrogens but not those of BT-SERMs, whereas antagonism of the G-protein coupled receptor, GPR30, was effective for both SERMs and estrogens.  Since SERMs have antioxidant activity, ER-independent mechanisms were studied using the classical phenolic antioxidants, BHT and Trolox, and the Nrf2-dependent cytoprotective electrophile, sulforaphane.  However, neuroprotection by these agents was not sensitive to GPR30 antagonism.  Collectively, these data indicate that the activity of neuroprotective BT-SERMs is GPR30-dependent and ER-independent and not mediated by antioxidant effects.  Comparison of novel BT-SERM derivs. and analogs identified a neuroprotective pharmacophore of potential use in design of novel neuroprotective agents with a spectrum of ER activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvBt-wQmRmLrVg90H21EOLACvtfcHk0lhCUN80xmvBbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D&md5=c1d5a55aee4f2271ec666b42f62b50c1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcn100106a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100106a%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelhamid%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DVandevrede%26aufirst%3DL.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DMichalsen%26aufirst%3DB.%26aulast%3DLitosh%26aufirst%3DV.%2BA.%26aulast%3DSchiefer%26aufirst%3DI.%2BT.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520provide%2520neuroprotection%2520by%2520a%2520novel%2520GPR30-dependent%2520mechanism%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D256%26epage%3D268%26doi%3D10.1021%2Fcn100106a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashgodom, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantvit, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overk, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Breemen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1124/dmd.108.023408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1124%2Fdmd.108.023408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=18936111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=161-169&author=Z.+Qinauthor=I.+Kastratiauthor=R.+T.+Ashgodomauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=Y.+Choiauthor=R.+B.+van+Breemenauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+modulation+of+oxidative+metabolism+in+design+of+improved+benzothiophene+selective+estrogen+receptor+modulators&doi=10.1124%2Fdmd.108.023408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Ashgodom, Rezene T.; Lantvit, Daniel D.; Overk, Cassia R.; Choi, Yongsoo; van Breemen, Richard B.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-169</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Raloxifene and arzoxifene are benzothiophene selective estrogen receptor modulators (SERMs) of clin. use in postmenopausal osteoporosis and treatment of breast cancer and potentially in hormone replacement therapy.  The benefits of arzoxifene are attributed to improved bioavailability over raloxifene, whereas the arzoxifene metabolite, desmethylarzoxifene (DMA) is a more potent antiestrogen.  As polyarom. phenolics, benzothiophene SERMs undergo oxidative metab. to electrophilic quinoids.  The long-term clin. use of SERMs demands increased understanding of correlations between structure and toxicity, with metab. being a key component.  A homologous series of 4'-substituted 4'-desmethoxyarzoxifene derivs. was developed, and metab. was studied in liver and intestinal microsomes.  Formation of glutathione conjugates was assayed in rat liver microsomes and novel adducts were characterized by liq. chromatog.-tandem mass spectrometry.  Formation of glucuronide conjugates was assayed in human intestine and liver microsomes, demonstrating formation of glucuronides ranging from 5 to 100% for the benzothiophene SERMs: this trend was inversely correlated with the loss of parent SERM in rat liver microsomal incubations.  MO calcns. generated thermodn. parameters for oxidn. that correlated with Hammett substituent consts.; however, metab. in liver microsomes correlated with a combination of both Hammett and Hansch lipophilicity parameters.  The results demonstrate a rich oxidative chem. for the benzothiophene SERMs, the amplitude of which can be powerfully modulated, in a predictable manner, by structural tuning of the 4'-substituent.  The predicted extensive metab. of DMA was confirmed in vivo and compared with the relatively stable arzoxifene and F-DMA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNnv4iRadE7Vg90H21EOLACvtfcHk0lhCUN80xmvBbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D&md5=0fb317771152e0fbe4ddfb9c79f0fb3d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.023408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.023408%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DAshgodom%26aufirst%3DR.%2BT.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520modulation%2520of%2520oxidative%2520metabolism%2520in%2520design%2520of%2520improved%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D161%26epage%3D169%26doi%3D10.1124%2Fdmd.108.023408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunlap, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantvit, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overk, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2418</span><span class="NLM_x">–</span> <span class="NLM_lpage">2428</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1535-7163.MCT-07-0268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=17876041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2418-2428&author=B.+Yuauthor=B.+M.+Dietzauthor=T.+Dunlapauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=P.+Yaoauthor=Z.+Qinauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+modulation+of+reactivity%2Factivity+in+design+of+improved+benzothiophene+selective+estrogen+receptor+modulators%3A+induction+of+chemopreventive+mechanisms&doi=10.1158%2F1535-7163.MCT-07-0268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: Induction of chemopreventive mechanisms</span></div><div class="casAuthors">Yu, Bolan; Dietz, Birgit M.; Dunlap, Tareisha; Kastrati, Irida; Lantvit, Daniel D.; Overk, Cassia R.; Yao, Ping; Qin, Zhihui; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2418-2428</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERM) raloxifene and arzoxifene are in clin. use and clin. trials for chemoprevention of breast cancer and other indications.  These SERMs are "oxidatively labile" and therefore have potential to activate antioxidant responsive element (ARE) transcription of genes for cytoprotective phase II enzymes such as NAD(P)H-dependent quinone oxidoreductase 1 (NQO1).  To study this possible mechanism of cancer chemoprevention, a family of benzothiophene SERMs was developed with modulated redox activity, including arzoxifene and its metabolite desmethylarzoxifene (DMA).  The relative antioxidant activity of these SERMs was assayed and correlated with induction of NQO1 in murine and human liver cells.  DMA was found to induce NQO1 and to activate ARE more strongly than other SERMs, including raloxifene and 4-hydroxytamoxifen.  Livers from female, juvenile rats treated for 3 days with estradiol and/or with the benzothiophene SERMs arzoxifene, DMA, and F-DMA showed substantial induction of NQO1 by the benzothiophene SERMs.  No persuasive evidence in this assay or in MCF-7 breast cancer cells was obtained of a major role for the estrogen receptor in induction of NQO1 by the benzothiophene SERMs.  These results suggest that arzoxifene might provide chemopreventive benefits over raloxifene and other SERMs via metab. to DMA and stimulation of ARE-mediated induction of phase II enzymes.  The correlation of SERM structure with antioxidant activity and NQO1 induction also suggests that oxidative bioactivation of SERMs may be modulated to enhance chemopreventive activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosSszy7YqBrrVg90H21EOLACvtfcHk0lhCUN80xmvBbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF&md5=11008f981dbbacdf5bd87e8919ef678a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0268%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DDietz%26aufirst%3DB.%2BM.%26aulast%3DDunlap%26aufirst%3DT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520modulation%2520of%2520reactivity%252Factivity%2520in%2520design%2520of%2520improved%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%253A%2520induction%2520of%2520chemopreventive%2520mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2418%26epage%3D2428%26doi%3D10.1158%2F1535-7163.MCT-07-0268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Overk, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asghodom, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantvit, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1520</span><span class="NLM_x">–</span> <span class="NLM_lpage">1526</span><span class="refDoi"> DOI: 10.1002/cmdc.200700104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1002%2Fcmdc.200700104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=17654759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1520-1526&author=C.+R.+Overkauthor=K.+W.+Pengauthor=R.+T.+Asghodomauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=Z.+Qinauthor=J.+Frasorauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structure-activity+relationships+for+a+family+of+benzothiophene+selective+estrogen+receptor+modulators+including+raloxifene+and+arzoxifene&doi=10.1002%2Fcmdc.200700104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene</span></div><div class="casAuthors">Overk, Cassia R.; Peng, Kuan-Wei; Asghodom, Rezene T.; Kastrati, Irida; Lantvit, Daniel D.; Qin, Zhihui; Frasor, Jonna; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1520-1526</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The search for the "ideal" selective estrogen receptor modulator (SERM) as a substitute for hormone replacement therapy (HRT) or use in cancer chemoprevention has focused on optimization of estrogen receptor (ER) ligand binding.  Based on the clin. and preclin. benzothiophene SERMs, raloxifene and arzoxifene, a family of SERMs has been developed to modulate activity and oxidative lability.  Antiestrogenic potency measured in human endometrial and breast cancer cells, and ER ligand binding data were correlated and seen to provide a guide to SERM design only when viewed in toto.  The in vitro studies were extended to the juvenile rat model, in which the desired antiestrogenic profile and putative cardiovascular benefits of SERMs were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJnWIhlKprLVg90H21EOLACvtfcHk0lii0Bk0szp9QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E&md5=da626d457446a6ed78ffa3f9939872b1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700104%26sid%3Dliteratum%253Aachs%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DPeng%26aufirst%3DK.%2BW.%26aulast%3DAsghodom%26aufirst%3DR.%2BT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructure-activity%2520relationships%2520for%2520a%2520family%2520of%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520including%2520raloxifene%2520and%2520arzoxifene%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1520%26epage%3D1526%26doi%3D10.1002%2Fcmdc.200700104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R. J.</span><span> </span><span class="NLM_article-title">Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4’F-DMA, a new benzothiophene selective estrogen receptor modulator</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">787</span><span class="refDoi"> DOI: 10.1021/tx050326r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050326r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=779-787&author=H.+Liuauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Chemical+modification+modulates+estrogenic+activity%2C+oxidative+reactivity%2C+and+metabolic+stability+in+4%E2%80%99F-DMA%2C+a+new+benzothiophene+selective+estrogen+receptor+modulator&doi=10.1021%2Ftx050326r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Modification Modulates Estrogenic Activity, Oxidative Reactivity, and Metabolic Stability in 4'F-DMA, a New Benzothiophene Selective Estrogen Receptor Modulator</span></div><div class="casAuthors">Liu, Hong; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-787</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERMs), raloxifene and arzoxifene, in the clinic or clin. trials for treatment of breast cancer and postmenopausal symptoms, are highly susceptible to oxidative metab. and formation of electrophilic metabolites.  4'F-DMA, fluoro-substituted desmethyl arzoxifene (DMA), showed attenuated oxidn. to quinoids in incubation with rat hepatocytes as well as in rat and human liver microsomes.  Incubations of 4'F-DMA with hepatocytes yielded only one glucuronide conjugate and no GSH conjugates, whereas DMA underwent greater metab. giving two glucuronide conjugates, one sulfate conjugate, and two GSH conjugates.  Phase I and phase II metab. were further evaluated in human small intestine microsomes and in human intestinal Caco-2 cells.  In comparison to DMA, 4'F-DMA formed significantly less glucuronide and sulfate conjugates.  The formation of quinoids was further explored in hepatocytes in which DMA was obsd. to give concn.- and time-dependent depletion of GSH accompanied by damage to DNA, which showed inverse dependence on GSH; in contrast, GSH depletion and DNA damage were almost completely abrogated in incubations with 4'F-DMA. 4'F-DMA shows ligand binding affinity to estrogen receptor (ER)α and ERβ with similarity to both raloxifene and to DMA.  ER-mediated biol. activity was measured with the ERE-luciferase reporter system in transfected MCF-7 cells and Ishikawa cells, and in MCF-7 cells, proliferation was measured.  In all systems, 4'F-DMA exhibited antiestrogenic activity of comparable potency to raloxifene but did not manifest estrogenic properties, mirroring previous results on inhibition of estradiol-mediated induction of alk. phosphatase activity in Ishikawa cells.  These results suggest that 4'F-DMA might be an improved benzothiophene SERM with similar antiestrogenic activity to raloxifene but improved metabolic stability and attenuated toxicity, showing that simple chem. modification can abrogate oxidative bioactivation to potentially toxic metabolites without loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FltiqRoLAbVg90H21EOLACvtfcHk0lii0Bk0szp9QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D&md5=2ce12134bb346a54dc42bca0bb432063</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Ftx050326r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050326r%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DChemical%2520modification%2520modulates%2520estrogenic%2520activity%252C%2520oxidative%2520reactivity%252C%2520and%2520metabolic%2520stability%2520in%25204%25E2%2580%2599F-DMA%252C%2520a%2520new%2520benzothiophene%2520selective%2520estrogen%2520receptor%2520modulator%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D779%26epage%3D787%26doi%3D10.1021%2Ftx050326r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Morello, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurz, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGregorio, M. W.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of selective estrogen receptor modulators</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.2165/00003088-200342040-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.2165%2F00003088-200342040-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=12648026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFWis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=361-372&author=K.+C.+Morelloauthor=G.+T.+Wurzauthor=M.+W.+DeGregorio&title=Pharmacokinetics+of+selective+estrogen+receptor+modulators&doi=10.2165%2F00003088-200342040-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of selective estrogen receptor modulators</span></div><div class="casAuthors">Morello, Karla C.; Wurz, Gregory T.; DeGregorio, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-372</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Selective estrogen receptor modulators (SERMs) are a class of compds. used to treat and prevent breast cancer and osteoporosis.  SERMs currently approved for use in patients include tamoxifen, toremifene and raloxifene.  These compds. are well tolerated in patients, and the most common adverse effects experienced in patients undergoing SERM therapy include vasomotor symptoms such as hot flashes and vaginal discharge.  New SERMs currently under development for use in the treatment and prevention of osteoporosis and breast cancer include ospemifene, a deriv. of toremifene, and arzoxifene, a compd. very similar in structure to raloxifene.  SERMs are administered orally at doses ranging from 20 to 60 mg/day.  Tamoxifen and toremifene have a bioavailability of approx. 100%, whereas that of raloxifene is only 2%.  SERMs are very highly bound to plasma proteins (>95%).  Tamoxifen and toremifene are metabolized by the cytochrome P 450 enzyme system, and raloxifene is metabolized by glucuronide conjugation.  The terminal elimination half-lives of these drugs range from 27.7 h to 7 days.  The pharmacokinetics of these compds. are affected in hepatically impaired patients, but not in renally impaired patients.  SERMs have several potential drug interactions with other agents, such as warfarin, rifampicin (rifampin), cholestyramine and aromatase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM59e60xM4P7Vg90H21EOLACvtfcHk0lii0Bk0szp9QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFWis7k%253D&md5=bad9ba129c37ed6003a4ff8738275353</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342040-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342040-00004%26sid%3Dliteratum%253Aachs%26aulast%3DMorello%26aufirst%3DK.%2BC.%26aulast%3DWurz%26aufirst%3DG.%2BT.%26aulast%3DDeGregorio%26aufirst%3DM.%2BW.%26atitle%3DPharmacokinetics%2520of%2520selective%2520estrogen%2520receptor%2520modulators%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26spage%3D361%26epage%3D372%26doi%3D10.2165%2F00003088-200342040-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Maximov, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">The Discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice</span> <span class="citation_source-journal">Curr. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span><span class="refDoi"> DOI: 10.2174/1574884711308020006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.2174%2F1574884711308020006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=23062036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1Ciu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=135-155&author=P.+Y.+Maximovauthor=T.+M.+Leeauthor=V.+C.+Jordan&title=The+Discovery+and+development+of+selective+estrogen+receptor+modulators+%28SERMs%29+for+clinical+practice&doi=10.2174%2F1574884711308020006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice</span></div><div class="casAuthors">Maximov, Philipp Y.; Lee, Theresa M.; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-155</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Selective estrogen receptor modulators (SERMs) are structurally different compds. that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists or antagonists.  These drugs have been intensively studied over the past decade and have proven to be a highly versatile group for the treatment of different conditions assocd. with postmenopausal women's health, including hormone responsive cancer and osteoporosis.  Tamoxifen, a failed contraceptive is currently used to treat all stages of breast cancer, chemoprevention in women at high risk for breast cancer and also has beneficial effects on bone mineral d. and serum lipids in postmenopausal women.  Raloxifene, a failed breast cancer drug, is the only SERM approved internationally for the prevention and treatment of postmenopausal osteoporosis and vertebral fractures.  However, although these SERMs have many benefits, they also have some potentially serious adverse effects, such as thromboembolic disorders and, in the case of tamoxifen, uterine cancer.  These adverse effects represent a major concern given that long-term therapy is required to prevent osteoporosis or prevent and treat breast cancer.  The search for the 'ideal' SERM, which would have estrogenic effects on bone and serum lipids, neutral effects on the uterus, and antiestrogenic effects on breast tissue, but none of the adverse effects assocd. with current therapies, is currently under way.  Ospemifene, lasofoxifene, bazedoxifene and arzoxifene, which are new SERM mols. with potentially greater efficacy and potency than previous SERMs, have been investigated for use in the treatment and prevention of osteoporosis.  These drugs have been shown to be comparably effective to conventional hormone replacement therapy in animal models, with potential indications for an improved safety profile.  Clin. efficacy data from ongoing phase III trials are available or are awaited for each SERM so that a true understanding of the therapeutic potential of these compds. can be obtained.  In this article, we describe the discovery and development of the group of medicines called SERMs.  The newer SERMs in late development: ospemifene, lasofoxifene, bazedoxifene, are arzoxifene are described in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHm6akpCPgJLVg90H21EOLACvtfcHk0lii0Bk0szp9QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1Ciu7o%253D&md5=7cddd250d63d64258fb21dacdd7d3043</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1574884711308020006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574884711308020006%26sid%3Dliteratum%253Aachs%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DT.%2BM.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DThe%2520Discovery%2520and%2520development%2520of%2520selective%2520estrogen%2520receptor%2520modulators%2520%2528SERMs%2529%2520for%2520clinical%2520practice%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D8%26spage%3D135%26epage%3D155%26doi%3D10.2174%2F1574884711308020006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2260</span><span class="NLM_x">–</span> <span class="NLM_lpage">2271</span><span class="refDoi"> DOI: 10.1021/tx800323w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800323w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=2260-2271&author=D.+Dalvieauthor=P.+Kangauthor=M.+Zientekauthor=C.+Xiangauthor=S.+Zhouauthor=R.+S.+Obach&title=Effect+of+intestinal+glucuronidation+in+limiting+hepatic+exposure+and+bioactivation+of+raloxifene+in+humans+and+rats&doi=10.1021%2Ftx800323w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Intestinal Glucuronidation in Limiting Hepatic Exposure and Bioactivation of Raloxifene in Humans and Rats</span></div><div class="casAuthors">Dalvie, Deepak; Kang, Ping; Zientek, Michael; Xiang, Cathie; Zhou, Sue; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2260-2271</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene (Evista) is a second generation selective estrogen receptor modulator used in the treatment of osteoporosis and for chemoprevention of breast cancer.  It is bioactivated to reactive intermediates, which covalently bind to proteins and form GSH conjugates upon incubation with NADPH and GSH-supplemented human and rat liver microsomes.  Despite these in vitro findings, no major raloxifene-related toxic events have been reported upon its oral administration to humans.  This disconnect between safety of raloxifene and its in vitro bioactivation is attributed to its presystemic metab. via glucuronidation.  Current studies investigated the effect of hepatic and intestinal glucuronidation in modulating hepatic availability of raloxifene and its subsequent bioactivation, in vitro.  The study design involved preincubation of raloxifene with intestinal microsomes followed by a sequential incubation with liver microsomes.  The degree of bioactivation of raloxifene was assessed from the percentage of GSH conjugate formed in liver microsomal incubations or the amt. of covalent binding of raloxifene-related material to liver microsomal proteins.  The results indicated that human intestinal glucuronidation limited the hepatic exposure of raloxifene that underwent bioactivation in the liver.  Similar expts. with rat microsomal prepns. showed very little effect of intestinal glucuronidation.  This effect of intestinal glucuronidation and the obsd. species difference were explained by comparing the efficiency (Clint) of glucuronidation and oxidn. in the two species.  These findings suggested that even though the rate of bioactivation in the two species was similar, the Clint of glucuronidation was 7.5-fold higher in the human intestine as compared to rats.  These results support the hypothesis that intestinal glucuronidation modulates the amt. of raloxifene undergoing bioactivation by liver and corroborate the importance of assessing other competitive metabolic pathways and species differences in metab. prior to extrapolation of bioactivation results from rats to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-CeHG1UEOrVg90H21EOLACvtfcHk0liEHzHNpjjYaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O&md5=69f878c5dd77d57379745df37cf9121b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx800323w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800323w%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DP.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DEffect%2520of%2520intestinal%2520glucuronidation%2520in%2520limiting%2520hepatic%2520exposure%2520and%2520bioactivation%2520of%2520raloxifene%2520in%2520humans%2520and%2520rats%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D2260%26epage%3D2271%26doi%3D10.1021%2Ftx800323w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kemp, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J. C.</span><span> </span><span class="NLM_article-title">Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">694</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1124/dmd.30.6.694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1124%2Fdmd.30.6.694" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=694-700&author=D.+C.+Kempauthor=P.+W.+Fanauthor=J.+C.+Stevens&title=Characterization+of+raloxifene+glucuronidation+in+vitro%3A+contribution+of+intestinal+metabolism+to+presystemic+clearance&doi=10.1124%2Fdmd.30.6.694"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.6.694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.6.694%26sid%3Dliteratum%253Aachs%26aulast%3DKemp%26aufirst%3DD.%2BC.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DStevens%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520raloxifene%2520glucuronidation%2520in%2520vitro%253A%2520contribution%2520of%2520intestinal%2520metabolism%2520to%2520presystemic%2520clearance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D694%26epage%3D700%26doi%3D10.1124%2Fdmd.30.6.694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Rosati, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Silva Jardine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toler, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebbinghaus, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhold, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newhouse, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjoa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetnam, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arriola, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirie, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkalcevic, G. T.</span><span> </span><span class="NLM_article-title">Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2928</span><span class="NLM_x">–</span> <span class="NLM_lpage">2931</span><span class="refDoi"> DOI: 10.1021/jm980048b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980048b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2928-2931&author=R.+L.+Rosatiauthor=P.+Da+Silva+Jardineauthor=K.+O.+Cameronauthor=D.+D.+Thompsonauthor=H.+Z.+Keauthor=S.+M.+Tolerauthor=T.+A.+Brownauthor=L.+C.+Panauthor=C.+F.+Ebbinghausauthor=A.+R.+Reinholdauthor=N.+C.+Elliottauthor=B.+N.+Newhouseauthor=C.+M.+Tjoaauthor=P.+M.+Sweetnamauthor=M.+J.+Coleauthor=M.+W.+Arriolaauthor=J.+W.+Gauthierauthor=D.+T.+Crawfordauthor=D.+F.+Nickersonauthor=C.+M.+Pirieauthor=H.+Qiauthor=H.+A.+Simmonsauthor=G.+T.+Tkalcevic&title=Discovery+and+preclinical+pharmacology+of+a+novel%2C+potent%2C+nonsteroidal+estrogen+receptor+agonist%2Fantagonist%2C+CP-336156%2C+a+diaryltetrahydronaphthalene&doi=10.1021%2Fjm980048b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm980048b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980048b%26sid%3Dliteratum%253Aachs%26aulast%3DRosati%26aufirst%3DR.%2BL.%26aulast%3DDa%2BSilva%2BJardine%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DToler%26aufirst%3DS.%2BM.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DPan%26aufirst%3DL.%2BC.%26aulast%3DEbbinghaus%26aufirst%3DC.%2BF.%26aulast%3DReinhold%26aufirst%3DA.%2BR.%26aulast%3DElliott%26aufirst%3DN.%2BC.%26aulast%3DNewhouse%26aufirst%3DB.%2BN.%26aulast%3DTjoa%26aufirst%3DC.%2BM.%26aulast%3DSweetnam%26aufirst%3DP.%2BM.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DArriola%26aufirst%3DM.%2BW.%26aulast%3DGauthier%26aufirst%3DJ.%2BW.%26aulast%3DCrawford%26aufirst%3DD.%2BT.%26aulast%3DNickerson%26aufirst%3DD.%2BF.%26aulast%3DPirie%26aufirst%3DC.%2BM.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DSimmons%26aufirst%3DH.%2BA.%26aulast%3DTkalcevic%26aufirst%3DG.%2BT.%26atitle%3DDiscovery%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520novel%252C%2520potent%252C%2520nonsteroidal%2520estrogen%2520receptor%2520agonist%252Fantagonist%252C%2520CP-336156%252C%2520a%2520diaryltetrahydronaphthalene%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2928%26epage%3D2931%26doi%3D10.1021%2Fjm980048b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">David, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellet-Rostaing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier dit Chabert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, M.</span><span> </span><span class="NLM_article-title">Fournier dit Chabert, J.; Lemaire, M. Efficient access to 2-aryl-3-substituted benzo[b]thiophenes</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3569</span><span class="NLM_x">–</span> <span class="NLM_lpage">3573</span><span class="refDoi"> DOI: 10.1021/jo0500378</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0500378" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=3569-3573&author=E.+Davidauthor=J.+Perrinauthor=S.+Pellet-Rostaingauthor=J.+Fournier+dit+Chabertauthor=M.+Lemaire&title=Fournier+dit+Chabert%2C+J.%3B+Lemaire%2C+M.+Efficient+access+to+2-aryl-3-substituted+benzo%5Bb%5Dthiophenes&doi=10.1021%2Fjo0500378"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjo0500378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0500378%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DE.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DPellet-Rostaing%26aufirst%3DS.%26aulast%3DFournier%2Bdit%2BChabert%26aufirst%3DJ.%26aulast%3DLemaire%26aufirst%3DM.%26atitle%3DFournier%2520dit%2520Chabert%252C%2520J.%253B%2520Lemaire%252C%2520M.%2520Efficient%2520access%2520to%25202-aryl-3-substituted%2520benzo%255Bb%255Dthiophenes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D3569%26epage%3D3573%26doi%3D10.1021%2Fjo0500378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Jia, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">Synthesis and properties of novel electroactive poly(amic acid) and polyimide copolymers bearing pendant oligoaniline groups</span> <span class="citation_source-journal">Polym. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1300</span><span class="NLM_x">–</span> <span class="NLM_lpage">1306</span><span class="refDoi"> DOI: 10.1039/c1py00035g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1039%2Fc1py00035g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Kgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1300-1306&author=X.+T.+Jiaauthor=D.+M.+Chaoauthor=H.+T.+Liuauthor=L.+B.+Heauthor=T.+Zhengauthor=X.+J.+Bianauthor=C.+Wang&title=Synthesis+and+properties+of+novel+electroactive+poly%28amic+acid%29+and+polyimide+copolymers+bearing+pendant+oligoaniline+groups&doi=10.1039%2Fc1py00035g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and properties of novel electroactive poly(amic acid) and polyimide copolymers bearing pendant oligoaniline groups</span></div><div class="casAuthors">Jia, Xiaoteng; Chao, Danming; Liu, Hongtao; He, Libing; Zheng, Tian; Bian, Xiujie; Wang, Ce</div><div class="citationInfo"><span class="NLM_cas:title">Polymer Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1300-1306</span>CODEN:
                <span class="NLM_cas:coden">PCOHC2</span>;
        ISSN:<span class="NLM_cas:issn">1759-9962</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of novel electroactive copolymers of poly(amic acid) (PAA) bearing pendant aniline tetramer groups were prepd. via direct polycondensation from novel electroactive diamine (EDA), 4,4'-diaminodiphenyl ether (p-ODA) and 3,3',4,4'-biphenyltetracarboxylic dianhydride (s-BPDA).  The structures of the copolymers were confirmed by FT-IR and 1H NMR measurements.  Then the prepd. PAA copolymers were heated at 300 °C to induce cyclization, and transformed into polyimide (PI) films.  The obtained PI films exhibited excellent thermal stability and outstanding mech. properties.  The PAA copolymers films had reversible redox couples with good cycle stability.  The stepwise oxidn. of as-prepd. PAA copolymers by ammonium persulfate is monitored by UV-vis spectroscopy.  The absorption peak at 571 nm underwent a red shift when it transformed from emeraldine state to pernigraniline state.  Moreover, the PAA copolymers films revealed electrochromic behaviors with a color change from yellowish at its neutral state, to green, and finally to dark blue.  They also exhibited extremely high optical contrast (%ΔT) up to 63% at 700 nm, moderate coloration efficiency (CE ≈ 100 cm2 C-1) and low switching times of 3.9 s at 0.8 V and 1.3 s for fast bleaching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVZIhyNBB6SLVg90H21EOLACvtfcHk0li7FiCAbjRkbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Kgs7Y%253D&md5=40c6e19cbf425e55a34a4f185c588007</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2Fc1py00035g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1py00035g%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DX.%2BT.%26aulast%3DChao%26aufirst%3DD.%2BM.%26aulast%3DLiu%26aufirst%3DH.%2BT.%26aulast%3DHe%26aufirst%3DL.%2BB.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DBian%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520properties%2520of%2520novel%2520electroactive%2520poly%2528amic%2520acid%2529%2520and%2520polyimide%2520copolymers%2520bearing%2520pendant%2520oligoaniline%2520groups%26jtitle%3DPolym.%2520Chem.%26date%3D2011%26volume%3D2%26spage%3D1300%26epage%3D1306%26doi%3D10.1039%2Fc1py00035g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Callis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Challinor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G.</span><span> </span><span class="NLM_article-title">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">748</span><span class="NLM_x">–</span> <span class="NLM_lpage">759</span><span class="refDoi"> DOI: 10.1177/1087057115580298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1177%2F1087057115580298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25851036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=748-759&author=R.+Callisauthor=A.+Rabowauthor=M.+Tongeauthor=R.+Bradburyauthor=M.+Challinorauthor=K.+Robertsauthor=K.+Jonesauthor=G.+Walker&title=A+screening+assay+cascade+to+identify+and+characterize+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1177%2F1087057115580298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span></div><div class="casAuthors">Callis, Rowena; Rabow, Alfred; Tonge, Michael; Bradbury, Robert; Challinor, Mairi; Roberts, Karen; Jones, Karen; Walker, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compds. with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments.  Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compds., but such approaches can be limited due to low throughput and sensitivity, resp.  We have used an endogenous cell-imaging strategy that has both the throughput and sensitivity to support a large-scale hit-to-lead program to identify novel compds.  A screening cascade with a suite of assays has been developed to characterize compds. that modulate estrogen receptor α (ERα)-mediated signaling or downregulate ERα levels in cells.  Initially, from a focused high-throughput screening, novel ERα binders were identified that could be modified chem. into ERα downregulators.  Following this, cellular assays helped det. the mechanism of action of compds. to distinguish between on-target and off-target compds. and differentiate SERDs, selective estrogen receptor modulator (SERM) compds., and agonist ERα ligands.  Data are shown to exemplify the characterization of ERα-mediated signaling inhibitors using a selection of literature compds. and illustrate how this cascade has been used to drive the chem. design of novel SERD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNNWMPPJDNrVg90H21EOLACvtfcHk0li7FiCAbjRkbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE&md5=13c27dbf08f315d469f81b2bcefb4499</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1177%2F1087057115580298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115580298%26sid%3Dliteratum%253Aachs%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DBradbury%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DA%2520screening%2520assay%2520cascade%2520to%2520identify%2520and%2520characterize%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D748%26epage%3D759%26doi%3D10.1177%2F1087057115580298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Jiang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yingling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1016/0303-7207(92)90104-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2F0303-7207%2892%2990104-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1301400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=77-86&author=S.+Y.+Jiangauthor=D.+M.+Wolfauthor=J.+M.+Yinglingauthor=C.+Changauthor=V.+C.+Jordan&title=An+estrogen+receptor+positive+MCF-7+clone+that+is+resistant+to+antiestrogens+and+estradiol&doi=10.1016%2F0303-7207%2892%2990104-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol</span></div><div class="casAuthors">Jiang, Shun Yuan; Wolf, Douglas M.; Yingling, Jonathan M.; Chang, Chawnshang; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    </div><div class="casAbstract">The antiestrogen tamoxifen has been successfully used to control estrogen receptor (ER)- and progesterone receptor-pos. breast cancer.  However, the development of antiestrogen resistance is frequently obsd. in patients following long-term treatment.  The development of antiestrogen resistance was studied in vitro, and an antiestrogen resistant variant of MCF-7 cells (clone 5C) was established after long-term culture in estrogen-free medium.  The growth of clone 5C cells was not altered by either estradiol or the antiestrogens 4-hydroxytamoxifen and ICI 164,384.  Estrogen-stimulated progesterone receptor and reporter gene expression were markedly reduced in 5C cells compared to wild-type MCF-7 cells.  Only minor alteration in the levels of ER and no alteration in the affinity of ER for ligand were found in 5C cells.  No mutation of ER cDNA in 5C cells was detected by polymerase chain reaction and DNA sequencing.  This study demonstrates that change(s) in ER-mediated gene expression rather than the amino acid sequence of the ER itself may be assocd. with the development of at least one form of antiestrogen resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7D95adwlHwLVg90H21EOLACvtfcHk0li7FiCAbjRkbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D&md5=3bfb8ea4c10526f1477410c7cf6a03d7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0303-7207%2892%2990104-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-7207%252892%252990104-E%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DS.%2BY.%26aulast%3DWolf%26aufirst%3DD.%2BM.%26aulast%3DYingling%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAn%2520estrogen%2520receptor%2520positive%2520MCF-7%2520clone%2520that%2520is%2520resistant%2520to%2520antiestrogens%2520and%2520estradiol%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D1992%26volume%3D90%26spage%3D77%26epage%3D86%26doi%3D10.1016%2F0303-7207%2892%2990104-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Molloy, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherezghiher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalsen, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maximov, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span> </span><span class="NLM_article-title">Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2515</span><span class="NLM_x">–</span> <span class="NLM_lpage">2526</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1535-7163.MCT-14-0319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25205655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2515-2526&author=M.+E.+Molloyauthor=B.+E.+Whiteauthor=T.+Gherezghiherauthor=B.+T.+Michalsenauthor=R.+Xiongauthor=H.+Patelauthor=H.+Zhaoauthor=P.+Y.+Maximovauthor=V.+C.+Jordanauthor=G.+R.+Thatcherauthor=D.+A.+Tonetti&title=Novel+selective+estrogen+mimics+for+the+treatment+of+tamoxifen-resistant+breast+cancer&doi=10.1158%2F1535-7163.MCT-14-0319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Molloy, Mary Ellen; White, Bethany E. Perez; Gherezghiher, Teshome; Michalsen, Bradley T.; Xiong, Rui; Patel, Hitisha; Zhao, Huiping; Maximov, Philipp Y.; Jordan, V. Craig; Thatcher, Gregory R. J.; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2515-2526</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endocrine-resistant breast cancer is a major clin. obstacle.  The use of 17β-estradiol (E2) has reemerged as a potential treatment option following exhaustive use of tamoxifen or aromatase inhibitors, although side effects have hindered its clin. usage.  Protein kinase C alpha (PKCα) expression was shown to be a predictor of disease outcome for patients receiving endocrine therapy and may predict a pos. response to an estrogenic treatment.  Here, we have investigated the use of novel benzothiophene selective estrogen mimics (SEM) as an alternative to E2 for the treatment of tamoxifen-resistant breast cancer.  Following in vitro characterization of SEMs, a panel of clin. relevant PKCα-expressing, tamoxifen-resistant models were used to investigate the antitumor effects of these compds.  SEM treatment resulted in growth inhibition and apoptosis of tamoxifen-resistant cell lines in vitro.  In vivo SEM treatment induced tumor regression of tamoxifen-resistant T47D:A18/PKCα and T47D:A18-TAM1 tumor models.  T47D:A18/PKCα tumor regression was accompanied by translocation of estrogen receptor (ER) α to extranuclear sites, possibly defining a mechanism through which these SEMs initiate tumor regression.  SEM treatment did not stimulate growth of E2-dependent T47D:A18/neo tumors.  In addn., unlike E2 or tamoxifen, treatment with SEMs did not stimulate uterine wt. gain.  These findings suggest the further development of SEMs as a feasible therapeutic strategy for the treatment of endocrine-resistant breast cancer without the side effects assocd. with E2.  Mol Cancer Ther; 13(11); 2515-26. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64x3RCcDeYbVg90H21EOLACvtfcHk0li7FiCAbjRkbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N&md5=203055e50477bcb1c98ea4c7844cf4b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0319%26sid%3Dliteratum%253Aachs%26aulast%3DMolloy%26aufirst%3DM.%2BE.%26aulast%3DWhite%26aufirst%3DB.%2BE.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DMichalsen%26aufirst%3DB.%2BT.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520selective%2520estrogen%2520mimics%2520for%2520the%2520treatment%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2515%26epage%3D2526%26doi%3D10.1158%2F1535-7163.MCT-14-0319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Wardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisele, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanArsdale, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dann, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primeau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5121</span><span class="NLM_x">–</span> <span class="NLM_lpage">5130</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1078-0432.CCR-15-0360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25991817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5121-5130&author=S.+E.+Wardellauthor=M.+J.+Ellisauthor=H.+M.+Alleyauthor=K.+Eiseleauthor=T.+VanArsdaleauthor=S.+G.+Dannauthor=K.+T.+Arndtauthor=T.+Primeauauthor=E.+Griffinauthor=J.+Shaoauthor=R.+Crowderauthor=J.+P.+Laiauthor=J.+D.+Norrisauthor=D.+P.+McDonnellauthor=S.+Li&title=Efficacy+of+SERD%2FSERM+hybrid-CDK4%2F6+inhibitor+combinations+in+models+of+endocrine+therapy-resistant+breast+cancer&doi=10.1158%2F1078-0432.CCR-15-0360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer</span></div><div class="casAuthors">Wardell, Suzanne E.; Ellis, Matthew J.; Alley, Holly M.; Eisele, Koleen; Van Arsdale, Todd; Dann, Stephen G.; Arndt, Kim T.; Primeau, Tina; Griffin, Elizabeth; Shao, Jieya; Crowder, Robert; Lai, Jin-Ping; Norris, John D.; McDonnell, Donald P.; Li, Shunqiang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5121-5130</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)-pos. breast cancer.  However, ESR1 mutations or other ligand-independent ESR1 activation mechanisms limit the duration of response.  The clin. efficacy of fulvestrant, a selective estrogen receptor downregulator (SERD) that competitively inhibits agonist binding to ESR1 and triggers receptor downregulation, has confirmed that ESR1 frequently remains engaged in endocrine therapy-resistant cancers.  We evaluated the activity of a new class of selective estrogen receptor modulators (SERM)/SERD hybrids (SSH) that downregulate ESR1 in relevant models of endocrine-resistant breast cancer.  Building on the observation that concurrent inhibition of ESR1 and the cyclin-dependent kinases 4 and 6 (CDK4/6) significantly increased progression-free survival in advanced patients, we explored the activity of different SERD- or SSH-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant ESR1+ breast cancer.  Exptl. Design: SERDs, SSHs, and the CDK4/6 inhibitor palbociclib were evaluated as single agents or in combination in established cellular and animal models of endocrine therapy-resistant ESR1+ breast cancer.  Results: The combination of palbociclib with a SERD or an SSH was shown to effectively inhibit the growth of MCF7 cell or ESR1-mutant patient-derived tumor xenografts.  In tamoxifen-resistant MCF7 xenografts, the palbociclib/SERD or SSH combination resulted in an increased duration of response as compared with either drug alone.  Conclusions: A SERD- or SSH-palbociclib combination has therapeutic potential in breast tumors resistant to endocrine therapies or those expressing ESR1 mutations.  Clin Cancer Res; 21(22); 5121-30. ©2015 AACR.  See related commentary by DeMichele and Chodosh, p.  4999.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZJESmSBzCpLVg90H21EOLACvtfcHk0lht6BqCese6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbnK&md5=73be58473ccda7c811fa010334c60479</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0360%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DEisele%26aufirst%3DK.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DDann%26aufirst%3DS.%2BG.%26aulast%3DArndt%26aufirst%3DK.%2BT.%26aulast%3DPrimeau%26aufirst%3DT.%26aulast%3DGriffin%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DJ.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DEfficacy%2520of%2520SERD%252FSERM%2520hybrid-CDK4%252F6%2520inhibitor%2520combinations%2520in%2520models%2520of%2520endocrine%2520therapy-resistant%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D5121%26epage%3D5130%26doi%3D10.1158%2F1078-0432.CCR-15-0360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Leek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimes, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, A.</span><span> </span><span class="NLM_article-title">Methods: using three-dimensional culture (spheroids) as an in vitro model of tumour hypoxia</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">899</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.1007/978-3-319-26666-4_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2F978-3-319-26666-4_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=899&publication_year=2016&pages=167-196&author=R.+Leekauthor=D.+R.+Grimesauthor=A.+L.+Harrisauthor=A.+McIntyre&title=Methods%3A+using+three-dimensional+culture+%28spheroids%29+as+an+in+vitro+model+of+tumour+hypoxia&doi=10.1007%2F978-3-319-26666-4_10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-26666-4_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-26666-4_10%26sid%3Dliteratum%253Aachs%26aulast%3DLeek%26aufirst%3DR.%26aulast%3DGrimes%26aufirst%3DD.%2BR.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DMcIntyre%26aufirst%3DA.%26atitle%3DMethods%253A%2520using%2520three-dimensional%2520culture%2520%2528spheroids%2529%2520as%2520an%2520in%2520vitro%2520model%2520of%2520tumour%2520hypoxia%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2016%26volume%3D899%26spage%3D167%26epage%3D196%26doi%3D10.1007%2F978-3-319-26666-4_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Davies, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arriagada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alencar, V. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonfill, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delmestri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inbar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khaled, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kielanowska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittra, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peralta, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pernas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petruzelka, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienkowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radhika, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubach, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tort, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urrutia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, R.</span><span> </span><span class="NLM_article-title">Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61963-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2FS0140-6736%2812%2961963-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=805-816&author=C.+Daviesauthor=H.+C.+Panauthor=J.+Godwinauthor=R.+Grayauthor=R.+Arriagadaauthor=V.+Rainaauthor=M.+Abrahamauthor=V.+H.+M.+Alencarauthor=A.+Badranauthor=X.+Bonfillauthor=J.+Bradburyauthor=M.+Clarkeauthor=R.+Collinsauthor=S.+R.+Davisauthor=A.+Delmestriauthor=J.+F.+Forbesauthor=P.+Haddadauthor=M.+F.+Houauthor=M.+Inbarauthor=H.+Khaledauthor=J.+Kielanowskaauthor=W.+H.+Kwanauthor=B.+S.+Mathewauthor=I.+Mittraauthor=B.+Mullerauthor=A.+Nicolucciauthor=O.+Peraltaauthor=F.+Pernasauthor=L.+Petruzelkaauthor=T.+Pienkowskiauthor=R.+Radhikaauthor=B.+Rajanauthor=M.+T.+Rubachauthor=S.+Tortauthor=G.+Urrutiaauthor=M.+Valentiniauthor=Y.+C.+Wangauthor=R.+Peto&title=Long-term+effects+of+continuing+adjuvant+tamoxifen+to+10+years+versus+stopping+at+5+years+after+diagnosis+of+oestrogen+receptor-positive+breast+cancer%3A+ATLAS%2C+a+randomised+trial&doi=10.1016%2FS0140-6736%2812%2961963-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961963-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961963-1%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DH.%2BC.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DArriagada%26aufirst%3DR.%26aulast%3DRaina%26aufirst%3DV.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DAlencar%26aufirst%3DV.%2BH.%2BM.%26aulast%3DBadran%26aufirst%3DA.%26aulast%3DBonfill%26aufirst%3DX.%26aulast%3DBradbury%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DS.%2BR.%26aulast%3DDelmestri%26aufirst%3DA.%26aulast%3DForbes%26aufirst%3DJ.%2BF.%26aulast%3DHaddad%26aufirst%3DP.%26aulast%3DHou%26aufirst%3DM.%2BF.%26aulast%3DInbar%26aufirst%3DM.%26aulast%3DKhaled%26aufirst%3DH.%26aulast%3DKielanowska%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DW.%2BH.%26aulast%3DMathew%26aufirst%3DB.%2BS.%26aulast%3DMittra%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DB.%26aulast%3DNicolucci%26aufirst%3DA.%26aulast%3DPeralta%26aufirst%3DO.%26aulast%3DPernas%26aufirst%3DF.%26aulast%3DPetruzelka%26aufirst%3DL.%26aulast%3DPienkowski%26aufirst%3DT.%26aulast%3DRadhika%26aufirst%3DR.%26aulast%3DRajan%26aufirst%3DB.%26aulast%3DRubach%26aufirst%3DM.%2BT.%26aulast%3DTort%26aufirst%3DS.%26aulast%3DUrrutia%26aufirst%3DG.%26aulast%3DValentini%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DPeto%26aufirst%3DR.%26atitle%3DLong-term%2520effects%2520of%2520continuing%2520adjuvant%2520tamoxifen%2520to%252010%2520years%2520versus%2520stopping%2520at%25205%2520years%2520after%2520diagnosis%2520of%2520oestrogen%2520receptor-positive%2520breast%2520cancer%253A%2520ATLAS%252C%2520a%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D805%26epage%3D816%26doi%3D10.1016%2FS0140-6736%2812%2961963-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Robinson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vats, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonigro, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyana-Sundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodges, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gursky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roychowdhury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienta, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rae, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Poznak, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunju, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span><span class="refDoi"> DOI: 10.1038/ng.2823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1038%2Fng.2823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=24185510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1446-1451&author=D.+R.+Robinsonauthor=Y.+M.+Wuauthor=P.+Vatsauthor=F.+Suauthor=R.+J.+Lonigroauthor=X.+Caoauthor=S.+Kalyana-Sundaramauthor=R.+Wangauthor=Y.+Ningauthor=L.+Hodgesauthor=A.+Gurskyauthor=J.+Siddiquiauthor=S.+A.+Tomlinsauthor=S.+Roychowdhuryauthor=K.+J.+Pientaauthor=S.+Y.+Kimauthor=J.+S.+Robertsauthor=J.+M.+Raeauthor=C.+H.+Van+Poznakauthor=D.+F.+Hayesauthor=R.+Chughauthor=L.+P.+Kunjuauthor=M.+Talpazauthor=A.+F.+Schottauthor=A.+M.+Chinnaiyan&title=Activating+ESR1+mutations+in+hormone-resistant+metastatic+breast+cancer&doi=10.1038%2Fng.2823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Vats, Pankaj; Su, Fengyun; Lonigro, Robert J.; Cao, Xuhong; Kalyana-Sundaram, Shanker; Wang, Rui; Ning, Yu; Hodges, Lynda; Gursky, Amy; Siddiqui, Javed; Tomlins, Scott A.; Roychowdhury, Sameek; Pienta, Kenneth J.; Kim, Scott Y.; Roberts, J. Scott; Rae, James M.; Van Poznak, Catherine H.; Hayes, Daniel F.; Chugh, Rashmi; Kunju, Lakshmi P.; Talpaz, Moshe; Schott, Anne F.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express estrogen receptor-α (ER-α, encoded by ESR1).  Through a prospective clin. sequencing program for advanced cancers, we enrolled 11 patients with ER-pos. metastatic breast cancer.  Whole-exome and transcriptome anal. showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain (LBD), all of whom had been treated with anti-estrogens and estrogen deprivation therapies.  A survey of The Cancer Genome Atlas (TCGA) identified four endometrial cancers with similar mutations of ESR1.  The five new LBD-localized ESR1 mutations identified here (encoding p.Leu536Gln, p.Tyr537Ser, p.Tyr537Cys, p.Tyr537Asn and p.Asp538Gly) were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.  Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQSL6mlhMOrVg90H21EOLACvtfcHk0lj39n8gNDtTYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN&md5=af9e69d6064726af238fe74dad7d2204</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fng.2823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2823%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DGursky%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DRae%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BPoznak%26aufirst%3DC.%2BH.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DActivating%2520ESR1%2520mutations%2520in%2520hormone-resistant%2520metastatic%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fng.2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Toy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakr, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gala, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span> </span><span class="NLM_article-title">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1445</span><span class="refDoi"> DOI: 10.1038/ng.2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1038%2Fng.2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=24185512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1439-1445&author=W.+Toyauthor=Y.+Shenauthor=H.+Wonauthor=B.+Greenauthor=R.+A.+Sakrauthor=M.+Willauthor=Z.+Liauthor=K.+Galaauthor=S.+Fanningauthor=T.+A.+Kingauthor=C.+Hudisauthor=D.+Chenauthor=T.+Taranauthor=G.+Hortobagyiauthor=G.+Greeneauthor=M.+Bergerauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=ESR1+ligand-binding+domain+mutations+in+hormone-resistant+breast+cancer&doi=10.1038%2Fng.2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span></div><div class="casAuthors">Toy, Weiyi; Shen, Yang; Won, Helen; Green, Bradley; Sakr, Rita A.; Will, Marie; Li, Zhiqiang; Gala, Kinisha; Fanning, Sean; King, Tari A.; Hudis, Clifford; Chen, David; Taran, Tetiana; Hortobagyi, Gabriel; Greene, Geoffrey; Berger, Michael; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition.  However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting.  We conducted a comprehensive genetic anal. of two independent cohorts of metastatic ER-pos. breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.  These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations.  Mol. dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor.  Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.  These data implicate LBD-mutant forms of ER in mediating clin. resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KQLxyqE3lrVg90H21EOLACvtfcHk0lj39n8gNDtTYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ&md5=1f7c247e079d08a463db4e20ec0f9d17</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fng.2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2822%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DSakr%26aufirst%3DR.%2BA.%26aulast%3DWill%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DGala%26aufirst%3DK.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DESR1%2520ligand-binding%2520domain%2520mutations%2520in%2520hormone-resistant%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26spage%3D1439%26epage%3D1445%26doi%3D10.1038%2Fng.2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Fanning, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayne, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dharmarajan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novick, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchamukhi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajkhorshid, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, G. L.</span><span> </span><span class="NLM_article-title">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span> <span class="citation_source-journal">Elife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e12792</span><span class="refDoi"> DOI: 10.7554/eLife.12792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.7554%2FeLife.12792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=26836308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e12792&author=S.+W.+Fanningauthor=C.+G.+Mayneauthor=V.+Dharmarajanauthor=K.+E.+Carlsonauthor=T.+A.+Martinauthor=S.+J.+Novickauthor=W.+Toyauthor=B.+Greenauthor=S.+Panchamukhiauthor=B.+S.+Katzenellenbogenauthor=E.+Tajkhorshidauthor=P.+R.+Griffinauthor=Y.+Shenauthor=S.+Chandarlapatyauthor=J.+A.+Katzenellenbogenauthor=G.+L.+Greene&title=Estrogen+receptor+alpha+somatic+mutations+Y537S+and+D538G+confer+breast+cancer+endocrine+resistance+by+stabilizing+the+activating+function-2+binding+conformation&doi=10.7554%2FeLife.12792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span></div><div class="casAuthors">Fanning, Sean W.; Mayne, Christopher G.; Dharmarajan, Venkatasubramanian; Carlson, Kathryn E.; Martin, Teresa A.; Novick, Scott J.; Toy, Weiyi; Green, Bradley; Panchamukhi, Srinivas; Katzenellenbogen, Benita S.; Tajkhorshid, Emad; Griffin, Patrick R.; Shen, Yang; Chandarlapaty, Sarat; Katzenellenbogen, John A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e12792/1-e12792/25</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), esp. Y537S and D538G, have been linked to acquired resistance to endocrine therapies.  Cell based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance.  Here, we integrate biophys. and structural biol. data to reveal how these mutations lead to a constitutively active and antiestrogen resistant ERα.  We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced.  Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuokHLHqfD7Vg90H21EOLACvtfcHk0lj39n8gNDtTYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D&md5=417a51b5b7c9c3976befd25db4fb2003</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.7554%2FeLife.12792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.12792%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DMartin%26aufirst%3DT.%2BA.%26aulast%3DNovick%26aufirst%3DS.%2BJ.%26aulast%3DToy%26aufirst%3DW.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DPanchamukhi%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DEstrogen%2520receptor%2520alpha%2520somatic%2520mutations%2520Y537S%2520and%2520D538G%2520confer%2520breast%2520cancer%2520endocrine%2520resistance%2520by%2520stabilizing%2520the%2520activating%2520function-2%2520binding%2520conformation%26jtitle%3DElife%26date%3D2016%26volume%3D5%26spage%3De12792%26doi%3D10.7554%2FeLife.12792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Robertson, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4530</span><span class="NLM_x">–</span> <span class="NLM_lpage">4535</span><span class="refDoi"> DOI: 10.1200/JCO.2008.21.1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1200%2FJCO.2008.21.1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=19704066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4530-4535&author=J.+F.+Robertsonauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=E.+Macphersonauthor=J.+Lindemannauthor=M.+J.+Ellis&title=Activity+of+fulvestrant+500+mg+versus+anastrozole+1+mg+as+first-line+treatment+for+advanced+breast+cancer%3A+results+from+the+FIRST+study&doi=10.1200%2FJCO.2008.21.1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span></div><div class="casAuthors">Robertson, John F. R.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; MacPherson, Euan; Lindemann, Justin; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4530-4535</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the clin. activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-pos. breast cancer in postmenopausal women.  Patients and Methods: FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study of a fulvestrant high-dose (HD) regimen (500 mg/mo plus 500 mg on day 14 of month 1) vs. anastrozole (1 mg/d).  The primary efficacy end point was clin. benefit rate (CBR), defined as the proportion of patients experiencing an objective response (OR) or stable disease for ≥ 24 wk.  The primary anal. was performed 6 mo after the last patient was randomly assigned.  Results: CBR was similar for fulvestrant HD (n = 102) and anastrozole (n = 103), 72.5% v 67.0%, resp. (odds ratio, 1.30; 95% CI, 0.72 to 2.38; P = .386).  Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%.  Time to progression (TTP) was significantly longer for fulvestrant vs. anastrozole (median TTP not reached for fulvestrant HD v 12.5 mo for anastrozole; hazard ratio, 0.63; 95% CI, 0.39 to 1.00; P = .0496).  Duration of OR and CB also numerically favored fulvestrant HD.  Both treatments were well tolerated, with no significant differences in the incidence of prespecified adverse events.  Conclusion: First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was assocd. with significantly longer TTP.  Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-OU2SQaTsabVg90H21EOLACvtfcHk0lj4uH0ZxVzsug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J&md5=a7a6f5cd7fcdbc8cb6839a2800cd5cb8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.1136%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivity%2520of%2520fulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520the%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4530%26epage%3D4535%26doi%3D10.1200%2FJCO.2008.21.1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Robertson, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ’FIRST’ study</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1007/s10549-012-2192-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2Fs10549-012-2192-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=23065000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2qt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2012&pages=503-511&author=J.+F.+Robertsonauthor=J.+P.+Lindemannauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=L.+Emersonauthor=A.+Deanauthor=M.+J.+Ellis&title=Fulvestrant+500+mg+versus+anastrozole+1+mg+for+the+first-line+treatment+of+advanced+breast+cancer%3A+follow-up+analysis+from+the+randomized+%E2%80%99FIRST%E2%80%99+study&doi=10.1007%2Fs10549-012-2192-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized FIRST' study</span></div><div class="casAuthors">Robertson, John F. R.; Lindemann, Justin P. O.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; Emerson, Laura; Dean, Andrew; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">503-511</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-pos. (HR+) advanced breast cancer.  At data cut-off, only 36 % of patients had progressed and the median time to progression (TTP) had not been reached for fulvestrant.  Here, we report follow-up data for TTP for fulvestrant 500 mg vs. anastrozole 1 mg.  Key inclusion criteria were postmenopausal women with estrogen receptor-pos. and/or progesterone receptor-pos. locally advanced or metastatic breast cancer and no prior endocrine therapy.  Key exclusion criteria were presence of life-threatening metastases and prior treatment with a non-approved drug.  Fulvestrant was administered 500 mg/mo plus 500 mg on day 14 of month 1; anastrozole was administered 1 mg/day.  TTP was defined by modified Response Evaluation Criteria in Solid Tumors v1.0 before data cut-off for the primary anal., and investigator opinion after data cut-off.  Best overall response to subsequent therapy and serious adverse events are also reported.  In total, 205 patients received fulvestrant 500 mg (n = 102) or anastrozole (n = 103).  Follow-up anal. was performed when 79.5 % of patients had discontinued study treatment.  Median TTP was 23.4 mo for fulvestrant vs. 13.1 mo for anastrozole; a 34 % redn. in risk of progression (hazard ratio 0.66; 95 % confidence interval: 0.47, 0.92; P = 0.01).  Best overall response to subsequent therapy and clin. benefit rate for subsequent endocrine therapy was similar between the treatment groups.  No new safety concerns for fulvestrant 500 mg were documented.  These longer-term, follow-up results confirm efficacy benefit for fulvestrant 500 mg vs. anastrozole as first-line endocrine therapy for HR+ advanced breast cancer in terms of TTP, and, importantly, show similar best overall response rates to subsequent endocrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy8Wj4FyrbY7Vg90H21EOLACvtfcHk0lj4uH0ZxVzsug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2qt7vM&md5=f4fd805737cb8eb7fc8d007fbcf99e01</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs10549-012-2192-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-012-2192-4%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26aulast%3DLindemann%26aufirst%3DJ.%2BP.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DEmerson%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DA.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DFulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520for%2520the%2520first-line%2520treatment%2520of%2520advanced%2520breast%2520cancer%253A%2520follow-up%2520analysis%2520from%2520the%2520randomized%2520%25E2%2580%2599FIRST%25E2%2580%2599%2520study%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D136%26spage%3D503%26epage%3D511%26doi%3D10.1007%2Fs10549-012-2192-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Zaman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winterhalder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasler-Strub, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochlitz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berset, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiliders, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondeau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neven, P.</span><span> </span><span class="NLM_article-title">Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1212</span><span class="NLM_x">–</span> <span class="NLM_lpage">1220</span><span class="refDoi"> DOI: 10.1016/j.ejca.2015.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.ejca.2015.03.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=1212-1220&author=K.+Zamanauthor=R.+Winterhalderauthor=C.+Mamotauthor=U.+Hasler-Strubauthor=C.+Rochlitzauthor=A.+Muellerauthor=C.+Bersetauthor=H.+Wilidersauthor=L.+Pereyauthor=C.+B.+Rudolfauthor=H.+Hawleauthor=S.+Rondeauauthor=P.+Neven&title=Fulvestrant+with+or+without+selumetinib%2C+a+MEK+1%2F2+inhibitor%2C+in+breast+cancer+progressing+after+aromatase+inhibitor+therapy%3A+a+multicentre+randomised+placebo-controlled+double-blind+phase+II+trial%2C+SAKK+21%2F08&doi=10.1016%2Fj.ejca.2015.03.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DZaman%26aufirst%3DK.%26aulast%3DWinterhalder%26aufirst%3DR.%26aulast%3DMamot%26aufirst%3DC.%26aulast%3DHasler-Strub%26aufirst%3DU.%26aulast%3DRochlitz%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DA.%26aulast%3DBerset%26aufirst%3DC.%26aulast%3DWiliders%26aufirst%3DH.%26aulast%3DPerey%26aufirst%3DL.%26aulast%3DRudolf%26aufirst%3DC.%2BB.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DRondeau%26aufirst%3DS.%26aulast%3DNeven%26aufirst%3DP.%26atitle%3DFulvestrant%2520with%2520or%2520without%2520selumetinib%252C%2520a%2520MEK%25201%252F2%2520inhibitor%252C%2520in%2520breast%2520cancer%2520progressing%2520after%2520aromatase%2520inhibitor%2520therapy%253A%2520a%2520multicentre%2520randomised%2520placebo-controlled%2520double-blind%2520phase%2520II%2520trial%252C%2520SAKK%252021%252F08%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2015%26volume%3D51%26spage%3D1212%26epage%3D1220%26doi%3D10.1016%2Fj.ejca.2015.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loibl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aktas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenegg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Saenz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margeli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liedtke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachsmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De la Haba-Rodriguez, J. R.</span><span> </span><span class="NLM_article-title">Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span><span class="refDoi"> DOI: 10.1200/JCO.2014.57.2388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1200%2FJCO.2014.57.2388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=25691671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntVWltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1045-1052&author=M.+Martinauthor=S.+Loiblauthor=G.+von+Minckwitzauthor=S.+Moralesauthor=N.+Martinezauthor=A.+Guerreroauthor=A.+Antonauthor=B.+Aktasauthor=W.+Schoeneggauthor=M.+Munozauthor=J.+A.+Garcia-Saenzauthor=M.+Gilauthor=M.+Ramosauthor=M.+Margeliauthor=E.+Carrascoauthor=C.+Liedtkeauthor=G.+Wachsmannauthor=K.+Mehtaauthor=J.+R.+De+la+Haba-Rodriguez&title=Phase+III+trial+evaluating+the+addition+of+bevacizumab+to+endocrine+therapy+as+first-line+treatment+for+advanced+breast+cancer%3A+the+letrozole%2Ffulvestrant+and+avastin+%28LEA%29+study&doi=10.1200%2FJCO.2014.57.2388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study</span></div><div class="casAuthors">Martin, Miguel; Loibl, Sibylle; von Minckwitz, Gunter; Morales, Serafin; Martinez, Noelia; Guerrero, Angel; Anton, Antonio; Aktas, Bahriye; Schoenegg, Winfried; Munoz, Montserrat; Garcia-Saenz, Jose ngel; Gil, Miguel; Ramos, Manuel; Margeli, Mireia; Carrasco, Eva; Liedtke, Cornelia; Wachsmann, Grischa; Mehta, Keyur; De la Haba-Rodriguez, Juan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1045-1052</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To test whether combining bevacizumab, an anti-vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET.  Patients and Methods: A multicenter, randomized, open-label, phase III, binational (Spain and Germany) study added bevacizumab (15 mg/kg every 3 wk) to ET (ET-B; letrozole or fulvestrant) as first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -neg. and hormone receptor-pos. advanced breast cancer.  We compared progression-free survival (PFS), overall survival (OS), overall response rate (ORR), response duration (RD), time to treatment failure (TTF), clin. benefit rate (CBR), and safety.  Results: From 380 patients recruited (2007 to 2011), 374 were analyzed by intent to-treat (184 patients on ET and 190 patients on ET-B).  Median age was 65 years, 270 patients (72%) had Eastern Cooperative Oncol. Group performance status of 0, 178 patients (48%) had visceral metastases, and 171 patients (46%) and 195 patients (52%) had received prior chemotherapy or ET, resp.  Median PFS was 14.4 mo in the ET arm and 19.3 mo in the ET-B arm (hazard ratio, 0.83; 95% CI, 0.65 to 1.06; P = .126).  ORR, CBR, and RD with ET vs. ET-B were 22% vs. 41% (P < .001), 67% vs. 77% (P = .041), and 13.3 mo vs. 17.6 mo (P = .434), resp.  TTF and OS were comparable in both arms.  Grade 3 to 4 hypertension, aminotransferase elevation, and proteinuria were significantly higher in the ET-B arm.  Eight patients (4.2%) receiving ET-B died during study or within 30 days of end of treatment.  Conclusion: The addn. of bevacizumab to ET in first-line treatment failed to produce a statistically significant increase in PFS or OS in women with HER2-neg./hormone receptor-pos. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGA5oKmTG3sLVg90H21EOLACvtfcHk0lgjWRzZwGe_Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntVWltLk%253D&md5=596f4923ccaf8126e492504efc2df4b6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.57.2388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.57.2388%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DN.%26aulast%3DGuerrero%26aufirst%3DA.%26aulast%3DAnton%26aufirst%3DA.%26aulast%3DAktas%26aufirst%3DB.%26aulast%3DSchoenegg%26aufirst%3DW.%26aulast%3DMunoz%26aufirst%3DM.%26aulast%3DGarcia-Saenz%26aufirst%3DJ.%2BA.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DM.%26aulast%3DMargeli%26aufirst%3DM.%26aulast%3DCarrasco%26aufirst%3DE.%26aulast%3DLiedtke%26aufirst%3DC.%26aulast%3DWachsmann%26aufirst%3DG.%26aulast%3DMehta%26aufirst%3DK.%26aulast%3DDe%2Bla%2BHaba-Rodriguez%26aufirst%3DJ.%2BR.%26atitle%3DPhase%2520III%2520trial%2520evaluating%2520the%2520addition%2520of%2520bevacizumab%2520to%2520endocrine%2520therapy%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520the%2520letrozole%252Ffulvestrant%2520and%2520avastin%2520%2528LEA%2529%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1045%26epage%3D1052%26doi%3D10.1200%2FJCO.2014.57.2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Yu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicinski, P.</span><span> </span><span class="NLM_article-title">Specific protection against breast cancers by cyclin D1 ablation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1038/35082500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1038%2F35082500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2001&pages=1017-1021&author=Q.+Yuauthor=Y.+Gengauthor=P.+Sicinski&title=Specific+protection+against+breast+cancers+by+cyclin+D1+ablation&doi=10.1038%2F35082500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2F35082500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35082500%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DGeng%26aufirst%3DY.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DSpecific%2520protection%2520against%2520breast%2520cancers%2520by%2520cyclin%2520D1%2520ablation%26jtitle%3DNature%26date%3D2001%26volume%3D411%26spage%3D1017%26epage%3D1021%26doi%3D10.1038%2F35082500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span><span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lgjWRzZwGe_Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Herrera-Abreu, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palafox, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asghar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutts, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Murillas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grueso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pancholi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span> </span><span class="NLM_article-title">Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">2301</span><span class="NLM_x">–</span> <span class="NLM_lpage">2313</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-0728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F0008-5472.CAN-15-0728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=27020857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2301-2313&author=M.+T.+Herrera-Abreuauthor=M.+Palafoxauthor=U.+Asgharauthor=M.+A.+Rivasauthor=R.+J.+Cuttsauthor=I.+Garcia-Murillasauthor=A.+Pearsonauthor=M.+Guzmanauthor=O.+Rodriguezauthor=J.+Gruesoauthor=M.+Belletauthor=J.+Cortesauthor=R.+Elliottauthor=S.+Pancholiauthor=J.+Baselgaauthor=M.+Dowsettauthor=L.+A.+Martinauthor=N.+C.+Turnerauthor=V.+Serra&title=Early+adaptation+and+acquired+resistance+to+CDK4%2F6+inhibition+in+estrogen+receptor-positive+breast+cancer&doi=10.1158%2F0008-5472.CAN-15-0728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Herrera-Abreu, Maria Teresa; Palafox, Marta; Asghar, Uzma; Rivas, Martin A.; Cutts, Rosalind J.; Garcia-Murillas, Isaac; Pearson, Alex; Guzman, Marta; Rodriguez, Olga; Grueso, Judit; Bellet, Meritxell; Corties, Javier; Elliott, Richard; Pancholi, Sunil; Baselga, Josiee; Dowsett, Mitch; Martin, Lesley-Ann; Turner, Nicholas C.; Serra, Violeta</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2301-2313</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of the CDK4/6 cell-cycle kinases have shown clin. efficacy in estrogen receptor (ER)-pos. metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance.  Here we report that ER-pos. breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry.  This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, which reduced the levels of cyclin D1 (CCND1) and other G1-S cyclins, abolished pRb phosphorylation, and inhibited activation of S-phase transcriptional programs.  Combined targeting of both CDK4/6 and PI3K triggered cancer cell apoptosis in vitro and in patient-derived tumor xenograft (PDX) models, resulting in tumor regression and improved disease control.  Furthermore, a triple combination of endocrine therapy, CDK4/6, and PI3K inhibition was more effective than paired combinations, provoking rapid tumor regressions in a PDX model.  Mechanistic investigations showed that acquired resistance to CDK4/6 inhibition resulted from bypass of cyclin D1-CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss.  Notably, although PI3K inhibitors could prevent resistance to CDK4/6 inhibitors, they failed to resensitize cells once resistance had been acquired.  However, we found that cells acquiring resistance to CDK4/6 inhibitors due to CCNE1 amplification could be resensitized by targeting CDK2.  Overall, our results illustrate convergent mechanisms of early adaptation and acquired resistance to CDK4/6 inhibitors that enable alternate means of S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHNNElBQntOLVg90H21EOLACvtfcHk0lgjWRzZwGe_Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D&md5=675a4562d545338fa16347c0a2f076f0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0728%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera-Abreu%26aufirst%3DM.%2BT.%26aulast%3DPalafox%26aufirst%3DM.%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DRivas%26aufirst%3DM.%2BA.%26aulast%3DCutts%26aufirst%3DR.%2BJ.%26aulast%3DGarcia-Murillas%26aufirst%3DI.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DBellet%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DL.%2BA.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DSerra%26aufirst%3DV.%26atitle%3DEarly%2520adaptation%2520and%2520acquired%2520resistance%2520to%2520CDK4%252F6%2520inhibition%2520in%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2301%26epage%3D2313%26doi%3D10.1158%2F0008-5472.CAN-15-0728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Joseph, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darimont, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrazate, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalla, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kategaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govek, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillot, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudente, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnefous, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giltnane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertz, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tantawy, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hager, J. H.</span><span> </span><span class="NLM_article-title">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span> <span class="citation_source-journal">Elife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e15828</span><span class="refDoi"> DOI: 10.7554/eLife.15828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.7554%2FeLife.15828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=27410477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e15828&author=J.+D.+Josephauthor=B.+Darimontauthor=W.+Zhouauthor=A.+Arrazateauthor=A.+Youngauthor=E.+Ingallaauthor=K.+Walterauthor=R.+A.+Blakeauthor=J.+Nonomiyaauthor=Z.+Guanauthor=L.+Kategayaauthor=S.+P.+Govekauthor=A.+G.+Laiauthor=M.+Kahramanauthor=D.+Brighamauthor=J.+Sensintaffarauthor=N.+Luauthor=G.+Shaoauthor=J.+Qianauthor=K.+Grillotauthor=M.+Moonauthor=R.+Prudenteauthor=E.+Bischoffauthor=K.+J.+Leeauthor=C.+Bonnefousauthor=K.+L.+Douglasauthor=J.+D.+Julienauthor=J.+Y.+Nagasawaauthor=A.+Aparicioauthor=J.+Kaufmanauthor=B.+Haleyauthor=J.+M.+Giltnaneauthor=I.+E.+Wertzauthor=M.+R.+Lacknerauthor=M.+A.+Nanniniauthor=D.+Sampathauthor=L.+Schwarzauthor=H.+C.+Manningauthor=M.+N.+Tantawyauthor=C.+L.+Arteagaauthor=R.+A.+Heymanauthor=P.+J.+Rixauthor=L.+Friedmanauthor=N.+D.+Smithauthor=C.+Metcalfeauthor=J.+H.+Hager&title=The+selective+estrogen+receptor+downregulator+GDC-0810+is+efficacious+in+diverse+models+of+ER%2B+breast+cancer&doi=10.7554%2FeLife.15828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span></div><div class="casAuthors">Joseph, James D.; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A.; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P.; Lai, Andiliy G.; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L.; Julien, Jackaline D.; Nagasawa, Johnny Y.; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M.; Wertz, Ingrid E.; Lackner, Mark R.; Nannini, Michelle A.; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L.; Heyman, Richard A.; Rix, Peter J.; Friedman, Lori; Smith, Nicholas D.; Metcalfe, Ciara; Hager, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e15828/1-e15828/34</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies.  The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERa signaling, and provides a strong rationale for continued targeting of ERa.  Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERa degrdn., antagonism and pharmacokinetic properties.  GDC-0810 induces a distinct ERa conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action.  GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERa mutations.  GDC-0810 is currently being evaluated in Phase II clin. studies in women with ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML4fZixufB7Vg90H21EOLACvtfcHk0lj10_J7tLQ72g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D&md5=cfdf9624f8b260a732b92caab0bb2d58</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.7554%2FeLife.15828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.15828%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DZ.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DJulien%26aufirst%3DJ.%2BD.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DNannini%26aufirst%3DM.%2BA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSchwarz%26aufirst%3DL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26aulast%3DTantawy%26aufirst%3DM.%2BN.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520selective%2520estrogen%2520receptor%2520downregulator%2520GDC-0810%2520is%2520efficacious%2520in%2520diverse%2520models%2520of%2520ER%252B%2520breast%2520cancer%26jtitle%3DElife%26date%3D2016%26volume%3D5%26spage%3De15828%26doi%3D10.7554%2FeLife.15828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Jordan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span> </span><span class="NLM_article-title">Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1023/B:BREA.0000041623.21338.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1023%2FB%3ABREA.0000041623.21338.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15377841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2004&pages=167-180&author=N.+J.+Jordanauthor=J.+M.+Geeauthor=D.+Barrowauthor=A.+E.+Wakelingauthor=R.+I.+Nicholson&title=Increased+constitutive+activity+of+PKB%2FAkt+in+tamoxifen+resistant+breast+cancer+MCF-7+cells&doi=10.1023%2FB%3ABREA.0000041623.21338.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells</span></div><div class="casAuthors">Jordan, Nicola J.; Gee, Julia M. W.; Barrow, Denise; Wakeling, Alan E.; Nicholson, Robert I.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-180</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">The tamoxifen-resistant (TAM-R) MCF-7 breast cancer cell line has been used as a model to identify the signaling pathways that enable resistant cancer cells to grow independently of steroid hormones.  In TAM-R cells, peptide growth factor signaling pathways appear to be important in modified cell behavior, growth and survival.  The PI3 kinase signaling components Akt1 and Akt2 are expressed at similar levels by both parental wild-type MCF-7 and TAM-R cells, but Akt1 phosphorylation is significantly increased in TAM-R cells grown under basal conditions.  High levels of basal Akt, GSK3α/β and p70S6 kinase phosphorylation are all inhibited by the PI3 kinase inhibitor, LY 294002.  The ligands for the EGFR/erbB1 receptor, EGF (epidermal growth factor) and TGFα (transforming growth factor-α) demonstrate an increased ability to activate Akt in TAM-R compared with parental MCF-7 cells and it is proposed that the preferred autocrine or paracrine activation of Akt occurs via the erbB heterodimer EGFR/erbB2 in TAM-R cells.  Akt phosphorylation is reduced by gefitinib ("Iressa"/ZD1839).  The results suggest that the PI3 kinase pathway plays a role in proliferation of TAM-R cells and is important in the increased EGF induced membrane ruffling detected in the resistant cells.  Increased Akt1 activation may contribute to the aggressive phenotype of tamoxifen resistant ER (estrogen receptor) pos. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJR02KTM_eirVg90H21EOLACvtfcHk0lj10_J7tLQ72g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOqtLc%253D&md5=0a4af8f540511d0145d806b92e74e99c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1023%2FB%3ABREA.0000041623.21338.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ABREA.0000041623.21338.47%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DN.%2BJ.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DBarrow%26aufirst%3DD.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DIncreased%2520constitutive%2520activity%2520of%2520PKB%252FAkt%2520in%2520tamoxifen%2520resistant%2520breast%2520cancer%2520MCF-7%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2004%26volume%3D87%26spage%3D167%26epage%3D180%26doi%3D10.1023%2FB%3ABREA.0000041623.21338.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Schiff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massarweh, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharwani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arpino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimawi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span> </span><span class="NLM_article-title">Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1007/s00280-005-0108-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2Fs00280-005-0108-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=16273359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gnu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=10-20&issue=Suppl+1&author=R.+Schiffauthor=S.+A.+Massarwehauthor=J.+Shouauthor=L.+Bharwaniauthor=G.+Arpinoauthor=M.+Rimawiauthor=C.+K.+Osborne&title=Advanced+concepts+in+estrogen+receptor+biology+and+breast+cancer+endocrine+resistance%3A+implicated+role+of+growth+factor+signaling+and+estrogen+receptor+coregulators&doi=10.1007%2Fs00280-005-0108-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators</span></div><div class="casAuthors">Schiff, Rachel; Massarweh, Suleiman A.; Shou, Jiang; Bharwani, Lavina; Arpino, Grazia; Rimawi, Mothaffar; Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">s10-s20</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor (ER), mediating estrogen-signaling stimuli, is a dominant regulator and a key therapeutic target in breast cancer etiol. and progression.  Endocrine therapy, blocking the ER pathway, is one of the most important systemic therapies in breast cancer management, but de novo and acquired resistance is still a major clin. problem.  New research highlights the role of both genomic and nongenomic ER activities and their intimate mol. crosstalk with growth factor receptor and other signaling kinase pathways in endocrine resistance.  These signaling pathways, when overexpressed and/or hyperactivated, can modulate both activities of ER, resulting in endocrine resistance.  Thus, these signal transduction receptors and signaling mols. may serve as both predictive markers and novel therapeutic targets to circumvent endocrine resistance.  Compelling exptl. and clin. evidence suggest that the epidermal growth factor/HER2/neu receptor (EGFR/HER2) pathway might play a distinct role in endocrine resistance, and esp. in resistance to selective estrogen receptor modulators (SERMs) such as tamoxifen.  Results from preclin. studies of treatment combinations with various endocrine therapy drugs together with several potent anti-EGFR/HER2 inhibitors are very promising, and clin. trials to see whether this new strategy is effective in patients are now ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRCyO-TiKZjrVg90H21EOLACvtfcHk0ljLyn6e3cokcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gnu73F&md5=22bd6e9f463a4f16afd19a5e74fe9883</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs00280-005-0108-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-005-0108-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DMassarweh%26aufirst%3DS.%2BA.%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DBharwani%26aufirst%3DL.%26aulast%3DArpino%26aufirst%3DG.%26aulast%3DRimawi%26aufirst%3DM.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DAdvanced%2520concepts%2520in%2520estrogen%2520receptor%2520biology%2520and%2520breast%2520cancer%2520endocrine%2520resistance%253A%2520implicated%2520role%2520of%2520growth%2520factor%2520signaling%2520and%2520estrogen%2520receptor%2520coregulators%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2005%26volume%3D56%26issue%3DSuppl%25201%26spage%3D10%26epage%3D20%26doi%3D10.1007%2Fs00280-005-0108-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Kilker, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planas-Silva, M. D.</span><span> </span><span class="NLM_article-title">Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells</span> <span class="citation_source-journal">J. Steroid Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1016/j.jsbmb.2004.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.jsbmb.2004.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15544931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=63-71&author=R.+L.+Kilkerauthor=M.+W.+Hartlauthor=T.+M.+Rutherfordauthor=M.+D.+Planas-Silva&title=Cyclin+D1+expression+is+dependent+on+estrogen+receptor+function+in+tamoxifen-resistant+breast+cancer+cells&doi=10.1016%2Fj.jsbmb.2004.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells</span></div><div class="casAuthors">Kilker, Robin L.; Hartl, Michael W.; Rutherford, Tina M.; Planas-Silva, Maricarmen D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">63-71</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of resistance to tamoxifen, the most common antiestrogen used in the treatment of breast cancer, is a frequent and severe clin. problem.  Tamoxifen-resistant tumors are still capable of responding to other hormonal therapies such as those that downregulate estrogen receptor expression.  Mechanisms leading to acquisition of tamoxifen-resistant but hormone-sensitive growth are not completely understood.  In tamoxifen-sensitive breast cancer cells, tamoxifen inhibits, whereas estrogen induces, expression of cyclin D1, a key cell cycle regulatory protein.  Ectopic expression of cyclin D1 can lead to antiestrogen resistance.  Thus, to det. whether cyclin D1 is involved in the growth of tamoxifen-resistant cells, the authors developed several tamoxifen-resistant variants from MCF-7 cells.  These variants grow in the absence of estrogen or in the presence of tamoxifen, but their growth is inhibited by estrogen receptor downregulators.  We show here that cyclin D1 expression is maintained at comparable levels in all tamoxifen-resistant variants, whereas pS2, another estrogen-regulated protein, is not.  The addn. of physiol. levels of estrogen further stimulates cyclin D1 expression and proliferation.  In contrast, treatment with estrogen receptor downregulators decreases cyclin D1 expression and proliferation.  Thus, changes in cyclin D1 expression upon 2nd-line hormonal therapy may predict hormonal sensitivity of tamoxifen-resistant tumors.  These studies suggest that estrogen receptor mediates cyclin D1 expression and growth of tamoxifen-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokX6Xvg8m6lbVg90H21EOLACvtfcHk0ljLyn6e3cokcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslWgsrk%253D&md5=9432e0d1038063db958deedde3d7cc40</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DKilker%26aufirst%3DR.%2BL.%26aulast%3DHartl%26aufirst%3DM.%2BW.%26aulast%3DRutherford%26aufirst%3DT.%2BM.%26aulast%3DPlanas-Silva%26aufirst%3DM.%2BD.%26atitle%3DCyclin%2520D1%2520expression%2520is%2520dependent%2520on%2520estrogen%2520receptor%2520function%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D92%26spage%3D63%26epage%3D71%26doi%3D10.1016%2Fj.jsbmb.2004.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Hui, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finney, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span> </span><span class="NLM_article-title">Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">6916</span><span class="NLM_x">–</span> <span class="NLM_lpage">6923</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6916-6923&author=R.+Huiauthor=G.+L.+Finneyauthor=J.+S.+Carrollauthor=C.+S.+Leeauthor=E.+A.+Musgroveauthor=R.+L.+Sutherland&title=Constitutive+overexpression+of+cyclin+D1+but+not+cyclin+E+confers+acute+resistance+to+antiestrogens+in+T-47D+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DR.%26aulast%3DFinney%26aufirst%3DG.%2BL.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DConstitutive%2520overexpression%2520of%2520cyclin%2520D1%2520but%2520not%2520cyclin%2520E%2520confers%2520acute%2520resistance%2520to%2520antiestrogens%2520in%2520T-47D%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6916%26epage%3D6923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Sherr, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. M.</span><span> </span><span class="NLM_article-title">Living with or without cyclins and cyclin-dependent kinases</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2699</span><span class="NLM_x">–</span> <span class="NLM_lpage">2711</span><span class="refDoi"> DOI: 10.1101/gad.1256504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1101%2Fgad.1256504" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=2699-2711&author=C.+J.+Sherrauthor=J.+M.+Roberts&title=Living+with+or+without+cyclins+and+cyclin-dependent+kinases&doi=10.1101%2Fgad.1256504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1101%2Fgad.1256504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1256504%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26atitle%3DLiving%2520with%2520or%2520without%2520cyclins%2520and%2520cyclin-dependent%2520kinases%26jtitle%3DGenes%2520Dev.%26date%3D2004%26volume%3D18%26spage%3D2699%26epage%3D2711%26doi%3D10.1101%2Fgad.1256504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Caldon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sergio, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthukaruppan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boersma, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barraclough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Print, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span> </span><span class="NLM_article-title">Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1499</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1158%2F1535-7163.MCT-11-0963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=22564725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1488-1499&author=C.+E.+Caldonauthor=C.+M.+Sergioauthor=J.+Kangauthor=A.+Muthukaruppanauthor=M.+N.+Boersmaauthor=A.+Stoneauthor=J.+Barracloughauthor=C.+S.+Leeauthor=M.+A.+Blackauthor=L.+D.+Millerauthor=J.+M.+Geeauthor=R.+I.+Nicholsonauthor=R.+L.+Sutherlandauthor=C.+G.+Printauthor=E.+A.+Musgrove&title=Cyclin+E2+overexpression+is+associated+with+endocrine+resistance+but+not+insensitivity+to+CDK2+inhibition+in+human+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-11-0963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells</span></div><div class="casAuthors">Caldon, C. Elizabeth; Sergio, C. Marcelo; Kang, Jian; Muthukaruppan, Anita; Boersma, Marijke N.; Stone, Andrew; Barraclough, Jane; Lee, Christine S.; Black, Michael A.; Miller, Lance D.; Gee, Julia M.; Nicholson, Rob I.; Sutherland, Robert L.; Print, Cristin G.; Musgrove, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1488-1499</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer.  We therefore examd. the role of cyclin E2 in antiestrogen resistance in vitro and its potential for therapeutic targeting through cyclin-dependent kinase (CDK) inhibition.  High expression of CCNE2, but not CCNE1, was characteristic of the luminal B and HER2 subtypes of breast cancer and was strongly predictive of shorter distant metastasis-free survival following endocrine therapy.  After antiestrogen treatment of MCF-7 breast cancer cells, cyclin E2 mRNA and protein were downregulated and cyclin E2-CDK2 activity decreased.  However, this regulation was lost in tamoxifen-resistant (MCF-7 TAMR) cells, which overexpressed cyclin E2.  Expression of either cyclin E1 or E2 in T-47D breast cancer cells conferred acute antiestrogen resistance, suggesting that cyclin E overexpression contributes to the antiestrogen resistance of tamoxifen-resistant cells.  Ectopic expression of cyclin E1 or E2 also reduced sensitivity to CDK4, but not CDK2, inhibition.  Proliferation of tamoxifen-resistant cells was inhibited by RNAi-mediated knockdown of cyclin E1, cyclin E2, or CDK2.  Furthermore, CDK2 inhibition of E-cyclin overexpressing cells and tamoxifen-resistant cells restored sensitivity to tamoxifen or CDK4 inhibition.  Cyclin E2 overexpression is therefore a potential mechanism of resistance to both endocrine therapy and CDK4 inhibition.  CDK2 inhibitors hold promise as a component of combination therapies in endocrine-resistant disease as they effectively inhibit cyclin E1 and E2 overexpressing cells and enhance the efficacy of other therapeutics.  Mol Cancer Ther; 11(7); 1488-99. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOrjoY6RnTk7Vg90H21EOLACvtfcHk0ljLyn6e3cokcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D&md5=0d1b47e6b62a4fce919aa5fcf40c227a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0963%26sid%3Dliteratum%253Aachs%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DSergio%26aufirst%3DC.%2BM.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DMuthukaruppan%26aufirst%3DA.%26aulast%3DBoersma%26aufirst%3DM.%2BN.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DBlack%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DL.%2BD.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DPrint%26aufirst%3DC.%2BG.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCyclin%2520E2%2520overexpression%2520is%2520associated%2520with%2520endocrine%2520resistance%2520but%2520not%2520insensitivity%2520to%2520CDK2%2520inhibition%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1488%26epage%3D1499%26doi%3D10.1158%2F1535-7163.MCT-11-0963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Caldon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span> </span><span class="NLM_article-title">Cell cycle control in breast cancer cells</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1002/jcb.20690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1002%2Fjcb.20690" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=261-274&author=C.+E.+Caldonauthor=R.+J.+Dalyauthor=R.+L.+Sutherlandauthor=E.+A.+Musgrove&title=Cell+cycle+control+in+breast+cancer+cells&doi=10.1002%2Fjcb.20690"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20690%26sid%3Dliteratum%253Aachs%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCell%2520cycle%2520control%2520in%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2006%26volume%3D97%26spage%3D261%26epage%3D274%26doi%3D10.1002%2Fjcb.20690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Moriai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, N.</span><span> </span><span class="NLM_article-title">Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span><span class="refDoi"> DOI: 10.1007/s10549-008-0164-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1007%2Fs10549-008-0164-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=18815881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvF2gsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2009&pages=261-271&author=R.+Moriaiauthor=N.+Tsujiauthor=M.+Moriaiauthor=D.+Kobayashiauthor=N.+Watanabe&title=Survivin+plays+as+a+resistant+factor+against+tamoxifen-induced+apoptosis+in+human+breast+cancer+cells&doi=10.1007%2Fs10549-008-0164-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells</span></div><div class="casAuthors">Moriai, Ryosuke; Tsuji, Naoki; Moriai, Mikako; Kobayashi, Daisuke; Watanabe, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-271</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tamoxifen has been the mainstay of endocrine therapy for estrogen receptor-pos. breast cancer.  However, approx. 40% of breast cancer patients do not respond to tamoxifen treatment.  Further, most tumors eventually acquire tamoxifen resistance.  Therefore, it is necessary to develop effective modalities to enhance the efficacy of tamoxifen in breast cancer treatment.  In this study, we investigated the mechanism by which breast cancer cells develop resistance against tamoxifen from the viewpoint of tamoxifen-induced apoptosis.  Overexpression of the anti-apoptotic mol. survivin rendered the human breast cancer cells MCF-7 resistant to tamoxifen-induced apoptosis.  To examine whether the down-regulation of survivin can enhance tamoxifen-induced apoptosis, we introduced siRNA targeting the survivin gene (survivin-siRNA) into MCF-7 cells.  Survivin-siRNA transfection not only induced apoptosis without tamoxifen treatment but also augmented the tamoxifen-induced apoptosis.  We have previously demonstrated that 3-hydroxy-3-methylglutaryl CoA reductase inhibitors (HRIs), which are widely used to reduce the serum cholesterol levels in hypercholesterolemia patients, decreases survivin expression in colon cancer cells.  To develop a pharmacol. approach for improving the efficacy of tamoxifen treatment, we detd. whether HRIs can enhance tamoxifen-induced apoptosis.  Lovastatin, an HRI, down-regulated the expression of survivin protein in MCF-7 cells in a dose-dependent manner.  In addn., the proportion of apoptotic cells induced by the tamoxifen and lovastatin combination was greater than the theor. additive effect.  These results suggest that survivin may function as a factor inducing resistance against tamoxifen-induced apoptosis, and the combined use of tamoxifen and HRI may be a novel approach to overcome tamoxifen resistance in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph8jSstaG16LVg90H21EOLACvtfcHk0li9Oo_SjeOLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvF2gsL4%253D&md5=6a8c3441a524e9daa89cb94b68a58a47</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs10549-008-0164-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-008-0164-5%26sid%3Dliteratum%253Aachs%26aulast%3DMoriai%26aufirst%3DR.%26aulast%3DTsuji%26aufirst%3DN.%26aulast%3DMoriai%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DD.%26aulast%3DWatanabe%26aufirst%3DN.%26atitle%3DSurvivin%2520plays%2520as%2520a%2520resistant%2520factor%2520against%2520tamoxifen-induced%2520apoptosis%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2009%26volume%3D117%26spage%3D261%26epage%3D271%26doi%3D10.1007%2Fs10549-008-0164-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoog, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncalves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiken, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saied, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuntoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchens, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phommaly, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavuri, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEachern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pluard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naughton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aft, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillanders, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSchryver, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Angulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, M. J.</span><span> </span><span class="NLM_article-title">Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-therapy-resistant+ESR1+variants+revealed+by+genomic+characterization+of+breast-cancer-derived+xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0li9Oo_SjeOLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-therapy-resistant%2520ESR1%2520variants%2520revealed%2520by%2520genomic%2520characterization%2520of%2520breast-cancer-derived%2520xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Pink, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2321</span><span class="NLM_x">–</span> <span class="NLM_lpage">2330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=2321-2330&author=J.+J.+Pinkauthor=V.+C.+Jordan&title=Models+of+estrogen+receptor+regulation+by+estrogens+and+antiestrogens+in+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPink%26aufirst%3DJ.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DModels%2520of%2520estrogen%2520receptor%2520regulation%2520by%2520estrogens%2520and%2520antiestrogens%2520in%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26spage%3D2321%26epage%3D2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osipo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kidawi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandel, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1746</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span><span class="refDoi"> DOI: 10.1093/jnci/dji400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1093%2Fjnci%2Fdji400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=16333030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=1746-1759&author=J.+S.+Lewisauthor=K.+Meekeauthor=C.+Osipoauthor=E.+A.+Rossauthor=N.+Kidawiauthor=T.+Liauthor=E.+Bellauthor=N.+S.+Chandelauthor=V.+C.+Jordan&title=Intrinsic+mechanism+of+estradiol-induced+apoptosis+in+breast+cancer+cells+resistant+to+estrogen+deprivation&doi=10.1093%2Fjnci%2Fdji400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation</span></div><div class="casAuthors">Lewis, Joan S.; Meeke, Kathleen; Osipo, Clodia; Ross, Eric A.; Kidawi, Noman; Li, Tianyu; Bell, Eric; Chandel, Navdeep S.; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1746-1759</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously developed an estrogen receptor (ER)-pos. breast cancer cell line (MCF-7:5C) that is resistant to long-term estrogen deprivation and undergoes rapid and complete apoptosis in the presence of physiol. concns. of 17β-estradiol.  Here, we investigated the role of the mitochondrial apoptotic pathway in this process.  Methods: Apoptosis in MCF-7:5C cells treated with estradiol, fulvestrant, or vehicle (control) was investigated by annexin V-propidium iodide double staining and 4',6-diamidino-2-phenylindole (DAPI) staining.  Apoptosis was also analyzed in MCF-7:5C cells transiently transfected with small interfering RNAs (siRNAs) to apoptotic pathway components.  Expression of apoptotic pathway intermediates was measured by western blot anal.  Mitochondrial transmembrane potential (ψm) was detd. by rhodamine-123 retention assay.  Mitochondrial pathway activity was detd. by cytochrome c release and cleavage of poly(ADP-ribose) polymerase (PARP) protein.  Tumorigenesis was studied in ovariectomized athymic mice that were injected with MCF-7:5C cells.  Differences between the treatment groups and control group were detd. by two-sample t test or one-factor anal. of variance.  All statistical tests were two-sided.  Results: MCF-7:5C cells treated with estradiol underwent apoptosis and showed increased expression of proapoptotic proteins, decreased ψm, enhanced cytochrome c release, and PARP cleavage compared with cells treated with fulvestrant or vehicle.  Blockade of Bax, Bim, and p53 mRNA expression by siRNA reduced estradiol-induced apoptosis relative to control by 76% [95% confidence interval (CI) = 73% to 79%, P<.001], 85% [95% CI = 90% to 80%, P<.001], and 40% [95% CI = 45% to 35%, P<.001], resp., whereas blockade of FasL by siRNA had no effect.  Estradiol caused complete regression of MCF-7:5C tumors in vivo.  Conclusion: The mitochondrial pathway of apoptosis plays a crit. role in estradiol-induced apoptosis in long-term estrogen-deprived breast cancer cells.  Physiol. concns. of estradiol could potentially be used to induce apoptosis and tumor regression in tumors that have developed resistance to aromatase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0fGAoI50tabVg90H21EOLACvtfcHk0lhwJvE8gRMhqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSjurnN&md5=8107a7d125731549936a7268fb9e1138</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdji400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdji400%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DMeeke%26aufirst%3DK.%26aulast%3DOsipo%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DE.%2BA.%26aulast%3DKidawi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DBell%26aufirst%3DE.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DIntrinsic%2520mechanism%2520of%2520estradiol-induced%2520apoptosis%2520in%2520breast%2520cancer%2520cells%2520resistant%2520to%2520estrogen%2520deprivation%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2005%26volume%3D97%26spage%3D1746%26epage%3D1759%26doi%3D10.1093%2Fjnci%2Fdji400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osipo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span> </span><span class="NLM_article-title">Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal</span> <span class="citation_source-journal">J. Steroid Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.jsbmb.2004.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2Fj.jsbmb.2004.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=15862958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVKks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=131-141&author=J.+S.+Lewisauthor=C.+Osipoauthor=K.+Meekeauthor=V.+C.+Jordan&title=Estrogen-induced+apoptosis+in+a+breast+cancer+model+resistant+to+long-term+estrogen+withdrawal&doi=10.1016%2Fj.jsbmb.2004.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal</span></div><div class="casAuthors">Lewis, J. S.; Osipo, C.; Meeke, K.; Jordan, V. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">131-141</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Estrogen suppression through the use of an aromatase inhibitor is an effective endocrine treatment option for postmenopausal breast cancer patients with estrogen receptor (ER)-pos. disease, however, there are concerns that long-term estrogen deprivation will inevitably lead to resistance.  To address the issue of acquired resistance to long-term estrogen deprivation our lab. has developed an ER+/PR- hormone-independent breast cancer cell line, MCF-7:5C which is a variant clone of wild-type MCF-7 cells.  Originally, these cells were cultured in estrogen-free MEM contg. 5% charcoal-stripped calf serum and were found to be resistant to both estradiol (E2) and antiestrogens.  Interestingly, a completely different phenomenon was obsd. when MCF-7:5C cells were cultured in phenol red-free RPMI 1640 medium contg. 10% charcoal-stripped fetal bovine serum (SFS).  Using DNA quantitation assays, the authors examd. the effect of E2 on the growth of MCF-7:5C cells under different media conditions.  These results showed that 10-9 M E2 caused a dramatic 90% redn. in the growth of MCF-7:5C cells cultured in RPMI medium contg. 10% SFS but did not have any significant inhibitory effects on cells cultured in MEM media.  Addnl. expts. were performed to det. whether the medium or the serum facilitated the inhibitory effects of E2 and the results indicated that it was the serum.  Annexin V and DAPI staining confirmed that the E2-induced growth inhibition of MCF-7:5C cells was due to apoptosis.  We also examd. the tumorigenic potential of MCF-7:5C cells by injecting 1 × 107 cells/site into ovariectomized athymic mice and found that these cells, previously cultured in RPMI media, spontaneously grew into tumors in the absence of E2.  Overall, these results show that low concns. (>10-11 M) of E2 are capable of inducing apoptosis in an aromatase resistant breast cancer cell model and that this effect is highly influenced by the medium in which the cells are grown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhS-VZhkUY2rVg90H21EOLACvtfcHk0lhwJvE8gRMhqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVKks74%253D&md5=5b11562cc6ecd12fc4056f8446f9f47f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DOsipo%26aufirst%3DC.%26aulast%3DMeeke%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DEstrogen-induced%2520apoptosis%2520in%2520a%2520breast%2520cancer%2520model%2520resistant%2520to%2520long-term%2520estrogen%2520withdrawal%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D94%26spage%3D131%26epage%3D141%26doi%3D10.1016%2Fj.jsbmb.2004.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Labarca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paigen, K.</span><span> </span><span class="NLM_article-title">A simple, rapid, and sensitive DNA assay procedure</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/0003-2697(80)90165-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2F0003-2697%2880%2990165-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1980&pages=344-352&author=C.+Labarcaauthor=K.+Paigen&title=A+simple%2C+rapid%2C+and+sensitive+DNA+assay+procedure&doi=10.1016%2F0003-2697%2880%2990165-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0003-2697%2880%2990165-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-2697%252880%252990165-7%26sid%3Dliteratum%253Aachs%26aulast%3DLabarca%26aufirst%3DC.%26aulast%3DPaigen%26aufirst%3DK.%26atitle%3DA%2520simple%252C%2520rapid%252C%2520and%2520sensitive%2520DNA%2520assay%2520procedure%26jtitle%3DAnal.%2520Biochem.%26date%3D1980%26volume%3D102%26spage%3D344%26epage%3D352%26doi%3D10.1016%2F0003-2697%2880%2990165-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Daxhelet, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coene, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoet, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocito, C. G.</span><span> </span><span class="NLM_article-title">Spectrofluorometry of dyes with DNAs of different base composition and conformation</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span><span class="refDoi"> DOI: 10.1016/0003-2697(89)90152-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1016%2F0003-2697%2889%2990152-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=1989&pages=401-403&author=G.+A.+Daxheletauthor=M.+M.+Coeneauthor=P.+P.+Hoetauthor=C.+G.+Cocito&title=Spectrofluorometry+of+dyes+with+DNAs+of+different+base+composition+and+conformation&doi=10.1016%2F0003-2697%2889%2990152-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2F0003-2697%2889%2990152-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-2697%252889%252990152-8%26sid%3Dliteratum%253Aachs%26aulast%3DDaxhelet%26aufirst%3DG.%2BA.%26aulast%3DCoene%26aufirst%3DM.%2BM.%26aulast%3DHoet%26aufirst%3DP.%2BP.%26aulast%3DCocito%26aufirst%3DC.%2BG.%26atitle%3DSpectrofluorometry%2520of%2520dyes%2520with%2520DNAs%2520of%2520different%2520base%2520composition%2520and%2520conformation%26jtitle%3DAnal.%2520Biochem.%26date%3D1989%26volume%3D179%26spage%3D401%26epage%3D403%26doi%3D10.1016%2F0003-2697%2889%2990152-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, H. N.</span><span> </span><span class="NLM_article-title">Photoaffinity labels for estrogen binding proteins of rat uterus</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4085</span><span class="NLM_x">–</span> <span class="NLM_lpage">4092</span><span class="refDoi"> DOI: 10.1021/bi00745a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00745a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1973&pages=4085-4092&author=J.+A.+Katzenellenbogenauthor=H.+J.+Johnsonauthor=H.+N.+Myers&title=Photoaffinity+labels+for+estrogen+binding+proteins+of+rat+uterus&doi=10.1021%2Fbi00745a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labels for estrogen binding proteins of rat uterus</span></div><div class="casAuthors">Katzenellenbogen, John A.; Johnson, Howard J., Jr.; Myers, Harvey N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4085-92</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The binding affinity of 14 estrone, estradiol, and hexestrol derivs. bearing a photosensitive function (either diazocarbonyl group or aryl azide) and their precursors for rat uterine estrogen binding protein was measured by a competitive binding assay.  Introduction of substituents lowered binding affinity in all cases, esp. when 1 or both of the hydroxyl groups were blocked.  Substituents at positions 2, 4, and 16 were tolerated reasonably well.  Derivs. in which the A-ring hydroxyl is internally hydrogen bonded to a nitro group have very low affinity, but the nitro group was well tolerated at position 4, where it does not hydrogen bond to the hydroxyl.  The binding affinity of all the derivs. reflected the relative binding affinity of the parent ligands:  hexestrol > estradiol > estrone.  3-Azidohexestrol [50548-21-5] and 3,3'-diazidohexestrol [50548-22-6] >5%, had the greatest binding affinity and could selectively label estrogen binding protein directly in the impure state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzUNSnonz6bLVg90H21EOLACvtfcHk0lgg3sAQ8ftmfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D&md5=99f1bdfa830d881939130942394e47be</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fbi00745a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00745a010%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BJ.%26aulast%3DMyers%26aufirst%3DH.%2BN.%26atitle%3DPhotoaffinity%2520labels%2520for%2520estrogen%2520binding%2520proteins%2520of%2520rat%2520uterus%26jtitle%3DBiochemistry%26date%3D1973%26volume%3D12%26spage%3D4085%26epage%3D4092%26doi%3D10.1021%2Fbi00745a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katzenellenbogen, J. A.</span><span> </span><span class="NLM_article-title">Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">14897</span><span class="NLM_x">–</span> <span class="NLM_lpage">14905</span><span class="refDoi"> DOI: 10.1021/bi971746l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi971746l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=14897-14905&author=K.+E.+Carlsonauthor=I.+Choiauthor=A.+Geeauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Altered+ligand+binding+properties+and+enhanced+stability+of+a+constitutively+active+estrogen+receptor%3A+evidence+that+an+open+pocket+conformation+is+required+for+ligand+interaction&doi=10.1021%2Fbi971746l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction</span></div><div class="casAuthors">Carlson, Kathryn E.; Choi, Inho; Gee, Arvin; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14897-14905</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To elucidate the ligand binding properties of the estrogen receptor (ER) and how ligand access to and release from the ligand binding pocket is affected by the conformational state of the receptor, the authors have measured the rates of estradiol assocn. and dissocn., the equil. binding, and the stability of estradiol binding to denaturants, comparing wild-type human ER and a point mutant (Y537S ER) that shows full constitutive activity, i.e., the same full transcriptional activity in the absence or presence of estrogen.  Ligand binding kinetics and affinity were measured with the full-length (1-595) ERs and with truncated forms of both receptors contg. domains C through F (including the DNA binding, hinge, and ligand binding domains, amino acids 175-595) or domains E and F (the ligand binding domain; amino acids 304-595).  With all ERs, the rates of ligand assocn. and dissocn. were considerably slower with the Y537S mutant ER than with wild-type ER (6-fold and 3-4-fold, resp.).  These marked differences in ligand on and off rates for the wild-type and Y537S receptors result in a predicted (k-1/k+1) and measured Kd that is 2-fold lower for Y537S ER compared to wild-type ER.  The binding of estradiol by wild-type ER was disrupted by high concns. of urea (above 2 M), whereas the Y537S ER was distinctly more resistant to this disruption.  These results are consistent with a model in which wild-type ER in the absence of ligand adopts a transcriptionally inactive collapsed pocket conformation, stabilized by specific interactions of Y537 with nearby regions of ER.  When estradiol is bound, the wild-type ER adopts a transcriptionally active, closed pocket (ligand occupied) conformation.  By contrast, the Y537S mutant ER favors the transcriptionally active closed pocket conformation, whether occupied by ligand or not, the latter state (closed pocket but unoccupied) accounting for its constitutive activity.  The authors' findings suggest that the entry or exit of ligand from the binding pocket requires that ER adopt an open pocket conformation.  The reduced rates of ligand assocn. and dissocn. in the constitutively active form of the ER, as well as its greater resistance to disruption of ligand binding by urea, support the supposition that the rate at which this open pocket conformation can be accessed from the unoccupied or ligand-occupied Y537S ER is slower than from the unoccupied or occupied forms of wild-type ER.  Thus, the binding and release of ligand by ER require that the receptor access an open pocket state, and the ease with which this state can be accessed is affected by mutations that alter receptor conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpASth-0158cLVg90H21EOLACvtfcHk0lgg3sAQ8ftmfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D&md5=905b74d7bd576c661a10daad28913fd8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fbi971746l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi971746l%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DGee%26aufirst%3DA.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAltered%2520ligand%2520binding%2520properties%2520and%2520enhanced%2520stability%2520of%2520a%2520constitutively%2520active%2520estrogen%2520receptor%253A%2520evidence%2520that%2520an%2520open%2520pocket%2520conformation%2520is%2520required%2520for%2520ligand%2520interaction%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D14897%26epage%3D14905%26doi%3D10.1021%2Fbi971746l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Chisamore, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentrem, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span> </span><span class="NLM_article-title">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3156</span><span class="NLM_x">–</span> <span class="NLM_lpage">3165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=11595710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3156-3165&author=M.+J.+Chisamoreauthor=Y.+Ahmedauthor=D.+J.+Bentremauthor=V.+C.+Jordanauthor=D.+A.+Tonetti&title=Novel+antitumor+effect+of+estradiol+in+athymic+mice+injected+with+a+T47D+breast+cancer+cell+line+overexpressing+protein+kinase+Calpha"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase cα</span></div><div class="casAuthors">Chisamore, Michael J.; Ahmed, Yasmin; Bentrem, David J.; Jordan, V. Craig; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3156-3165</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to tamoxifen (TAM) represents a significant challenge to the management of breast cancer.  We previously reported that the estrogen receptor (ER)-neg. hormone-independent T47D:C42 cell line has both elevated protein kinase Cα (PKCα) protein expression and basal activator protein-1 activity compared with the parental ER+ (hormone-dependent) T47D:A18 cell line.  Stable transfection of PKCα to the T47D:A18 breast cancer cell line results in increased basal activator protein-1 activity, reduced ER function, increased proliferation rate, and hormone-independent growth (Tonetti et al., Br. J. Cancer, 83: 782-791, 2000).  In this report, we further characterize the role of PKCα overexpression in vivo to elucidate a possible mol. mechanism of tamoxifen resistance.  To det. whether the T47D:A18/PKCα cell line would produce hormone-independent tumors in athymic mice, we injected T47D:A18, T47D:A18/neo, or the T47D:A18/PKCα20 cell clones bilaterally into the mammary fat pads of athymic mice.  Tumor growth was evaluated following treatment with estradiol (E2), TAM, and the pure antiestrogen, ICI 182780.  Mice receiving either T47D:A18 or T47D:A18/neo cells produced tumors that grew in response to E2 treatment, whereas the untreated control and TAM-treated groups showed no tumor growth.  Interestingly, mice receiving the T47D:A18/PKCα20 clone produced tumors in both the control and TAM groups, whereas tumor growth was inhibited in mice treated with E2.  PKCα was also overexpressed in an MCF-7 tumor model that also exhibited TAM-stimulated and E2-induced regression.  These results suggest that overexpression of PKCα in breast tumors results in hormone-independent tumor growth that cannot be inhibited by TAM treatment.  Furthermore, the finding that E2 has an antitumor effect on breast tumors overexpressing PKCα is a novel observation that may have important therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Yd2zilR7XbVg90H21EOLACvtfcHk0ljQl2X2OCSCYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D&md5=e132ea7de154480f42b7f701b796401c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChisamore%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DY.%26aulast%3DBentrem%26aufirst%3DD.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520antitumor%2520effect%2520of%2520estradiol%2520in%2520athymic%2520mice%2520injected%2520with%2520a%2520T47D%2520breast%2520cancer%2520cell%2520line%2520overexpressing%2520protein%2520kinase%2520Calpha%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3156%26epage%3D3165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Perez White, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonetti, D. A.</span><span> </span><span class="NLM_article-title">Extranuclear ERalpha is associated with regression of T47D PKCalpha-overexpressing, tamoxifen-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="refDoi"> DOI: 10.1186/1476-4598-12-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=10.1186%2F1476-4598-12-34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=23634843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt12qt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=34&author=B.+Perez+Whiteauthor=M.+E.+Molloyauthor=H.+Zhaoauthor=Y.+Zhangauthor=D.+A.+Tonetti&title=Extranuclear+ERalpha+is+associated+with+regression+of+T47D+PKCalpha-overexpressing%2C+tamoxifen-resistant+breast+cancer&doi=10.1186%2F1476-4598-12-34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer</span></div><div class="casAuthors">Perez White, Bethany; Molloy, Mary Ellen; Zhao, Huiping; Zhang, Yiyun; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Prior to the introduction of tamoxifen, high dose estradiol was used to treat breast cancer patients with similar efficacy as tamoxifen, albeit with some undesirable side effects.  There is renewed interest to utilize estradiol to treat endocrine resistant breast cancers, esp. since findings from several preclin. models and clin. trials indicate that estradiol may be a rational second-line therapy in patients exhibiting resistance to tamoxifen and/or aromatase inhibitors.  We and others reported that breast cancer patients bearing protein kinase C alpha (PKCα)-expressing tumors exhibit endocrine resistance and tumor aggressiveness.  Our T47D:A18/PKCα preclin. model is tamoxifen-resistant, hormone-independent, yet is inhibited by 17β-estradiol (E2) in vivo.  We previously reported that E2-induced T47D:A18/PKCα tumor regression requires extranuclear ERα and interaction with the extracellular matrix.  Methods: T47D:A18/PKCα cells were grown in vitro using two-dimensional (2D) cell culture, three-dimensional (3D) Matrigel and in vivo by establishing xenografts in athymic mice.  Immunofluoresence confocal microscopy and co-localization were applied to det. estrogen receptor alpha (ERα) subcellular localization.  Co-immunopptn. and western blot were used to examine interaction of ERα with caveolin-1.  Results: We report that although T47D:A18/PKCα cells are cross-resistant to raloxifene in cell culture and in Matrigel, raloxifene induces regression of tamoxifen-resistant tumors.  ERα rapidly translocates to extranuclear sites during T47D:A18/PKCα tumor regression in response to both raloxifene and E2, whereas ERα is primarily localized in the nucleus in proliferating tumors.  E2 treatment induced complete tumor regression whereas cessation of raloxifene treatment resulted in tumor regrowth accompanied by re-localization of ERα to the nucleus.  T47D:A18/neo tumors that do not overexpress PKCα maintain ERα in the nucleus during tamoxifen-mediated regression.  An assocn. between ERα and caveolin-1 increases in tumors regressing in response to E2.  Conclusions: Extranuclear ERα plays a role in the regression of PKCα-overexpressing tamoxifen-resistant tumors.  These studies underline the unique role of extranuclear ERα in E2- and raloxifene-induced tumor regression that may have implications for treatment of endocrine-resistant PKCα-expressing tumors encountered in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3dl-xeGYbWbVg90H21EOLACvtfcHk0ljQl2X2OCSCYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt12qt7w%253D&md5=cc902496a93ae81c99847d5f16b89512</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-34%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%2BWhite%26aufirst%3DB.%26aulast%3DMolloy%26aufirst%3DM.%2BE.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DExtranuclear%2520ERalpha%2520is%2520associated%2520with%2520regression%2520of%2520T47D%2520PKCalpha-overexpressing%252C%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D34%26doi%3D10.1186%2F1476-4598-12-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K','PDB','1R5K'); return false;">PDB: 1R5K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC','PDB','5ACC'); return false;">PDB: 5ACC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ak2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ak2','PDB','5ak2'); return false;">PDB: 5ak2</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01355">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_41543"></div></div></div></div></div><hr /></hr><p class="last">. The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01355">10.1021/acs.jmedchem.6b01355</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_001.csv">CSV</a>)</p></li><li><p class="inline">ER degradation of compounds <b>28a</b>, <b>28c</b>, <b>24b</b>, and <b>24c</b> (100 nM) verified by western blot; cell survival data (DNA) of compound <b>16b</b> in TR MCF-7:5C and TS MCF-7:WS8 cells; additional materials and methods; characterization data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf">PDF</a>)</p></li><li><p class="inline">3D structure of 1R5K (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_003.pdb">PDB</a>)</p></li><li><p class="inline">3D structure of 5AK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_001.csv">jm6b01355_si_001.csv (2.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_002.pdf">jm6b01355_si_002.pdf (450.75 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_003.pdb">jm6b01355_si_003.pdb (207.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01355/suppl_file/jm6b01355_si_004.pdb">jm6b01355_si_004.pdb (336.71 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01355%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01355" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995e3ecb843cca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
